manuscript.id,cohort,treatment,composite.endpoint.responder,disease.control.6month,lab.category,lab.test,visit,study.day,lab.value,lower.limit.normal,upper.limit.normal,baseline.flag,baseline.value,change.from.baseline,percent.change.from.baseline
10A,A,NKTR-214 + Nivolumab,N,N,,CTC,Baseline,1,0,NA,NA,Y,0,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 4 Day 1 A,63,0,NA,NA,,0,0,NA
10A,A,NKTR-214 + Nivolumab,N,N,,CTC,End of Treatment A,86,3,NA,NA,,0,3,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-19,25,0,59,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,22,0,59,Y,22,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,26,0,59,,22,4,18.2
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,21,21,0,59,,22,-1,-4.5
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,28,22,0,59,,22,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 A,43,19,0,59,,22,-3,-13.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 8 A,50,30,0,59,,22,8,36.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,67,9,0,59,,22,-13,-59.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 8 A,71,28,0,59,,22,6,27.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,86,23,0,59,,22,1,4.5
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 A,190,12,0,59,,22,-10,-45.5
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-19,3.6,3.5,4.7,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.5,3.5,4.7,Y,3.5,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,2.9,3.5,4.7,,3.5,-0.6000000000000001,-17.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,21,3.5,3.5,4.7,,3.5,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,28,2.9,3.5,4.7,,3.5,-0.6000000000000001,-17.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 A,43,3.4,3.5,4.7,,3.5,-0.10000000000000009,-2.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 8 A,50,3.1,3.5,4.7,,3.5,-0.3999999999999999,-11.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,67,3,3.5,4.7,,3.5,-0.5,-14.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 4 Day 8 A,71,2.4,3.5,4.7,,3.5,-1.1,-31.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment A,86,3.4,3.5,4.7,,3.5,-0.10000000000000009,-2.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 A,190,3.3,3.5,4.7,,3.5,-0.20000000000000018,-5.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-19,112,56,119,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,131,56,119,Y,131,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,99,56,119,,131,-32,-24.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,21,131,56,119,,131,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,28,106,56,119,,131,-25,-19.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 A,43,131,56,119,,131,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 8 A,50,136,56,119,,131,5,3.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,67,115,56,119,,131,-16,-12.2
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 8 A,71,124,56,119,,131,-7,-5.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,86,118,56,119,,131,-13,-9.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 A,190,266,56,119,,131,135,103.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-19,26,0,41,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,18,0,41,Y,18,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,23,0,41,,18,5,27.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,21,19,0,41,,18,1,5.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,28,17,0,41,,18,-1,-5.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 A,43,17,0,41,,18,-1,-5.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 8 A,50,15,0,41,,18,-3,-16.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,67,7,0,41,,18,-11,-61.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 8 A,71,26,0,41,,18,8,44.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,86,19,0,41,,18,1,5.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 A,190,13,0,41,,18,-5,-27.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-19,21,6,20,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,14,6,20,Y,14,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,8,14,6,20,,14,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,21,13,6,20,,14,-1,-7.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 8 A,28,33,6,20,,14,19,135.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 A,43,16,6,20,,14,2,14.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 8 A,50,59,6,20,,14,45,321.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,67,47,6,20,,14,33,235.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 4 Day 8 A,71,17,6,20,,14,3,21.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,End of Treatment A,86,19,6,20,,14,5,35.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 A,190,22,6,20,,14,8,57.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-19,26,21,32,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,29,21,32,Y,29,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,29,21,32,,29,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,21,26,21,32,,29,-3,-10.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,28,33,21,32,,29,4,13.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 A,43,31,21,32,,29,2,6.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 8 A,50,28,21,32,,29,-1,-3.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,67,21,21,32,,29,-8,-27.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 4 Day 8 A,71,31,21,32,,29,2,6.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment A,86,28,21,32,,29,-1,-3.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 A,190,25,21,32,,29,-4,-13.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-19,9,8.6,10.2,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9,8.6,10.2,Y,9,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,8.9,8.6,10.2,,9,-0.09999999999999964,-1.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,21,8.9,8.6,10.2,,9,-0.09999999999999964,-1.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,28,9.8,8.6,10.2,,9,0.8000000000000007,8.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 A,43,9.2,8.6,10.2,,9,0.1999999999999993,2.2
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 8 A,50,10.1,8.6,10.2,,9,1.0999999999999996,12.2
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,67,8.6,8.6,10.2,,9,-0.40000000000000036,-4.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 4 Day 8 A,71,8.7,8.6,10.2,,9,-0.3000000000000007,-3.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment A,86,8.6,8.6,10.2,,9,-0.40000000000000036,-4.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 A,190,8.5,8.6,10.2,,9,-0.5,-5.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-19,109,97,108,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,108,97,108,Y,108,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,104,97,108,,108,-4,-3.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,21,105,97,108,,108,-3,-2.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,28,105,97,108,,108,-3,-2.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 A,43,102,97,108,,108,-6,-5.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 8 A,50,100,97,108,,108,-8,-7.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,67,101,97,108,,108,-7,-6.5
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 4 Day 8 A,71,107,97,108,,108,-1,-0.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment A,86,103,97,108,,108,-5,-4.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 A,190,103,97,108,,108,-5,-4.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-19,0.9,0.7,1.3,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.9,0.7,1.3,Y,0.9,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,0.93,0.7,1.3,,0.9,0.030000000000000027,3.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,21,1,0.7,1.3,,0.9,0.09999999999999998,11.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,28,1.36,0.7,1.3,,0.9,0.4600000000000001,51.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 A,43,0.96,0.7,1.3,,0.9,0.05999999999999994,6.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 8 A,50,3.29,0.7,1.3,,0.9,2.39,265.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,67,8.89,0.7,1.3,,0.9,7.99,887.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 4 Day 8 A,71,1.21,0.7,1.3,,0.9,0.30999999999999994,34.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment A,86,1.07,0.7,1.3,,0.9,0.17000000000000004,18.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 A,190,1.73,0.7,1.3,,0.9,0.83,92.2
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-19,99,70,99,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,81,70,99,Y,81,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 A,8,104,70,99,,81,23,28.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,21,99,70,99,,81,18,22.2
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,28,104,70,99,,81,23,28.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 A,43,94,70,99,,81,13,16
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 8 A,50,88,70,99,,81,7,8.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,67,118,70,99,,81,37,45.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 4 Day 8 A,71,104,70,99,,81,23,28.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment A,86,153,70,99,,81,72,88.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 A,190,108,70,99,,81,27,33.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-19,160,0,250,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,154,0,250,Y,154,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,8,184,0,250,,154,30,19.5
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,21,247,0,250,,154,93,60.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,28,175,0,250,,154,21,13.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 A,43,191,0,250,,154,37,24
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 8 A,50,167,0,250,,154,13,8.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment A,86,203,0,250,,154,49,31.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 A,190,224,0,250,,154,70,45.5
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-19,3.9,3.4,5,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,3.6,3.4,5,Y,3.6,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,3.6,3.4,5,,3.6,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,21,4,3.4,5,,3.6,0.3999999999999999,11.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,28,3.7,3.4,5,,3.6,0.10000000000000009,2.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 A,43,3.5,3.4,5,,3.6,-0.10000000000000009,-2.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 8 A,50,3.5,3.4,5,,3.6,-0.10000000000000009,-2.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,67,3.8,3.4,5,,3.6,0.19999999999999973,5.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 4 Day 8 A,71,3.6,3.4,5,,3.6,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment A,86,3.8,3.4,5,,3.6,0.19999999999999973,5.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 A,190,3.7,3.4,5,,3.6,0.10000000000000009,2.8
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-19,145,136,145,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,145,136,145,Y,145,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,8,142,136,145,,145,-3,-2.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,21,142,136,145,,145,-3,-2.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,28,145,136,145,,145,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 A,43,140,136,145,,145,-5,-3.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 8 A,50,139,136,145,,145,-6,-4.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,67,134,136,145,,145,-11,-7.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 4 Day 8 A,71,143,136,145,,145,-2,-1.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment A,86,139,136,145,,145,-6,-4.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 A,190,139,136,145,,145,-6,-4.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-19,0.4,0.3,1.2,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.3,0.3,1.2,Y,0.3,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.3,0.3,1.2,,0.3,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,21,0.7,0.3,1.2,,0.3,0.39999999999999997,133.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,28,0.2,0.3,1.2,,0.3,-0.09999999999999998,-33.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 A,43,0.4,0.3,1.2,,0.3,0.10000000000000003,33.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 8 A,50,0.2,0.3,1.2,,0.3,-0.09999999999999998,-33.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,67,0.4,0.3,1.2,,0.3,0.10000000000000003,33.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 4 Day 8 A,71,0.2,0.3,1.2,,0.3,-0.09999999999999998,-33.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment A,86,0.5,0.3,1.2,,0.3,0.2,66.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 A,190,0.5,0.3,1.2,,0.3,0.2,66.7
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-19,7,6.4,8.2,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.2,6.4,8.2,Y,7.2,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,8,6.4,6.4,8.2,,7.2,-0.7999999999999998,-11.1
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,21,7.3,6.4,8.2,,7.2,0.09999999999999964,1.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,28,6.8,6.4,8.2,,7.2,-0.40000000000000036,-5.6
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 A,43,7.1,6.4,8.2,,7.2,-0.10000000000000053,-1.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 8 A,50,6.9,6.4,8.2,,7.2,-0.2999999999999998,-4.2
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,67,6.7,6.4,8.2,,7.2,-0.5,-6.9
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 4 Day 8 A,71,6.1,6.4,8.2,,7.2,-1.1000000000000005,-15.3
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment A,86,7.3,6.4,8.2,,7.2,0.09999999999999964,1.4
10A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 A,190,7.3,6.4,8.2,,7.2,0.09999999999999964,1.4
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-19,27.7,22.5,34.5,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,27.4,22.5,34.5,Y,27.4,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 A,8,28.6,22.5,34.5,,27.4,1.2000000000000028,4.4
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 A,21,28.1,22.5,34.5,,27.4,0.7000000000000028,2.6
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 8 A,28,30.6,22.5,34.5,,27.4,3.200000000000003,11.7
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 A,43,28.1,22.5,34.5,,27.4,0.7000000000000028,2.6
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 8 A,50,26.8,22.5,34.5,,27.4,-0.5999999999999979,-2.2
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 A,63,27.9,22.5,34.5,,27.4,0.5,1.8
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment A,86,28,22.5,34.5,,27.4,0.6000000000000014,2.2
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Follow-up 110 A,190,32,22.5,34.5,,27.4,4.600000000000001,16.8
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-19,0.93,0.8,1.2,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,0.99,0.8,1.2,Y,0.99,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 A,8,0.99,0.8,1.2,,0.99,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 A,21,0.98,0.8,1.2,,0.99,-0.010000000000000009,-1
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 8 A,28,1.03,0.8,1.2,,0.99,0.040000000000000036,4
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 A,43,0.94,0.8,1.2,,0.99,-0.050000000000000044,-5.1
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 8 A,50,1.02,0.8,1.2,,0.99,0.030000000000000027,3
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 A,63,0.93,0.8,1.2,,0.99,-0.05999999999999994,-6.1
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment A,86,0.98,0.8,1.2,,0.99,-0.010000000000000009,-1
10A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Follow-up 110 A,190,1.08,0.8,1.2,,0.99,0.09000000000000008,9.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-19,0.03,0,0.1,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.04,0,0.1,Y,0.04,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0.02,0,0.1,,0.04,-0.02,-50
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0.02,0,0.1,,0.04,-0.02,-50
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,8,0.02,0,0.1,,0.04,-0.02,-50
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,21,0.07,0,0.1,,0.04,0.030000000000000006,75
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,28,0.05,0,0.1,,0.04,0.010000000000000002,25
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 A,43,0.08,0,0.1,,0.04,0.04,100
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 8 A,50,0.06,0,0.1,,0.04,0.019999999999999997,50
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 4 Day 1 A,63,0.08,0,0.1,,0.04,0.04,100
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 4 Day 8 A,71,0,0,0.1,,0.04,-0.04,-100
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,End of Treatment A,86,0.05,0,0.1,,0.04,0.010000000000000002,25
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 A,190,0.06,0,0.1,,0.04,0.019999999999999997,50
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-19,0.08,0,0.5,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.11,0,0.5,Y,0.11,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.12,0,0.5,,0.11,0.009999999999999995,9.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.22,0,0.5,,0.11,0.11,100
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.54,0,0.5,,0.11,0.43000000000000005,390.9
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,21,0.42,0,0.5,,0.11,0.31,281.8
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 8 A,28,6,0,0.5,,0.11,5.89,5354.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 A,43,0.94,0,0.5,,0.11,0.83,754.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 8 A,50,11.45,0,0.5,,0.11,11.34,10309.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 4 Day 1 A,63,2.32,0,0.5,,0.11,2.21,2009.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 4 Day 8 A,71,16.89,0,0.5,,0.11,16.78,15254.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment A,86,3.41,0,0.5,,0.11,3.3000000000000003,3000
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 A,190,0.01,0,0.5,,0.11,-0.1,-90.9
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-19,4.12,4.5,6,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.01,4.5,6,Y,4.01,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,4.02,4.5,6,,4.01,0.009999999999999787,0.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,3.93,4.5,6,,4.01,-0.07999999999999963,-2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,3.61,4.5,6,,4.01,-0.3999999999999999,-10
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,21,4.1,4.5,6,,4.01,0.08999999999999986,2.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,28,3.85,4.5,6,,4.01,-0.1599999999999997,-4
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 A,43,4,4.5,6,,4.01,-0.009999999999999787,-0.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 8 A,50,4.01,4.5,6,,4.01,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 A,63,3.82,4.5,6,,4.01,-0.18999999999999995,-4.7
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 8 A,71,3.59,4.5,6,,4.01,-0.41999999999999993,-10.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment A,86,3.48,4.5,6,,4.01,-0.5299999999999998,-13.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 A,190,3.31,4.5,6,,4.01,-0.6999999999999997,-17.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-19,38.8,41,53,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,38.6,41,53,Y,38.6,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,38.3,41,53,,38.6,-0.30000000000000426,-0.8
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,36.3,41,53,,38.6,-2.3000000000000043,-6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,33.1,41,53,,38.6,-5.5,-14.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,21,39.2,41,53,,38.6,0.6000000000000014,1.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,28,36.9,41,53,,38.6,-1.7000000000000028,-4.4
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 A,43,37.6,41,53,,38.6,-1,-2.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 8 A,50,37.4,41,53,,38.6,-1.2000000000000028,-3.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 A,63,36.1,41,53,,38.6,-2.5,-6.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 8 A,71,33.4,41,53,,38.6,-5.200000000000003,-13.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment A,86,32.8,41,53,,38.6,-5.800000000000004,-15
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 A,190,30.4,41,53,,38.6,-8.200000000000003,-21.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-19,13.1,13.5,17.5,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,12.8,13.5,17.5,Y,12.8,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,12.6,13.5,17.5,,12.8,-0.20000000000000107,-1.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,12.8,13.5,17.5,,12.8,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,11.6,13.5,17.5,,12.8,-1.200000000000001,-9.4
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,21,12.8,13.5,17.5,,12.8,0,0
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,28,12.1,13.5,17.5,,12.8,-0.7000000000000011,-5.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 A,43,12.6,13.5,17.5,,12.8,-0.20000000000000107,-1.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 8 A,50,12.6,13.5,17.5,,12.8,-0.20000000000000107,-1.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 A,63,11.9,13.5,17.5,,12.8,-0.9000000000000004,-7
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 8 A,71,11.2,13.5,17.5,,12.8,-1.6000000000000014,-12.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment A,86,10.8,13.5,17.5,,12.8,-2,-15.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 A,190,10.1,13.5,17.5,,12.8,-2.700000000000001,-21.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-19,0.9,1,4.8,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.03,1,4.8,Y,1.03,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.39,1,4.8,,1.03,-0.64,-62.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.19,1,4.8,,1.03,-0.8400000000000001,-81.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,1.92,1,4.8,,1.03,0.8899999999999999,86.4
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,21,1.35,1,4.8,,1.03,0.32000000000000006,31.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,28,2.25,1,4.8,,1.03,1.22,118.4
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 A,43,1.46,1,4.8,,1.03,0.42999999999999994,41.7
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 8 A,50,2.92,1,4.8,,1.03,1.89,183.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 4 Day 1 A,63,1.86,1,4.8,,1.03,0.8300000000000001,80.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 4 Day 8 A,71,3.16,1,4.8,,1.03,2.13,206.8
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment A,86,1.26,1,4.8,,1.03,0.22999999999999998,22.3
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 A,190,0.89,1,4.8,,1.03,-0.14,-13.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-19,0.35,0.1,0.9,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.36,0.1,0.9,Y,0.36,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.35,0.1,0.9,,0.36,-0.010000000000000009,-2.8
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.52,0.1,0.9,,0.36,0.16000000000000003,44.4
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,8,0.59,0.1,0.9,,0.36,0.22999999999999998,63.9
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,21,0.67,0.1,0.9,,0.36,0.31000000000000005,86.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,28,0.74,0.1,0.9,,0.36,0.38,105.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 A,43,0.4,0.1,0.9,,0.36,0.040000000000000036,11.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 8 A,50,0.76,0.1,0.9,,0.36,0.4,111.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 4 Day 1 A,63,0.48,0.1,0.9,,0.36,0.12,33.3
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 4 Day 8 A,71,1.26,0.1,0.9,,0.36,0.9,250
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment A,86,0.51,0.1,0.9,,0.36,0.15000000000000002,41.7
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 A,190,1.13,0.1,0.9,,0.36,0.7699999999999999,213.9
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-19,3.36,1.8,7.7,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.03,1.8,7.7,Y,3.03,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,4.47,1.8,7.7,,3.03,1.44,47.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,5.84,1.8,7.7,,3.03,2.81,92.7
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,8,3.32,1.8,7.7,,3.03,0.29000000000000004,9.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,21,5.75,1.8,7.7,,3.03,2.72,89.8
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,28,2.62,1.8,7.7,,3.03,-0.4099999999999997,-13.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 A,43,3.82,1.8,7.7,,3.03,0.79,26.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 8 A,50,3.72,1.8,7.7,,3.03,0.6900000000000004,22.8
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 4 Day 1 A,63,4.67,1.8,7.7,,3.03,1.6400000000000001,54.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 4 Day 8 A,71,2.96,1.8,7.7,,3.03,-0.06999999999999984,-2.3
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment A,86,3.76,1.8,7.7,,3.03,0.73,24.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 A,190,9,1.8,7.7,,3.03,5.970000000000001,197
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-19,226,150,400,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,208,150,400,Y,208,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,185,150,400,,208,-23,-11.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,160,150,400,,208,-48,-23.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,167,150,400,,208,-41,-19.7
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,21,277,150,400,,208,69,33.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,28,227,150,400,,208,19,9.1
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 A,43,268,150,400,,208,60,28.8
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 8 A,50,246,150,400,,208,38,18.3
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 4 Day 1 A,63,241,150,400,,208,33,15.9
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 4 Day 8 A,71,275,150,400,,208,67,32.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment A,86,242,150,400,,208,34,16.3
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 A,190,223,150,400,,208,15,7.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-19,4.73,3.5,10.8,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,4.58,3.5,10.8,Y,4.58,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,5.37,3.5,10.8,,4.58,0.79,17.2
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,6.82,3.5,10.8,,4.58,2.24,48.9
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,6.41,3.5,10.8,,4.58,1.83,40
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,21,8.27,3.5,10.8,,4.58,3.6899999999999995,80.6
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,28,11.67,3.5,10.8,,4.58,7.09,154.8
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 A,43,6.71,3.5,10.8,,4.58,2.13,46.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 8 A,50,18.95,3.5,10.8,,4.58,14.37,313.8
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 4 Day 1 A,63,9.42,3.5,10.8,,4.58,4.84,105.7
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 4 Day 8 A,71,24.27,3.5,10.8,,4.58,19.689999999999998,429.9
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment A,86,9,3.5,10.8,,4.58,4.42,96.5
10A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 A,190,11.31,3.5,10.8,,4.58,6.73,146.9
10A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-19,63.55,NA,NA,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,64.56,NA,NA,Y,64.56,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,21,59.87,NA,NA,,64.56,-4.690000000000005,-7.3
10A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 A,43,70.49,NA,NA,,64.56,5.929999999999993,9.2
10A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 4 Day 1 A,63,92.93,NA,NA,,64.56,28.370000000000005,43.9
10A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment A,86,95.46,NA,NA,,64.56,30.89999999999999,47.9
10A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 A,190,141.1,NA,NA,,64.56,76.53999999999999,118.6
10A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-19,1.54,0.44,7.11,,NA,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.41,0.44,7.11,Y,1.41,NA,NA
10A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,21,1.54,0.44,7.11,,1.41,0.13000000000000012,9.2
10A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 A,43,1.51,0.44,7.11,,1.41,0.10000000000000009,7.1
10A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 A,63,1.7,0.44,7.11,,1.41,0.29000000000000004,20.6
10A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,86,1.42,0.44,7.11,,1.41,0.010000000000000009,0.7
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 2 Day 1 B,29,189,NA,NA,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-7,10,1,45,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,13,1,45,Y,13,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,29,24,1,45,,13,11,84.6
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,57,11,1,45,,13,-2,-15.4
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-7,3.1,3.5,4.9,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.2,3.5,4.9,Y,3.2,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,29,2.8,3.5,4.9,,3.2,-0.40000000000000036,-12.5
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment B,57,3.2,3.5,4.9,,3.2,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-7,78,38,126,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,89,38,126,Y,89,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,29,69,38,126,,89,-20,-22.5
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,57,85,38,126,,89,-4,-4.5
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-7,13,1,35,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,15,1,35,Y,15,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,29,28,1,35,,15,13,86.7
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,57,24,1,35,,15,9,60
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-7,19,6,23,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Baseline,1,18,6,23,Y,18,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 B,29,12,6,23,,18,-6,-33.3
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,End of Treatment B,57,14,6,23,,18,-4,-22.2
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-7,25,22,30,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,23,22,30,Y,23,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 B,29,21,22,30,,23,-2,-8.7
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment B,57,24,22,30,,23,1,4.3
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-7,8.8,8.5,10.5,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8.7,8.5,10.5,Y,8.7,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,29,7.8,8.5,10.5,,8.7,-0.8999999999999995,-10.3
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment B,57,8.1,8.5,10.5,,8.7,-0.5999999999999996,-6.9
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-7,107,96,108,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,107,96,108,Y,107,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,29,106,96,108,,107,-1,-0.9
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment B,57,106,96,108,,107,-1,-0.9
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-7,1.34,0.7,1.3,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1.31,0.7,1.3,Y,1.31,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,29,1.02,0.7,1.3,,1.31,-0.29000000000000004,-22.1
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment B,57,1.09,0.7,1.3,,1.31,-0.21999999999999997,-16.8
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-7,104,60,100,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,102,60,100,Y,102,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 B,29,94,60,100,,102,-8,-7.8
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,End of Treatment B,57,109,60,100,,102,7,6.9
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-7,183,100,220,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,196,100,220,Y,196,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,29,304,100,220,,196,108,55.1
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,57,351,100,220,,196,155,79.1
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-7,4.1,3.5,5.2,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.5,3.5,5.2,Y,4.5,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,29,4,3.5,5.2,,4.5,-0.5,-11.1
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment B,57,3.7,3.5,5.2,,4.5,-0.7999999999999998,-17.8
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-7,141,135,145,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,140,135,145,Y,140,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 B,29,139,135,145,,140,-1,-0.7
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,End of Treatment B,57,138,135,145,,140,-2,-1.4
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-7,0.4,0.1,1.2,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.4,0.1,1.2,Y,0.4,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,29,0.6,0.1,1.2,,0.4,0.19999999999999996,50
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment B,57,0.9,0.1,1.2,,0.4,0.5,125
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-7,6.3,6,8.3,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.6,6,8.3,Y,6.6,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 B,29,6.8,6,8.3,,6.6,0.20000000000000018,3
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment B,57,6.9,6,8.3,,6.6,0.3000000000000007,4.5
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-7,43.8,25.4,34.9,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,35.4,25.4,34.9,Y,35.4,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,29,50.3,25.4,34.9,,35.4,14.899999999999999,42.1
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,57,46.4,25.4,34.9,,35.4,11,31.1
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-7,2.3,2,3,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.6,2,3,Y,1.6,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,29,3,2,3,,1.6,1.4,87.5
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,57,2.7,2,3,,1.6,1.1,68.8
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-7,24.5,12.3,14.9,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,18.3,12.3,14.9,Y,18.3,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,29,30.2,12.3,14.9,,18.3,11.899999999999999,65
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment B,57,28.1,12.3,14.9,,18.3,9.8,53.6
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 B,1,0,0,0.2,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 B,29,0,0,0.2,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,End of Treatment B,57,0,0,0.2,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 B,1,0.1,0,0.6,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.6,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 B,29,0.2,0,0.6,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment B,57,0.1,0,0.6,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 B,1,3.81,4.5,6,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.81,4.5,6,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,29,3.2,4.5,6,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,57,2.95,4.5,6,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 B,1,32.8,42,52,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,32.8,42,52,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,29,27,42,52,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment B,57,25.5,42,52,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 B,1,10.9,13.9,16.3,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,10.9,13.9,16.3,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,29,8.9,13.9,16.3,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment B,57,8.6,13.9,16.3,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 B,1,0.9,1,4.5,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.9,1,4.5,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 B,29,0.8,1,4.5,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment B,57,1,1,4.5,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 B,1,0.3,0.2,1,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.3,0.2,1,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 B,29,0.4,0.2,1,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,End of Treatment B,57,0.2,0.2,1,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 B,1,2.5,1.9,8,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,2.5,1.9,8,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 B,29,3.1,1.9,8,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment B,57,2.9,1.9,8,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 B,1,103,150,450,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,103,150,450,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,29,71,150,450,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment B,57,64,150,450,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,TESTR,Baseline,1,14.39,300,1080,Y,14.39,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 B,1,3.8,4.5,11,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,3.8,4.5,11,Y,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 B,29,4.5,4.5,11,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment B,57,4.2,4.5,11,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,,-7,2103,NA,NA,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,2651,NA,NA,Y,2651,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,29,2803,NA,NA,,2651,152,5.7
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment B,57,4229,NA,NA,,2651,1578,59.5
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),End of Treatment B,57,0.77,0.8,1.5,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-7,3.6,0.4,4.2,,NA,NA,NA
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,4.59,0.4,4.2,Y,4.59,0,0
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,29,3.48,0.4,4.2,,4.59,-1.1099999999999999,-24.2
10B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,57,6,0.4,4.2,,4.59,1.4100000000000001,30.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,23,NA,NA,Y,23,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,29,20,NA,NA,,23,-3,-13
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 C,57,28,NA,NA,,23,5,21.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 3 Day 1 C,85,71,NA,NA,,23,48,208.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 4 Day 1 C,113,59,NA,NA,,23,36,156.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-6,12,3,61,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,16,3,61,Y,16,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,19,3,61,,16,3,18.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,15,21,3,61,,16,5,31.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,15,3,61,,16,-1,-6.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,29,14,3,61,,16,-2,-12.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,40,13,3,61,,16,-3,-18.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 C,57,14,3,61,,16,-2,-12.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 C,85,13,3,61,,16,-3,-18.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 C,113,10,3,61,,16,-6,-37.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 C,141,48,3,61,,16,32,200
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-6,3.9,3.8,5.5,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.9,3.8,5.5,Y,3.9,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,3.8,3.8,5.5,,3.9,-0.10000000000000009,-2.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,15,3.8,3.8,5.5,,3.9,-0.10000000000000009,-2.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,3.9,3.8,5.5,,3.9,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,29,3.7,3.8,5.5,,3.9,-0.19999999999999973,-5.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,40,3.8,3.8,5.5,,3.9,-0.10000000000000009,-2.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,57,3.7,3.8,5.5,,3.9,-0.19999999999999973,-5.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 C,85,3.8,3.8,5.5,,3.9,-0.10000000000000009,-2.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 4 Day 1 C,113,3.8,3.8,5.5,,3.9,-0.10000000000000009,-2.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 5 Day 1 C,141,3.7,3.8,5.5,,3.9,-0.19999999999999973,-5.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-6,74,33,98,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,76,33,98,Y,76,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,78,33,98,,76,2,2.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,15,79,33,98,,76,3,3.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,93,33,98,,76,17,22.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,29,108,33,98,,76,32,42.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,40,91,33,98,,76,15,19.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,57,85,33,98,,76,9,11.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 C,85,87,33,98,,76,11,14.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 C,113,84,33,98,,76,8,10.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 C,141,104,33,98,,76,28,36.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-6,25,5,38,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,24,5,38,Y,24,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,24,5,38,,24,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,15,23,5,38,,24,-1,-4.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,22,5,38,,24,-2,-8.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,29,23,5,38,,24,-1,-4.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,40,30,5,38,,24,6,25
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,57,22,5,38,,24,-2,-8.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 C,85,41,5,38,,24,17,70.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 C,113,36,5,38,,24,12,50
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 C,141,31,5,38,,24,7,29.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-6,24,7,25,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,23,7,25,Y,23,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,31,7,25,,23,8,34.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,15,33,7,25,,23,10,43.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,19,7,25,,23,-4,-17.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,29,20,7,25,,23,-3,-13
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,40,19,7,25,,23,-4,-17.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 C,57,26,7,25,,23,3,13
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 C,85,24,7,25,,23,1,4.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 4 Day 1 C,113,20,7,25,,23,-3,-13
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 5 Day 1 C,141,23,7,25,,23,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-6,22,21,31,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,25,21,31,Y,25,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,25,21,31,,25,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,15,26,21,31,,25,1,4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,26,21,31,,25,1,4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,29,25,21,31,,25,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,40,24,21,31,,25,-1,-4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 C,57,25,21,31,,25,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 C,85,25,21,31,,25,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 4 Day 1 C,113,27,21,31,,25,2,8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 5 Day 1 C,141,20,21,31,,25,-5,-20
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-6,9.6,8.7,10.1,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.8,8.7,10.1,Y,9.8,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,9.9,8.7,10.1,,9.8,0.09999999999999964,1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,15,9.9,8.7,10.1,,9.8,0.09999999999999964,1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,8.6,8.7,10.1,,9.8,-1.200000000000001,-12.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,29,9.3,8.7,10.1,,9.8,-0.5,-5.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,40,9.3,8.7,10.1,,9.8,-0.5,-5.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,57,9.1,8.7,10.1,,9.8,-0.7000000000000011,-7.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 C,85,8.7,8.7,10.1,,9.8,-1.1000000000000014,-11.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 C,113,9.1,8.7,10.1,,9.8,-0.7000000000000011,-7.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 C,141,9,8.7,10.1,,9.8,-0.8000000000000007,-8.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-6,104,99,107,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,99,99,107,Y,99,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,104,99,107,,99,5,5.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,15,101,99,107,,99,2,2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,103,99,107,,99,4,4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,29,104,99,107,,99,5,5.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,40,99,99,107,,99,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,57,103,99,107,,99,4,4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 C,85,100,99,107,,99,1,1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 C,113,101,99,107,,99,2,2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 C,141,107,99,107,,99,8,8.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-6,0.8,0.7,1.3,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1.05,0.7,1.3,Y,1.05,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,0.92,0.7,1.3,,1.05,-0.13,-12.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,15,1.31,0.7,1.3,,1.05,0.26,24.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,0.85,0.7,1.3,,1.05,-0.20000000000000007,-19
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,29,0.88,0.7,1.3,,1.05,-0.17000000000000004,-16.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,40,0.9,0.7,1.3,,1.05,-0.15000000000000002,-14.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,57,0.85,0.7,1.3,,1.05,-0.20000000000000007,-19
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 C,85,0.84,0.7,1.3,,1.05,-0.21000000000000008,-20
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 C,113,0.84,0.7,1.3,,1.05,-0.21000000000000008,-20
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 C,141,0.78,0.7,1.3,,1.05,-0.27,-25.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-6,97,63,130,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,87,63,130,Y,87,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,84,63,130,,87,-3,-3.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,15,96,63,130,,87,9,10.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,77,63,130,,87,-10,-11.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,29,92,63,130,,87,5,5.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,40,98,63,130,,87,11,12.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 C,57,94,63,130,,87,7,8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 C,85,106,63,130,,87,19,21.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 4 Day 1 C,113,94,63,130,,87,7,8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 5 Day 1 C,141,83,63,130,,87,-4,-4.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-6,228,100,210,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,226,100,210,Y,226,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,209,100,210,,226,-17,-7.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,15,202,100,210,,226,-24,-10.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,216,100,210,,226,-10,-4.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,29,205,100,210,,226,-21,-9.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,40,274,100,210,,226,48,21.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 C,57,201,100,210,,226,-25,-11.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 C,85,327,100,210,,226,101,44.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 C,113,275,100,210,,226,49,21.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 C,141,204,100,210,,226,-22,-9.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-6,3.6,3.5,5.1,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,3.5,3.5,5.1,Y,3.5,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,3.8,3.5,5.1,,3.5,0.2999999999999998,8.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,15,3.9,3.5,5.1,,3.5,0.3999999999999999,11.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,3.4,3.5,5.1,,3.5,-0.10000000000000009,-2.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,29,3.9,3.5,5.1,,3.5,0.3999999999999999,11.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,40,4,3.5,5.1,,3.5,0.5,14.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,57,3.6,3.5,5.1,,3.5,0.10000000000000009,2.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 C,85,3.6,3.5,5.1,,3.5,0.10000000000000009,2.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 C,113,4,3.5,5.1,,3.5,0.5,14.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 C,141,3.9,3.5,5.1,,3.5,0.3999999999999999,11.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-6,140,136,145,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,137,136,145,Y,137,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,140,136,145,,137,3,2.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,15,138,136,145,,137,1,0.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,138,136,145,,137,1,0.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,29,140,136,145,,137,3,2.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,40,136,136,145,,137,-1,-0.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 C,57,140,136,145,,137,3,2.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 C,85,135,136,145,,137,-2,-1.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 4 Day 1 C,113,139,136,145,,137,2,1.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 5 Day 1 C,141,141,136,145,,137,4,2.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-6,0.5,0.1,1.4,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.7,0.1,1.4,Y,0.7,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.3,0.1,1.4,,0.7,-0.39999999999999997,-57.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,15,0.4,0.1,1.4,,0.7,-0.29999999999999993,-42.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.3,0.1,1.4,,0.7,-0.39999999999999997,-57.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,29,0.2,0.1,1.4,,0.7,-0.49999999999999994,-71.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,40,0.4,0.1,1.4,,0.7,-0.29999999999999993,-42.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,57,0.4,0.1,1.4,,0.7,-0.29999999999999993,-42.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 C,85,0.4,0.1,1.4,,0.7,-0.29999999999999993,-42.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 4 Day 1 C,113,0.4,0.1,1.4,,0.7,-0.29999999999999993,-42.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 5 Day 1 C,141,0.3,0.1,1.4,,0.7,-0.39999999999999997,-57.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-6,6.7,6.3,8.1,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.2,6.3,8.1,Y,7.2,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,6.9,6.3,8.1,,7.2,-0.2999999999999998,-4.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,15,7.1,6.3,8.1,,7.2,-0.10000000000000053,-1.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,7.1,6.3,8.1,,7.2,-0.10000000000000053,-1.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,29,6.5,6.3,8.1,,7.2,-0.7000000000000002,-9.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,40,7,6.3,8.1,,7.2,-0.20000000000000018,-2.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 C,57,7.1,6.3,8.1,,7.2,-0.10000000000000053,-1.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 C,85,6.6,6.3,8.1,,7.2,-0.6000000000000005,-8.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 4 Day 1 C,113,6.8,6.3,8.1,,7.2,-0.40000000000000036,-5.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 5 Day 1 C,141,6.5,6.3,8.1,,7.2,-0.7000000000000002,-9.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,UREA,Cycle 4 Day 1 C,113,6.8,NA,NA,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-6,26.6,25.5,36,Y,26.6,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-6,1,0.9,1.3,Y,1,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,-6,10.7,12.1,15.2,Y,10.7,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-6,0,0,0.1,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.1,Y,0,0,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0.6,0,0.1,,0,0.6,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,15,0.1,0,0.1,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.1,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,29,0.1,0,0.1,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 C,40,0.1,0,0.1,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 C,57,0,0,0.1,,0,0,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 C,85,0,0,0.1,,0,0,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 4 Day 1 C,113,0,0,0.1,,0,0,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 5 Day 1 C,141,0,0,0.1,,0,0,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-6,0.1,0,0.4,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0,0,0.4,Y,0,0,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0.1,0,0.4,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,15,0.1,0,0.4,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0.1,0,0.4,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,29,0.2,0,0.4,,0,0.2,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 C,40,0,0,0.4,,0,0,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 C,57,0.1,0,0.4,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 C,85,0,0,0.4,,0,0,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 4 Day 1 C,113,0.1,0,0.4,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 5 Day 1 C,141,0.1,0,0.4,,0,0.1,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-6,3.71,4,6,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.95,4,6,Y,3.95,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,3.83,4,6,,3.95,-0.1200000000000001,-3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,15,3.85,4,6,,3.95,-0.10000000000000009,-2.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.77,4,6,,3.95,-0.18000000000000016,-4.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,29,11.3,4,6,,3.95,7.3500000000000005,186.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,40,3.54,4,6,,3.95,-0.41000000000000014,-10.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,57,3.45,4,6,,3.95,-0.5,-12.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 C,85,3.58,4,6,,3.95,-0.3700000000000001,-9.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 C,113,3.45,4,6,,3.95,-0.5,-12.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 C,141,3.05,4,6,,3.95,-0.9000000000000004,-22.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-6,32,43.5,48,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,34.7,43.5,48,Y,34.7,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,33.5,43.5,48,,34.7,-1.2000000000000028,-3.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,15,33,43.5,48,,34.7,-1.7000000000000028,-4.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,32.4,43.5,48,,34.7,-2.3000000000000043,-6.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,29,31.6,43.5,48,,34.7,-3.1000000000000014,-8.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,40,30.2,43.5,48,,34.7,-4.5000000000000036,-13
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,57,28.9,43.5,48,,34.7,-5.800000000000004,-16.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 C,85,29.4,43.5,48,,34.7,-5.300000000000004,-15.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 C,113,28.8,43.5,48,,34.7,-5.900000000000002,-17
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 C,141,24.8,43.5,48,,34.7,-9.900000000000002,-28.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-6,10.3,13.9,16.3,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.1,13.9,16.3,Y,11.1,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,10.5,13.9,16.3,,11.1,-0.5999999999999996,-5.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,15,10.6,13.9,16.3,,11.1,-0.5,-4.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,10.4,13.9,16.3,,11.1,-0.6999999999999993,-6.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,29,9.9,13.9,16.3,,11.1,-1.1999999999999993,-10.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,40,9.5,13.9,16.3,,11.1,-1.5999999999999996,-14.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,57,9,13.9,16.3,,11.1,-2.0999999999999996,-18.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 C,85,9.2,13.9,16.3,,11.1,-1.9000000000000004,-17.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 C,113,8.9,13.9,16.3,,11.1,-2.1999999999999993,-19.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 C,141,7.7,13.9,16.3,,11.1,-3.3999999999999995,-30.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-6,1,0.9,2.6,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.9,0.9,2.6,Y,0.9,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,1.5,0.9,2.6,,0.9,0.6,66.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,15,1.6,0.9,2.6,,0.9,0.7000000000000001,77.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,1.5,0.9,2.6,,0.9,0.6,66.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,29,1.5,0.9,2.6,,0.9,0.6,66.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 C,40,1.3,0.9,2.6,,0.9,0.4,44.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 C,57,1,0.9,2.6,,0.9,0.09999999999999998,11.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 C,85,0.8,0.9,2.6,,0.9,-0.09999999999999998,-11.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 4 Day 1 C,113,1,0.9,2.6,,0.9,0.09999999999999998,11.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 5 Day 1 C,141,1.2,0.9,2.6,,0.9,0.29999999999999993,33.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-6,0.4,0.1,0.9,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.7,0.1,0.9,Y,0.7,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,2.2,0.1,0.9,,0.7,1.5000000000000002,214.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,15,5.9,0.1,0.9,,0.7,5.2,742.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,1.3,0.1,0.9,,0.7,0.6000000000000001,85.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,29,3.6,0.1,0.9,,0.7,2.9000000000000004,414.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 C,40,2,0.1,0.9,,0.7,1.3,185.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 C,57,0.4,0.1,0.9,,0.7,-0.29999999999999993,-42.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 C,85,0.3,0.1,0.9,,0.7,-0.39999999999999997,-57.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 4 Day 1 C,113,0.6,0.1,0.9,,0.7,-0.09999999999999998,-14.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 5 Day 1 C,141,0.4,0.1,0.9,,0.7,-0.29999999999999993,-42.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-6,3.1,1.8,6.5,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,6.4,1.8,6.5,Y,6.4,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,5,1.8,6.5,,6.4,-1.4000000000000004,-21.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,15,7.7,1.8,6.5,,6.4,1.2999999999999998,20.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,3.3,1.8,6.5,,6.4,-3.1000000000000005,-48.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,29,5.8,1.8,6.5,,6.4,-0.6000000000000005,-9.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 C,40,3.3,1.8,6.5,,6.4,-3.1000000000000005,-48.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 C,57,4.4,1.8,6.5,,6.4,-2,-31.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 C,85,2.8,1.8,6.5,,6.4,-3.6000000000000005,-56.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 4 Day 1 C,113,4.4,1.8,6.5,,6.4,-2,-31.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 5 Day 1 C,141,3.9,1.8,6.5,,6.4,-2.5000000000000004,-39.1
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-6,201,150,450,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,228,150,450,Y,228,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,304,150,450,,228,76,33.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,15,301,150,450,,228,73,32
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,369,150,450,,228,141,61.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,29,314,150,450,,228,86,37.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,40,202,150,450,,228,-26,-11.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,57,261,150,450,,228,33,14.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 C,85,176,150,450,,228,-52,-22.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 4 Day 1 C,113,184,150,450,,228,-44,-19.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 5 Day 1 C,141,159,150,450,,228,-69,-30.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-6,4.6,4,11,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,8.1,4,11,Y,8.1,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,8.9,4,11,,8.1,0.8000000000000007,9.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,15,15.7,4,11,,8.1,7.6,93.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,6.3,4,11,,8.1,-1.7999999999999998,-22.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,29,11.3,4,11,,8.1,3.200000000000001,39.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,40,6.7,4,11,,8.1,-1.3999999999999995,-17.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 C,57,5.9,4,11,,8.1,-2.1999999999999993,-27.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 C,85,3.9,4,11,,8.1,-4.199999999999999,-51.9
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 4 Day 1 C,113,6.1,4,11,,8.1,-2,-24.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 5 Day 1 C,141,5.7,4,11,,8.1,-2.3999999999999995,-29.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-6,1352.96,NA,NA,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,3945.5,NA,NA,Y,3945.5,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,1635.97,NA,NA,,3945.5,-2309.5299999999997,-58.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,29,1568.58,NA,NA,,3945.5,-2376.92,-60.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,57,2390.63,NA,NA,,3945.5,-1554.87,-39.4
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 C,85,3110.55,NA,NA,,3945.5,-834.9499999999998,-21.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 4 Day 1 C,113,3245.31,NA,NA,,3945.5,-700.19,-17.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 5 Day 1 C,141,3728.01,NA,NA,,3945.5,-217.48999999999978,-5.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-6,3.37,0.4,4,,NA,NA,NA
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,3.02,0.4,4,Y,3.02,0,0
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,3,0.4,4,,3.02,-0.020000000000000018,-0.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,15,3.36,0.4,4,,3.02,0.33999999999999986,11.3
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,2.21,0.4,4,,3.02,-0.81,-26.8
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,29,2.34,0.4,4,,3.02,-0.6800000000000002,-22.5
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,40,2.73,0.4,4,,3.02,-0.29000000000000004,-9.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,57,1.85,0.4,4,,3.02,-1.17,-38.7
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 C,85,2.64,0.4,4,,3.02,-0.3799999999999999,-12.6
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 C,113,3.63,0.4,4,,3.02,0.6099999999999999,20.2
10C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 C,141,2.8,0.4,4,,3.02,-0.2200000000000002,-7.3
11A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 A,22,10,NA,NA,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-14,45,1,45,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,50,1,45,Y,50,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,185,1,45,,50,135,270
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,22,34,1,45,,50,-16,-32
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,27,71,1,45,,50,21,42
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,36,38,1,45,,50,-12,-24
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 A,134,53,1,45,,50,3,6
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-14,4,3.5,4.9,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.4,3.5,4.9,Y,3.4,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,3,3.5,4.9,,3.4,-0.3999999999999999,-11.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,22,3.7,3.5,4.9,,3.4,0.30000000000000027,8.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,27,3.1,3.5,4.9,,3.4,-0.2999999999999998,-8.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment A,36,3.6,3.5,4.9,,3.4,0.20000000000000018,5.9
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 A,134,3.7,3.5,4.9,,3.4,0.30000000000000027,8.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-14,141,38,126,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,134,38,126,Y,134,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,192,38,126,,134,58,43.3
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,22,202,38,126,,134,68,50.7
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,27,180,38,126,,134,46,34.3
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,36,179,38,126,,134,45,33.6
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 A,134,202,38,126,,134,68,50.7
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-14,48,1,35,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,55,1,35,Y,55,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,104,1,35,,55,49,89.1
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,22,42,1,35,,55,-13,-23.6
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,27,28,1,35,,55,-27,-49.1
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,36,33,1,35,,55,-22,-40
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 A,134,71,1,35,,55,16,29.1
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-14,16,6,23,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,19,6,23,Y,19,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,8,12,6,23,,19,-7,-36.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,22,22,6,23,,19,3,15.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 8 A,27,20,6,23,,19,1,5.3
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,End of Treatment A,36,27,6,23,,19,8,42.1
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 A,134,26,6,23,,19,7,36.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-14,30,22,30,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,29,22,30,Y,29,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,28,22,30,,29,-1,-3.4
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,22,34,22,30,,29,5,17.2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,27,27,22,30,,29,-2,-6.9
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment A,36,25,22,30,,29,-4,-13.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 A,134,24,22,30,,29,-5,-17.2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-14,10.7,8.5,10.5,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8.8,8.5,10.5,Y,8.8,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,9.2,8.5,10.5,,8.8,0.3999999999999986,4.5
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,22,10.1,8.5,10.5,,8.8,1.299999999999999,14.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,27,9.5,8.5,10.5,,8.8,0.6999999999999993,8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment A,36,9.4,8.5,10.5,,8.8,0.5999999999999996,6.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 A,134,9.4,8.5,10.5,,8.8,0.5999999999999996,6.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-14,104,96,108,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,102,96,108,Y,102,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,104,96,108,,102,2,2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,22,104,96,108,,102,2,2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,27,105,96,108,,102,3,2.9
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment A,36,99,96,108,,102,-3,-2.9
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 A,134,103,96,108,,102,1,1
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-14,0.97,0.7,1.3,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.79,0.7,1.3,Y,0.79,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,0.81,0.7,1.3,,0.79,0.020000000000000018,2.5
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,22,0.85,0.7,1.3,,0.79,0.05999999999999994,7.6
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,27,0.77,0.7,1.3,,0.79,-0.020000000000000018,-2.5
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment A,36,0.79,0.7,1.3,,0.79,0,0
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 A,134,0.86,0.7,1.3,,0.79,0.06999999999999995,8.9
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-14,101,60,100,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,92,60,100,Y,92,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 A,8,90,60,100,,92,-2,-2.2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,22,85,60,100,,92,-7,-7.6
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,27,124,60,100,,92,32,34.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment A,36,134,60,100,,92,42,45.7
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 A,134,103,60,100,,92,11,12
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-14,266,100,220,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,304,100,220,Y,304,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,8,282,100,220,,304,-22,-7.2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,22,244,100,220,,304,-60,-19.7
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,27,224,100,220,,304,-80,-26.3
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment A,36,205,100,220,,304,-99,-32.6
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-14,5.1,3.5,5.2,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,3.8,3.5,5.2,Y,3.8,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,4.9,3.5,5.2,,3.8,1.1000000000000005,28.9
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,22,4.8,3.5,5.2,,3.8,1,26.3
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,27,5.2,3.5,5.2,,3.8,1.4000000000000004,36.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment A,36,4.3,3.5,5.2,,3.8,0.5,13.2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 A,134,4.4,3.5,5.2,,3.8,0.6000000000000005,15.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-14,145,135,145,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,139,135,145,Y,139,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,8,139,135,145,,139,0,0
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,22,142,135,145,,139,3,2.2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,27,140,135,145,,139,1,0.7
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment A,36,135,135,145,,139,-4,-2.9
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 A,134,136,135,145,,139,-3,-2.2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-14,0.6,0.1,1.2,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.6,0.1,1.2,Y,0.6,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.6,0.1,1.2,,0.6,0,0
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,22,0.5,0.1,1.2,,0.6,-0.09999999999999998,-16.7
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,27,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment A,36,0.6,0.1,1.2,,0.6,0,0
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 A,134,0.5,0.1,1.2,,0.6,-0.09999999999999998,-16.7
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-14,7.6,6,8.3,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.5,6,8.3,Y,6.5,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,8,6,6,8.3,,6.5,-0.5,-7.7
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,22,7.2,6,8.3,,6.5,0.7000000000000002,10.8
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,27,6.3,6,8.3,,6.5,-0.20000000000000018,-3.1
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment A,36,6.9,6,8.3,,6.5,0.40000000000000036,6.2
11A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 A,134,6.6,6,8.3,,6.5,0.09999999999999964,1.5
11A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-14,28.2,25.4,34.9,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,28.3,25.4,34.9,Y,28.3,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 A,8,27,25.4,34.9,,28.3,-1.3000000000000007,-4.6
11A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-14,0.9,2,3,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1,2,3,Y,1,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 A,8,0.9,2,3,,1,-0.09999999999999998,-10
11A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-14,12.3,12.3,14.9,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.7,12.3,14.9,Y,12.7,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 A,8,12.2,12.3,14.9,,12.7,-0.5,-3.9
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-14,0.1,0,0.2,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.1,0,0.2,Y,0.1,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0,0,0.2,,0.1,-0.1,-100
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0,0,0.2,,0.1,-0.1,-100
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,8,0.1,0,0.2,,0.1,0,0
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,22,0,0,0.2,,0.1,-0.1,-100
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,27,0.1,0,0.2,,0.1,0,0
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,End of Treatment A,36,0,0,0.2,,0.1,-0.1,-100
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 A,134,0.1,0,0.2,,0.1,0,0
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-14,0.2,0,0.6,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.2,0,0.6,Y,0.2,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.2,0,0.6,,0.2,0,0
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.1,0,0.6,,0.2,-0.1,-50
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.9,0,0.6,,0.2,0.7,350
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,22,0.8,0,0.6,,0.2,0.6000000000000001,300
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 8 A,27,2.8,0,0.6,,0.2,2.5999999999999996,1300
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment A,36,0,0,0.6,,0.2,-0.2,-100
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 A,134,0,0,0.6,,0.2,-0.2,-100
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-14,4.47,4.5,6,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.05,4.5,6,Y,4.05,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,4.02,4.5,6,,4.05,-0.03000000000000025,-0.7
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,4.24,4.5,6,,4.05,0.1900000000000004,4.7
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,3.66,4.5,6,,4.05,-0.3899999999999997,-9.6
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,22,4.05,4.5,6,,4.05,0,0
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,27,3.73,4.5,6,,4.05,-0.31999999999999984,-7.9
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment A,36,4.13,4.5,6,,4.05,0.08000000000000007,2
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 A,134,3.29,4.5,6,,4.05,-0.7599999999999998,-18.8
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-14,43.5,42,52,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,39,42,52,Y,39,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,38.8,42,52,,39,-0.20000000000000284,-0.5
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,40.9,42,52,,39,1.8999999999999986,4.9
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,35.1,42,52,,39,-3.8999999999999986,-10
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,22,39.3,42,52,,39,0.29999999999999716,0.8
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,27,35.6,42,52,,39,-3.3999999999999986,-8.7
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment A,36,39.4,42,52,,39,0.3999999999999986,1
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 A,134,32.2,42,52,,39,-6.799999999999997,-17.4
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-14,15.1,13.9,16.3,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,13.4,13.9,16.3,Y,13.4,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,13.3,13.9,16.3,,13.4,-0.09999999999999964,-0.7
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,14,13.9,16.3,,13.4,0.5999999999999996,4.5
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,12.1,13.9,16.3,,13.4,-1.3000000000000007,-9.7
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,22,13.3,13.9,16.3,,13.4,-0.09999999999999964,-0.7
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,27,12,13.9,16.3,,13.4,-1.4000000000000004,-10.4
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment A,36,13.5,13.9,16.3,,13.4,0.09999999999999964,0.7
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 A,134,11.2,13.9,16.3,,13.4,-2.200000000000001,-16.4
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-14,1.4,1,4.5,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.9,1,4.5,Y,0.9,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.5,1,4.5,,0.9,-0.4,-44.4
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.2,1,4.5,,0.9,-0.7,-77.8
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,2.8,1,4.5,,0.9,1.9,211.1
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,22,1.4,1,4.5,,0.9,0.4999999999999999,55.6
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,27,1.8,1,4.5,,0.9,0.9,100
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment A,36,0.8,1,4.5,,0.9,-0.09999999999999998,-11.1
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 A,134,1.1,1,4.5,,0.9,0.20000000000000007,22.2
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-14,0.7,0.2,1,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.5,0.2,1,Y,0.5,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.6,0.2,1,,0.5,0.09999999999999998,20
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.4,0.2,1,,0.5,-0.09999999999999998,-20
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,8,1,0.2,1,,0.5,0.5,100
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,22,0.6,0.2,1,,0.5,0.09999999999999998,20
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,27,0.9,0.2,1,,0.5,0.4,80
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment A,36,0.2,0.2,1,,0.5,-0.3,-60
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 A,134,1,0.2,1,,0.5,0.5,100
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-14,4.6,1.9,8,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4.1,1.9,8,Y,4.1,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,5,1.9,8,,4.1,0.9000000000000004,22
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,5.5,1.9,8,,4.1,1.4000000000000004,34.1
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,8,4.6,1.9,8,,4.1,0.5,12.2
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,22,3.8,1.9,8,,4.1,-0.2999999999999998,-7.3
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,27,9.1,1.9,8,,4.1,5,122
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment A,36,7,1.9,8,,4.1,2.9000000000000004,70.7
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 A,134,6.2,1.9,8,,4.1,2.1000000000000005,51.2
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-14,157,150,450,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,146,150,450,Y,146,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,129,150,450,,146,-17,-11.6
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,117,150,450,,146,-29,-19.9
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,171,150,450,,146,25,17.1
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,22,181,150,450,,146,35,24
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,27,153,150,450,,146,7,4.8
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment A,36,216,150,450,,146,70,47.9
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 A,134,178,150,450,,146,32,21.9
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,TESTR,Baseline,-14,28.2,300,1080,Y,28.2,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-14,7,4.5,11,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.7,4.5,11,Y,5.7,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,6.3,4.5,11,,5.7,0.5999999999999996,10.5
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,6.3,4.5,11,,5.7,0.5999999999999996,10.5
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,9.4,4.5,11,,5.7,3.7,64.9
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,22,6.6,4.5,11,,5.7,0.8999999999999995,15.8
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,27,14.7,4.5,11,,5.7,9,157.9
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment A,36,8.1,4.5,11,,5.7,2.3999999999999995,42.1
11A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 A,134,8.4,4.5,11,,5.7,2.7,47.4
11A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-14,0.25,NA,NA,,NA,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,0.24,NA,NA,Y,0.24,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,22,0.4,NA,NA,,0.24,0.16000000000000003,66.7
11A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment A,36,0.68,NA,NA,,0.24,0.44000000000000006,183.3
11A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 A,134,0.63,NA,NA,,0.24,0.39,162.5
11A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,-23,0.8,0.4,4.2,Y,0.8,NA,NA
11A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,22,1.06,0.4,4.2,,0.8,0.26,32.5
11A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,36,0.02,0.4,4.2,,0.8,-0.78,-97.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,,CTC,Baseline,1,6,NA,NA,Y,6,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,,CTC,Cycle 2 Day 1 B,30,3,NA,NA,,6,-3,-50
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,,CTC,Cycle 3 Day 1 B,58,14,NA,NA,,6,8,133.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,,CTC,Cycle 4 Day 1 B,86,16,NA,NA,,6,10,166.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,,CTC,End of Treatment B,114,28,NA,NA,,6,22,366.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),,-11,29,1,45,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,31,1,45,Y,31,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,9,39,1,45,,31,8,25.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,16,49,1,45,,31,18,58.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,30,34,1,45,,31,3,9.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,58,45,1,45,,31,14,45.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 B,86,65,1,45,,31,34,109.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,114,57,1,45,,31,26,83.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 B,200,32,1,45,,31,1,3.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Albumin (g/dL),,-11,3.7,3.5,4.9,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Baseline,1,3.9,3.5,4.9,Y,3.9,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,9,3.8,3.5,4.9,,3.9,-0.10000000000000009,-2.6
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,16,3.8,3.5,4.9,,3.9,-0.10000000000000009,-2.6
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,30,3.9,3.5,4.9,,3.9,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,58,3.8,3.5,4.9,,3.9,-0.10000000000000009,-2.6
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Cycle 4 Day 1 B,86,3.9,3.5,4.9,,3.9,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Albumin (g/dL),End of Treatment B,114,3.9,3.5,4.9,,3.9,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Follow-up 110 B,200,3.1,3.5,4.9,,3.9,-0.7999999999999998,-20.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),,-11,136,38,126,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,129,38,126,Y,129,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,9,124,38,126,,129,-5,-3.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,16,113,38,126,,129,-16,-12.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,30,139,38,126,,129,10,7.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,58,156,38,126,,129,27,20.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 B,86,187,38,126,,129,58,45
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,114,224,38,126,,129,95,73.6
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 B,200,95,38,126,,129,-34,-26.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),,-11,22,1,35,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,21,1,35,Y,21,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,9,27,1,35,,21,6,28.6
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,16,36,1,35,,21,15,71.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,30,25,1,35,,21,4,19
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,58,32,1,35,,21,11,52.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 B,86,51,1,35,,21,30,142.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,114,43,1,35,,21,22,104.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 B,200,30,1,35,,21,9,42.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,BUN,,-11,11,6,23,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,BUN,Baseline,1,14,6,23,Y,14,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,BUN,Cycle 1 Day 8 B,9,17,6,23,,14,3,21.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,BUN,Cycle 1 Day 15 B,16,13,6,23,,14,-1,-7.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,BUN,Cycle 2 Day 1 B,30,12,6,23,,14,-2,-14.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,BUN,Cycle 3 Day 1 B,58,14,6,23,,14,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,BUN,Cycle 4 Day 1 B,86,14,6,23,,14,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,BUN,End of Treatment B,114,12,6,23,,14,-2,-14.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,BUN,Follow-up 110 B,200,9,6,23,,14,-5,-35.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Bicarbonate,,-11,27,22,30,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Bicarbonate,Baseline,1,26,22,30,Y,26,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Bicarbonate,Cycle 1 Day 8 B,9,26,22,30,,26,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Bicarbonate,Cycle 1 Day 15 B,16,26,22,30,,26,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Bicarbonate,Cycle 2 Day 1 B,30,27,22,30,,26,1,3.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Bicarbonate,Cycle 3 Day 1 B,58,27.8,22,30,,26,1.8000000000000007,6.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Bicarbonate,Cycle 4 Day 1 B,86,26.3,22,30,,26,0.3000000000000007,1.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Bicarbonate,End of Treatment B,114,25.9,22,30,,26,-0.10000000000000142,-0.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Bicarbonate,Follow-up 110 B,200,26.1,22,30,,26,0.10000000000000142,0.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),,-11,9.2,8.5,10.5,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Baseline,1,9.7,8.5,10.5,Y,9.7,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,9,9.6,8.5,10.5,,9.7,-0.09999999999999964,-1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,16,9.3,8.5,10.5,,9.7,-0.3999999999999986,-4.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,30,9.7,8.5,10.5,,9.7,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,58,9.5,8.5,10.5,,9.7,-0.1999999999999993,-2.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 B,86,10,8.5,10.5,,9.7,0.3000000000000007,3.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),End of Treatment B,114,10,8.5,10.5,,9.7,0.3000000000000007,3.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Follow-up 110 B,200,8,8.5,10.5,,9.7,-1.6999999999999993,-17.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),,-11,104,96,108,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Baseline,1,106,96,108,Y,106,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,9,105,96,108,,106,-1,-0.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,16,107,96,108,,106,1,0.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,30,106,96,108,,106,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,58,105,96,108,,106,-1,-0.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 B,86,104,96,108,,106,-2,-1.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),End of Treatment B,114,104,96,108,,106,-2,-1.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Follow-up 110 B,200,106,96,108,,106,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),,-11,0.65,0.7,1.3,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Baseline,1,0.78,0.7,1.3,Y,0.78,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,9,0.72,0.7,1.3,,0.78,-0.06000000000000005,-7.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,16,0.75,0.7,1.3,,0.78,-0.030000000000000027,-3.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,30,0.74,0.7,1.3,,0.78,-0.040000000000000036,-5.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,58,0.77,0.7,1.3,,0.78,-0.010000000000000009,-1.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 B,86,0.78,0.7,1.3,,0.78,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),End of Treatment B,114,0.84,0.7,1.3,,0.78,0.05999999999999994,7.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Follow-up 110 B,200,0.68,0.7,1.3,,0.78,-0.09999999999999998,-12.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Glucose,,-11,212,60,100,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Glucose,Baseline,1,82,60,100,Y,82,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Glucose,Cycle 1 Day 8 B,9,226,60,100,,82,144,175.6
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Glucose,Cycle 1 Day 15 B,16,139,60,100,,82,57,69.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Glucose,Cycle 2 Day 1 B,30,152,60,100,,82,70,85.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Glucose,Cycle 3 Day 1 B,58,170,60,100,,82,88,107.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Glucose,Cycle 4 Day 1 B,86,127,60,100,,82,45,54.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Glucose,End of Treatment B,114,161,60,100,,82,79,96.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Glucose,Follow-up 110 B,200,173,60,100,,82,91,111
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),,-11,150,100,220,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,150,100,220,Y,150,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,9,159,100,220,,150,9,6
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,16,187,100,220,,150,37,24.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,30,161,100,220,,150,11,7.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,58,154,100,220,,150,4,2.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 B,86,154,100,220,,150,4,2.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,114,152,100,220,,150,2,1.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),,-11,4,3.5,5.2,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Baseline,1,4.3,3.5,5.2,Y,4.3,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,9,5,3.5,5.2,,4.3,0.7000000000000002,16.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,16,4.3,3.5,5.2,,4.3,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,30,4.8,3.5,5.2,,4.3,0.5,11.6
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,58,4.5,3.5,5.2,,4.3,0.20000000000000018,4.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 B,86,4.4,3.5,5.2,,4.3,0.10000000000000053,2.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),End of Treatment B,114,4.6,3.5,5.2,,4.3,0.2999999999999998,7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Follow-up 110 B,200,4.7,3.5,5.2,,4.3,0.40000000000000036,9.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Sodium,,-11,139,135,145,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Sodium,Baseline,1,142,135,145,Y,142,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Sodium,Cycle 1 Day 8 B,9,142,135,145,,142,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Sodium,Cycle 1 Day 15 B,16,142,135,145,,142,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Sodium,Cycle 2 Day 1 B,30,142,135,145,,142,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Sodium,Cycle 3 Day 1 B,58,141,135,145,,142,-1,-0.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Sodium,Cycle 4 Day 1 B,86,141,135,145,,142,-1,-0.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Sodium,End of Treatment B,114,140,135,145,,142,-2,-1.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Sodium,Follow-up 110 B,200,139,135,145,,142,-3,-2.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Bilirubin,,-11,0.5,0.1,1.2,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Bilirubin,Baseline,1,0.4,0.1,1.2,Y,0.4,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,9,0.5,0.1,1.2,,0.4,0.09999999999999998,25
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,16,0.4,0.1,1.2,,0.4,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,30,0.6,0.1,1.2,,0.4,0.19999999999999996,50
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,58,0.5,0.1,1.2,,0.4,0.09999999999999998,25
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Bilirubin,Cycle 4 Day 1 B,86,0.6,0.1,1.2,,0.4,0.19999999999999996,50
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Bilirubin,End of Treatment B,114,0.7,0.1,1.2,,0.4,0.29999999999999993,75
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Bilirubin,Follow-up 110 B,200,0.8,0.1,1.2,,0.4,0.4,100
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Protein,,-11,6.6,6,8.3,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Protein,Baseline,1,6.9,6,8.3,Y,6.9,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Protein,Cycle 1 Day 8 B,9,6.9,6,8.3,,6.9,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Protein,Cycle 1 Day 15 B,16,6.8,6,8.3,,6.9,-0.10000000000000053,-1.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Protein,Cycle 2 Day 1 B,30,6.9,6,8.3,,6.9,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Protein,Cycle 3 Day 1 B,58,6.7,6,8.3,,6.9,-0.20000000000000018,-2.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Protein,Cycle 4 Day 1 B,86,7,6,8.3,,6.9,0.09999999999999964,1.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Protein,End of Treatment B,114,7.1,6,8.3,,6.9,0.1999999999999993,2.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Chemistry,Total Protein,Follow-up 110 B,200,5.4,6,8.3,,6.9,-1.5,-21.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),,-11,34.8,25.4,34.9,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,31.1,25.4,34.9,Y,31.1,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,9,32.4,25.4,34.9,,31.1,1.2999999999999972,4.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 15 B,16,34.2,25.4,34.9,,31.1,3.1000000000000014,10
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,30,32.5,25.4,34.9,,31.1,1.3999999999999986,4.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 B,58,32.5,25.4,34.9,,31.1,1.3999999999999986,4.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 B,86,33.4,NA,NA,,31.1,2.299999999999997,7.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,114,33.8,25.4,34.9,,31.1,2.6999999999999957,8.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-11,1,2,3,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.1,2,3,Y,1.1,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,9,1,2,3,,1.1,-0.10000000000000009,-9.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 15 B,16,1.1,2,3,,1.1,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,30,1,2,3,,1.1,-0.10000000000000009,-9.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 B,58,1,2,3,,1.1,-0.10000000000000009,-9.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 B,86,1,NA,NA,,1.1,-0.10000000000000009,-9.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,114,1,2,3,,1.1,-0.10000000000000009,-9.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Time (PT),,-11,13.1,12.3,14.9,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Time (PT),Baseline,1,13.5,12.3,14.9,Y,13.5,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,9,13,12.3,14.9,,13.5,-0.5,-3.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 15 B,16,13.7,12.3,14.9,,13.5,0.1999999999999993,1.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,30,13.3,12.3,14.9,,13.5,-0.1999999999999993,-1.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 B,58,13,12.3,14.9,,13.5,-0.5,-3.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Time (PT),Cycle 4 Day 1 B,86,13.1,NA,NA,,13.5,-0.40000000000000036,-3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Coagulation,Prothrombin Time (PT),End of Treatment B,114,12.8,12.3,14.9,,13.5,-0.6999999999999993,-5.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Basophils,,-11,0,0,0.2,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Basophils,Cycle 1 Day 8 B,9,0,0,0.2,,0,0,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Basophils,Cycle 1 Day 15 B,16,0,0,0.2,,0,0,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Basophils,Cycle 2 Day 1 B,30,0,0,0.2,,0,0,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Basophils,Cycle 3 Day 1 B,58,0,0,0.2,,0,0,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Basophils,Cycle 4 Day 1 B,86,0,0,0.2,,0,0,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Basophils,End of Treatment B,114,0,0,0.2,,0,0,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Basophils,Follow-up 110 B,200,0,0,0.2,,0,0,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Eosinophils,,-11,0.2,0,0.6,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.6,Y,0.1,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Eosinophils,Cycle 1 Day 8 B,9,0.2,0,0.6,,0.1,0.1,100
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Eosinophils,Cycle 1 Day 15 B,16,0.1,0,0.6,,0.1,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Eosinophils,Cycle 2 Day 1 B,30,0.1,0,0.6,,0.1,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Eosinophils,Cycle 3 Day 1 B,58,0.1,0,0.6,,0.1,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Eosinophils,Cycle 4 Day 1 B,86,0.2,0,0.6,,0.1,0.1,100
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Eosinophils,End of Treatment B,114,0.2,0,0.6,,0.1,0.1,100
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Eosinophils,Follow-up 110 B,200,0,0,0.6,,0.1,-0.1,-100
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),,-11,4.12,4.5,6,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.16,4.5,6,Y,4.16,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,9,4.1,4.5,6,,4.16,-0.0600000000000005,-1.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,16,4.11,4.5,6,,4.16,-0.04999999999999982,-1.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,30,3.92,4.5,6,,4.16,-0.2400000000000002,-5.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,58,4.07,4.5,6,,4.16,-0.08999999999999986,-2.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 B,86,4.17,4.5,6,,4.16,0.009999999999999787,0.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,114,4.12,4.5,6,,4.16,-0.040000000000000036,-1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,200,3.48,4.5,6,,4.16,-0.6800000000000002,-16.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),,-11,35.5,42,52,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Baseline,1,35.7,42,52,Y,35.7,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,9,35,42,52,,35.7,-0.7000000000000028,-2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,16,35.1,42,52,,35.7,-0.6000000000000014,-1.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,30,33.5,42,52,,35.7,-2.200000000000003,-6.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,58,34.7,42,52,,35.7,-1,-2.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 B,86,35.4,42,52,,35.7,-0.30000000000000426,-0.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),End of Treatment B,114,35.8,42,52,,35.7,0.09999999999999432,0.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Follow-up 110 B,200,30.4,42,52,,35.7,-5.300000000000004,-14.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),,-11,12.2,13.9,16.3,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Baseline,1,12.1,13.9,16.3,Y,12.1,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,9,12,13.9,16.3,,12.1,-0.09999999999999964,-0.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,16,11.9,13.9,16.3,,12.1,-0.1999999999999993,-1.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,30,11.6,13.9,16.3,,12.1,-0.5,-4.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,58,11.5,13.9,16.3,,12.1,-0.5999999999999996,-5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 B,86,11.9,13.9,16.3,,12.1,-0.1999999999999993,-1.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),End of Treatment B,114,12.2,13.9,16.3,,12.1,0.09999999999999964,0.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Follow-up 110 B,200,10.2,13.9,16.3,,12.1,-1.9000000000000004,-15.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Lymphocytes,,-11,1.9,1,4.5,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Lymphocytes,Baseline,1,2.2,1,4.5,Y,2.2,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Lymphocytes,Cycle 1 Day 8 B,9,1.4,1,4.5,,2.2,-0.8000000000000003,-36.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Lymphocytes,Cycle 1 Day 15 B,16,1.4,1,4.5,,2.2,-0.8000000000000003,-36.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Lymphocytes,Cycle 2 Day 1 B,30,1.3,1,4.5,,2.2,-0.9000000000000001,-40.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Lymphocytes,Cycle 3 Day 1 B,58,1.2,1,4.5,,2.2,-1.0000000000000002,-45.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Lymphocytes,Cycle 4 Day 1 B,86,1.6,1,4.5,,2.2,-0.6000000000000001,-27.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Lymphocytes,End of Treatment B,114,1.6,1,4.5,,2.2,-0.6000000000000001,-27.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Lymphocytes,Follow-up 110 B,200,1.1,1,4.5,,2.2,-1.1,-50
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Monocytes,,-11,0.3,0.2,1,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Monocytes,Baseline,1,0.4,0.2,1,Y,0.4,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Monocytes,Cycle 1 Day 8 B,9,1,0.2,1,,0.4,0.6,150
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Monocytes,Cycle 1 Day 15 B,16,1.9,0.2,1,,0.4,1.5,375
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Monocytes,Cycle 2 Day 1 B,30,0.5,0.2,1,,0.4,0.09999999999999998,25
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Monocytes,Cycle 3 Day 1 B,58,0.3,0.2,1,,0.4,-0.10000000000000003,-25
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Monocytes,Cycle 4 Day 1 B,86,0.4,0.2,1,,0.4,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Monocytes,End of Treatment B,114,0.4,0.2,1,,0.4,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Monocytes,Follow-up 110 B,200,0.5,0.2,1,,0.4,0.09999999999999998,25
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Neutrophils,,-11,2.5,1.9,8,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Neutrophils,Baseline,1,2.6,1.9,8,Y,2.6,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Neutrophils,Cycle 1 Day 8 B,9,2.1,1.9,8,,2.6,-0.5,-19.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Neutrophils,Cycle 1 Day 15 B,16,2,1.9,8,,2.6,-0.6000000000000001,-23.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Neutrophils,Cycle 2 Day 1 B,30,2.1,1.9,8,,2.6,-0.5,-19.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Neutrophils,Cycle 3 Day 1 B,58,2,1.9,8,,2.6,-0.6000000000000001,-23.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Neutrophils,Cycle 4 Day 1 B,86,2.4,1.9,8,,2.6,-0.20000000000000018,-7.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Neutrophils,End of Treatment B,114,2.4,1.9,8,,2.6,-0.20000000000000018,-7.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Neutrophils,Follow-up 110 B,200,1.6,1.9,8,,2.6,-1,-38.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Platelets (10^9/L),,-11,300,150,450,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Baseline,1,291,150,450,Y,291,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,9,261,150,450,,291,-30,-10.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,16,217,150,450,,291,-74,-25.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,30,304,150,450,,291,13,4.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,58,268,150,450,,291,-23,-7.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Cycle 4 Day 1 B,86,279,150,450,,291,-12,-4.1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Platelets (10^9/L),End of Treatment B,114,288,150,450,,291,-3,-1
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Follow-up 110 B,200,287,150,450,,291,-4,-1.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,TESTR,Baseline,-11,6.81,300,1080,Y,6.81,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,White Blood Cells,,-11,4.9,4.5,11,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,White Blood Cells,Baseline,1,5.4,4.5,11,Y,5.4,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,White Blood Cells,Cycle 1 Day 8 B,9,4.6,4.5,11,,5.4,-0.8000000000000007,-14.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,White Blood Cells,Cycle 1 Day 15 B,16,5.5,4.5,11,,5.4,0.09999999999999964,1.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,White Blood Cells,Cycle 2 Day 1 B,30,4,4.5,11,,5.4,-1.4000000000000004,-25.9
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,White Blood Cells,Cycle 3 Day 1 B,58,3.7,4.5,11,,5.4,-1.7000000000000002,-31.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,White Blood Cells,Cycle 4 Day 1 B,86,4.6,4.5,11,,5.4,-0.8000000000000007,-14.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,White Blood Cells,End of Treatment B,114,4.6,4.5,11,,5.4,-0.8000000000000007,-14.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Hematology,White Blood Cells,Follow-up 110 B,200,3.2,4.5,11,,5.4,-2.2,-40.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Prostate-specific antigen,PSA,,-11,67.04,NA,NA,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Prostate-specific antigen,PSA,Baseline,1,75.37,NA,NA,Y,75.37,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,30,92.35,NA,NA,,75.37,16.97999999999999,22.5
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 B,58,84.57,NA,NA,,75.37,9.199999999999989,12.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Prostate-specific antigen,PSA,Cycle 4 Day 1 B,86,66.64,NA,NA,,75.37,-8.730000000000004,-11.6
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Prostate-specific antigen,PSA,End of Treatment B,114,121.15,NA,NA,,75.37,45.78,60.7
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Prostate-specific antigen,PSA,Follow-up 110 B,200,153.64,NA,NA,,75.37,78.26999999999998,103.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Thyroid Function Testing,Free thyroxine (FT4),End of Treatment B,114,0.9,0.8,1.5,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-11,3.49,0.4,4.2,,NA,NA,NA
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.39,0.4,4.2,Y,2.39,0,0
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,9,1.5,0.4,4.2,,2.39,-0.8900000000000001,-37.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,16,3.04,0.4,4.2,,2.39,0.6499999999999999,27.2
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,30,2.19,0.4,4.2,,2.39,-0.20000000000000018,-8.4
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,58,3.64,0.4,4.2,,2.39,1.25,52.3
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 B,86,3.82,0.4,4.2,,2.39,1.4299999999999997,59.8
11B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,114,5.71,0.4,4.2,,2.39,3.32,138.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,23,NA,NA,Y,23,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,30,23,NA,NA,,23,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 C,61,19,NA,NA,,23,-4,-17.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,End of Treatment C,89,26,NA,NA,,23,3,13
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-6,16,0,55,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,17,0,55,Y,17,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,19,0,55,,17,2,11.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,15,22,0,55,,17,5,29.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,21,0,55,,17,4,23.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,30,19,0,55,,17,2,11.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,38,25,0,55,,17,8,47.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 C,61,20,0,55,,17,3,17.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,89,20,0,55,,17,3,17.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 C,173,19,0,55,,17,2,11.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-6,4.1,3.8,5,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4.2,3.8,5,Y,4.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,4.3,3.8,5,,4.2,0.09999999999999964,2.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,15,4.2,3.8,5,,4.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,4.2,3.8,5,,4.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,30,4.1,3.8,5,,4.2,-0.10000000000000053,-2.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,38,4.2,3.8,5,,4.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,61,4.2,3.8,5,,4.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,89,4.2,3.8,5,,4.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 C,173,4.2,3.8,5,,4.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-6,95,0,130,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,95,0,130,Y,95,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,104,0,130,,95,9,9.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,15,92,0,130,,95,-3,-3.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,95,0,130,,95,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,30,92,0,130,,95,-3,-3.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,38,85,0,130,,95,-10,-10.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,61,90,0,130,,95,-5,-5.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,89,102,0,130,,95,7,7.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 C,173,108,0,130,,95,13,13.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-6,19,0,37,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,22,0,37,Y,22,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,22,0,37,,22,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,15,26,0,37,,22,4,18.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,22,0,37,,22,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,30,25,0,37,,22,3,13.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,38,26,0,37,,22,4,18.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,61,22,0,37,,22,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,89,23,0,37,,22,1,4.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 C,173,21,0,37,,22,-1,-4.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-6,16,6,20,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,14,6,20,Y,14,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,19,6,20,,14,5,35.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,15,14,6,20,,14,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,16,6,20,,14,2,14.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,30,15,6,20,,14,1,7.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,38,15,6,20,,14,1,7.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 C,61,14,6,20,,14,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,89,13,6,20,,14,-1,-7.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 C,173,15,6,20,,14,1,7.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-6,26,18,29,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,24,18,29,Y,24,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,25,18,29,,24,1,4.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,15,28,18,29,,24,4,16.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,27,18,29,,24,3,12.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,30,25,18,29,,24,1,4.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,38,25,18,29,,24,1,4.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 C,61,27,18,29,,24,3,12.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment C,89,24,18,29,,24,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 C,173,27,18,29,,24,3,12.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-6,9.7,8.5,10.5,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.4,8.5,10.5,Y,9.4,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,9.8,8.5,10.5,,9.4,0.40000000000000036,4.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,15,9.2,8.5,10.5,,9.4,-0.20000000000000107,-2.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,9.6,8.5,10.5,,9.4,0.1999999999999993,2.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,30,9.3,8.5,10.5,,9.4,-0.09999999999999964,-1.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,38,9.7,8.5,10.5,,9.4,0.29999999999999893,3.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,61,9.7,8.5,10.5,,9.4,0.29999999999999893,3.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,89,9.5,8.5,10.5,,9.4,0.09999999999999964,1.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 C,173,9.8,8.5,10.5,,9.4,0.40000000000000036,4.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-6,105,98,109,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,108,98,109,Y,108,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,106,98,109,,108,-2,-1.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,15,109,98,109,,108,1,0.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,107,98,109,,108,-1,-0.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,30,107,98,109,,108,-1,-0.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,38,105,98,109,,108,-3,-2.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,61,107,98,109,,108,-1,-0.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,89,108,98,109,,108,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 C,173,105,98,109,,108,-3,-2.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-6,0.9,0.6,1.3,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.9,0.6,1.3,Y,0.9,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,1,0.6,1.3,,0.9,0.09999999999999998,11.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,15,1.1,0.6,1.3,,0.9,0.20000000000000007,22.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,0.9,0.6,1.3,,0.9,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,30,0.9,0.6,1.3,,0.9,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,38,1.1,0.6,1.3,,0.9,0.20000000000000007,22.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,61,0.9,0.6,1.3,,0.9,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,89,0.9,0.6,1.3,,0.9,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 C,173,1,0.6,1.3,,0.9,0.09999999999999998,11.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-6,128,70,140,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,102,70,140,Y,102,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,94,70,140,,102,-8,-7.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,15,93,70,140,,102,-9,-8.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,95,70,140,,102,-7,-6.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,30,105,70,140,,102,3,2.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,38,94,70,140,,102,-8,-7.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 C,61,100,70,140,,102,-2,-2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,89,102,70,140,,102,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 C,173,97,70,140,,102,-5,-4.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,-6,157,130,250,Y,157,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,189,130,250,,157,32,20.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,15,238,130,250,,157,81,51.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,224,130,250,,157,67,42.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,30,221,130,250,,157,64,40.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,38,249,130,250,,157,92,58.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 C,61,191,130,250,,157,34,21.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,89,202,130,250,,157,45,28.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 C,173,197,130,250,,157,40,25.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-6,4,3.5,5.1,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.3,3.5,5.1,Y,4.3,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,4.5,3.5,5.1,,4.3,0.20000000000000018,4.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,15,4.3,3.5,5.1,,4.3,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.2,3.5,5.1,,4.3,-0.09999999999999964,-2.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,30,4.2,3.5,5.1,,4.3,-0.09999999999999964,-2.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,38,4.2,3.5,5.1,,4.3,-0.09999999999999964,-2.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,61,4.2,3.5,5.1,,4.3,-0.09999999999999964,-2.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,89,4.2,3.5,5.1,,4.3,-0.09999999999999964,-2.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 C,173,4.3,3.5,5.1,,4.3,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-6,140,133,143,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,142,133,143,Y,142,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,140,133,143,,142,-2,-1.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,15,142,133,143,,142,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,142,133,143,,142,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,30,140,133,143,,142,-2,-1.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,38,139,133,143,,142,-3,-2.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 C,61,141,133,143,,142,-1,-0.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,89,141,133,143,,142,-1,-0.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 C,173,141,133,143,,142,-1,-0.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-6,0.5,0,1.2,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.5,0,1.2,Y,0.5,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.3,0,1.2,,0.5,-0.2,-40
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,15,0.3,0,1.2,,0.5,-0.2,-40
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.5,0,1.2,,0.5,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,30,0.3,0,1.2,,0.5,-0.2,-40
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,38,0.4,0,1.2,,0.5,-0.09999999999999998,-20
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,61,0.4,0,1.2,,0.5,-0.09999999999999998,-20
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,89,0.4,0,1.2,,0.5,-0.09999999999999998,-20
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 C,173,0.4,0,1.2,,0.5,-0.09999999999999998,-20
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-6,6.5,6.3,8.1,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.6,6.3,8.1,Y,6.6,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,6.8,6.3,8.1,,6.6,0.20000000000000018,3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,15,6.5,6.3,8.1,,6.6,-0.09999999999999964,-1.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,6.7,6.3,8.1,,6.6,0.10000000000000053,1.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,30,6.4,6.3,8.1,,6.6,-0.1999999999999993,-3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,38,6.7,6.3,8.1,,6.6,0.10000000000000053,1.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 C,61,6.8,6.3,8.1,,6.6,0.20000000000000018,3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,89,6.9,6.3,8.1,,6.6,0.3000000000000007,4.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 C,173,7,6.3,8.1,,6.6,0.40000000000000036,6.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-6,28.5,22.5,36.5,Y,28.5,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,8,29.8,22.5,36.5,,28.5,1.3000000000000007,4.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,15,28.4,22.5,36.5,,28.5,-0.10000000000000142,-0.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,22,30.1,22.5,36.5,,28.5,1.6000000000000014,5.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 1 C,30,29,22.5,36.5,,28.5,0.5,1.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 C,38,27.1,22.5,36.5,,28.5,-1.3999999999999986,-4.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 C,61,29.9,22.5,36.5,,28.5,1.3999999999999986,4.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment C,89,30.3,22.5,36.5,,28.5,1.8000000000000007,6.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Follow-up 110 C,173,29.4,22.5,36.5,,28.5,0.8999999999999986,3.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-6,0.98,0.8,1.2,Y,0.98,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,8,0.92,0.8,1.2,,0.98,-0.05999999999999994,-6.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,15,1.01,0.8,1.2,,0.98,0.030000000000000027,3.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,22,0.99,0.8,1.2,,0.98,0.010000000000000009,1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 1 C,30,0.96,0.8,1.2,,0.98,-0.020000000000000018,-2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 C,38,1.06,0.8,1.2,,0.98,0.08000000000000007,8.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 C,61,0.91,0.8,1.2,,0.98,-0.06999999999999995,-7.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment C,89,0.98,0.8,1.2,,0.98,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Follow-up 110 C,173,0.97,0.8,1.2,,0.98,-0.010000000000000009,-1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,-6,13,11.1,15.2,Y,13,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,8,12.4,11.1,15.2,,13,-0.5999999999999996,-4.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,15,13.3,11.1,15.2,,13,0.3000000000000007,2.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,22,13.1,11.1,15.2,,13,0.09999999999999964,0.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 1 C,30,12.8,11.1,15.2,,13,-0.1999999999999993,-1.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 C,38,13.8,11.1,15.2,,13,0.8000000000000007,6.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 C,61,12.3,11.1,15.2,,13,-0.6999999999999993,-5.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment C,89,13,11.1,15.2,,13,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Follow-up 110 C,173,12.7,11.1,15.2,,13,-0.3000000000000007,-2.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-6,0,0,0.2,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0,0,0.2,,0,0,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,15,0,0,0.2,,0,0,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0,0,0.2,,0,0,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,30,0,0,0.2,,0,0,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 C,38,0,0,0.2,,0,0,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 C,61,0,0,0.2,,0,0,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,89,0,0,0.2,,0,0,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 C,173,0,0,0.2,,0,0,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-6,0.3,0,0.7,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.2,0,0.7,Y,0.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0.3,0,0.7,,0.2,0.09999999999999998,50
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,15,0.2,0,0.7,,0.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0.2,0,0.7,,0.2,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,30,0.4,0,0.7,,0.2,0.2,100
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 C,38,0.5,0,0.7,,0.2,0.3,150
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 C,61,0.7,0,0.7,,0.2,0.49999999999999994,250
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,89,0.4,0,0.7,,0.2,0.2,100
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 C,173,0.4,0,0.7,,0.2,0.2,100
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-6,4.47,3.95,5.54,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.3,3.95,5.54,Y,4.3,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,4.55,3.95,5.54,,4.3,0.25,5.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,15,4.25,3.95,5.54,,4.3,-0.04999999999999982,-1.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,4.35,3.95,5.54,,4.3,0.04999999999999982,1.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,30,4.27,3.95,5.54,,4.3,-0.03000000000000025,-0.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,38,4.41,3.95,5.54,,4.3,0.11000000000000032,2.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,61,4.3,3.95,5.54,,4.3,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,89,4.46,3.95,5.54,,4.3,0.16000000000000014,3.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 C,173,4.58,3.95,5.54,,4.3,0.28000000000000025,6.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-6,41.9,37.5,49.3,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,40.1,37.5,49.3,Y,40.1,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,42.6,37.5,49.3,,40.1,2.5,6.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,15,39.4,37.5,49.3,,40.1,-0.7000000000000028,-1.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,40.6,37.5,49.3,,40.1,0.5,1.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,30,40,37.5,49.3,,40.1,-0.10000000000000142,-0.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,38,40.8,37.5,49.3,,40.1,0.6999999999999957,1.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,61,41.2,37.5,49.3,,40.1,1.1000000000000014,2.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,89,40.8,37.5,49.3,,40.1,0.6999999999999957,1.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 C,173,42.8,37.5,49.3,,40.1,2.6999999999999957,6.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-6,14.2,12.5,16.2,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,13.5,12.5,16.2,Y,13.5,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,14.3,12.5,16.2,,13.5,0.8000000000000007,5.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,15,13.3,12.5,16.2,,13.5,-0.1999999999999993,-1.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,13.6,12.5,16.2,,13.5,0.09999999999999964,0.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,30,13.5,12.5,16.2,,13.5,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,38,13.8,12.5,16.2,,13.5,0.3000000000000007,2.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,61,13.7,12.5,16.2,,13.5,0.1999999999999993,1.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,89,13.7,12.5,16.2,,13.5,0.1999999999999993,1.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 C,173,13.8,12.5,16.2,,13.5,0.3000000000000007,2.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-6,1.9,0.9,3.2,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.4,0.9,3.2,Y,1.4,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,2.1,0.9,3.2,,1.4,0.7000000000000002,50
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,15,2.4,0.9,3.2,,1.4,1,71.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,1.7,0.9,3.2,,1.4,0.30000000000000004,21.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,30,2.5,0.9,3.2,,1.4,1.1,78.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 C,38,1.8,0.9,3.2,,1.4,0.40000000000000013,28.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 C,61,1.9,0.9,3.2,,1.4,0.5,35.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,89,1.9,0.9,3.2,,1.4,0.5,35.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 C,173,1.6,0.9,3.2,,1.4,0.20000000000000018,14.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-6,0.4,0,1.3,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.4,0,1.3,Y,0.4,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,1.3,0,1.3,,0.4,0.9,225
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,15,1.9,0,1.3,,0.4,1.5,375
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,1.4,0,1.3,,0.4,0.9999999999999999,250
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,30,1.8,0,1.3,,0.4,1.4,350
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 C,38,2.6,0,1.3,,0.4,2.2,550
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 C,61,0,0,1.3,,0.4,-0.4,-100
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,89,0.5,0,1.3,,0.4,0.09999999999999998,25
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 C,173,0.5,0,1.3,,0.4,0.09999999999999998,25
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-6,3.5,1.5,7.5,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.1,1.5,7.5,Y,3.1,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,4,1.5,7.5,,3.1,0.8999999999999999,29
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,15,4.2,1.5,7.5,,3.1,1.1,35.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,3.4,1.5,7.5,,3.1,0.2999999999999998,9.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,30,4.3,1.5,7.5,,3.1,1.1999999999999997,38.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 C,38,4.4,1.5,7.5,,3.1,1.3000000000000003,41.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 C,61,3.7,1.5,7.5,,3.1,0.6000000000000001,19.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,89,3.2,1.5,7.5,,3.1,0.10000000000000009,3.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 C,173,4.4,1.5,7.5,,3.1,1.3000000000000003,41.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-6,239,160,400,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,231,160,400,Y,231,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,245,160,400,,231,14,6.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,15,180,160,400,,231,-51,-22.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,305,160,400,,231,74,32
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,30,280,160,400,,231,49,21.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,38,222,160,400,,231,-9,-3.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,61,219,160,400,,231,-12,-5.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,89,202,160,400,,231,-29,-12.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 C,173,227,160,400,,231,-4,-1.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-6,6.1,4,11,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.1,4,11,Y,5.1,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,7.8,4,11,,5.1,2.7,52.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,15,8.7,4,11,,5.1,3.5999999999999996,70.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,6.8,4,11,,5.1,1.7000000000000002,33.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,30,9,4,11,,5.1,3.9000000000000004,76.5
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,38,9.4,4,11,,5.1,4.300000000000001,84.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 C,61,6.7,4,11,,5.1,1.6000000000000005,31.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,89,6,4,11,,5.1,0.9000000000000004,17.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 C,173,7,4,11,,5.1,1.9000000000000004,37.3
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-6,3.94,NA,NA,,NA,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,4.64,NA,NA,Y,4.64,0,0
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,10.71,NA,NA,,4.64,6.070000000000001,130.8
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,30,13.96,NA,NA,,4.64,9.32,200.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,61,19.95,NA,NA,,4.64,15.309999999999999,330
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,89,23.3,NA,NA,,4.64,18.66,402.2
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 C,173,15.41,NA,NA,,4.64,10.77,232.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,-6,1.49,0.6,4.8,Y,1.49,NA,NA
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,1.44,0.6,4.8,,1.49,-0.050000000000000044,-3.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,15,1.59,0.6,4.8,,1.49,0.10000000000000009,6.7
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,1.22,0.6,4.8,,1.49,-0.27,-18.1
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,30,2.08,0.6,4.8,,1.49,0.5900000000000001,39.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,38,1.6,0.6,4.8,,1.49,0.1100000000000001,7.4
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,61,2.04,0.6,4.8,,1.49,0.55,36.9
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,89,2.14,0.6,4.8,,1.49,0.6500000000000001,43.6
11C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 C,173,1.52,0.6,4.8,,1.49,0.030000000000000027,2
12A,A,NKTR-214 + Nivolumab,N,N,,CTC,Baseline,1,34,NA,NA,Y,34,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 A,22,154,NA,NA,,34,120,352.9
12A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 3 Day 1 A,43,144,NA,NA,,34,110,323.5
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-17,11,3,61,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,10,3,61,Y,10,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,22,3,61,,10,12,120
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,22,12,3,61,,10,2,20
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,29,16,3,61,,10,6,60
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 A,43,8,3,61,,10,-2,-20
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 8 A,50,18,3,61,,10,8,80
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 A,164,6,3,61,,10,-4,-40
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-17,4.4,3.8,5.5,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4,3.8,5.5,Y,4,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,22,4.1,3.8,5.5,,4,0.09999999999999964,2.5
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,29,4,3.8,5.5,,4,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 A,43,4.1,3.8,5.5,,4,0.09999999999999964,2.5
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 8 A,50,4,3.8,5.5,,4,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 A,164,3.6,3.8,5.5,,4,-0.3999999999999999,-10
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-17,124,33,98,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,123,33,98,Y,123,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,104,33,98,,123,-19,-15.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,22,141,33,98,,123,18,14.6
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,29,139,33,98,,123,16,13
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 A,43,145,33,98,,123,22,17.9
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 8 A,50,171,33,98,,123,48,39
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 A,164,84,33,98,,123,-39,-31.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-17,16,5,38,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,15,5,38,Y,15,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,22,5,38,,15,7,46.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,22,16,5,38,,15,1,6.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,29,16,5,38,,15,1,6.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 A,43,19,5,38,,15,4,26.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 8 A,50,23,5,38,,15,8,53.3
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 A,164,22,5,38,,15,7,46.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-17,13,7,25,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,9,7,25,Y,9,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,8,13,7,25,,9,4,44.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,22,10,7,25,,9,1,11.1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 8 A,29,13,7,25,,9,4,44.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 A,43,11,7,25,,9,2,22.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 8 A,50,8,7,25,,9,-1,-11.1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 A,164,11,7,25,,9,2,22.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-17,24,21,31,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,27,21,31,Y,27,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,27,21,31,,27,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,22,27,21,31,,27,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,29,26,21,31,,27,-1,-3.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 A,43,23,21,31,,27,-4,-14.8
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 8 A,50,28,21,31,,27,1,3.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 A,164,26,21,31,,27,-1,-3.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-17,9.7,8.7,10.1,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.4,8.7,10.1,Y,9.4,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,9.4,8.7,10.1,,9.4,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,22,9.3,8.7,10.1,,9.4,-0.09999999999999964,-1.1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,29,9.1,8.7,10.1,,9.4,-0.3000000000000007,-3.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 A,43,9.3,8.7,10.1,,9.4,-0.09999999999999964,-1.1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 8 A,50,9.2,8.7,10.1,,9.4,-0.20000000000000107,-2.1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 A,164,9.2,8.7,10.1,,9.4,-0.20000000000000107,-2.1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-17,104,99,107,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,103,99,107,Y,103,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,102,99,107,,103,-1,-1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,22,103,99,107,,103,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,29,104,99,107,,103,1,1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 A,43,106,99,107,,103,3,2.9
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 8 A,50,105,99,107,,103,2,1.9
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 A,164,104,99,107,,103,1,1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-17,0.86,0.7,1.3,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.83,0.7,1.3,Y,0.83,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,0.86,0.7,1.3,,0.83,0.030000000000000027,3.6
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,22,0.81,0.7,1.3,,0.83,-0.019999999999999907,-2.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,29,0.85,0.7,1.3,,0.83,0.020000000000000018,2.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 A,43,0.82,0.7,1.3,,0.83,-0.010000000000000009,-1.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 8 A,50,0.9,0.7,1.3,,0.83,0.07000000000000006,8.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 A,164,0.72,0.7,1.3,,0.83,-0.10999999999999999,-13.3
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-17,89,63,130,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,95,63,130,Y,95,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 A,8,99,63,130,,95,4,4.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,22,80,63,130,,95,-15,-15.8
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,29,89,63,130,,95,-6,-6.3
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 A,43,118,63,130,,95,23,24.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 8 A,50,84,63,130,,95,-11,-11.6
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 A,164,101,63,130,,95,6,6.3
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-17,280,100,210,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,250,100,210,Y,250,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,8,185,100,210,,250,-65,-26
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,22,219,100,210,,250,-31,-12.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,29,212,100,210,,250,-38,-15.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 A,43,226,100,210,,250,-24,-9.6
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 8 A,50,262,100,210,,250,12,4.8
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 A,164,373,100,210,,250,123,49.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-17,4,3.5,5.1,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,3.7,3.5,5.1,Y,3.7,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,3.6,3.5,5.1,,3.7,-0.10000000000000009,-2.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,22,4.1,3.5,5.1,,3.7,0.39999999999999947,10.8
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,29,4.3,3.5,5.1,,3.7,0.5999999999999996,16.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 A,43,4.2,3.5,5.1,,3.7,0.5,13.5
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 8 A,50,4,3.5,5.1,,3.7,0.2999999999999998,8.1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 A,164,3.8,3.5,5.1,,3.7,0.09999999999999964,2.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-17,139,136,145,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,139,136,145,Y,139,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,8,142,136,145,,139,3,2.2
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,22,141,136,145,,139,2,1.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,29,140,136,145,,139,1,0.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 A,43,139,136,145,,139,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 8 A,50,143,136,145,,139,4,2.9
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 A,164,139,136,145,,139,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-17,1.04,0.1,1.4,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.62,0.1,1.4,Y,0.62,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.25,0.1,1.4,,0.62,-0.37,-59.7
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,22,0.54,0.1,1.4,,0.62,-0.07999999999999996,-12.9
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,29,0.52,0.1,1.4,,0.62,-0.09999999999999998,-16.1
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 A,43,0.91,0.1,1.4,,0.62,0.29000000000000004,46.8
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 8 A,50,0.37,0.1,1.4,,0.62,-0.25,-40.3
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 A,164,0.42,0.1,1.4,,0.62,-0.2,-32.3
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-17,6.9,6.3,8.1,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.8,6.3,8.1,Y,6.8,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,8,6.7,6.3,8.1,,6.8,-0.09999999999999964,-1.5
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,22,6.9,6.3,8.1,,6.8,0.10000000000000053,1.5
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,29,6.5,6.3,8.1,,6.8,-0.2999999999999998,-4.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 A,43,7,6.3,8.1,,6.8,0.20000000000000018,2.9
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 8 A,50,6.5,6.3,8.1,,6.8,-0.2999999999999998,-4.4
12A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 A,164,6.4,6.3,8.1,,6.8,-0.39999999999999947,-5.9
12A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-17,25.7,25.5,36,Y,25.7,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-17,0.98,0.9,1.3,Y,0.98,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,-17,10.3,12.1,15.2,Y,10.3,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-17,0,0,0.1,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.1,Y,0,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0,0,0.1,,0,0,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0,0,0.1,,0,0,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,8,0,0,0.1,,0,0,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,22,0.1,0,0.1,,0,0.1,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,29,0.1,0,0.1,,0,0.1,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 A,43,0.1,0,0.1,,0,0.1,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 8 A,50,0,0,0.1,,0,0,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 A,164,0,0,0.1,,0,0,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-17,0.2,0,0.4,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.4,Y,0.1,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.1,0,0.4,,0.1,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.3,0,0.4,,0.1,0.19999999999999998,200
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.8,0,0.4,,0.1,0.7000000000000001,700
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,22,0.2,0,0.4,,0.1,0.1,100
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 8 A,29,5.6,0,0.4,,0.1,5.5,5500
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 A,43,0.4,0,0.4,,0.1,0.30000000000000004,300
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 8 A,50,5.9,0,0.4,,0.1,5.800000000000001,5800
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 A,164,0,0,0.4,,0.1,-0.1,-100
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-17,3.98,4,6,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.5,4,6,Y,3.5,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,3.44,4,6,,3.5,-0.06000000000000005,-1.7
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,3.64,4,6,,3.5,0.14000000000000012,4
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,3.48,4,6,,3.5,-0.020000000000000018,-0.6
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,22,3.5,4,6,,3.5,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,29,3.67,4,6,,3.5,0.16999999999999993,4.9
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 A,43,3.77,4,6,,3.5,0.27,7.7
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 8 A,50,3.7,4,6,,3.5,0.20000000000000018,5.7
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 A,164,2.28,4,6,,3.5,-1.2200000000000002,-34.9
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-17,38.3,43.5,48,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,34.5,43.5,48,Y,34.5,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,33.7,43.5,48,,34.5,-0.7999999999999972,-2.3
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,35.2,43.5,48,,34.5,0.7000000000000028,2
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,33.8,43.5,48,,34.5,-0.7000000000000028,-2
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,22,34.2,43.5,48,,34.5,-0.29999999999999716,-0.9
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,29,35.4,43.5,48,,34.5,0.8999999999999986,2.6
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 A,43,36.1,43.5,48,,34.5,1.6000000000000014,4.6
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 8 A,50,35.6,43.5,48,,34.5,1.1000000000000014,3.2
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 A,164,21.9,43.5,48,,34.5,-12.600000000000001,-36.5
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-17,12.5,13.9,16.3,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.1,13.9,16.3,Y,11.1,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,10.9,13.9,16.3,,11.1,-0.1999999999999993,-1.8
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,11.4,13.9,16.3,,11.1,0.3000000000000007,2.7
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,10.9,13.9,16.3,,11.1,-0.1999999999999993,-1.8
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,22,10.8,13.9,16.3,,11.1,-0.29999999999999893,-2.7
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,29,11.3,13.9,16.3,,11.1,0.20000000000000107,1.8
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 A,43,11.6,13.9,16.3,,11.1,0.5,4.5
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 8 A,50,11.5,13.9,16.3,,11.1,0.40000000000000036,3.6
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 A,164,6.7,13.9,16.3,,11.1,-4.3999999999999995,-39.6
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-17,0.6,0.9,2.6,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.7,0.9,2.6,Y,0.7,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.2,0.9,2.6,,0.7,-0.49999999999999994,-71.4
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.1,0.9,2.6,,0.7,-0.6,-85.7
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,1.2,0.9,2.6,,0.7,0.5,71.4
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,22,0.8,0.9,2.6,,0.7,0.10000000000000009,14.3
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,29,2.9,0.9,2.6,,0.7,2.2,314.3
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 A,43,0.9,0.9,2.6,,0.7,0.20000000000000007,28.6
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 8 A,50,1.2,0.9,2.6,,0.7,0.5,71.4
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 A,164,0.3,0.9,2.6,,0.7,-0.39999999999999997,-57.1
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-17,0.3,0.1,0.9,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.7,0.1,0.9,Y,0.7,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.6,0.1,0.9,,0.7,-0.09999999999999998,-14.3
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.4,0.1,0.9,,0.7,-0.29999999999999993,-42.9
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,8,0.4,0.1,0.9,,0.7,-0.29999999999999993,-42.9
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,22,0.3,0.1,0.9,,0.7,-0.39999999999999997,-57.1
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,29,0.6,0.1,0.9,,0.7,-0.09999999999999998,-14.3
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 A,43,0.2,0.1,0.9,,0.7,-0.49999999999999994,-71.4
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 8 A,50,0.6,0.1,0.9,,0.7,-0.09999999999999998,-14.3
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 A,164,0.4,0.1,0.9,,0.7,-0.29999999999999993,-42.9
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-17,2.2,1.8,6.5,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4.7,1.8,6.5,Y,4.7,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,3.8,1.8,6.5,,4.7,-0.9000000000000004,-19.1
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,4.2,1.8,6.5,,4.7,-0.5,-10.6
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,8,4.6,1.8,6.5,,4.7,-0.10000000000000053,-2.1
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,22,2.4,1.8,6.5,,4.7,-2.3000000000000003,-48.9
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,29,1.7,1.8,6.5,,4.7,-3,-63.8
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 A,43,2.3,1.8,6.5,,4.7,-2.4000000000000004,-51.1
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 8 A,50,3.6,1.8,6.5,,4.7,-1.1,-23.4
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 A,164,3.8,1.8,6.5,,4.7,-0.9000000000000004,-19.1
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-17,216,150,450,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,207,150,450,Y,207,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,172,150,450,,207,-35,-16.9
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,145,150,450,,207,-62,-30
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,233,150,450,,207,26,12.6
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,22,297,150,450,,207,90,43.5
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,29,235,150,450,,207,28,13.5
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 A,43,261,150,450,,207,54,26.1
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 8 A,50,195,150,450,,207,-12,-5.8
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 A,164,292,150,450,,207,85,41.1
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,TESTR,Baseline,-17,13,181,758,Y,13,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-17,3.3,4,11,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,6.3,4,11,Y,6.3,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,4.7,4,11,,6.3,-1.5999999999999996,-25.4
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,5.1,4,11,,6.3,-1.2000000000000002,-19
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,7.1,4,11,,6.3,0.7999999999999998,12.7
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,22,3.7,4,11,,6.3,-2.5999999999999996,-41.3
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,29,11,4,11,,6.3,4.7,74.6
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 A,43,3.8,4,11,,6.3,-2.5,-39.7
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 8 A,50,11.3,4,11,,6.3,5.000000000000001,79.4
12A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 A,164,4.7,4,11,,6.3,-1.5999999999999996,-25.4
12A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-17,34.53,NA,NA,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,44.24,NA,NA,Y,44.24,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,22,56.27,NA,NA,,44.24,12.030000000000001,27.2
12A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 A,43,80.3,NA,NA,,44.24,36.059999999999995,81.5
12A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 A,164,388.79,NA,NA,,44.24,344.55,778.8
12A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-17,1.55,0.4,4,,NA,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,0.91,0.4,4,Y,0.91,NA,NA
12A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,22,0.91,0.4,4,,0.91,0,0
12A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 A,43,0.84,0.4,4,,0.91,-0.07000000000000006,-7.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Baseline,1,69,NA,NA,Y,69,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 2 Day 1 B,31,11,NA,NA,,69,-58,-84.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 3 Day 1 B,60,24,NA,NA,,69,-45,-65.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 4 Day 1 B,87,17,NA,NA,,69,-52,-75.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 5 Day 1 B,115,27,NA,NA,,69,-42,-60.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 6 Day 1 B,143,66,NA,NA,,69,-3,-4.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-13,19,1,45,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,28,1,45,Y,28,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,29,1,45,,28,1,3.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,15,23,1,45,,28,-5,-17.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,31,22,1,45,,28,-6,-21.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,60,25,1,45,,28,-3,-10.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 B,87,23,1,45,,28,-5,-17.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 B,115,27,1,45,,28,-1,-3.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 6 Day 1 B,143,24,1,45,,28,-4,-14.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,171,36,1,45,,28,8,28.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-13,3.2,3.5,4.9,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.2,3.5,4.9,Y,3.2,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,3.5,3.5,4.9,,3.2,0.2999999999999998,9.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,15,3.2,3.5,4.9,,3.2,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,31,3.3,3.5,4.9,,3.2,0.09999999999999964,3.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,60,3.5,3.5,4.9,,3.2,0.2999999999999998,9.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 4 Day 1 B,87,3.4,3.5,4.9,,3.2,0.19999999999999973,6.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 5 Day 1 B,115,3.4,3.5,4.9,,3.2,0.19999999999999973,6.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 6 Day 1 B,143,3.5,3.5,4.9,,3.2,0.2999999999999998,9.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment B,171,3.6,3.5,4.9,,3.2,0.3999999999999999,12.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-13,61,38,126,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,75,38,126,Y,75,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,82,38,126,,75,7,9.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,15,73,38,126,,75,-2,-2.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,31,82,38,126,,75,7,9.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,60,75,38,126,,75,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 B,87,88,38,126,,75,13,17.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 B,115,108,38,126,,75,33,44
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 6 Day 1 B,143,107,38,126,,75,32,42.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,171,132,38,126,,75,57,76
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-13,31,1,35,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,39,1,35,Y,39,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,34,1,35,,39,-5,-12.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,15,30,1,35,,39,-9,-23.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,31,31,1,35,,39,-8,-20.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,60,34,1,35,,39,-5,-12.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 B,87,26,1,35,,39,-13,-33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 B,115,36,1,35,,39,-3,-7.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 6 Day 1 B,143,35,1,35,,39,-4,-10.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,171,63,1,35,,39,24,61.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-13,28,6,23,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Baseline,1,33,6,23,Y,33,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 B,8,23,6,23,,33,-10,-30.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 15 B,15,28,6,23,,33,-5,-15.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 B,31,25,6,23,,33,-8,-24.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 B,60,32,6,23,,33,-1,-3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 4 Day 1 B,87,22,6,23,,33,-11,-33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 5 Day 1 B,115,23,6,23,,33,-10,-30.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 6 Day 1 B,143,22,6,23,,33,-11,-33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,End of Treatment B,171,26,6,23,,33,-7,-21.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-13,28.8,22,30,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,28.8,22,30,Y,28.8,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,28.6,22,30,,28.8,-0.1999999999999993,-0.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 15 B,15,29,22,30,,28.8,0.1999999999999993,0.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 B,31,29.7,22,30,,28.8,0.8999999999999986,3.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 B,60,29.6,22,30,,28.8,0.8000000000000007,2.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 4 Day 1 B,87,24.8,22,30,,28.8,-4,-13.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 5 Day 1 B,115,28.2,22,30,,28.8,-0.6000000000000014,-2.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 6 Day 1 B,143,30.3,22,30,,28.8,1.5,5.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment B,171,28.2,22,30,,28.8,-0.6000000000000014,-2.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-13,8.9,8.5,10.5,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8.9,8.5,10.5,Y,8.9,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,9.3,8.5,10.5,,8.9,0.40000000000000036,4.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,15,8.8,8.5,10.5,,8.9,-0.09999999999999964,-1.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,31,9,8.5,10.5,,8.9,0.09999999999999964,1.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,60,9.3,8.5,10.5,,8.9,0.40000000000000036,4.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 B,87,9.3,8.5,10.5,,8.9,0.40000000000000036,4.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 B,115,9.4,8.5,10.5,,8.9,0.5,5.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 6 Day 1 B,143,9.1,8.5,10.5,,8.9,0.1999999999999993,2.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment B,171,9.3,8.5,10.5,,8.9,0.40000000000000036,4.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-13,108,96,108,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,106,96,108,Y,106,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,104,96,108,,106,-2,-1.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,15,107,96,108,,106,1,0.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,31,103,96,108,,106,-3,-2.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,60,104,96,108,,106,-2,-1.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 B,87,105,96,108,,106,-1,-0.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 B,115,105,96,108,,106,-1,-0.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 6 Day 1 B,143,104,96,108,,106,-2,-1.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment B,171,103,96,108,,106,-3,-2.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-13,1.15,0.7,1.3,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1.34,0.7,1.3,Y,1.34,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,1.12,0.7,1.3,,1.34,-0.21999999999999997,-16.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,15,1.14,0.7,1.3,,1.34,-0.20000000000000018,-14.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,31,1.15,0.7,1.3,,1.34,-0.19000000000000017,-14.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,60,1.21,0.7,1.3,,1.34,-0.13000000000000012,-9.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 B,87,1.17,0.7,1.3,,1.34,-0.17000000000000015,-12.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 B,115,1.14,0.7,1.3,,1.34,-0.20000000000000018,-14.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 6 Day 1 B,143,1.2,0.7,1.3,,1.34,-0.14000000000000012,-10.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment B,171,1.29,0.7,1.3,,1.34,-0.050000000000000044,-3.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-13,77,60,100,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,80,60,100,Y,80,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 B,8,77,60,100,,80,-3,-3.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 15 B,15,73,60,100,,80,-7,-8.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 B,31,79,60,100,,80,-1,-1.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 B,60,94,60,100,,80,14,17.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 4 Day 1 B,87,72,60,100,,80,-8,-10
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 5 Day 1 B,115,91,60,100,,80,11,13.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 6 Day 1 B,143,71,60,100,,80,-9,-11.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,End of Treatment B,171,95,60,100,,80,15,18.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-13,229,100,220,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,241,100,220,Y,241,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,233,100,220,,241,-8,-3.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,15,236,100,220,,241,-5,-2.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,31,229,100,220,,241,-12,-5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,60,229,100,220,,241,-12,-5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 B,87,187,100,220,,241,-54,-22.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 B,115,236,100,220,,241,-5,-2.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 6 Day 1 B,143,234,100,220,,241,-7,-2.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,171,348,100,220,,241,107,44.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-13,4.8,3.5,5.2,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.4,3.5,5.2,Y,4.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.3,3.5,5.2,,4.4,-0.10000000000000053,-2.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,15,4,3.5,5.2,,4.4,-0.40000000000000036,-9.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,31,4.7,3.5,5.2,,4.4,0.2999999999999998,6.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,60,4.4,3.5,5.2,,4.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 B,87,4,3.5,5.2,,4.4,-0.40000000000000036,-9.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 B,115,4.8,3.5,5.2,,4.4,0.39999999999999947,9.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 6 Day 1 B,143,4.1,3.5,5.2,,4.4,-0.3000000000000007,-6.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment B,171,4.3,3.5,5.2,,4.4,-0.10000000000000053,-2.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-13,143,135,145,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,141,135,145,Y,141,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 B,8,140,135,145,,141,-1,-0.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 15 B,15,141,135,145,,141,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 B,31,139,135,145,,141,-2,-1.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 B,60,140,135,145,,141,-1,-0.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 4 Day 1 B,87,140,135,145,,141,-1,-0.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 5 Day 1 B,115,140,135,145,,141,-1,-0.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 6 Day 1 B,143,139,135,145,,141,-2,-1.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,End of Treatment B,171,139,135,145,,141,-2,-1.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-13,0.4,0.1,1.2,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.3,0.1,1.2,Y,0.3,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.3,0.1,1.2,,0.3,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,15,0.4,0.1,1.2,,0.3,0.10000000000000003,33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,31,0.4,0.1,1.2,,0.3,0.10000000000000003,33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,60,0.3,0.1,1.2,,0.3,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 4 Day 1 B,87,0.4,0.1,1.2,,0.3,0.10000000000000003,33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 5 Day 1 B,115,0.4,0.1,1.2,,0.3,0.10000000000000003,33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 6 Day 1 B,143,0.5,0.1,1.2,,0.3,0.2,66.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment B,171,0.4,0.1,1.2,,0.3,0.10000000000000003,33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-13,6,6,8.3,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.3,6,8.3,Y,6.3,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 B,8,6.8,6,8.3,,6.3,0.5,7.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 15 B,15,6.5,6,8.3,,6.3,0.20000000000000018,3.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 B,31,6.5,6,8.3,,6.3,0.20000000000000018,3.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 B,60,6.8,6,8.3,,6.3,0.5,7.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 4 Day 1 B,87,6.5,6,8.3,,6.3,0.20000000000000018,3.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 5 Day 1 B,115,6.7,6,8.3,,6.3,0.40000000000000036,6.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 6 Day 1 B,143,6.6,6,8.3,,6.3,0.2999999999999998,4.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment B,171,7.1,6,8.3,,6.3,0.7999999999999998,12.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-13,27.9,25.4,34.9,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,28.6,25.4,34.9,Y,28.6,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,29.9,25.4,34.9,,28.6,1.2999999999999972,4.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 15 B,15,31.3,25.4,34.9,,28.6,2.6999999999999993,9.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,31,30.4,25.4,34.9,,28.6,1.7999999999999972,6.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 B,60,28.2,25.4,34.9,,28.6,-0.40000000000000213,-1.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 B,87,28.3,25.4,34.9,,28.6,-0.3000000000000007,-1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 5 Day 1 B,115,31,25.4,34.9,,28.6,2.3999999999999986,8.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 6 Day 1 B,143,31,25.4,34.9,,28.6,2.3999999999999986,8.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,171,32.6,25.4,34.9,,28.6,4,14
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-13,1,2,3,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.1,2,3,Y,1.1,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,1,2,3,,1.1,-0.10000000000000009,-9.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 15 B,15,1.1,2,3,,1.1,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,31,1.1,2,3,,1.1,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 B,60,1.1,2,3,,1.1,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 B,87,1.1,2,3,,1.1,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 5 Day 1 B,115,1.1,2,3,,1.1,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 6 Day 1 B,143,1.1,2,3,,1.1,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,171,1.1,2,3,,1.1,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-13,13.2,12.3,14.9,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,13.5,12.3,14.9,Y,13.5,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,13,12.3,14.9,,13.5,-0.5,-3.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 15 B,15,13.7,12.3,14.9,,13.5,0.1999999999999993,1.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,31,13.7,12.3,14.9,,13.5,0.1999999999999993,1.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 B,60,13.4,12.3,14.9,,13.5,-0.09999999999999964,-0.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 4 Day 1 B,87,13.7,12.3,14.9,,13.5,0.1999999999999993,1.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 5 Day 1 B,115,13.6,12.3,14.9,,13.5,0.09999999999999964,0.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 6 Day 1 B,143,13.7,12.3,14.9,,13.5,0.1999999999999993,1.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment B,171,13.1,12.3,14.9,,13.5,-0.40000000000000036,-3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,,-13,0,0,0.2,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 B,8,0,0,0.2,,0,0,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 15 B,15,0,0,0.2,,0,0,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 B,31,0.1,0,0.2,,0,0.1,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 B,60,0,0,0.2,,0,0,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 4 Day 1 B,87,0,0,0.2,,0,0,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 5 Day 1 B,115,0,0,0.2,,0,0,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 6 Day 1 B,143,0,0,0.2,,0,0,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,End of Treatment B,171,0.1,0,0.2,,0,0.1,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,,-13,1,0,0.6,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.6,0,0.6,Y,0.6,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.4,0,0.6,,0.6,-0.19999999999999996,-33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 15 B,15,0.4,0,0.6,,0.6,-0.19999999999999996,-33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 B,31,0.6,0,0.6,,0.6,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 B,60,0.9,0,0.6,,0.6,0.30000000000000004,50
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 4 Day 1 B,87,0.4,0,0.6,,0.6,-0.19999999999999996,-33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 5 Day 1 B,115,0.4,0,0.6,,0.6,-0.19999999999999996,-33.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 6 Day 1 B,143,0.2,0,0.6,,0.6,-0.39999999999999997,-66.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment B,171,0.3,0,0.6,,0.6,-0.3,-50
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-13,3.13,4.5,6,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.02,4.5,6,Y,3.02,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,3.32,4.5,6,,3.02,0.2999999999999998,9.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,15,3.02,4.5,6,,3.02,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,31,3.12,4.5,6,,3.02,0.10000000000000009,3.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,60,2.98,4.5,6,,3.02,-0.040000000000000036,-1.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 B,87,2.58,4.5,6,,3.02,-0.43999999999999995,-14.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 B,115,3.19,4.5,6,,3.02,0.16999999999999993,5.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 6 Day 1 B,143,3.22,4.5,6,,3.02,0.20000000000000018,6.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,171,3.02,4.5,6,,3.02,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-13,29.8,42,52,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,28.7,42,52,Y,28.7,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,31.5,42,52,,28.7,2.8000000000000007,9.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,15,28.6,42,52,,28.7,-0.09999999999999787,-0.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,31,29.3,42,52,,28.7,0.6000000000000014,2.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,60,28.3,42,52,,28.7,-0.3999999999999986,-1.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 B,87,24.6,42,52,,28.7,-4.099999999999998,-14.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 B,115,29.8,42,52,,28.7,1.1000000000000014,3.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 6 Day 1 B,143,30.5,42,52,,28.7,1.8000000000000007,6.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment B,171,29.2,42,52,,28.7,0.5,1.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-13,9.9,13.9,16.3,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,9.4,13.9,16.3,Y,9.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,10.3,13.9,16.3,,9.4,0.9000000000000004,9.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,15,9.4,13.9,16.3,,9.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,31,9.5,13.9,16.3,,9.4,0.09999999999999964,1.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,60,9.2,13.9,16.3,,9.4,-0.20000000000000107,-2.1
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 B,87,8.1,13.9,16.3,,9.4,-1.3000000000000007,-13.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 B,115,9.9,13.9,16.3,,9.4,0.5,5.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 6 Day 1 B,143,10.1,13.9,16.3,,9.4,0.6999999999999993,7.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment B,171,9.7,13.9,16.3,,9.4,0.29999999999999893,3.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,,-13,0.5,1,4.5,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.7,1,4.5,Y,0.7,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,0.6,1,4.5,,0.7,-0.09999999999999998,-14.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 15 B,15,0.9,1,4.5,,0.7,0.20000000000000007,28.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 B,31,0.4,1,4.5,,0.7,-0.29999999999999993,-42.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 B,60,0.6,1,4.5,,0.7,-0.09999999999999998,-14.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 4 Day 1 B,87,0.9,1,4.5,,0.7,0.20000000000000007,28.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 5 Day 1 B,115,0.7,1,4.5,,0.7,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 6 Day 1 B,143,0.5,1,4.5,,0.7,-0.19999999999999996,-28.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment B,171,0.5,1,4.5,,0.7,-0.19999999999999996,-28.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,,-13,0.4,0.2,1,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.4,0.2,1,Y,0.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 B,8,1,0.2,1,,0.4,0.6,150
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 15 B,15,2.2,0.2,1,,0.4,1.8000000000000003,450
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 B,31,0.7,0.2,1,,0.4,0.29999999999999993,75
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 B,60,0.4,0.2,1,,0.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 4 Day 1 B,87,0.4,0.2,1,,0.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 5 Day 1 B,115,0.4,0.2,1,,0.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 6 Day 1 B,143,0.4,0.2,1,,0.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,End of Treatment B,171,0.3,0.2,1,,0.4,-0.10000000000000003,-25
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,,-13,1.8,1.9,8,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,1.6,1.9,8,Y,1.6,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 B,8,2.03,1.9,8,,1.6,0.4299999999999997,26.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 15 B,15,3.53,1.9,8,,1.6,1.9299999999999997,120.6
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 B,31,3,1.9,8,,1.6,1.4,87.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 B,60,1.3,1.9,8,,1.6,-0.30000000000000004,-18.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 4 Day 1 B,87,0.9,1.9,8,,1.6,-0.7000000000000001,-43.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 5 Day 1 B,115,2.2,1.9,8,,1.6,0.6000000000000001,37.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 6 Day 1 B,143,2,1.9,8,,1.6,0.3999999999999999,25
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment B,171,2.1,1.9,8,,1.6,0.5,31.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-13,207,150,450,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,181,150,450,Y,181,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,233,150,450,,181,52,28.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,15,203,150,450,,181,22,12.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,31,334,150,450,,181,153,84.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,60,173,150,450,,181,-8,-4.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 4 Day 1 B,87,185,150,450,,181,4,2.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 5 Day 1 B,115,201,150,450,,181,20,11
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 6 Day 1 B,143,205,150,450,,181,24,13.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment B,171,213,150,450,,181,32,17.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,TESTR,Baseline,-13,10.92,300,1080,Y,10.92,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,,-13,3.7,4.5,11,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,3.4,4.5,11,Y,3.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,3.9,4.5,11,,3.4,0.5,14.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 15 B,15,6.2,4.5,11,,3.4,2.8000000000000003,82.4
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 B,31,4.8,4.5,11,,3.4,1.4,41.2
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 B,60,3.2,4.5,11,,3.4,-0.19999999999999973,-5.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 4 Day 1 B,87,3.2,4.5,11,,3.4,-0.19999999999999973,-5.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 5 Day 1 B,115,3.7,4.5,11,,3.4,0.30000000000000027,8.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 6 Day 1 B,143,3.9,4.5,11,,3.4,0.5,14.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment B,171,3.4,4.5,11,,3.4,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,,-13,14.28,NA,NA,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,11.78,NA,NA,Y,11.78,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,31,5.24,NA,NA,,11.78,-6.539999999999999,-55.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 B,60,5.9,NA,NA,,11.78,-5.879999999999999,-49.9
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 4 Day 1 B,87,8.62,NA,NA,,11.78,-3.16,-26.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 5 Day 1 B,115,14.17,NA,NA,,11.78,2.3900000000000006,20.3
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 6 Day 1 B,143,24.24,NA,NA,,11.78,12.459999999999999,105.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment B,171,25.65,NA,NA,,11.78,13.87,117.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),Cycle 6 Day 1 B,143,0.42,0.8,1.5,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),End of Treatment B,171,0.42,0.8,1.5,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-13,3.11,0.4,4.2,,NA,NA,NA
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,3.61,0.4,4.2,Y,3.61,0,0
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,3.51,NA,NA,,3.61,-0.10000000000000009,-2.8
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,15,3.14,0.4,4.2,,3.61,-0.46999999999999975,-13
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,31,3.78,0.4,4.2,,3.61,0.16999999999999993,4.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,60,0.18,0.4,4.2,,3.61,-3.4299999999999997,-95
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 B,87,0.01,0.4,4.2,,3.61,-3.6,-99.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 B,115,2.98,0.4,4.2,,3.61,-0.6299999999999999,-17.5
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 6 Day 1 B,143,27.86,0.4,4.2,,3.61,24.25,671.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,171,44.21,0.4,4.2,,3.61,40.6,1124.7
12B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Triiodothyronine (T3),End of Treatment B,171,0.25,2.5,3.9,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Baseline,1,0,NA,NA,Y,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 1 Day 1 C,29,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 3 Day 1 C,85,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 4 Day 1 C,114,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 5 Day 1 C,141,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 6 Day 1 C,169,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 7 Day 1 C,197,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 8 Day 1 C,225,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 9 Day 1 C,253,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 10 Day 1 C,281,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 12 Day 1 C,337,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 5 Day 1 C,421,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,Cycle 17 Day 1 C,478,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,,CTC,End of Treatment C,505,0,NA,NA,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,-113,9,3,61,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,-14,6,3,61,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,10,3,61,Y,10,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,12,3,61,,10,2,20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,16,11,3,61,,10,1,10
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,10,3,61,,10,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,29,7,3,61,,10,-3,-30
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,36,11,3,61,,10,1,10
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 C,57,7,3,61,,10,-3,-30
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 C,85,11,3,61,,10,1,10
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 C,114,13,3,61,,10,3,30
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 C,138,8,3,61,,10,-2,-20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 6 Day 1 C,169,6,3,61,,10,-4,-40
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 7 Day 1 C,197,7,3,61,,10,-3,-30
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 8 Day 1 C,225,7,3,61,,10,-3,-30
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 10 Day 1 C,281,7,3,61,,10,-3,-30
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 11 Day 1 C,309,10,3,61,,10,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 12 Day 1 C,337,8,3,61,,10,-2,-20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 13 Day 1 C,365,6,3,61,,10,-4,-40
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 14 Day 1 C,393,9,3,61,,10,-1,-10
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 15 Day 1 C,421,6,3,61,,10,-4,-40
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,449,16,3,61,,10,6,60
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,478,7,3,61,,10,-3,-30
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,505,6,3,61,,10,-4,-40
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,-113,4.1,3.8,5.5,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,-14,4.4,3.8,5.5,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Baseline,1,4,3.8,5.5,Y,4,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),I-P Lead In C,8,4.2,3.8,5.5,,4,0.20000000000000018,5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),I-P Lead In C,16,4,3.8,5.5,,4,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),I-P Lead In C,22,3.8,3.8,5.5,,4,-0.20000000000000018,-5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,29,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,36,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,57,3.8,3.8,5.5,,4,-0.20000000000000018,-5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 1 C,85,3.7,3.8,5.5,,4,-0.2999999999999998,-7.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 4 Day 1 C,114,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 5 Day 1 C,138,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 6 Day 1 C,169,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 7 Day 1 C,197,4,3.8,5.5,,4,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 8 Day 1 C,225,4.1,3.8,5.5,,4,0.09999999999999964,2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 10 Day 1 C,281,3.8,3.8,5.5,,4,-0.20000000000000018,-5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 11 Day 1 C,309,4.1,3.8,5.5,,4,0.09999999999999964,2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 12 Day 1 C,337,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 13 Day 1 C,365,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 14 Day 1 C,393,4,3.8,5.5,,4,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 15 Day 1 C,421,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,449,3.5,3.8,5.5,,4,-0.5,-12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,478,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),End of Treatment C,505,3.6,3.8,5.5,,4,-0.3999999999999999,-10
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,-113,33,33,98,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,-14,80,33,98,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,83,33,98,Y,83,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,80,33,98,,83,-3,-3.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,16,69,33,98,,83,-14,-16.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,73,33,98,,83,-10,-12
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,29,76,33,98,,83,-7,-8.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,36,72,33,98,,83,-11,-13.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,57,50,33,98,,83,-33,-39.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 C,85,44,33,98,,83,-39,-47
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 C,114,35,33,98,,83,-48,-57.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 C,138,29,33,98,,83,-54,-65.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 6 Day 1 C,169,27,33,98,,83,-56,-67.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 7 Day 1 C,197,32,33,98,,83,-51,-61.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 8 Day 1 C,225,32,33,98,,83,-51,-61.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 10 Day 1 C,281,28,33,98,,83,-55,-66.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 11 Day 1 C,309,33,33,98,,83,-50,-60.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 12 Day 1 C,337,30,33,98,,83,-53,-63.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 13 Day 1 C,365,30,33,98,,83,-53,-63.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 14 Day 1 C,393,29,33,98,,83,-54,-65.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 15 Day 1 C,421,34,33,98,,83,-49,-59
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,449,32,33,98,,83,-51,-61.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,478,34,33,98,,83,-49,-59
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,505,29,33,98,,83,-54,-65.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-113,11,5,38,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-14,11,5,38,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,12,5,38,Y,12,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,15,5,38,,12,3,25
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,16,15,5,38,,12,3,25
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,73,5,38,,12,61,508.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,29,13,5,38,,12,1,8.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,36,16,5,38,,12,4,33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,57,10,5,38,,12,-2,-16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 C,85,10,5,38,,12,-2,-16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 C,114,11,5,38,,12,-1,-8.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 C,138,11,5,38,,12,-1,-8.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 6 Day 1 C,169,14,5,38,,12,2,16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 7 Day 1 C,197,13,5,38,,12,1,8.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 8 Day 1 C,225,10,5,38,,12,-2,-16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 10 Day 1 C,281,12,5,38,,12,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 11 Day 1 C,309,13,5,38,,12,1,8.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 12 Day 1 C,337,10,5,38,,12,-2,-16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 13 Day 1 C,365,9,5,38,,12,-3,-25
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 14 Day 1 C,393,10,5,38,,12,-2,-16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 15 Day 1 C,421,11,5,38,,12,-1,-8.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,449,14,5,38,,12,2,16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,478,10,5,38,,12,-2,-16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,505,10,5,38,,12,-2,-16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,,-113,21,7,25,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,,-14,42,7,25,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Baseline,1,35,7,25,Y,35,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,I-P Lead In C,8,31,7,25,,35,-4,-11.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,I-P Lead In C,16,28,7,25,,35,-7,-20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,I-P Lead In C,22,37,7,25,,35,2,5.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 1 C,29,24,7,25,,35,-11,-31.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 8 C,36,21,7,25,,35,-14,-40
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 2 Day 1 C,57,34,7,25,,35,-1,-2.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 3 Day 1 C,85,34,7,25,,35,-1,-2.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 4 Day 1 C,114,33,7,25,,35,-2,-5.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 5 Day 1 C,138,25,7,25,,35,-10,-28.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 6 Day 1 C,169,20,7,25,,35,-15,-42.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 7 Day 1 C,197,46,7,25,,35,11,31.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 8 Day 1 C,225,38,7,25,,35,3,8.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 10 Day 1 C,281,10,7,25,,35,-25,-71.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 11 Day 1 C,309,19,7,25,,35,-16,-45.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 12 Day 1 C,337,28,7,25,,35,-7,-20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 13 Day 1 C,365,30,7,25,,35,-5,-14.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 14 Day 1 C,393,27,7,25,,35,-8,-22.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,Cycle 15 Day 1 C,421,40,7,25,,35,5,14.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,,449,15,7,25,,35,-20,-57.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,,478,21,7,25,,35,-14,-40
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,BUN,End of Treatment C,505,15,7,25,,35,-20,-57.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,,-113,20,21,31,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,,-14,23,21,31,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Baseline,1,25,21,31,Y,25,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,I-P Lead In C,8,23,21,31,,25,-2,-8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,I-P Lead In C,16,24,21,31,,25,-1,-4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,I-P Lead In C,22,23,21,31,,25,-2,-8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 1 C,29,22,21,31,,25,-3,-12
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 8 C,36,20,21,31,,25,-5,-20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 2 Day 1 C,57,18,21,31,,25,-7,-28
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 3 Day 1 C,85,20,21,31,,25,-5,-20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 4 Day 1 C,114,22,21,31,,25,-3,-12
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 5 Day 1 C,138,21,21,31,,25,-4,-16
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 6 Day 1 C,169,22,21,31,,25,-3,-12
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 7 Day 1 C,197,19,21,31,,25,-6,-24
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 8 Day 1 C,225,22,21,31,,25,-3,-12
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 10 Day 1 C,281,20,21,31,,25,-5,-20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 11 Day 1 C,309,24,21,31,,25,-1,-4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 12 Day 1 C,337,23,21,31,,25,-2,-8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 13 Day 1 C,365,18,21,31,,25,-7,-28
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 14 Day 1 C,393,19,21,31,,25,-6,-24
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 15 Day 1 C,421,21,21,31,,25,-4,-16
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,,449,23,21,31,,25,-2,-8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,,478,22,21,31,,25,-3,-12
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Bicarbonate,End of Treatment C,505,25,21,31,,25,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,-113,9.1,8.7,10.1,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,-14,10,8.7,10.1,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Baseline,1,9.6,8.7,10.1,Y,9.6,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),I-P Lead In C,8,9.4,8.7,10.1,,9.6,-0.1999999999999993,-2.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),I-P Lead In C,16,9.4,8.7,10.1,,9.6,-0.1999999999999993,-2.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),I-P Lead In C,22,8.9,8.7,10.1,,9.6,-0.6999999999999993,-7.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,29,9,8.7,10.1,,9.6,-0.5999999999999996,-6.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,36,8.1,8.7,10.1,,9.6,-1.5,-15.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,57,8.2,8.7,10.1,,9.6,-1.4000000000000004,-14.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 C,85,8.3,8.7,10.1,,9.6,-1.299999999999999,-13.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 C,114,8.7,8.7,10.1,,9.6,-0.9000000000000004,-9.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 C,138,9,8.7,10.1,,9.6,-0.5999999999999996,-6.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 6 Day 1 C,169,9,8.7,10.1,,9.6,-0.5999999999999996,-6.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 7 Day 1 C,197,9.5,8.7,10.1,,9.6,-0.09999999999999964,-1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 8 Day 1 C,225,9.3,8.7,10.1,,9.6,-0.29999999999999893,-3.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 10 Day 1 C,281,7.9,8.7,10.1,,9.6,-1.6999999999999993,-17.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 11 Day 1 C,309,9.5,8.7,10.1,,9.6,-0.09999999999999964,-1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 12 Day 1 C,337,9.1,8.7,10.1,,9.6,-0.5,-5.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 13 Day 1 C,365,8.8,8.7,10.1,,9.6,-0.7999999999999989,-8.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 14 Day 1 C,393,8.7,8.7,10.1,,9.6,-0.9000000000000004,-9.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 15 Day 1 C,421,9.1,8.7,10.1,,9.6,-0.5,-5.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,449,8.9,8.7,10.1,,9.6,-0.6999999999999993,-7.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,478,9.2,8.7,10.1,,9.6,-0.40000000000000036,-4.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),End of Treatment C,505,8.6,8.7,10.1,,9.6,-1,-10.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,-113,102,99,107,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,-14,103,99,107,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Baseline,1,107,99,107,Y,107,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),I-P Lead In C,8,105,99,107,,107,-2,-1.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),I-P Lead In C,16,106,99,107,,107,-1,-0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),I-P Lead In C,22,106,99,107,,107,-1,-0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,29,108,99,107,,107,1,0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,36,111,99,107,,107,4,3.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,57,108,99,107,,107,1,0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 C,85,109,99,107,,107,2,1.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 C,114,109,99,107,,107,2,1.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 C,138,107,99,107,,107,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 6 Day 1 C,169,104,99,107,,107,-3,-2.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 7 Day 1 C,197,109,99,107,,107,2,1.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 8 Day 1 C,225,104,99,107,,107,-3,-2.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 10 Day 1 C,281,107,99,107,,107,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 11 Day 1 C,309,106,99,107,,107,-1,-0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 12 Day 1 C,337,104,99,107,,107,-3,-2.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 13 Day 1 C,365,108,99,107,,107,1,0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 14 Day 1 C,393,110,99,107,,107,3,2.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 15 Day 1 C,421,111,99,107,,107,4,3.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,449,107,99,107,,107,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,478,107,99,107,,107,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),End of Treatment C,505,108,99,107,,107,1,0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,-113,1.16,0.7,1.3,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,-14,1.35,0.7,1.3,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Baseline,1,1.14,0.7,1.3,Y,1.14,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),I-P Lead In C,8,1.15,0.7,1.3,,1.14,0.010000000000000009,0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),I-P Lead In C,16,1.17,0.7,1.3,,1.14,0.030000000000000027,2.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),I-P Lead In C,22,1.3,0.7,1.3,,1.14,0.16000000000000014,14
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,29,1.06,0.7,1.3,,1.14,-0.07999999999999985,-7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,36,0.87,0.7,1.3,,1.14,-0.2699999999999999,-23.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,57,0.98,0.7,1.3,,1.14,-0.15999999999999992,-14
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 C,85,1.14,0.7,1.3,,1.14,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 C,114,1.02,0.7,1.3,,1.14,-0.11999999999999988,-10.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 C,138,1.04,0.7,1.3,,1.14,-0.09999999999999987,-8.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 6 Day 1 C,169,1.33,0.7,1.3,,1.14,0.19000000000000017,16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 7 Day 1 C,197,1.29,0.7,1.3,,1.14,0.15000000000000013,13.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 8 Day 1 C,225,1.47,0.7,1.3,,1.14,0.33000000000000007,28.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 10 Day 1 C,281,0.83,0.7,1.3,,1.14,-0.30999999999999994,-27.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 11 Day 1 C,309,0.92,0.7,1.3,,1.14,-0.21999999999999986,-19.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 12 Day 1 C,337,1.15,0.7,1.3,,1.14,0.010000000000000009,0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 13 Day 1 C,365,1.2,0.7,1.3,,1.14,0.06000000000000005,5.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 14 Day 1 C,393,1.19,0.7,1.3,,1.14,0.050000000000000044,4.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 15 Day 1 C,421,1.25,0.7,1.3,,1.14,0.1100000000000001,9.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,449,1.1,0.7,1.3,,1.14,-0.039999999999999813,-3.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,478,1.03,0.7,1.3,,1.14,-0.10999999999999988,-9.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),End of Treatment C,505,0.92,0.7,1.3,,1.14,-0.21999999999999986,-19.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,,-113,93,63,130,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,,-14,97,63,130,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Baseline,1,97,63,130,Y,97,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,I-P Lead In C,8,94,63,130,,97,-3,-3.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,I-P Lead In C,16,98,63,130,,97,1,1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,I-P Lead In C,22,88,63,130,,97,-9,-9.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 1 C,29,106,63,130,,97,9,9.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 8 C,36,98,63,130,,97,1,1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 2 Day 1 C,57,93,63,130,,97,-4,-4.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 3 Day 1 C,85,89,63,130,,97,-8,-8.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 4 Day 1 C,114,92,63,130,,97,-5,-5.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 5 Day 1 C,138,84,63,130,,97,-13,-13.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 6 Day 1 C,169,94,63,130,,97,-3,-3.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 7 Day 1 C,197,95,63,130,,97,-2,-2.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 8 Day 1 C,225,102,63,130,,97,5,5.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 10 Day 1 C,281,82,63,130,,97,-15,-15.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 11 Day 1 C,309,92,63,130,,97,-5,-5.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 12 Day 1 C,337,92,63,130,,97,-5,-5.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 13 Day 1 C,365,92,63,130,,97,-5,-5.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 14 Day 1 C,393,119,63,130,,97,22,22.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 15 Day 1 C,421,105,63,130,,97,8,8.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,,449,96,63,130,,97,-1,-1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,,478,100,63,130,,97,3,3.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Glucose,End of Treatment C,505,97,63,130,,97,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-113,132,100,210,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-14,162,100,210,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,155,100,210,Y,155,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,168,100,210,,155,13,8.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,16,218,100,210,,155,63,40.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,231,100,210,,155,76,49
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,29,207,100,210,,155,52,33.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,36,277,100,210,,155,122,78.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 C,57,154,100,210,,155,-1,-0.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 C,85,156,100,210,,155,1,0.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 C,114,139,100,210,,155,-16,-10.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 C,138,144,100,210,,155,-11,-7.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 6 Day 1 C,169,167,100,210,,155,12,7.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 7 Day 1 C,197,143,100,210,,155,-12,-7.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 8 Day 1 C,225,156,100,210,,155,1,0.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 10 Day 1 C,281,150,100,210,,155,-5,-3.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 11 Day 1 C,309,142,100,210,,155,-13,-8.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 12 Day 1 C,337,139,100,210,,155,-16,-10.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 13 Day 1 C,365,169,100,210,,155,14,9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 14 Day 1 C,393,129,100,210,,155,-26,-16.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 15 Day 1 C,421,158,100,210,,155,3,1.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,449,123,100,210,,155,-32,-20.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,478,162,100,210,,155,7,4.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,505,139,100,210,,155,-16,-10.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,-113,4.4,3.5,5.1,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,-14,5.2,3.5,5.1,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Baseline,1,4.7,3.5,5.1,Y,4.7,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),I-P Lead In C,8,5,3.5,5.1,,4.7,0.2999999999999998,6.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),I-P Lead In C,16,4.9,3.5,5.1,,4.7,0.20000000000000018,4.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.9,3.5,5.1,,4.7,0.20000000000000018,4.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,29,4.2,3.5,5.1,,4.7,-0.5,-10.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,36,5.1,3.5,5.1,,4.7,0.39999999999999947,8.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,57,5.3,3.5,5.1,,4.7,0.5999999999999996,12.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 C,85,5.4,3.5,5.1,,4.7,0.7000000000000002,14.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 C,114,4.9,3.5,5.1,,4.7,0.20000000000000018,4.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 C,138,4.6,3.5,5.1,,4.7,-0.10000000000000053,-2.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 6 Day 1 C,169,4.7,3.5,5.1,,4.7,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 7 Day 1 C,197,4.8,3.5,5.1,,4.7,0.09999999999999964,2.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 8 Day 1 C,225,5.1,3.5,5.1,,4.7,0.39999999999999947,8.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 10 Day 1 C,281,4.1,3.5,5.1,,4.7,-0.6000000000000005,-12.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 11 Day 1 C,309,4.7,3.5,5.1,,4.7,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 12 Day 1 C,337,4.4,3.5,5.1,,4.7,-0.2999999999999998,-6.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 13 Day 1 C,365,4.5,3.5,5.1,,4.7,-0.20000000000000018,-4.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 14 Day 1 C,393,3.5,3.5,5.1,,4.7,-1.2000000000000002,-25.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 15 Day 1 C,421,3.8,3.5,5.1,,4.7,-0.9000000000000004,-19.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,449,4.1,3.5,5.1,,4.7,-0.6000000000000005,-12.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,478,3.8,3.5,5.1,,4.7,-0.9000000000000004,-19.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),End of Treatment C,505,3.6,3.5,5.1,,4.7,-1.1,-23.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,,-113,131,136,145,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,,-14,136,136,145,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Baseline,1,138,136,145,Y,138,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,I-P Lead In C,8,137,136,145,,138,-1,-0.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,I-P Lead In C,16,137,136,145,,138,-1,-0.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,I-P Lead In C,22,136,136,145,,138,-2,-1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 1 C,29,136,136,145,,138,-2,-1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 8 C,36,138,136,145,,138,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 2 Day 1 C,57,132,136,145,,138,-6,-4.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 3 Day 1 C,85,134,136,145,,138,-4,-2.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 4 Day 1 C,114,139,136,145,,138,1,0.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 5 Day 1 C,138,138,136,145,,138,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 6 Day 1 C,169,133,136,145,,138,-5,-3.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 7 Day 1 C,197,138,136,145,,138,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 8 Day 1 C,225,135,136,145,,138,-3,-2.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 10 Day 1 C,281,138,136,145,,138,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 11 Day 1 C,309,138,136,145,,138,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 12 Day 1 C,337,135,136,145,,138,-3,-2.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 13 Day 1 C,365,137,136,145,,138,-1,-0.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 14 Day 1 C,393,138,136,145,,138,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 15 Day 1 C,421,140,136,145,,138,2,1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,,449,139,136,145,,138,1,0.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,,478,139,136,145,,138,1,0.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Sodium,End of Treatment C,505,140,136,145,,138,2,1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,-113,0.3,0.1,1.4,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,-14,0.4,0.1,1.4,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Baseline,1,0.3,0.1,1.4,Y,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,I-P Lead In C,8,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,I-P Lead In C,16,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,I-P Lead In C,22,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,29,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,36,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,57,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 3 Day 1 C,85,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 4 Day 1 C,114,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 5 Day 1 C,138,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 6 Day 1 C,169,0.4,0.1,1.4,,0.3,0.10000000000000003,33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 7 Day 1 C,197,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 8 Day 1 C,225,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 10 Day 1 C,281,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 11 Day 1 C,309,0.4,0.1,1.4,,0.3,0.10000000000000003,33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 12 Day 1 C,337,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 13 Day 1 C,365,0.4,0.1,1.4,,0.3,0.10000000000000003,33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 14 Day 1 C,393,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 15 Day 1 C,421,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,449,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,478,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Bilirubin,End of Treatment C,505,0.3,0.1,1.4,,0.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,,-113,7.4,6.3,8.1,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,,-14,8.2,6.3,8.1,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Baseline,1,7.3,6.3,8.1,Y,7.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,I-P Lead In C,8,7.6,6.3,8.1,,7.3,0.2999999999999998,4.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,I-P Lead In C,16,7.2,6.3,8.1,,7.3,-0.09999999999999964,-1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,I-P Lead In C,22,7.1,6.3,8.1,,7.3,-0.20000000000000018,-2.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 1 C,29,7.2,6.3,8.1,,7.3,-0.09999999999999964,-1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 8 C,36,7.6,6.3,8.1,,7.3,0.2999999999999998,4.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 2 Day 1 C,57,7.3,6.3,8.1,,7.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 3 Day 1 C,85,7,6.3,8.1,,7.3,-0.2999999999999998,-4.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 4 Day 1 C,114,7.2,6.3,8.1,,7.3,-0.09999999999999964,-1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 5 Day 1 C,138,7.2,6.3,8.1,,7.3,-0.09999999999999964,-1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 6 Day 1 C,169,7.2,6.3,8.1,,7.3,-0.09999999999999964,-1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 7 Day 1 C,197,7.3,6.3,8.1,,7.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 8 Day 1 C,225,7.5,6.3,8.1,,7.3,0.20000000000000018,2.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 10 Day 1 C,281,6.5,6.3,8.1,,7.3,-0.7999999999999998,-11
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 11 Day 1 C,309,7.6,6.3,8.1,,7.3,0.2999999999999998,4.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 12 Day 1 C,337,7.4,6.3,8.1,,7.3,0.10000000000000053,1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 13 Day 1 C,365,7.2,6.3,8.1,,7.3,-0.09999999999999964,-1.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 14 Day 1 C,393,7.1,6.3,8.1,,7.3,-0.20000000000000018,-2.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 15 Day 1 C,421,7.3,6.3,8.1,,7.3,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,,449,6.5,6.3,8.1,,7.3,-0.7999999999999998,-11
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,,478,7,6.3,8.1,,7.3,-0.2999999999999998,-4.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Chemistry,Total Protein,End of Treatment C,505,6.6,6.3,8.1,,7.3,-0.7000000000000002,-9.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-14,27,25.5,36,Y,27,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-14,1.09,0.9,1.3,Y,1.09,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Baseline,-14,11.7,12.1,15.2,Y,11.7,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,,-14,0.1,0,0.1,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Baseline,1,0,0,0.1,Y,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,I-P Lead In C,8,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,I-P Lead In C,16,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 1 C,29,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 8 C,36,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 2 Day 1 C,57,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 3 Day 1 C,85,0,0,0.1,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 4 Day 1 C,114,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 5 Day 1 C,138,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 6 Day 1 C,169,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 7 Day 1 C,197,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 8 Day 1 C,225,0,0,0.1,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 9 Day 1 C,253,0,0,0.1,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 10 Day 1 C,281,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 11 Day 1 C,309,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 12 Day 1 C,337,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 13 Day 1 C,365,0.1,0,0.2,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 14 Day 1 C,393,0,0,0.1,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,Cycle 15 Day 1 C,421,0,0,0.1,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,,449,0,0,0.1,,0,0,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,,478,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Basophils,End of Treatment C,505,0.1,0,0.1,,0,0.1,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,,-14,0.1,0,0.4,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Baseline,1,0.1,0,0.4,Y,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,I-P Lead In C,8,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,I-P Lead In C,16,0.2,0,0.4,,0.1,0.1,100
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,I-P Lead In C,22,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 1 C,29,0.6,0,0.4,,0.1,0.5,500
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 8 C,36,0.5,0,0.4,,0.1,0.4,400
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 2 Day 1 C,57,0.2,0,0.4,,0.1,0.1,100
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 3 Day 1 C,85,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 4 Day 1 C,114,0.2,0,0.4,,0.1,0.1,100
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 5 Day 1 C,138,0.2,0,0.4,,0.1,0.1,100
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 6 Day 1 C,169,0.2,0,0.4,,0.1,0.1,100
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 7 Day 1 C,197,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 8 Day 1 C,225,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 9 Day 1 C,253,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 10 Day 1 C,281,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 11 Day 1 C,309,0.2,0,0.4,,0.1,0.1,100
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 12 Day 1 C,337,0.2,0,0.4,,0.1,0.1,100
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 13 Day 1 C,365,0.1,0,0.7,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 14 Day 1 C,393,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 15 Day 1 C,421,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,,449,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,,478,0.1,0,0.4,,0.1,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Eosinophils,End of Treatment C,505,0.2,0,0.4,,0.1,0.1,100
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),,-14,4.01,4,6,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Baseline,1,3.81,4,6,Y,3.81,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,3.93,4,6,,3.81,0.1200000000000001,3.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),I-P Lead In C,16,3.75,4,6,,3.81,-0.06000000000000005,-1.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.6,4,6,,3.81,-0.20999999999999996,-5.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,29,3.71,4,6,,3.81,-0.10000000000000009,-2.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,36,3.64,4,6,,3.81,-0.16999999999999993,-4.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,57,3.39,4,6,,3.81,-0.41999999999999993,-11
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 C,85,3.56,4,6,,3.81,-0.25,-6.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 C,114,3.91,4,6,,3.81,0.10000000000000009,2.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 C,138,3.91,4,6,,3.81,0.10000000000000009,2.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 6 Day 1 C,169,3.85,4,6,,3.81,0.040000000000000036,1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 7 Day 1 C,197,3.72,4,6,,3.81,-0.08999999999999986,-2.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 8 Day 1 C,225,3.88,4,6,,3.81,0.06999999999999984,1.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 9 Day 1 C,253,3.82,4,6,,3.81,0.009999999999999787,0.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 10 Day 1 C,281,3.88,4,6,,3.81,0.06999999999999984,1.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 11 Day 1 C,309,4.25,4,6,,3.81,0.43999999999999995,11.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 12 Day 1 C,337,4.16,4,6,,3.81,0.3500000000000001,9.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 13 Day 1 C,365,3.9,4.7,6.1,,3.81,0.08999999999999986,2.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 14 Day 1 C,393,4.06,4,6,,3.81,0.24999999999999956,6.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 15 Day 1 C,421,3.84,4,6,,3.81,0.029999999999999805,0.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),,449,3.68,4,6,,3.81,-0.1299999999999999,-3.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),,478,3.93,4,6,,3.81,0.1200000000000001,3.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),End of Treatment C,505,3.85,4,6,,3.81,0.040000000000000036,1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),,-14,34,43.5,48,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Baseline,1,32.9,43.5,48,Y,32.9,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),I-P Lead In C,8,34.1,43.5,48,,32.9,1.2000000000000028,3.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),I-P Lead In C,16,32.4,43.5,48,,32.9,-0.5,-1.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),I-P Lead In C,22,31.4,43.5,48,,32.9,-1.5,-4.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,29,31.9,43.5,48,,32.9,-1,-3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,36,31.9,43.5,48,,32.9,-1,-3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,57,29.8,43.5,48,,32.9,-3.099999999999998,-9.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 C,85,31.7,43.5,48,,32.9,-1.1999999999999993,-3.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 C,114,34.9,43.5,48,,32.9,2,6.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 C,138,34.6,43.5,48,,32.9,1.7000000000000028,5.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 6 Day 1 C,169,33.5,43.5,48,,32.9,0.6000000000000014,1.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 7 Day 1 C,197,32.3,43.5,48,,32.9,-0.6000000000000014,-1.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 8 Day 1 C,225,33.9,43.5,48,,32.9,1,3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 9 Day 1 C,253,31.8,43.5,48,,32.9,-1.0999999999999979,-3.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 10 Day 1 C,281,33.2,43.5,48,,32.9,0.30000000000000426,0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 11 Day 1 C,309,35.8,43.5,48,,32.9,2.8999999999999986,8.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 12 Day 1 C,337,34.9,43.5,48,,32.9,2,6.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 13 Day 1 C,365,32.5,42,52,,32.9,-0.3999999999999986,-1.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 14 Day 1 C,393,33.6,43.5,48,,32.9,0.7000000000000028,2.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 15 Day 1 C,421,32.1,43.5,48,,32.9,-0.7999999999999972,-2.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),,449,31.2,43.5,48,,32.9,-1.6999999999999993,-5.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),,478,34.2,43.5,48,,32.9,1.3000000000000043,4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),End of Treatment C,505,32.5,43.5,48,,32.9,-0.3999999999999986,-1.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),,-14,10.9,13.9,16.3,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Baseline,1,10.6,13.9,16.3,Y,10.6,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,11.2,13.9,16.3,,10.6,0.5999999999999996,5.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),I-P Lead In C,16,10.6,13.9,16.3,,10.6,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,10.2,13.9,16.3,,10.6,-0.40000000000000036,-3.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,29,10.5,13.9,16.3,,10.6,-0.09999999999999964,-0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,36,10.2,13.9,16.3,,10.6,-0.40000000000000036,-3.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,57,9.6,13.9,16.3,,10.6,-1,-9.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 C,85,10.3,13.9,16.3,,10.6,-0.29999999999999893,-2.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 C,114,11,13.9,16.3,,10.6,0.40000000000000036,3.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 C,138,11.1,13.9,16.3,,10.6,0.5,4.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 6 Day 1 C,169,10.8,13.9,16.3,,10.6,0.20000000000000107,1.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 7 Day 1 C,197,10.3,13.9,16.3,,10.6,-0.29999999999999893,-2.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 8 Day 1 C,225,10.8,13.9,16.3,,10.6,0.20000000000000107,1.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 9 Day 1 C,253,10.4,13.9,16.3,,10.6,-0.1999999999999993,-1.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 10 Day 1 C,281,10.6,13.9,16.3,,10.6,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 11 Day 1 C,309,11.7,13.9,16.3,,10.6,1.0999999999999996,10.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 12 Day 1 C,337,11.3,13.9,16.3,,10.6,0.7000000000000011,6.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 13 Day 1 C,365,10.7,14,18,,10.6,0.09999999999999964,0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 14 Day 1 C,393,10.9,13.9,16.3,,10.6,0.3000000000000007,2.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 15 Day 1 C,421,10.5,13.9,16.3,,10.6,-0.09999999999999964,-0.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),,449,10.2,13.9,16.3,,10.6,-0.40000000000000036,-3.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),,478,11.2,13.9,16.3,,10.6,0.5999999999999996,5.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),End of Treatment C,505,10.8,13.9,16.3,,10.6,0.20000000000000107,1.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,,-14,1.5,0.9,2.6,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Baseline,1,1.7,0.9,2.6,Y,1.7,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,I-P Lead In C,8,1.7,0.9,2.6,,1.7,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,I-P Lead In C,16,2.4,0.9,2.6,,1.7,0.7,41.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,I-P Lead In C,22,2.2,0.9,2.6,,1.7,0.5000000000000002,29.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 1 C,29,3,0.9,2.6,,1.7,1.3,76.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 8 C,36,2.5,0.9,2.6,,1.7,0.8,47.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 2 Day 1 C,57,1.6,0.9,2.6,,1.7,-0.09999999999999987,-5.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 3 Day 1 C,85,1.4,0.9,2.6,,1.7,-0.30000000000000004,-17.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 4 Day 1 C,114,2,0.9,2.6,,1.7,0.30000000000000004,17.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 5 Day 1 C,138,1.7,0.9,2.6,,1.7,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 6 Day 1 C,169,1.9,0.9,2.6,,1.7,0.19999999999999996,11.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 7 Day 1 C,197,1.6,0.9,2.6,,1.7,-0.09999999999999987,-5.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 8 Day 1 C,225,1.7,0.9,2.6,,1.7,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 9 Day 1 C,253,1.4,0.9,2.6,,1.7,-0.30000000000000004,-17.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 10 Day 1 C,281,1.2,0.9,2.6,,1.7,-0.5,-29.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 11 Day 1 C,309,1.5,0.9,2.6,,1.7,-0.19999999999999996,-11.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 12 Day 1 C,337,1.6,0.9,2.6,,1.7,-0.09999999999999987,-5.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 13 Day 1 C,365,1.5,0.6,3.4,,1.7,-0.19999999999999996,-11.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 14 Day 1 C,393,1.3,0.9,2.6,,1.7,-0.3999999999999999,-23.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 15 Day 1 C,421,1.5,0.9,2.6,,1.7,-0.19999999999999996,-11.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,,449,1.3,0.9,2.6,,1.7,-0.3999999999999999,-23.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,,478,1.1,0.9,2.6,,1.7,-0.5999999999999999,-35.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Lymphocytes,End of Treatment C,505,1.4,0.9,2.6,,1.7,-0.30000000000000004,-17.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,,-14,0.8,0.1,0.9,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Baseline,1,0.8,0.1,0.9,Y,0.8,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,I-P Lead In C,8,2.2,0.1,0.9,,0.8,1.4000000000000001,175
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,I-P Lead In C,16,8.4,0.1,0.9,,0.8,7.6000000000000005,950
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,I-P Lead In C,22,2.7,0.1,0.9,,0.8,1.9000000000000001,237.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 1 C,29,7,0.1,0.9,,0.8,6.2,775
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 8 C,36,13.4,0.1,0.9,,0.8,12.6,1575
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 2 Day 1 C,57,0.7,0.1,0.9,,0.8,-0.10000000000000009,-12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 3 Day 1 C,85,0.7,0.1,0.9,,0.8,-0.10000000000000009,-12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 4 Day 1 C,114,0.8,0.1,0.9,,0.8,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 5 Day 1 C,138,0.7,0.1,0.9,,0.8,-0.10000000000000009,-12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 6 Day 1 C,169,0.9,0.1,0.9,,0.8,0.09999999999999998,12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 7 Day 1 C,197,0.8,0.1,0.9,,0.8,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 8 Day 1 C,225,0.9,0.1,0.9,,0.8,0.09999999999999998,12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 9 Day 1 C,253,0.8,0.1,0.9,,0.8,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 10 Day 1 C,281,0.7,0.1,0.9,,0.8,-0.10000000000000009,-12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 11 Day 1 C,309,0.8,0.1,0.9,,0.8,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 12 Day 1 C,337,0.8,0.1,0.9,,0.8,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 13 Day 1 C,365,0.9,0,0.9,,0.8,0.09999999999999998,12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 14 Day 1 C,393,0.9,0.1,0.9,,0.8,0.09999999999999998,12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 15 Day 1 C,421,0.8,0.1,0.9,,0.8,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,,449,0.7,0.1,0.9,,0.8,-0.10000000000000009,-12.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,,478,0.8,0.1,0.9,,0.8,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Monocytes,End of Treatment C,505,0.6,0.1,0.9,,0.8,-0.20000000000000007,-25
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,,-14,3.7,1.8,6.5,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Baseline,1,4,1.8,6.5,Y,4,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,I-P Lead In C,8,4.4,1.8,6.5,,4,0.40000000000000036,10
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,I-P Lead In C,16,6.9,1.8,6.5,,4,2.9000000000000004,72.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,I-P Lead In C,22,3.2,1.8,6.5,,4,-0.7999999999999998,-20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 1 C,29,7.3,1.8,6.5,,4,3.3,82.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 8 C,36,7.7,1.8,6.5,,4,3.7,92.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 2 Day 1 C,57,3.1,1.8,6.5,,4,-0.8999999999999999,-22.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 3 Day 1 C,85,3.6,1.8,6.5,,4,-0.3999999999999999,-10
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 4 Day 1 C,114,2.6,1.8,6.5,,4,-1.4,-35
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 5 Day 1 C,138,2.6,1.8,6.5,,4,-1.4,-35
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 6 Day 1 C,169,3.1,1.8,6.5,,4,-0.8999999999999999,-22.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 7 Day 1 C,197,2.9,1.8,6.5,,4,-1.1,-27.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 8 Day 1 C,225,2.7,1.8,6.5,,4,-1.2999999999999998,-32.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 9 Day 1 C,253,3.3,1.8,6.5,,4,-0.7000000000000002,-17.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 10 Day 1 C,281,3.9,1.8,6.5,,4,-0.10000000000000009,-2.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 11 Day 1 C,309,2.4,1.8,6.5,,4,-1.6,-40
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 12 Day 1 C,337,3.1,1.8,6.5,,4,-0.8999999999999999,-22.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 13 Day 1 C,365,1.8,2,6.9,,4,-2.2,-55
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 14 Day 1 C,393,3.2,1.8,6.5,,4,-0.7999999999999998,-20
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 15 Day 1 C,421,2.4,1.8,6.5,,4,-1.6,-40
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,,449,2.6,1.8,6.5,,4,-1.4,-35
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,,478,2.5,1.8,6.5,,4,-1.5,-37.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Neutrophils,End of Treatment C,505,1.9,1.8,6.5,,4,-2.1,-52.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),,-14,342,150,450,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Baseline,1,304,150,450,Y,304,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),I-P Lead In C,8,325,150,450,,304,21,6.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),I-P Lead In C,16,304,150,450,,304,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),I-P Lead In C,22,367,150,450,,304,63,20.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,29,393,150,450,,304,89,29.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,36,262,150,450,,304,-42,-13.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,57,296,150,450,,304,-8,-2.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 1 C,85,284,150,450,,304,-20,-6.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 1 C,114,313,150,450,,304,9,3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 5 Day 1 C,138,284,150,450,,304,-20,-6.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 6 Day 1 C,169,287,150,450,,304,-17,-5.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 7 Day 1 C,197,281,150,450,,304,-23,-7.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 8 Day 1 C,225,257,150,450,,304,-47,-15.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 9 Day 1 C,253,301,150,450,,304,-3,-1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 10 Day 1 C,281,324,150,450,,304,20,6.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 11 Day 1 C,309,317,150,450,,304,13,4.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 12 Day 1 C,337,284,150,450,,304,-20,-6.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 13 Day 1 C,365,285,130,400,,304,-19,-6.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 14 Day 1 C,393,271,150,450,,304,-33,-10.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 15 Day 1 C,421,262,150,450,,304,-42,-13.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),,449,267,150,450,,304,-37,-12.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),,478,287,150,450,,304,-17,-5.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),End of Treatment C,505,298,150,450,,304,-6,-2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,,-14,6.1,4,11,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Baseline,1,6.6,4,11,Y,6.6,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,I-P Lead In C,8,8.4,4,11,,6.6,1.8000000000000007,27.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,I-P Lead In C,16,18.5,4,11,,6.6,11.9,180.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,I-P Lead In C,22,8.4,4,11,,6.6,1.8000000000000007,27.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 1 C,29,18.8,4,11,,6.6,12.200000000000001,184.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 8 C,36,24.5,4,11,,6.6,17.9,271.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 2 Day 1 C,57,5.7,4,11,,6.6,-0.8999999999999995,-13.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 3 Day 1 C,85,5.9,4,11,,6.6,-0.6999999999999993,-10.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 4 Day 1 C,114,5.6,4,11,,6.6,-1,-15.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 5 Day 1 C,138,5.2,4,11,,6.6,-1.3999999999999995,-21.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 6 Day 1 C,169,6.1,4,11,,6.6,-0.5,-7.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 7 Day 1 C,197,5.6,4,11,,6.6,-1,-15.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 8 Day 1 C,225,5.4,4,11,,6.6,-1.1999999999999993,-18.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 9 Day 1 C,253,5.6,4,11,,6.6,-1,-15.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 10 Day 1 C,281,5.9,4,11,,6.6,-0.6999999999999993,-10.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 11 Day 1 C,309,4.9,4,11,,6.6,-1.6999999999999993,-25.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 12 Day 1 C,337,5.8,4,11,,6.6,-0.7999999999999998,-12.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 13 Day 1 C,365,4.4,4.8,10.8,,6.6,-2.1999999999999993,-33.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 14 Day 1 C,393,5.5,4,11,,6.6,-1.0999999999999996,-16.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 15 Day 1 C,421,4.8,4,11,,6.6,-1.7999999999999998,-27.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,,449,4.7,4,11,,6.6,-1.8999999999999995,-28.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,,478,4.7,4,11,,6.6,-1.8999999999999995,-28.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Hematology,White Blood Cells,End of Treatment C,505,4.1,4,11,,6.6,-2.5,-37.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,,-14,59.14,NA,NA,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Baseline,1,54.99,NA,NA,Y,54.99,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,I-P Lead In C,22,52.82,NA,NA,,54.99,-2.1700000000000017,-3.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,29,61.57,NA,NA,,54.99,6.579999999999998,12
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,57,51.61,NA,NA,,54.99,-3.3800000000000026,-6.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 3 Day 1 C,85,23.84,NA,NA,,54.99,-31.150000000000002,-56.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 4 Day 1 C,114,24.01,NA,NA,,54.99,-30.98,-56.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 5 Day 1 C,138,26.15,NA,NA,,54.99,-28.840000000000003,-52.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 6 Day 1 C,169,17.76,NA,NA,,54.99,-37.230000000000004,-67.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 7 Day 1 C,197,17.91,NA,NA,,54.99,-37.08,-67.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 8 Day 1 C,225,17.24,NA,NA,,54.99,-37.75,-68.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 9 Day 1 C,253,16.22,NA,NA,,54.99,-38.77,-70.5
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 10 Day 1 C,281,14.72,NA,NA,,54.99,-40.27,-73.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 11 Day 1 C,309,17.57,NA,NA,,54.99,-37.42,-68
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 12 Day 1 C,337,15.47,NA,NA,,54.99,-39.52,-71.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 13 Day 1 C,365,18.56,NA,NA,,54.99,-36.43000000000001,-66.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 14 Day 1 C,393,22.07,NA,NA,,54.99,-32.92,-59.9
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 15 Day 1 C,421,23.6,NA,NA,,54.99,-31.39,-57.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Prostate-specific antigen,PSA,End of Treatment C,505,19.41,NA,NA,,54.99,-35.58,-64.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-14,1.05,0.4,4,,NA,NA,NA
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,0.76,0.4,4,Y,0.76,0,0
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,0.78,0.4,4,,0.76,0.020000000000000018,2.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,16,0.78,0.4,4,,0.76,0.020000000000000018,2.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,0.85,0.4,4,,0.76,0.08999999999999997,11.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,29,0.83,0.4,4,,0.76,0.06999999999999995,9.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,36,0.6,0.4,4,,0.76,-0.16000000000000003,-21.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,57,0.62,0.4,4,,0.76,-0.14,-18.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 C,85,1.4,0.4,4,,0.76,0.6399999999999999,84.2
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 C,114,0.72,0.4,4,,0.76,-0.040000000000000036,-5.3
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 C,138,0.55,0.4,4,,0.76,-0.20999999999999996,-27.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 6 Day 1 C,169,0.61,0.4,4,,0.76,-0.15000000000000002,-19.7
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 7 Day 1 C,197,0.97,0.4,4,,0.76,0.20999999999999996,27.6
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 8 Day 1 C,225,1.23,0.4,4,,0.76,0.47,61.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 9 Day 1 C,253,0.59,0.4,4,,0.76,-0.17000000000000004,-22.4
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 10 Day 1 C,281,0.67,0.4,4,,0.76,-0.08999999999999997,-11.8
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 11 Day 1 C,309,1.08,0.4,4,,0.76,0.32000000000000006,42.1
12C,C,CDX-301 + INO-5151 + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 12 Day 1 C,337,0.89,0.4,4,,0.76,0.13,17.1
13A,A,NKTR-214 + Nivolumab,N,N,,CTC,Baseline,1,1,NA,NA,Y,1,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-14,25,0,59,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,21,0,59,Y,21,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-14,3.8,3.5,4.7,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.6,3.5,4.7,Y,3.6,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-14,59,56,119,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,61,56,119,Y,61,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-14,17,0,41,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,13,0,41,Y,13,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-14,15,6,20,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,17,6,20,Y,17,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-14,31,21,32,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,27,21,32,Y,27,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-14,9.6,8.6,10.2,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8.8,8.6,10.2,Y,8.8,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-14,104,97,108,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,97,97,108,Y,97,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-14,0.84,0.7,1.3,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1.23,0.7,1.3,Y,1.23,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-14,117,70,99,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,116,70,99,Y,116,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-14,191,0,250,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,203,0,250,Y,203,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-14,4,3.4,5,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,3.7,3.4,5,Y,3.7,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-14,142,136,145,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,135,136,145,Y,135,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-14,0.4,0.3,1.2,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.5,0.3,1.2,Y,0.5,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-14,7.3,6.4,8.2,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.4,6.4,8.2,Y,7.4,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-14,31,22.5,34.5,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,32.6,22.5,34.5,Y,32.6,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-14,0.97,0.8,1.2,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.04,0.8,1.2,Y,1.04,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-14,0.05,0,0.1,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.04,0,0.1,Y,0.04,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-14,0.21,0,0.5,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.03,0,0.5,Y,0.03,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-14,4.76,4.5,6,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.34,4.5,6,Y,4.34,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-14,41.3,41,53,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,36.7,41,53,Y,36.7,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-14,13.2,13.5,17.5,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,12,13.5,17.5,Y,12,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-14,1.64,1,4.8,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.9,1,4.8,Y,0.9,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-14,0.76,0.1,0.9,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,1.4,0.1,0.9,Y,1.4,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-14,6.25,1.8,7.7,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,13.46,1.8,7.7,Y,13.46,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-14,372,150,400,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,332,150,400,Y,332,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-14,8.94,3.5,10.8,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,15.88,3.5,10.8,Y,15.88,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-14,11.93,NA,NA,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,13.77,NA,NA,Y,13.77,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-14,3.39,0.44,7.11,,NA,NA,NA
13A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.66,0.44,7.11,Y,2.66,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 2 Day 1 B,30,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 3 Day 1 B,58,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 6 Day 1 B,142,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 7 Day 1 B,170,5,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 8 Day 1 B,198,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 9 Day 1 B,226,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 10 Day 1 B,255,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 11 Day 1 B,282,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 12 Day 1 B,310,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 13 Day 1 B,338,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 14 Day 1 B,366,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 15 Day 1 B,395,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 16 Day 1 B,422,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 17 Day 1 B,450,2,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 18 Day 1 B,478,1,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 19 Day 1 B,506,2,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 20 Day 1 B,534,3,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 21 Day 1 B,562,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 22 Day 1 B,591,0,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,End of Treatment B,618,3,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,-11,15,0,55,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,16,0,55,Y,16,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,14,0,55,,16,-2,-12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,15,17,0,55,,16,1,6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,30,16,0,55,,16,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,58,18,0,55,,16,2,12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 B,89,18,0,41,,16,2,12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 B,114,17,0,55,,16,1,6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 6 Day 1 B,142,16,0,55,,16,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 7 Day 1 B,170,15,0,55,,16,-1,-6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 8 Day 1 B,198,14,0,55,,16,-2,-12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 9 Day 1 B,226,15,0,55,,16,-1,-6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 10 Day 1 B,255,17,0,55,,16,1,6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 11 Day 1 B,282,20,0,55,,16,4,25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 12 Day 1 B,310,17,0,55,,16,1,6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 13 Day 1 B,338,14,0,55,,16,-2,-12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 14 Day 1 B,366,17,0,55,,16,1,6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 15 Day 1 B,395,16,0,55,,16,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 16 Day 1 B,422,15,0,55,,16,-1,-6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 17 Day 1 B,450,17,0,55,,16,1,6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 18 Day 1 B,478,14,0,55,,16,-2,-12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 19 Day 1 B,506,14,0,55,,16,-2,-12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 20 Day 1 B,534,15,0,55,,16,-1,-6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 21 Day 1 B,562,15,0,55,,16,-1,-6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 22 Day 1 B,591,15,0,55,,16,-1,-6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,618,14,0,55,,16,-2,-12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 B,702,17,0,55,,16,1,6.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,-11,4.2,3.8,5,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Baseline,1,3.9,3.8,5,Y,3.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,15,4.2,3.8,5,,3.9,0.30000000000000027,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,30,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,58,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 4 Day 1 B,89,4.4,3.5,5.2,,3.9,0.5000000000000004,12.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 5 Day 1 B,114,4.2,3.8,5,,3.9,0.30000000000000027,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 6 Day 1 B,142,4.3,3.8,5,,3.9,0.3999999999999999,10.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 7 Day 1 B,170,4.3,3.8,5,,3.9,0.3999999999999999,10.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 8 Day 1 B,198,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 9 Day 1 B,226,4.3,3.8,5,,3.9,0.3999999999999999,10.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 10 Day 1 B,255,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 11 Day 1 B,282,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 12 Day 1 B,310,4.3,3.8,5,,3.9,0.3999999999999999,10.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 13 Day 1 B,338,4.3,3.8,5,,3.9,0.3999999999999999,10.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 14 Day 1 B,366,4.2,3.8,5,,3.9,0.30000000000000027,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 15 Day 1 B,395,4.3,3.8,5,,3.9,0.3999999999999999,10.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 16 Day 1 B,422,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 17 Day 1 B,450,4.3,3.8,5,,3.9,0.3999999999999999,10.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 18 Day 1 B,478,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 19 Day 1 B,506,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 20 Day 1 B,534,3.9,3.8,5,,3.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 21 Day 1 B,562,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 22 Day 1 B,591,4.1,3.8,5,,3.9,0.19999999999999973,5.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),End of Treatment B,618,4.3,3.8,5,,3.9,0.3999999999999999,10.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Follow-up 110 B,702,4.2,3.8,5,,3.9,0.30000000000000027,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,-11,80,0,130,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,80,0,130,Y,80,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,81,0,130,,80,1,1.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,15,83,0,130,,80,3,3.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,30,79,0,130,,80,-1,-1.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,58,76,0,130,,80,-4,-5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 B,89,81,40,130,,80,1,1.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 B,114,90,0,130,,80,10,12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 6 Day 1 B,142,83,0,130,,80,3,3.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 7 Day 1 B,170,73,0,130,,80,-7,-8.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 8 Day 1 B,198,70,0,130,,80,-10,-12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 9 Day 1 B,226,70,0,130,,80,-10,-12.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 10 Day 1 B,255,74,0,130,,80,-6,-7.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 11 Day 1 B,282,69,0,130,,80,-11,-13.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 12 Day 1 B,310,67,0,130,,80,-13,-16.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 13 Day 1 B,338,67,0,130,,80,-13,-16.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 14 Day 1 B,366,68,0,130,,80,-12,-15
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 15 Day 1 B,395,63,0,130,,80,-17,-21.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 16 Day 1 B,422,62,0,130,,80,-18,-22.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 17 Day 1 B,450,64,0,130,,80,-16,-20
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 18 Day 1 B,478,59,0,130,,80,-21,-26.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 19 Day 1 B,506,57,0,130,,80,-23,-28.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 20 Day 1 B,534,61,0,130,,80,-19,-23.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 21 Day 1 B,562,64,0,130,,80,-16,-20
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 22 Day 1 B,591,64,0,130,,80,-16,-20
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,618,67,0,130,,80,-13,-16.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 B,702,72,0,130,,80,-8,-10
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-11,21,0,37,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,20,0,37,Y,20,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,20,0,37,,20,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,15,25,0,37,,20,5,25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,30,20,0,37,,20,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,58,22,0,37,,20,2,10
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 B,89,21,0,40,,20,1,5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 B,114,22,0,37,,20,2,10
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 6 Day 1 B,142,20,0,37,,20,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 7 Day 1 B,170,20,0,37,,20,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 8 Day 1 B,198,21,0,37,,20,1,5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 9 Day 1 B,226,20,0,37,,20,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 10 Day 1 B,255,20,0,37,,20,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 11 Day 1 B,282,22,0,37,,20,2,10
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 12 Day 1 B,310,21,0,37,,20,1,5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 13 Day 1 B,338,19,0,37,,20,-1,-5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 14 Day 1 B,366,21,0,37,,20,1,5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 15 Day 1 B,395,18,0,37,,20,-2,-10
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 16 Day 1 B,422,18,0,37,,20,-2,-10
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 17 Day 1 B,450,19,0,37,,20,-1,-5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 18 Day 1 B,478,18,0,37,,20,-2,-10
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 19 Day 1 B,506,19,0,37,,20,-1,-5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 20 Day 1 B,534,19,0,37,,20,-1,-5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 21 Day 1 B,562,18,0,37,,20,-2,-10
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 22 Day 1 B,591,19,0,37,,20,-1,-5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,618,18,0,37,,20,-2,-10
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 B,702,20,0,37,,20,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,,-11,22,6,20,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Baseline,1,27,6,20,Y,27,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 8 B,8,22,6,20,,27,-5,-18.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 15 B,15,22,6,20,,27,-5,-18.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 2 Day 1 B,30,25,6,20,,27,-2,-7.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 3 Day 1 B,58,24,6,20,,27,-3,-11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 4 Day 1 B,89,29,6,23,,27,2,7.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 5 Day 1 B,114,26,6,20,,27,-1,-3.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 6 Day 1 B,142,25,6,20,,27,-2,-7.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 7 Day 1 B,170,31,6,20,,27,4,14.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 8 Day 1 B,198,23,6,20,,27,-4,-14.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 9 Day 1 B,226,32,6,20,,27,5,18.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 10 Day 1 B,255,24,6,20,,27,-3,-11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 11 Day 1 B,282,23,6,20,,27,-4,-14.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 12 Day 1 B,310,23,6,20,,27,-4,-14.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 13 Day 1 B,338,22,6,20,,27,-5,-18.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 14 Day 1 B,366,28,6,20,,27,1,3.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 15 Day 1 B,395,27,6,20,,27,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 16 Day 1 B,422,24,6,20,,27,-3,-11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 17 Day 1 B,450,22,6,20,,27,-5,-18.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 18 Day 1 B,478,24,6,20,,27,-3,-11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 19 Day 1 B,506,22,6,20,,27,-5,-18.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 20 Day 1 B,534,25,6,20,,27,-2,-7.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 21 Day 1 B,562,21,6,20,,27,-6,-22.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 22 Day 1 B,591,22,6,20,,27,-5,-18.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,End of Treatment B,618,25,6,20,,27,-2,-7.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Follow-up 110 B,702,27,6,20,,27,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,,-11,27,18,29,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Baseline,1,25,18,29,Y,25,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,25,18,29,,25,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 15 B,15,26,18,29,,25,1,4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 2 Day 1 B,30,27,18,29,,25,2,8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 3 Day 1 B,58,26,18,29,,25,1,4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 4 Day 1 B,89,25,18,29,,25,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 5 Day 1 B,114,27,18,29,,25,2,8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 6 Day 1 B,142,25,18,29,,25,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 7 Day 1 B,170,28,18,29,,25,3,12
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 8 Day 1 B,198,22,18,29,,25,-3,-12
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 9 Day 1 B,226,21,18,29,,25,-4,-16
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 10 Day 1 B,255,21,18,29,,25,-4,-16
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 11 Day 1 B,282,23,18,29,,25,-2,-8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 12 Day 1 B,310,26,18,29,,25,1,4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 13 Day 1 B,338,27,18,29,,25,2,8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 14 Day 1 B,366,26,18,29,,25,1,4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 15 Day 1 B,395,26,18,29,,25,1,4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 16 Day 1 B,422,26,18,29,,25,1,4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 17 Day 1 B,450,27,18,29,,25,2,8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 18 Day 1 B,478,26,18,29,,25,1,4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 19 Day 1 B,506,24,18,29,,25,-1,-4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 20 Day 1 B,534,23,18,29,,25,-2,-8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 21 Day 1 B,562,25,18,29,,25,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 22 Day 1 B,591,22,18,29,,25,-3,-12
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,End of Treatment B,618,27,18,29,,25,2,8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Follow-up 110 B,702,27,18,29,,25,2,8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,-11,9.3,8.5,10.5,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Baseline,1,9.4,8.5,10.5,Y,9.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,9.3,8.5,10.5,,9.4,-0.09999999999999964,-1.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,15,9.6,8.5,10.5,,9.4,0.1999999999999993,2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,30,9.5,8.5,10.5,,9.4,0.09999999999999964,1.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,58,9.5,8.5,10.5,,9.4,0.09999999999999964,1.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 B,89,10.2,8.4,10.2,,9.4,0.7999999999999989,8.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 B,114,9.7,8.5,10.5,,9.4,0.29999999999999893,3.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 6 Day 1 B,142,9.5,8.5,10.5,,9.4,0.09999999999999964,1.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 7 Day 1 B,170,9.4,8.5,10.5,,9.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 8 Day 1 B,198,9.1,8.5,10.5,,9.4,-0.3000000000000007,-3.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 9 Day 1 B,226,9.2,8.5,10.5,,9.4,-0.20000000000000107,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 10 Day 1 B,255,8.9,8.5,10.5,,9.4,-0.5,-5.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 11 Day 1 B,282,9.2,8.5,10.5,,9.4,-0.20000000000000107,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 12 Day 1 B,310,9.1,8.5,10.5,,9.4,-0.3000000000000007,-3.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 13 Day 1 B,338,9.8,8.5,10.5,,9.4,0.40000000000000036,4.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 14 Day 1 B,366,9.2,8.5,10.5,,9.4,-0.20000000000000107,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 15 Day 1 B,395,9.2,8.5,10.5,,9.4,-0.20000000000000107,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 16 Day 1 B,422,9.3,8.5,10.5,,9.4,-0.09999999999999964,-1.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 17 Day 1 B,450,9.8,8.5,10.5,,9.4,0.40000000000000036,4.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 18 Day 1 B,478,9.2,8.5,10.5,,9.4,-0.20000000000000107,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 19 Day 1 B,506,9.1,8.5,10.5,,9.4,-0.3000000000000007,-3.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 20 Day 1 B,534,9.1,8.5,10.5,,9.4,-0.3000000000000007,-3.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 21 Day 1 B,562,9.3,8.5,10.5,,9.4,-0.09999999999999964,-1.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 22 Day 1 B,591,9.3,8.5,10.5,,9.4,-0.09999999999999964,-1.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),End of Treatment B,618,9.9,8.5,10.5,,9.4,0.5,5.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Follow-up 110 B,702,10.1,8.5,10.5,,9.4,0.6999999999999993,7.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,-11,109,98,109,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Baseline,1,108,98,109,Y,108,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,107,98,109,,108,-1,-0.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,15,105,98,109,,108,-3,-2.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,30,106,98,109,,108,-2,-1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,58,106,98,109,,108,-2,-1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 B,89,105,98,107,,108,-3,-2.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 B,114,107,98,109,,108,-1,-0.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 6 Day 1 B,142,107,98,109,,108,-1,-0.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 7 Day 1 B,170,107,98,109,,108,-1,-0.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 8 Day 1 B,198,109,98,109,,108,1,0.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 9 Day 1 B,226,108,98,109,,108,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 10 Day 1 B,255,108,98,109,,108,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 11 Day 1 B,282,104,98,109,,108,-4,-3.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 12 Day 1 B,310,103,98,109,,108,-5,-4.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 13 Day 1 B,338,105,98,109,,108,-3,-2.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 14 Day 1 B,366,104,98,109,,108,-4,-3.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 15 Day 1 B,395,105,98,109,,108,-3,-2.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 16 Day 1 B,422,105,98,109,,108,-3,-2.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 17 Day 1 B,450,106,98,109,,108,-2,-1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 18 Day 1 B,478,106,98,109,,108,-2,-1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 19 Day 1 B,506,104,98,109,,108,-4,-3.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 20 Day 1 B,534,107,98,109,,108,-1,-0.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 21 Day 1 B,562,106,98,109,,108,-2,-1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 22 Day 1 B,591,106,98,109,,108,-2,-1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),End of Treatment B,618,105,98,109,,108,-3,-2.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Follow-up 110 B,702,105,98,109,,108,-3,-2.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,-11,0.9,0.6,1.3,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Baseline,1,0.9,0.6,1.3,Y,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,0.8,0.6,1.3,,0.9,-0.09999999999999998,-11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,15,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,30,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,58,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 B,89,0.95,0.7,1.3,,0.9,0.04999999999999993,5.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 B,114,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 6 Day 1 B,142,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 7 Day 1 B,170,1.1,0.6,1.3,,0.9,0.20000000000000007,22.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 8 Day 1 B,198,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 9 Day 1 B,226,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 10 Day 1 B,255,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 11 Day 1 B,282,1.2,0.6,1.3,,0.9,0.29999999999999993,33.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 12 Day 1 B,310,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 13 Day 1 B,338,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 14 Day 1 B,366,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 15 Day 1 B,395,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 16 Day 1 B,422,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 17 Day 1 B,450,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 18 Day 1 B,478,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 19 Day 1 B,506,0.9,0.6,1.3,,0.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 20 Day 1 B,534,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 21 Day 1 B,562,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 22 Day 1 B,591,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),End of Treatment B,618,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Follow-up 110 B,702,1,0.6,1.3,,0.9,0.09999999999999998,11.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,,-11,106,70,140,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Baseline,1,104,70,140,Y,104,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 8 B,8,122,70,140,,104,18,17.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 15 B,15,112,70,140,,104,8,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 2 Day 1 B,30,99,70,140,,104,-5,-4.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 3 Day 1 B,58,83,70,140,,104,-21,-20.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 4 Day 1 B,89,102,74,109,,104,-2,-1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 5 Day 1 B,114,101,70,140,,104,-3,-2.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 6 Day 1 B,142,95,70,140,,104,-9,-8.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 7 Day 1 B,170,116,70,140,,104,12,11.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 8 Day 1 B,198,105,70,140,,104,1,1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 9 Day 1 B,226,126,70,140,,104,22,21.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 10 Day 1 B,255,153,70,140,,104,49,47.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 11 Day 1 B,282,168,70,140,,104,64,61.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 12 Day 1 B,310,94,70,140,,104,-10,-9.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 13 Day 1 B,338,97,70,140,,104,-7,-6.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 14 Day 1 B,366,99,70,140,,104,-5,-4.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 15 Day 1 B,395,97,70,140,,104,-7,-6.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 16 Day 1 B,422,103,70,140,,104,-1,-1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 17 Day 1 B,450,108,70,140,,104,4,3.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 18 Day 1 B,478,99,70,140,,104,-5,-4.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 19 Day 1 B,506,99,70,140,,104,-5,-4.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 20 Day 1 B,534,135,70,140,,104,31,29.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 21 Day 1 B,562,100,70,140,,104,-4,-3.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 22 Day 1 B,591,138,70,140,,104,34,32.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,End of Treatment B,618,101,70,140,,104,-3,-2.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Follow-up 110 B,702,106,70,140,,104,2,1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-11,175,130,250,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,161,130,250,Y,161,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,181,130,250,,161,20,12.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,15,229,130,250,,161,68,42.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,30,195,130,250,,161,34,21.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,58,181,130,250,,161,20,12.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 B,89,200,NA,NA,,161,39,24.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 B,114,173,130,250,,161,12,7.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 6 Day 1 B,142,186,130,250,,161,25,15.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 7 Day 1 B,170,177,130,250,,161,16,9.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 8 Day 1 B,198,174,130,250,,161,13,8.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 9 Day 1 B,226,164,130,250,,161,3,1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 10 Day 1 B,255,166,130,250,,161,5,3.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 11 Day 1 B,282,164,130,250,,161,3,1.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 12 Day 1 B,310,180,130,250,,161,19,11.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 13 Day 1 B,338,201,130,250,,161,40,24.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 14 Day 1 B,366,183,130,250,,161,22,13.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 15 Day 1 B,395,183,130,250,,161,22,13.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 16 Day 1 B,422,208,130,250,,161,47,29.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 17 Day 1 B,450,207,130,250,,161,46,28.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 18 Day 1 B,478,190,130,250,,161,29,18
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 19 Day 1 B,506,201,130,250,,161,40,24.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 20 Day 1 B,534,192,130,250,,161,31,19.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 21 Day 1 B,562,190,130,250,,161,29,18
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 22 Day 1 B,591,201,130,250,,161,40,24.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,618,229,130,250,,161,68,42.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 B,702,190,130,250,,161,29,18
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,-11,4.3,3.5,5.1,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Baseline,1,4.3,3.5,5.1,Y,4.3,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.5,3.5,5.1,,4.3,0.20000000000000018,4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,15,4.5,3.5,5.1,,4.3,0.20000000000000018,4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,30,4.4,3.5,5.1,,4.3,0.10000000000000053,2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,58,4.4,3.5,5.1,,4.3,0.10000000000000053,2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 B,89,5,3.5,5.1,,4.3,0.7000000000000002,16.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 B,114,4.6,3.5,5.1,,4.3,0.2999999999999998,7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 6 Day 1 B,142,4.5,3.5,5.1,,4.3,0.20000000000000018,4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 7 Day 1 B,170,4.9,3.5,5.1,,4.3,0.6000000000000005,14
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 8 Day 1 B,198,4.1,3.5,5.1,,4.3,-0.20000000000000018,-4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 9 Day 1 B,226,4.3,3.5,5.1,,4.3,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 10 Day 1 B,255,4.2,3.5,5.1,,4.3,-0.09999999999999964,-2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 11 Day 1 B,282,3.8,3.5,5.1,,4.3,-0.5,-11.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 12 Day 1 B,310,4.6,3.5,5.1,,4.3,0.2999999999999998,7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 13 Day 1 B,338,5.1,3.5,5.1,,4.3,0.7999999999999998,18.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 14 Day 1 B,366,4.4,3.5,5.1,,4.3,0.10000000000000053,2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 15 Day 1 B,395,4.5,3.5,5.1,,4.3,0.20000000000000018,4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 16 Day 1 B,422,4.4,3.5,5.1,,4.3,0.10000000000000053,2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 17 Day 1 B,450,4.5,3.5,5.1,,4.3,0.20000000000000018,4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 18 Day 1 B,478,4.4,3.5,5.1,,4.3,0.10000000000000053,2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 19 Day 1 B,506,4.3,3.5,5.1,,4.3,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 20 Day 1 B,534,4.1,3.5,5.1,,4.3,-0.20000000000000018,-4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 21 Day 1 B,562,4.6,3.5,5.1,,4.3,0.2999999999999998,7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 22 Day 1 B,591,4,3.5,5.1,,4.3,-0.2999999999999998,-7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),End of Treatment B,618,4.6,3.5,5.1,,4.3,0.2999999999999998,7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Follow-up 110 B,702,4.6,3.5,5.1,,4.3,0.2999999999999998,7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,,-11,143,133,143,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Baseline,1,142,133,143,Y,142,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 8 B,8,142,133,143,,142,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 15 B,15,141,133,143,,142,-1,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 2 Day 1 B,30,141,133,143,,142,-1,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 3 Day 1 B,58,141,133,143,,142,-1,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 4 Day 1 B,89,142,136,145,,142,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 5 Day 1 B,114,142,133,143,,142,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 6 Day 1 B,142,140,133,143,,142,-2,-1.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 7 Day 1 B,170,141,133,143,,142,-1,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 8 Day 1 B,198,140,133,143,,142,-2,-1.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 9 Day 1 B,226,140,133,143,,142,-2,-1.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 10 Day 1 B,255,140,133,143,,142,-2,-1.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 11 Day 1 B,282,138,133,143,,142,-4,-2.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 12 Day 1 B,310,139,133,143,,142,-3,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 13 Day 1 B,338,141,133,143,,142,-1,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 14 Day 1 B,366,139,133,143,,142,-3,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 15 Day 1 B,395,140,133,143,,142,-2,-1.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 16 Day 1 B,422,139,133,143,,142,-3,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 17 Day 1 B,450,141,133,143,,142,-1,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 18 Day 1 B,478,141,133,143,,142,-1,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 19 Day 1 B,506,135,133,143,,142,-7,-4.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 20 Day 1 B,534,139,133,143,,142,-3,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 21 Day 1 B,562,140,133,143,,142,-2,-1.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 22 Day 1 B,591,139,133,143,,142,-3,-2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,End of Treatment B,618,141,133,143,,142,-1,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Follow-up 110 B,702,141,133,143,,142,-1,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,-11,0.3,0,1.2,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Baseline,1,0.4,0,1.2,Y,0.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,15,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,30,0.4,0,1.2,,0.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,58,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 4 Day 1 B,89,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 5 Day 1 B,114,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 6 Day 1 B,142,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 7 Day 1 B,170,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 8 Day 1 B,198,0.4,0,1.2,,0.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 9 Day 1 B,226,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 10 Day 1 B,255,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 11 Day 1 B,282,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 12 Day 1 B,310,0.4,0,1.2,,0.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 13 Day 1 B,338,0.4,0,1.2,,0.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 14 Day 1 B,366,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 15 Day 1 B,395,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 16 Day 1 B,422,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 17 Day 1 B,450,0.4,0,1.2,,0.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 18 Day 1 B,478,0.2,0,1.2,,0.4,-0.2,-50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 19 Day 1 B,506,0.4,0,1.2,,0.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 20 Day 1 B,534,0.2,0,1.2,,0.4,-0.2,-50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 21 Day 1 B,562,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 22 Day 1 B,591,0.4,0,1.2,,0.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,End of Treatment B,618,0.3,0,1.2,,0.4,-0.10000000000000003,-25
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Follow-up 110 B,702,0.4,0,1.2,,0.4,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,,-11,7,6.3,8.1,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Baseline,1,6.5,6.3,8.1,Y,6.5,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 8 B,8,6.9,6.3,8.1,,6.5,0.40000000000000036,6.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 15 B,15,7.4,6.3,8.1,,6.5,0.9000000000000004,13.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 2 Day 1 B,30,7.2,6.3,8.1,,6.5,0.7000000000000002,10.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 3 Day 1 B,58,7,6.3,8.1,,6.5,0.5,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 4 Day 1 B,89,7.5,6.4,8.3,,6.5,1,15.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 5 Day 1 B,114,7.3,6.3,8.1,,6.5,0.7999999999999998,12.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 6 Day 1 B,142,7.3,6.3,8.1,,6.5,0.7999999999999998,12.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 7 Day 1 B,170,7.3,6.3,8.1,,6.5,0.7999999999999998,12.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 8 Day 1 B,198,7,6.3,8.1,,6.5,0.5,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 9 Day 1 B,226,7.2,6.3,8.1,,6.5,0.7000000000000002,10.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 10 Day 1 B,255,7,6.3,8.1,,6.5,0.5,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 11 Day 1 B,282,7,6.3,8.1,,6.5,0.5,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 12 Day 1 B,310,7.4,6.3,8.1,,6.5,0.9000000000000004,13.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 13 Day 1 B,338,7.5,6.3,8.1,,6.5,1,15.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 14 Day 1 B,366,7.5,6.3,8.1,,6.5,1,15.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 15 Day 1 B,395,7.5,6.3,8.1,,6.5,1,15.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 16 Day 1 B,422,7.2,6.3,8.1,,6.5,0.7000000000000002,10.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 17 Day 1 B,450,7.5,6.3,8.1,,6.5,1,15.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 18 Day 1 B,478,7.2,6.3,8.1,,6.5,0.7000000000000002,10.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 19 Day 1 B,506,7.1,6.3,8.1,,6.5,0.5999999999999996,9.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 20 Day 1 B,534,6.9,6.3,8.1,,6.5,0.40000000000000036,6.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 21 Day 1 B,562,7.3,6.3,8.1,,6.5,0.7999999999999998,12.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 22 Day 1 B,591,7.1,6.3,8.1,,6.5,0.5999999999999996,9.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,End of Treatment B,618,7.9,6.3,8.1,,6.5,1.4000000000000004,21.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Follow-up 110 B,702,7.5,6.3,8.1,,6.5,1,15.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),,-11,27,23.7,34.8,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,28.3,23.7,34.8,Y,28.3,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,28.7,23.7,34.8,,28.3,0.3999999999999986,1.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 15 B,15,27.2,23.7,34.8,,28.3,-1.1000000000000014,-3.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,30,28.9,23.7,34.8,,28.3,0.5999999999999979,2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 B,58,27.3,23.7,34.8,,28.3,-1,-3.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 B,89,29,23,25,,28.3,0.6999999999999993,2.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 5 Day 1 B,114,24.7,22.5,36.5,,28.3,-3.6000000000000014,-12.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 6 Day 1 B,142,28.3,22.5,36.5,,28.3,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 7 Day 1 B,170,29.8,22.5,36.5,,28.3,1.5,5.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 8 Day 1 B,198,29.7,22.5,36.5,,28.3,1.3999999999999986,4.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 9 Day 1 B,226,32,22.5,36.5,,28.3,3.6999999999999993,13.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 10 Day 1 B,255,29.2,22.5,36.5,,28.3,0.8999999999999986,3.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 11 Day 1 B,282,30,22.5,36.5,,28.3,1.6999999999999993,6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 12 Day 1 B,310,29.4,22.5,36.5,,28.3,1.0999999999999979,3.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 13 Day 1 B,338,28.9,22.5,36.5,,28.3,0.5999999999999979,2.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 14 Day 1 B,366,28.4,22.5,36.5,,28.3,0.09999999999999787,0.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 15 Day 1 B,395,29.2,22.5,36.5,,28.3,0.8999999999999986,3.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 16 Day 1 B,422,29.1,22.5,36.5,,28.3,0.8000000000000007,2.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 17 Day 1 B,450,30.2,22.5,36.5,,28.3,1.8999999999999986,6.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 18 Day 1 B,478,29,22.5,36.5,,28.3,0.6999999999999993,2.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 19 Day 1 B,506,28.2,22.5,36.5,,28.3,-0.10000000000000142,-0.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 20 Day 1 B,534,30.8,NA,NA,,28.3,2.5,8.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 21 Day 1 B,562,28.3,22.5,36.5,,28.3,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 22 Day 1 B,591,28.8,22.5,36.5,,28.3,0.5,1.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,618,29.7,22.5,36.5,,28.3,1.3999999999999986,4.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-11,1.06,0.8,1.2,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.02,0.8,1.2,Y,1.02,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,1.03,0.8,1.2,,1.02,0.010000000000000009,1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 15 B,15,1.03,0.8,1.2,,1.02,0.010000000000000009,1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,30,1.04,0.8,1.2,,1.02,0.020000000000000018,2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 B,58,1.03,0.8,1.2,,1.02,0.010000000000000009,1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 B,89,1,0.9,1.1,,1.02,-0.020000000000000018,-2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 5 Day 1 B,114,0.92,0.8,1.2,,1.02,-0.09999999999999998,-9.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 6 Day 1 B,142,0.94,0.8,1.2,,1.02,-0.08000000000000007,-7.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 7 Day 1 B,170,0.99,0.8,1.2,,1.02,-0.030000000000000027,-2.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 8 Day 1 B,198,0.99,0.8,1.2,,1.02,-0.030000000000000027,-2.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 9 Day 1 B,226,1,0.8,1.2,,1.02,-0.020000000000000018,-2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 10 Day 1 B,255,1.01,0.8,1.2,,1.02,-0.010000000000000009,-1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 11 Day 1 B,282,1.05,0.8,1.2,,1.02,0.030000000000000027,2.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 12 Day 1 B,310,1.03,0.8,1.2,,1.02,0.010000000000000009,1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 13 Day 1 B,338,0.99,0.8,1.2,,1.02,-0.030000000000000027,-2.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 14 Day 1 B,366,0.98,0.8,1.2,,1.02,-0.040000000000000036,-3.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 15 Day 1 B,395,0.96,0.8,1.2,,1.02,-0.06000000000000005,-5.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 16 Day 1 B,422,1,0.8,1.2,,1.02,-0.020000000000000018,-2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 17 Day 1 B,450,1.03,0.8,1.2,,1.02,0.010000000000000009,1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 18 Day 1 B,478,1.01,0.8,1.2,,1.02,-0.010000000000000009,-1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 19 Day 1 B,506,0.99,0.8,1.2,,1.02,-0.030000000000000027,-2.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 20 Day 1 B,534,0.98,NA,NA,,1.02,-0.040000000000000036,-3.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 21 Day 1 B,562,0.97,0.8,1.2,,1.02,-0.050000000000000044,-4.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 22 Day 1 B,591,1.03,0.8,1.2,,1.02,0.010000000000000009,1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,618,1.06,0.8,1.2,,1.02,0.040000000000000036,3.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),,-11,13.3,10.6,14.7,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Baseline,1,12.9,10.6,14.7,Y,12.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,13,10.6,14.7,,12.9,0.09999999999999964,0.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 1 Day 15 B,15,13,10.6,14.7,,12.9,0.09999999999999964,0.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,30,13.1,10.6,14.7,,12.9,0.1999999999999993,1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 B,58,13,10.6,14.7,,12.9,0.09999999999999964,0.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 4 Day 1 B,89,13.1,12,14.2,,12.9,0.1999999999999993,1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 5 Day 1 B,114,12.4,11.1,15.2,,12.9,-0.5,-3.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 6 Day 1 B,142,12.6,11.1,15.2,,12.9,-0.3000000000000007,-2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 7 Day 1 B,170,13.1,11.1,15.2,,12.9,0.1999999999999993,1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 8 Day 1 B,198,13.1,11.1,15.2,,12.9,0.1999999999999993,1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 9 Day 1 B,226,13.2,11.1,15.2,,12.9,0.29999999999999893,2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 10 Day 1 B,255,13.3,11.1,15.2,,12.9,0.40000000000000036,3.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 11 Day 1 B,282,13.7,11.1,15.2,,12.9,0.7999999999999989,6.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 12 Day 1 B,310,13.5,11.1,15.2,,12.9,0.5999999999999996,4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 13 Day 1 B,338,13.1,11.1,15.2,,12.9,0.1999999999999993,1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 14 Day 1 B,366,12.8,11.1,15.2,,12.9,-0.09999999999999964,-0.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 15 Day 1 B,395,12.5,11.1,15.2,,12.9,-0.40000000000000036,-3.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 16 Day 1 B,422,13,11.1,15.2,,12.9,0.09999999999999964,0.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 17 Day 1 B,450,13.3,11.1,15.2,,12.9,0.40000000000000036,3.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 18 Day 1 B,478,13.1,11.1,15.2,,12.9,0.1999999999999993,1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 19 Day 1 B,506,12.9,11.1,15.2,,12.9,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 20 Day 1 B,534,12.8,NA,NA,,12.9,-0.09999999999999964,-0.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 21 Day 1 B,562,12.7,11.1,15.2,,12.9,-0.20000000000000107,-1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 22 Day 1 B,591,13.4,11.1,15.2,,12.9,0.5,3.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),End of Treatment B,618,13.6,11.1,15.2,,12.9,0.6999999999999993,5.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,,-11,0,0,0.2,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 8 B,8,0.2,0,0.2,,0,0.2,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 15 B,15,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 2 Day 1 B,30,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 3 Day 1 B,58,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 4 Day 1 B,89,0.08,0,0.1,,0,0.08,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 5 Day 1 B,114,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 6 Day 1 B,142,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 8 Day 1 B,198,0,0,0.2,,0,0,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 9 Day 1 B,226,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 10 Day 1 B,255,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 11 Day 1 B,282,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 12 Day 1 B,310,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 13 Day 1 B,338,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 14 Day 1 B,366,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 15 Day 1 B,395,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 16 Day 1 B,422,0,0,0.2,,0,0,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 17 Day 1 B,450,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 18 Day 1 B,478,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 19 Day 1 B,506,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 20 Day 1 B,534,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 21 Day 1 B,562,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 22 Day 1 B,591,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,End of Treatment B,618,0.1,0,0.2,,0,0.1,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Follow-up 110 B,702,0,0,0.2,,0,0,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,,-11,0.1,0,0.7,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Baseline,1,0.2,0,0.7,Y,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 15 B,15,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 2 Day 1 B,30,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 3 Day 1 B,58,0.3,0,0.7,,0.2,0.09999999999999998,50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 4 Day 1 B,89,0.28,0,0.5,,0.2,0.08000000000000002,40
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 5 Day 1 B,114,0.5,0,0.7,,0.2,0.3,150
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 6 Day 1 B,142,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 7 Day 1 B,170,0,0,0.7,,0.2,-0.2,-100
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 8 Day 1 B,198,0.3,0,0.7,,0.2,0.09999999999999998,50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 9 Day 1 B,226,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 10 Day 1 B,255,0.3,0,0.7,,0.2,0.09999999999999998,50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 11 Day 1 B,282,0.3,0,0.7,,0.2,0.09999999999999998,50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 12 Day 1 B,310,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 13 Day 1 B,338,0.4,0,0.7,,0.2,0.2,100
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 14 Day 1 B,366,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 15 Day 1 B,395,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 16 Day 1 B,422,0.1,0,0.7,,0.2,-0.1,-50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 17 Day 1 B,450,0.1,0,0.7,,0.2,-0.1,-50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 18 Day 1 B,478,0.1,0,0.7,,0.2,-0.1,-50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 19 Day 1 B,506,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 20 Day 1 B,534,0.1,0,0.7,,0.2,-0.1,-50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 21 Day 1 B,562,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 22 Day 1 B,591,0.2,0,0.7,,0.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,End of Treatment B,618,0.1,0,0.7,,0.2,-0.1,-50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Follow-up 110 B,702,0.1,0,0.7,,0.2,-0.1,-50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),,-11,3.96,3.95,5.54,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Baseline,1,4.06,3.95,5.54,Y,4.06,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,4.25,3.95,5.54,,4.06,0.1900000000000004,4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,15,4.29,3.95,5.54,,4.06,0.23000000000000043,5.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,30,3.94,3.95,5.54,,4.06,-0.11999999999999966,-3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,58,3.94,3.95,5.54,,4.06,-0.11999999999999966,-3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 B,89,4.07,4.4,5.6,,4.06,0.010000000000000675,0.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 B,114,4.21,3.95,5.54,,4.06,0.15000000000000036,3.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 6 Day 1 B,142,4.5,3.95,5.54,,4.06,0.4400000000000004,10.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 7 Day 1 B,170,4.26,3.95,5.54,,4.06,0.20000000000000018,4.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 8 Day 1 B,198,4.3,3.95,5.54,,4.06,0.2400000000000002,5.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 9 Day 1 B,226,4.33,3.95,5.54,,4.06,0.27000000000000046,6.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 10 Day 1 B,255,4.14,3.95,5.54,,4.06,0.08000000000000007,2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 11 Day 1 B,282,4.19,3.95,5.54,,4.06,0.13000000000000078,3.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 12 Day 1 B,310,4.36,3.95,5.54,,4.06,0.3000000000000007,7.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 13 Day 1 B,338,4.42,3.95,5.54,,4.06,0.3600000000000003,8.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 14 Day 1 B,366,4.32,3.95,5.54,,4.06,0.2600000000000007,6.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 15 Day 1 B,395,4.33,3.95,5.54,,4.06,0.27000000000000046,6.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 16 Day 1 B,422,4.35,3.95,5.54,,4.06,0.29000000000000004,7.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 17 Day 1 B,450,4.46,3.95,5.54,,4.06,0.40000000000000036,9.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 18 Day 1 B,478,4.28,3.95,5.54,,4.06,0.22000000000000064,5.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 19 Day 1 B,506,4.43,3.95,5.54,,4.06,0.3700000000000001,9.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 20 Day 1 B,534,4.13,3.95,5.54,,4.06,0.07000000000000028,1.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 21 Day 1 B,562,4.41,3.95,5.54,,4.06,0.35000000000000053,8.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 22 Day 1 B,591,4.49,3.95,5.54,,4.06,0.4300000000000006,10.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),End of Treatment B,618,4.55,3.95,5.54,,4.06,0.4900000000000002,12.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,702,4.4,3.95,5.54,,4.06,0.34000000000000075,8.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),,-11,39.4,37.5,49.3,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Baseline,1,40.1,37.5,49.3,Y,40.1,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,41.7,37.5,49.3,,40.1,1.6000000000000014,4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,15,42,37.5,49.3,,40.1,1.8999999999999986,4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,30,39.3,37.5,49.3,,40.1,-0.8000000000000043,-2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,58,39.4,37.5,49.3,,40.1,-0.7000000000000028,-1.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 B,89,39.8,39,48,,40.1,-0.30000000000000426,-0.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 B,114,41.3,37.5,49.3,,40.1,1.1999999999999957,3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 6 Day 1 B,142,43.4,37.5,49.3,,40.1,3.299999999999997,8.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 7 Day 1 B,170,42.1,37.5,49.3,,40.1,2,5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 8 Day 1 B,198,41.5,37.5,49.3,,40.1,1.3999999999999986,3.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 9 Day 1 B,226,41.8,37.5,49.3,,40.1,1.6999999999999957,4.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 10 Day 1 B,255,40.8,37.5,49.3,,40.1,0.6999999999999957,1.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 11 Day 1 B,282,41.5,37.5,49.3,,40.1,1.3999999999999986,3.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 12 Day 1 B,310,41.9,37.5,49.3,,40.1,1.7999999999999972,4.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 13 Day 1 B,338,43.4,37.5,49.3,,40.1,3.299999999999997,8.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 14 Day 1 B,366,41.8,37.5,49.3,,40.1,1.6999999999999957,4.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 15 Day 1 B,395,42.2,37.5,49.3,,40.1,2.1000000000000014,5.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 16 Day 1 B,422,42,37.5,49.3,,40.1,1.8999999999999986,4.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 17 Day 1 B,450,43.6,37.5,49.3,,40.1,3.5,8.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 18 Day 1 B,478,42.1,37.5,49.3,,40.1,2,5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 19 Day 1 B,506,43,37.5,49.3,,40.1,2.8999999999999986,7.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 20 Day 1 B,534,40.2,37.5,49.3,,40.1,0.10000000000000142,0.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 21 Day 1 B,562,42.8,37.5,49.3,,40.1,2.6999999999999957,6.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 22 Day 1 B,591,43.9,37.5,49.3,,40.1,3.799999999999997,9.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),End of Treatment B,618,44.5,37.5,49.3,,40.1,4.399999999999999,11
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Follow-up 110 B,702,42.7,37.5,49.3,,40.1,2.6000000000000014,6.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),,-11,13,12.5,16.2,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Baseline,1,13.2,12.5,16.2,Y,13.2,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,13.7,12.5,16.2,,13.2,0.5,3.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,15,13.8,12.5,16.2,,13.2,0.6000000000000014,4.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,30,12.7,12.5,16.2,,13.2,-0.5,-3.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,58,12.7,12.5,16.2,,13.2,-0.5,-3.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 B,89,12.9,13,17,,13.2,-0.29999999999999893,-2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 B,114,13.4,12.5,16.2,,13.2,0.20000000000000107,1.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 6 Day 1 B,142,14.2,12.5,16.2,,13.2,1,7.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 7 Day 1 B,170,13.6,12.5,16.2,,13.2,0.40000000000000036,3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 8 Day 1 B,198,13.6,12.5,16.2,,13.2,0.40000000000000036,3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 9 Day 1 B,226,14.1,12.5,16.2,,13.2,0.9000000000000004,6.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 10 Day 1 B,255,13.5,12.5,16.2,,13.2,0.3000000000000007,2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 11 Day 1 B,282,13.6,12.5,16.2,,13.2,0.40000000000000036,3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 12 Day 1 B,310,14.2,12.5,16.2,,13.2,1,7.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 13 Day 1 B,338,14.2,12.5,16.2,,13.2,1,7.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 14 Day 1 B,366,13.9,12.5,16.2,,13.2,0.7000000000000011,5.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 15 Day 1 B,395,14.1,12.5,16.2,,13.2,0.9000000000000004,6.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 16 Day 1 B,422,13.9,12.5,16.2,,13.2,0.7000000000000011,5.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 17 Day 1 B,450,14.3,12.5,16.2,,13.2,1.1000000000000014,8.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 18 Day 1 B,478,14,12.5,16.2,,13.2,0.8000000000000007,6.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 19 Day 1 B,506,14.1,12.5,16.2,,13.2,0.9000000000000004,6.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 20 Day 1 B,534,13.3,12.5,16.2,,13.2,0.10000000000000142,0.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 21 Day 1 B,562,13.9,12.5,16.2,,13.2,0.7000000000000011,5.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 22 Day 1 B,591,14.3,12.5,16.2,,13.2,1.1000000000000014,8.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),End of Treatment B,618,14.4,12.5,16.2,,13.2,1.200000000000001,9.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Follow-up 110 B,702,13.8,12.5,16.2,,13.2,0.6000000000000014,4.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,,-11,1.1,0.9,3.2,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Baseline,1,1.1,0.9,3.2,Y,1.1,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,1.4,0.9,3.2,,1.1,0.2999999999999998,27.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 15 B,15,1.8,0.9,3.2,,1.1,0.7,63.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 2 Day 1 B,30,1.3,0.9,3.2,,1.1,0.19999999999999996,18.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 3 Day 1 B,58,1.1,0.9,3.2,,1.1,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 4 Day 1 B,89,0.95,1,3.4,,1.1,-0.15000000000000013,-13.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 5 Day 1 B,114,1,0.9,3.2,,1.1,-0.10000000000000009,-9.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 6 Day 1 B,142,1.2,0.9,3.2,,1.1,0.09999999999999987,9.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 7 Day 1 B,170,0.7,0.9,3.2,,1.1,-0.40000000000000013,-36.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 8 Day 1 B,198,1.2,0.9,3.2,,1.1,0.09999999999999987,9.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 9 Day 1 B,226,1.2,0.9,3.2,,1.1,0.09999999999999987,9.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 10 Day 1 B,255,1.3,0.9,3.2,,1.1,0.19999999999999996,18.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 11 Day 1 B,282,1.2,0.9,3.2,,1.1,0.09999999999999987,9.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 12 Day 1 B,310,1.5,0.9,3.2,,1.1,0.3999999999999999,36.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 13 Day 1 B,338,1.4,0.9,3.2,,1.1,0.2999999999999998,27.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 14 Day 1 B,366,1.6,0.9,3.2,,1.1,0.5,45.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 15 Day 1 B,395,1.5,0.9,3.2,,1.1,0.3999999999999999,36.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 16 Day 1 B,422,1.5,0.9,3.2,,1.1,0.3999999999999999,36.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 17 Day 1 B,450,1.6,0.9,3.2,,1.1,0.5,45.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 18 Day 1 B,478,1.6,0.9,3.2,,1.1,0.5,45.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 19 Day 1 B,506,1.6,0.9,3.2,,1.1,0.5,45.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 20 Day 1 B,534,1.3,0.9,3.2,,1.1,0.19999999999999996,18.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 21 Day 1 B,562,1.5,0.9,3.2,,1.1,0.3999999999999999,36.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 22 Day 1 B,591,1.7,0.9,3.2,,1.1,0.5999999999999999,54.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,End of Treatment B,618,1.7,0.9,3.2,,1.1,0.5999999999999999,54.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Follow-up 110 B,702,1.1,0.9,3.2,,1.1,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,,-11,0.8,0,1.3,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Baseline,1,0.6,0,1.3,Y,0.6,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 8 B,8,1.7,0,1.3,,0.6,1.1,183.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 15 B,15,4.4,0,1.3,,0.6,3.8000000000000003,633.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 2 Day 1 B,30,1,0,1.3,,0.6,0.4,66.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 3 Day 1 B,58,0.7,0,1.3,,0.6,0.09999999999999998,16.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 4 Day 1 B,89,0.71,0,1,,0.6,0.10999999999999999,18.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 5 Day 1 B,114,0.6,0,1.3,,0.6,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 6 Day 1 B,142,0.8,0,1.3,,0.6,0.20000000000000007,33.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 7 Day 1 B,170,0.6,0,1.3,,0.6,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 8 Day 1 B,198,0.6,0,1.3,,0.6,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 9 Day 1 B,226,0.7,0,1.3,,0.6,0.09999999999999998,16.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 10 Day 1 B,255,0.6,0,1.3,,0.6,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 11 Day 1 B,282,0.6,0,1.3,,0.6,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 12 Day 1 B,310,0.8,0,1.3,,0.6,0.20000000000000007,33.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 13 Day 1 B,338,0.8,0,1.3,,0.6,0.20000000000000007,33.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 14 Day 1 B,366,0.9,0,1.3,,0.6,0.30000000000000004,50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 15 Day 1 B,395,1,0,1.3,,0.6,0.4,66.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 16 Day 1 B,422,1,0,1.3,,0.6,0.4,66.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 17 Day 1 B,450,0.9,0,1.3,,0.6,0.30000000000000004,50
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 18 Day 1 B,478,0.8,0,1.3,,0.6,0.20000000000000007,33.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 19 Day 1 B,506,0.8,0,1.3,,0.6,0.20000000000000007,33.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 20 Day 1 B,534,0.4,0,1.3,,0.6,-0.19999999999999996,-33.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 21 Day 1 B,562,0.8,0,1.3,,0.6,0.20000000000000007,33.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 22 Day 1 B,591,0.6,0,1.3,,0.6,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,End of Treatment B,618,1,0,1.3,,0.6,0.4,66.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Follow-up 110 B,702,0.7,0,1.3,,0.6,0.09999999999999998,16.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,,-11,3.2,1.5,7.5,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Baseline,1,3.1,1.5,7.5,Y,3.1,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 8 B,8,1.5,1.5,7.5,,3.1,-1.6,-51.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 15 B,15,4.4,1.5,7.5,,3.1,1.3000000000000003,41.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 2 Day 1 B,30,4.1,1.5,7.5,,3.1,0.9999999999999996,32.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 3 Day 1 B,58,3.2,1.5,7.5,,3.1,0.10000000000000009,3.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 4 Day 1 B,89,3.94,2,7.7,,3.1,0.8399999999999999,27.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 5 Day 1 B,114,3.1,1.5,7.5,,3.1,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 6 Day 1 B,142,4.6,1.5,7.5,,3.1,1.4999999999999996,48.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 7 Day 1 B,170,5.2,1.5,7.5,,3.1,2.1,67.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 8 Day 1 B,198,3.4,1.5,7.5,,3.1,0.2999999999999998,9.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 9 Day 1 B,226,3.7,1.5,7.5,,3.1,0.6000000000000001,19.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 10 Day 1 B,255,3.6,1.5,7.5,,3.1,0.5,16.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 11 Day 1 B,282,3.8,1.5,7.5,,3.1,0.6999999999999997,22.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 12 Day 1 B,310,4.6,1.5,7.5,,3.1,1.4999999999999996,48.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 13 Day 1 B,338,5,1.5,7.5,,3.1,1.9,61.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 14 Day 1 B,366,5,1.5,7.5,,3.1,1.9,61.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 15 Day 1 B,395,5.1,1.5,7.5,,3.1,1.9999999999999996,64.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 16 Day 1 B,422,4.7,1.5,7.5,,3.1,1.6,51.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 17 Day 1 B,450,7,1.5,7.5,,3.1,3.9,125.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 18 Day 1 B,478,4.6,1.5,7.5,,3.1,1.4999999999999996,48.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 19 Day 1 B,506,4.6,1.5,7.5,,3.1,1.4999999999999996,48.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 20 Day 1 B,534,4.4,1.5,7.5,,3.1,1.3000000000000003,41.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 21 Day 1 B,562,4.6,1.5,7.5,,3.1,1.4999999999999996,48.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 22 Day 1 B,591,4.6,1.5,7.5,,3.1,1.4999999999999996,48.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,End of Treatment B,618,4.8,1.5,7.5,,3.1,1.6999999999999997,54.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Follow-up 110 B,702,4.4,1.5,7.5,,3.1,1.3000000000000003,41.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),,-11,246,160,400,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Baseline,1,246,160,400,Y,246,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,226,160,400,,246,-20,-8.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,15,249,160,400,,246,3,1.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,30,347,160,400,,246,101,41.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,58,236,160,400,,246,-10,-4.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 1 B,89,265,150,350,,246,19,7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 5 Day 1 B,114,278,160,400,,246,32,13
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 6 Day 1 B,142,233,160,400,,246,-13,-5.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 7 Day 1 B,170,249,160,400,,246,3,1.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 8 Day 1 B,198,241,160,400,,246,-5,-2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 9 Day 1 B,226,247,160,400,,246,1,0.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 10 Day 1 B,255,232,160,400,,246,-14,-5.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 11 Day 1 B,282,232,160,400,,246,-14,-5.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 12 Day 1 B,310,260,160,400,,246,14,5.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 13 Day 1 B,338,261,160,400,,246,15,6.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 14 Day 1 B,366,254,160,400,,246,8,3.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 15 Day 1 B,395,275,160,400,,246,29,11.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 16 Day 1 B,422,242,160,400,,246,-4,-1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 17 Day 1 B,450,242,160,400,,246,-4,-1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 18 Day 1 B,478,250,160,400,,246,4,1.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 19 Day 1 B,506,245,160,400,,246,-1,-0.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 20 Day 1 B,534,282,160,400,,246,36,14.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 21 Day 1 B,562,254,160,400,,246,8,3.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 22 Day 1 B,591,245,160,400,,246,-1,-0.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),End of Treatment B,618,279,160,400,,246,33,13.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Follow-up 110 B,702,259,160,400,,246,13,5.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,TESTR,Baseline,-11,30,221,716,Y,30,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,,-11,5.3,4,11,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Baseline,1,5.1,4,11,Y,5.1,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,5.1,4,11,,5.1,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 15 B,15,10.9,4,11,,5.1,5.800000000000001,113.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 2 Day 1 B,30,6.6,4,11,,5.1,1.5,29.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 3 Day 1 B,58,5.3,4,11,,5.1,0.20000000000000018,3.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 4 Day 1 B,89,5.98,4,10.4,,5.1,0.8800000000000008,17.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 5 Day 1 B,114,5.2,4,11,,5.1,0.10000000000000053,2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 6 Day 1 B,142,6.9,4,11,,5.1,1.8000000000000007,35.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 7 Day 1 B,170,6.6,4,11,,5.1,1.5,29.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 8 Day 1 B,198,5.7,4,11,,5.1,0.6000000000000005,11.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 9 Day 1 B,226,5.9,4,11,,5.1,0.8000000000000007,15.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 10 Day 1 B,255,5.8,4,11,,5.1,0.7000000000000002,13.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 11 Day 1 B,282,6,4,11,,5.1,0.9000000000000004,17.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 12 Day 1 B,310,7.3,4,11,,5.1,2.2,43.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 13 Day 1 B,338,7.7,4,11,,5.1,2.6000000000000005,51
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 14 Day 1 B,366,7.8,4,11,,5.1,2.7,52.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 15 Day 1 B,395,7.9,4,11,,5.1,2.8000000000000007,54.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 16 Day 1 B,422,7.4,4,11,,5.1,2.3000000000000007,45.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 17 Day 1 B,450,9.7,4,11,,5.1,4.6,90.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 18 Day 1 B,478,7.2,4,11,,5.1,2.1000000000000005,41.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 19 Day 1 B,506,7.2,4,11,,5.1,2.1000000000000005,41.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 20 Day 1 B,534,6.3,4,11,,5.1,1.2000000000000002,23.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 21 Day 1 B,562,7.2,4,11,,5.1,2.1000000000000005,41.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 22 Day 1 B,591,7.2,4,11,,5.1,2.1000000000000005,41.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,End of Treatment B,618,7.7,4,11,,5.1,2.6000000000000005,51
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Follow-up 110 B,702,6.4,4,11,,5.1,1.3000000000000007,25.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,,-11,22.03,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Baseline,1,22.21,NA,NA,Y,22.21,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,30,16.46,NA,NA,,22.21,-5.75,-25.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 3 Day 1 B,58,4.28,NA,NA,,22.21,-17.93,-80.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 4 Day 1 B,89,1.9,NA,NA,,22.21,-20.310000000000002,-91.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 5 Day 1 B,114,1.01,NA,NA,,22.21,-21.2,-95.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 6 Day 1 B,142,0.49,NA,NA,,22.21,-21.720000000000002,-97.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 7 Day 1 B,170,0.28,NA,NA,,22.21,-21.93,-98.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 8 Day 1 B,198,0.17,NA,NA,,22.21,-22.04,-99.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 9 Day 1 B,226,0.14,NA,NA,,22.21,-22.07,-99.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 10 Day 1 B,255,0.17,NA,NA,,22.21,-22.04,-99.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 11 Day 1 B,282,0.21,NA,NA,,22.21,-22,-99.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 12 Day 1 B,310,0.27,NA,NA,,22.21,-21.94,-98.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 13 Day 1 B,338,0.41,NA,NA,,22.21,-21.8,-98.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 14 Day 1 B,366,0.6,NA,NA,,22.21,-21.61,-97.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 15 Day 1 B,395,0.95,NA,NA,,22.21,-21.26,-95.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 16 Day 1 B,422,1.34,NA,NA,,22.21,-20.87,-94
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 17 Day 1 B,450,2.03,NA,NA,,22.21,-20.18,-90.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 18 Day 1 B,478,2.47,NA,NA,,22.21,-19.740000000000002,-88.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 19 Day 1 B,506,3.38,NA,NA,,22.21,-18.830000000000002,-84.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 20 Day 1 B,534,5.3,NA,NA,,22.21,-16.91,-76.1
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 21 Day 1 B,562,6.69,NA,NA,,22.21,-15.52,-69.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 22 Day 1 B,591,8.93,NA,NA,,22.21,-13.280000000000001,-59.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,End of Treatment B,618,12.35,NA,NA,,22.21,-9.860000000000001,-44.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Follow-up 110 B,702,3.36,NA,NA,,22.21,-18.85,-84.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 3 Day 1 B,58,1.09,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 4 Day 1 B,89,1.4,NA,NA,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-11,2.49,0.6,4.8,,NA,NA,NA
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.61,0.6,4.8,Y,2.61,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,1.6,0.6,4.8,,2.61,-1.0099999999999998,-38.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,15,2.49,0.6,4.8,,2.61,-0.11999999999999966,-4.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,30,1.52,0.6,4.8,,2.61,-1.0899999999999999,-41.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,58,0.36,0.6,4.8,,2.61,-2.25,-86.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 B,89,0.16,0.3,4.2,,2.61,-2.4499999999999997,-93.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 B,114,0.96,0.6,4.8,,2.61,-1.65,-63.2
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 6 Day 1 B,142,1.66,0.6,4.8,,2.61,-0.95,-36.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 7 Day 1 B,170,1.86,0.6,4.8,,2.61,-0.7499999999999998,-28.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 8 Day 1 B,198,2.99,0.6,4.8,,2.61,0.38000000000000034,14.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 9 Day 1 B,226,3.18,0.6,4.8,,2.61,0.5700000000000003,21.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 10 Day 1 B,255,2.93,0.6,4.8,,2.61,0.3200000000000003,12.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 11 Day 1 B,282,2.67,0.6,4.8,,2.61,0.06000000000000005,2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 12 Day 1 B,310,2.41,0.6,4.8,,2.61,-0.19999999999999973,-7.7
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 13 Day 1 B,338,2.38,0.6,4.8,,2.61,-0.22999999999999998,-8.8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 14 Day 1 B,366,2.61,0.6,4.8,,2.61,0,0
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 15 Day 1 B,395,2.95,0.6,4.8,,2.61,0.3400000000000003,13
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 16 Day 1 B,422,1.92,0.6,4.8,,2.61,-0.69,-26.4
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 17 Day 1 B,450,2.21,0.6,4.8,,2.61,-0.3999999999999999,-15.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 18 Day 1 B,478,2.55,0.6,4.8,,2.61,-0.06000000000000005,-2.3
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 19 Day 1 B,506,2.23,0.6,4.8,,2.61,-0.3799999999999999,-14.6
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 20 Day 1 B,534,1.75,0.6,4.8,,2.61,-0.8599999999999999,-33
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 21 Day 1 B,562,2.3,0.6,4.8,,2.61,-0.31000000000000005,-11.9
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 22 Day 1 B,591,2.57,0.6,4.8,,2.61,-0.040000000000000036,-1.5
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,618,2.4,0.6,4.8,,2.61,-0.20999999999999996,-8
13B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 B,702,1.8,0.6,4.8,,2.61,-0.8099999999999998,-31
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,10,NA,NA,Y,10,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,End of Treatment C,40,12,NA,NA,,10,2,20
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-12,14,1,45,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,17,1,45,Y,17,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,17,1,45,,17,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,15,23,1,45,,17,6,35.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,23,1,45,,17,6,35.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,40,62,1,45,,17,45,264.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-12,3.4,3.5,4.9,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.5,3.5,4.9,Y,3.5,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,3.6,3.5,4.9,,3.5,0.10000000000000009,2.9
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,15,3.4,3.5,4.9,,3.5,-0.10000000000000009,-2.9
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,3.3,3.5,4.9,,3.5,-0.20000000000000018,-5.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,40,3,3.5,4.9,,3.5,-0.5,-14.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-12,136,38,126,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,169,38,126,Y,169,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,199,38,126,,169,30,17.8
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,15,210,38,126,,169,41,24.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,212,38,126,,169,43,25.4
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,40,309,38,126,,169,140,82.8
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-12,25,1,35,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,30,1,35,Y,30,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,30,1,35,,30,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,15,40,1,35,,30,10,33.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,40,1,35,,30,10,33.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,40,57,1,35,,30,27,90
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-12,20,6,23,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,18,6,23,Y,18,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,16,6,23,,18,-2,-11.1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,15,18,6,23,,18,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,19,6,23,,18,1,5.6
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,40,20,6,23,,18,2,11.1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-12,27,22,30,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,23.4,22,30,Y,23.4,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,26.2,22,30,,23.4,2.8000000000000007,12
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,15,24.3,22,30,,23.4,0.9000000000000021,3.8
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,26.2,22,30,,23.4,2.8000000000000007,12
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment C,40,26.1,22,30,,23.4,2.700000000000003,11.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-12,9.2,8.5,10.5,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8.9,8.5,10.5,Y,8.9,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,8.8,8.5,10.5,,8.9,-0.09999999999999964,-1.1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,15,8.8,8.5,10.5,,8.9,-0.09999999999999964,-1.1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,8.5,8.5,10.5,,8.9,-0.40000000000000036,-4.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,40,8.4,8.5,10.5,,8.9,-0.5,-5.6
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-12,107,96,108,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,105,96,108,Y,105,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,102,96,108,,105,-3,-2.9
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,15,103,96,108,,105,-2,-1.9
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,101,96,108,,105,-4,-3.8
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,40,98,96,108,,105,-7,-6.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-12,0.71,0.7,1.3,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.69,0.7,1.3,Y,0.69,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,0.74,0.7,1.3,,0.69,0.050000000000000044,7.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,15,0.75,0.7,1.3,,0.69,0.06000000000000005,8.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,0.79,0.7,1.3,,0.69,0.10000000000000009,14.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,40,0.63,0.7,1.3,,0.69,-0.05999999999999994,-8.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-12,82,60,100,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,103,60,100,Y,103,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,85,60,100,,103,-18,-17.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,15,87,60,100,,103,-16,-15.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,102,60,100,,103,-1,-1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,40,92,60,100,,103,-11,-10.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-12,1004,100,220,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,1023,100,220,Y,1023,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,1211,100,220,,1023,188,18.4
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,15,1370,100,220,,1023,347,33.9
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,1587,100,220,,1023,564,55.1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,40,2137,100,220,,1023,1114,108.9
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-12,4.7,3.5,5.2,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.5,3.5,5.2,Y,4.5,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,4.6,3.5,5.2,,4.5,0.09999999999999964,2.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,15,4.4,3.5,5.2,,4.5,-0.09999999999999964,-2.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.5,3.5,5.2,,4.5,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,40,4.6,3.5,5.2,,4.5,0.09999999999999964,2.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-12,141,135,145,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,138,135,145,Y,138,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,137,135,145,,138,-1,-0.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,15,137,135,145,,138,-1,-0.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,133,135,145,,138,-5,-3.6
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,40,131,135,145,,138,-7,-5.1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-12,0.3,0.1,1.2,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.3,0.1,1.2,Y,0.3,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.3,0.1,1.2,,0.3,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,15,0.3,0.1,1.2,,0.3,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.3,0.1,1.2,,0.3,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,40,0.4,0.1,1.2,,0.3,0.10000000000000003,33.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-12,6.7,6,8.3,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.7,6,8.3,Y,6.7,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,6.8,6,8.3,,6.7,0.09999999999999964,1.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,15,6.7,6,8.3,,6.7,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,6.3,6,8.3,,6.7,-0.40000000000000036,-6
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,40,6.2,6,8.3,,6.7,-0.5,-7.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,UREA,,-12,20,6,23,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,UREA,Baseline,1,18,6,23,Y,18,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,UREA,I-P Lead In C,8,16,6,23,,18,-2,-11.1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,UREA,I-P Lead In C,15,18,6,23,,18,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,UREA,I-P Lead In C,22,19,6,23,,18,1,5.6
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,UREA,End of Treatment C,40,20,6,23,,18,2,11.1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-12,36,25.4,34.9,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,33.2,25.4,34.9,Y,33.2,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,8,34.2,25.4,34.9,,33.2,1,3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,22,36,25.4,34.9,,33.2,2.799999999999997,8.4
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-12,1.1,2,3,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1,2,3,Y,1,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,8,1.1,2,3,,1,0.10000000000000009,10
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,22,1.1,2,3,,1,0.10000000000000009,10
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-12,13.5,12.3,14.9,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.9,12.3,14.9,Y,12.9,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,8,13.7,12.3,14.9,,12.9,0.7999999999999989,6.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,22,13.5,12.3,14.9,,12.9,0.5999999999999996,4.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-12,0,0,0.2,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0.1,0,0.2,,0,0.1,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,15,0,0,0.2,,0,0,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.2,,0,0.1,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,40,0.1,0,0.2,,0,0.1,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-12,0.1,0,0.6,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.6,Y,0.1,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0.1,0,0.6,,0.1,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,15,0.1,0,0.6,,0.1,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0.1,0,0.6,,0.1,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,40,0.1,0,0.6,,0.1,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-12,4.14,4.5,6,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.03,4.5,6,Y,4.03,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,4.04,4.5,6,,4.03,0.009999999999999787,0.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,15,4.06,4.5,6,,4.03,0.02999999999999936,0.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.81,4.5,6,,4.03,-0.2200000000000002,-5.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,40,4.03,4.5,6,,4.03,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-12,36.5,42,52,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,35.2,42,52,Y,35.2,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,35.3,42,52,,35.2,0.09999999999999432,0.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,15,35.3,42,52,,35.2,0.09999999999999432,0.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,32.8,42,52,,35.2,-2.4000000000000057,-6.8
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,40,34.9,42,52,,35.2,-0.30000000000000426,-0.9
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-12,12.1,13.9,16.3,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.6,13.9,16.3,Y,11.6,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,11.8,13.9,16.3,,11.6,0.20000000000000107,1.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,15,11.4,13.9,16.3,,11.6,-0.1999999999999993,-1.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,10.7,13.9,16.3,,11.6,-0.9000000000000004,-7.8
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,40,11.2,13.9,16.3,,11.6,-0.40000000000000036,-3.4
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-12,0.6,1,4.5,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.6,1,4.5,Y,0.6,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,0.9,1,4.5,,0.6,0.30000000000000004,50
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,15,0.9,1,4.5,,0.6,0.30000000000000004,50
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,0.6,1,4.5,,0.6,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,40,0.7,1,4.5,,0.6,0.09999999999999998,16.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-12,0.6,0.2,1,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.4,0.2,1,Y,0.4,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,2.5,0.2,1,,0.4,2.1,525
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,15,3.2,0.2,1,,0.4,2.8000000000000003,700
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,1.9,0.2,1,,0.4,1.5,375
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,40,0.9,0.2,1,,0.4,0.5,125
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-12,3.2,1.9,8,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,2.7,1.9,8,Y,2.7,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,3.8,1.9,8,,2.7,1.0999999999999996,40.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,15,3.9,1.9,8,,2.7,1.1999999999999997,44.4
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,3.08,1.9,8,,2.7,0.3799999999999999,14.1
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,40,6.3,1.9,8,,2.7,3.5999999999999996,133.3
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-12,271,150,450,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,289,150,450,Y,289,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,275,150,450,,289,-14,-4.8
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,15,274,150,450,,289,-15,-5.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,333,150,450,,289,44,15.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,40,357,150,450,,289,68,23.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-12,4.4,4.5,11,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,3.8,4.5,11,Y,3.8,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,7.4,4.5,11,,3.8,3.6000000000000005,94.7
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,15,8.1,4.5,11,,3.8,4.3,113.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,5.7,4.5,11,,3.8,1.9000000000000004,50
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,40,8.1,4.5,11,,3.8,4.3,113.2
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,1,7.84,NA,NA,,7.84,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,7.84,NA,NA,Y,7.84,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,8.22,NA,NA,,7.84,0.3800000000000008,4.8
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,40,7.53,NA,NA,,7.84,-0.3099999999999996,-4
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-12,2.11,0.4,4.2,,NA,NA,NA
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.95,0.4,4.2,Y,1.95,0,0
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,2.37,0.4,4.2,,1.95,0.42000000000000015,21.5
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,15,2.2,0.4,4.2,,1.95,0.2500000000000002,12.8
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,3.05,0.4,4.2,,1.95,1.0999999999999999,56.4
13C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,40,2.06,0.4,4.2,,1.95,0.1100000000000001,5.6
14A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 3 Day 1 A,44,0,NA,NA,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 5 Day 1 A,86,0,NA,NA,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),,-13,14,0,59,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,20,0,59,Y,20,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,14,0,59,,20,-6,-30
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,23,23,0,59,,20,3,15
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,30,34,0,59,,20,14,70
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 A,44,15,0,59,,20,-5,-25
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 8 A,51,15,0,59,,20,-5,-25
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 8 A,71,16,0,59,,20,-4,-20
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,99,22,0,59,,20,2,10
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),,-13,4.1,3.5,4.7,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Baseline,1,3.8,3.5,4.7,Y,3.8,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,3,3.5,4.7,,3.8,-0.7999999999999998,-21.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,23,3.4,3.5,4.7,,3.8,-0.3999999999999999,-10.5
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,30,2.9,3.5,4.7,,3.8,-0.8999999999999999,-23.7
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 1 A,44,3.1,3.5,4.7,,3.8,-0.6999999999999997,-18.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 8 A,51,2.7,3.5,4.7,,3.8,-1.0999999999999996,-28.9
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 4 Day 8 A,71,3,3.5,4.7,,3.8,-0.7999999999999998,-21.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),End of Treatment A,99,3,3.5,4.7,,3.8,-0.7999999999999998,-21.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),,-13,90,56,119,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,94,56,119,Y,94,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,88,56,119,,94,-6,-6.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,23,110,56,119,,94,16,17
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,30,76,56,119,,94,-18,-19.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 A,44,76,56,119,,94,-18,-19.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 8 A,51,72,56,119,,94,-22,-23.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 8 A,71,80,56,119,,94,-14,-14.9
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,99,90,56,119,,94,-4,-4.3
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-13,12,0,41,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,13,0,41,Y,13,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,7,0,41,,13,-6,-46.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,23,16,0,41,,13,3,23.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,30,9,0,41,,13,-4,-30.8
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 A,44,8,0,41,,13,-5,-38.5
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 8 A,51,9,0,41,,13,-4,-30.8
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 8 A,71,11,0,41,,13,-2,-15.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,99,17,0,41,,13,4,30.8
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,,-13,10,6,20,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Baseline,1,10,6,20,Y,10,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 1 Day 8 A,8,9,6,20,,10,-1,-10
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 2 Day 1 A,23,15,6,20,,10,5,50
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 2 Day 8 A,30,14,6,20,,10,4,40
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 3 Day 1 A,44,9,6,20,,10,-1,-10
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 3 Day 8 A,51,6,6,20,,10,-4,-40
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 4 Day 8 A,71,7,6,20,,10,-3,-30
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,End of Treatment A,99,10,6,20,,10,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,,-13,28,21,32,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Baseline,1,27,21,32,Y,27,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,29,21,32,,27,2,7.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 2 Day 1 A,23,26,21,32,,27,-1,-3.7
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 2 Day 8 A,30,27,21,32,,27,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 3 Day 1 A,44,27,21,32,,27,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 3 Day 8 A,51,30,21,32,,27,3,11.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 4 Day 8 A,71,27,21,32,,27,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,End of Treatment A,99,28,21,32,,27,1,3.7
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),,-13,9.7,8.6,10.2,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Baseline,1,9.1,8.6,10.2,Y,9.1,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,8.8,8.6,10.2,,9.1,-0.29999999999999893,-3.3
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,23,9.3,8.6,10.2,,9.1,0.20000000000000107,2.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,30,8.5,8.6,10.2,,9.1,-0.5999999999999996,-6.6
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 A,44,8.6,8.6,10.2,,9.1,-0.5,-5.5
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 8 A,51,8.2,8.6,10.2,,9.1,-0.9000000000000004,-9.9
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 4 Day 8 A,71,8,8.6,10.2,,9.1,-1.0999999999999996,-12.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),End of Treatment A,99,8.7,8.6,10.2,,9.1,-0.40000000000000036,-4.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),,-13,92,97,108,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Baseline,1,92,97,108,Y,92,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,92,97,108,,92,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,23,96,97,108,,92,4,4.3
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,30,97,97,108,,92,5,5.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 A,44,95,97,108,,92,3,3.3
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 8 A,51,94,97,108,,92,2,2.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 4 Day 8 A,71,89,97,108,,92,-3,-3.3
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),End of Treatment A,99,90,97,108,,92,-2,-2.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),,-13,0.66,0.7,1.3,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Baseline,1,0.63,0.7,1.3,Y,0.63,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,0.59,0.7,1.3,,0.63,-0.040000000000000036,-6.3
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,23,0.56,0.7,1.3,,0.63,-0.06999999999999995,-11.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,30,0.64,0.7,1.3,,0.63,0.010000000000000009,1.6
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 A,44,0.63,0.7,1.3,,0.63,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 8 A,51,0.62,0.7,1.3,,0.63,-0.010000000000000009,-1.6
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 4 Day 8 A,71,0.63,0.7,1.3,,0.63,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),End of Treatment A,99,0.65,0.7,1.3,,0.63,0.020000000000000018,3.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,,-13,94,70,99,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Baseline,1,96,70,99,Y,96,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 1 Day 8 A,8,99,70,99,,96,3,3.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 2 Day 1 A,23,122,70,99,,96,26,27.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 2 Day 8 A,30,121,70,99,,96,25,26
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 3 Day 1 A,44,113,70,99,,96,17,17.7
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 3 Day 8 A,51,90,70,99,,96,-6,-6.3
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 4 Day 8 A,71,68,70,99,,96,-28,-29.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,End of Treatment A,99,103,70,99,,96,7,7.3
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-13,130,0,250,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,135,0,250,Y,135,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,8,119,0,250,,135,-16,-11.9
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,23,122,0,250,,135,-13,-9.6
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,30,120,0,250,,135,-15,-11.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 A,44,328,0,250,,135,193,143
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 8 A,51,116,0,250,,135,-19,-14.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment A,99,192,0,250,,135,57,42.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),,-13,4.8,3.4,5,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Baseline,1,4.8,3.4,5,Y,4.8,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,4.6,3.4,5,,4.8,-0.20000000000000018,-4.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,23,4.6,3.4,5,,4.8,-0.20000000000000018,-4.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,30,4.6,3.4,5,,4.8,-0.20000000000000018,-4.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 A,44,4.3,3.4,5,,4.8,-0.5,-10.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 8 A,51,4.3,3.4,5,,4.8,-0.5,-10.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 4 Day 8 A,71,3.7,3.4,5,,4.8,-1.0999999999999996,-22.9
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),End of Treatment A,99,4.6,3.4,5,,4.8,-0.20000000000000018,-4.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,,-13,129,136,145,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Baseline,1,127,136,145,Y,127,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 1 Day 8 A,8,128,136,145,,127,1,0.8
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 2 Day 1 A,23,130,136,145,,127,3,2.4
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 2 Day 8 A,30,131,136,145,,127,4,3.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 3 Day 1 A,44,129,136,145,,127,2,1.6
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 3 Day 8 A,51,128,136,145,,127,1,0.8
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 4 Day 8 A,71,122,136,145,,127,-5,-3.9
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,End of Treatment A,99,126,136,145,,127,-1,-0.8
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,,-13,0.7,0.3,1.2,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Baseline,1,0.6,0.3,1.2,Y,0.6,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.3,0.3,1.2,,0.6,-0.3,-50
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,23,0.6,0.3,1.2,,0.6,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,30,0.5,0.3,1.2,,0.6,-0.09999999999999998,-16.7
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 3 Day 1 A,44,0.5,0.3,1.2,,0.6,-0.09999999999999998,-16.7
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 3 Day 8 A,51,0.3,0.3,1.2,,0.6,-0.3,-50
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 4 Day 8 A,71,0.3,0.3,1.2,,0.6,-0.3,-50
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,End of Treatment A,99,0.3,0.3,1.2,,0.6,-0.3,-50
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,,-13,7.7,6.4,8.2,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Baseline,1,7.4,6.4,8.2,Y,7.4,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 1 Day 8 A,8,6.2,6.4,8.2,,7.4,-1.2000000000000002,-16.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 2 Day 1 A,23,7.1,6.4,8.2,,7.4,-0.3000000000000007,-4.1
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 2 Day 8 A,30,6,6.4,8.2,,7.4,-1.4000000000000004,-18.9
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 3 Day 1 A,44,6.4,6.4,8.2,,7.4,-1,-13.5
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 3 Day 8 A,51,5.7,6.4,8.2,,7.4,-1.7000000000000002,-23
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 4 Day 8 A,71,6.2,6.4,8.2,,7.4,-1.2000000000000002,-16.2
14A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,End of Treatment A,99,6.8,6.4,8.2,,7.4,-0.6000000000000005,-8.1
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),,-13,32.7,22.5,34.5,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,34,22.5,34.5,Y,34,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 A,8,32.7,22.5,34.5,,34,-1.2999999999999972,-3.8
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 A,23,29.9,22.5,34.5,,34,-4.100000000000001,-12.1
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 8 A,30,32,22.5,34.5,,34,-2,-5.9
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 A,44,35,22.5,34.5,,34,1,2.9
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 8 A,51,35.6,22.5,34.5,,34,1.6000000000000014,4.7
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 A,64,37.4,22.5,34.5,,34,3.3999999999999986,10
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment A,99,40.1,22.5,34.5,,34,6.100000000000001,17.9
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-13,1.06,0.8,1.2,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.08,0.8,1.2,Y,1.08,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 A,8,1.06,0.8,1.2,,1.08,-0.020000000000000018,-1.9
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 A,23,1.11,0.8,1.2,,1.08,0.030000000000000027,2.8
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 8 A,30,1.44,0.8,1.2,,1.08,0.3599999999999999,33.3
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 A,44,1.14,0.8,1.2,,1.08,0.05999999999999983,5.6
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 8 A,51,1.08,0.8,1.2,,1.08,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 A,64,1.05,0.8,1.2,,1.08,-0.030000000000000027,-2.8
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 8 A,71,1.1,0.8,1.2,,1.08,0.020000000000000018,1.9
14A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment A,99,1.22,0.8,1.2,,1.08,0.1399999999999999,13
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,,-13,0.04,0,0.1,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Baseline,1,0.03,0,0.1,Y,0.03,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 2 A,2,0.03,0,0.1,,0.03,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 3 A,3,0.01,0,0.1,,0.03,-0.019999999999999997,-66.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 8 A,8,0.03,0,0.1,,0.03,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 2 Day 1 A,23,0.06,0,0.1,,0.03,0.03,100
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 2 Day 8 A,30,0.01,0,0.1,,0.03,-0.019999999999999997,-66.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 3 Day 1 A,44,0.06,0,0.1,,0.03,0.03,100
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 3 Day 8 A,51,0.03,0,0.1,,0.03,0,0
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 4 Day 1 A,64,0.06,0,0.1,,0.03,0.03,100
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,End of Treatment A,99,0.05,0,0.1,,0.03,0.020000000000000004,66.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,,-13,0.12,0,0.5,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Baseline,1,0.15,0,0.5,Y,0.15,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.14,0,0.5,,0.15,-0.009999999999999981,-6.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.19,0,0.5,,0.15,0.04000000000000001,26.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.83,0,0.5,,0.15,0.6799999999999999,453.3
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 2 Day 1 A,23,0.45,0,0.5,,0.15,0.30000000000000004,200
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 2 Day 8 A,30,1.32,0,0.5,,0.15,1.1700000000000002,780
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 3 Day 1 A,44,0.4,0,0.5,,0.15,0.25,166.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 3 Day 8 A,51,2.48,0,0.5,,0.15,2.33,1553.3
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 4 Day 1 A,64,0.55,0,0.5,,0.15,0.4,266.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,End of Treatment A,99,0.16,0,0.5,,0.15,0.010000000000000009,6.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),,-13,4.17,4.5,6,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Baseline,1,4.06,4.5,6,Y,4.06,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,3.82,4.5,6,,4.06,-0.23999999999999977,-5.9
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,4.02,4.5,6,,4.06,-0.040000000000000036,-1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,3.66,4.5,6,,4.06,-0.39999999999999947,-9.9
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,23,3.85,4.5,6,,4.06,-0.20999999999999952,-5.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,30,3.42,4.5,6,,4.06,-0.6399999999999997,-15.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 A,44,3.94,4.5,6,,4.06,-0.11999999999999966,-3
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 8 A,51,3.7,4.5,6,,4.06,-0.35999999999999943,-8.9
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 A,64,3.91,4.5,6,,4.06,-0.14999999999999947,-3.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 8 A,71,3.9,4.5,6,,4.06,-0.1599999999999997,-3.9
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),End of Treatment A,99,3.58,4.5,6,,4.06,-0.47999999999999954,-11.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),,-13,42.2,41,53,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Baseline,1,40.1,41,53,Y,40.1,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,38.7,41,53,,40.1,-1.3999999999999986,-3.5
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,39.7,41,53,,40.1,-0.3999999999999986,-1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,36,41,53,,40.1,-4.100000000000001,-10.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,23,38.7,41,53,,40.1,-1.3999999999999986,-3.5
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,30,33.7,41,53,,40.1,-6.399999999999999,-16
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 A,44,39.3,41,53,,40.1,-0.8000000000000043,-2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 8 A,51,36.4,41,53,,40.1,-3.700000000000003,-9.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 A,64,38.7,41,53,,40.1,-1.3999999999999986,-3.5
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 8 A,71,37.2,41,53,,40.1,-2.8999999999999986,-7.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),End of Treatment A,99,34.8,41,53,,40.1,-5.300000000000004,-13.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),,-13,14.2,13.5,17.5,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Baseline,1,13.5,13.5,17.5,Y,13.5,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,12.9,13.5,17.5,,13.5,-0.5999999999999996,-4.4
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,13.4,13.5,17.5,,13.5,-0.09999999999999964,-0.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,12.2,13.5,17.5,,13.5,-1.3000000000000007,-9.6
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,23,12.7,13.5,17.5,,13.5,-0.8000000000000007,-5.9
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,30,11.1,13.5,17.5,,13.5,-2.4000000000000004,-17.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 A,44,12.9,13.5,17.5,,13.5,-0.5999999999999996,-4.4
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 8 A,51,12.2,13.5,17.5,,13.5,-1.3000000000000007,-9.6
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 A,64,12.9,13.5,17.5,,13.5,-0.5999999999999996,-4.4
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 8 A,71,12.7,13.5,17.5,,13.5,-0.8000000000000007,-5.9
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),End of Treatment A,99,11.5,13.5,17.5,,13.5,-2,-14.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,,-13,1.16,1,4.8,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Baseline,1,1.14,1,4.8,Y,1.14,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.3,1,4.8,,1.14,-0.8399999999999999,-73.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.16,1,4.8,,1.14,-0.9799999999999999,-86
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,1.91,1,4.8,,1.14,0.77,67.5
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 2 Day 1 A,23,1.25,1,4.8,,1.14,0.1100000000000001,9.6
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 2 Day 8 A,30,0.57,1,4.8,,1.14,-0.57,-50
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 3 Day 1 A,44,0.68,1,4.8,,1.14,-0.45999999999999985,-40.4
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 3 Day 8 A,51,1.36,1,4.8,,1.14,0.2200000000000002,19.3
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 4 Day 1 A,64,1.37,1,4.8,,1.14,0.2300000000000002,20.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,End of Treatment A,99,1.21,1,4.8,,1.14,0.07000000000000006,6.1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,,-13,0.56,0.1,0.9,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Baseline,1,0.57,0.1,0.9,Y,0.57,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.55,0.1,0.9,,0.57,-0.019999999999999907,-3.5
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.58,0.1,0.9,,0.57,0.010000000000000009,1.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 8 A,8,0.72,0.1,0.9,,0.57,0.15000000000000002,26.3
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 2 Day 1 A,23,0.61,0.1,0.9,,0.57,0.040000000000000036,7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 2 Day 8 A,30,0.25,0.1,0.9,,0.57,-0.31999999999999995,-56.1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 3 Day 1 A,44,0.37,0.1,0.9,,0.57,-0.19999999999999996,-35.1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 3 Day 8 A,51,0.44,0.1,0.9,,0.57,-0.12999999999999995,-22.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 4 Day 1 A,64,0.36,0.1,0.9,,0.57,-0.20999999999999996,-36.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,End of Treatment A,99,0.62,0.1,0.9,,0.57,0.050000000000000044,8.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,,-13,2.82,1.8,7.7,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Baseline,1,2.94,1.8,7.7,Y,2.94,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 2 A,2,3.46,1.8,7.7,,2.94,0.52,17.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 3 A,3,4.97,1.8,7.7,,2.94,2.03,69
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 8 A,8,2.97,1.8,7.7,,2.94,0.03000000000000025,1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 2 Day 1 A,23,2.23,1.8,7.7,,2.94,-0.71,-24.1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 2 Day 8 A,30,4.65,1.8,7.7,,2.94,1.7100000000000004,58.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 3 Day 1 A,44,4.81,1.8,7.7,,2.94,1.8699999999999997,63.6
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 3 Day 8 A,51,2.33,1.8,7.7,,2.94,-0.6099999999999999,-20.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 4 Day 1 A,64,3.71,1.8,7.7,,2.94,0.77,26.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,End of Treatment A,99,4.85,1.8,7.7,,2.94,1.9099999999999997,65
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),,-13,230,150,400,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Baseline,1,264,150,400,Y,264,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,233,150,400,,264,-31,-11.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,210,150,400,,264,-54,-20.5
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,203,150,400,,264,-61,-23.1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,23,260,150,400,,264,-4,-1.5
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,30,175,150,400,,264,-89,-33.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 1 A,44,232,150,400,,264,-32,-12.1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 8 A,51,151,150,400,,264,-113,-42.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 1 A,64,275,150,400,,264,11,4.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 8 A,71,171,150,400,,264,-93,-35.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),End of Treatment A,99,191,150,400,,264,-73,-27.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,TESTR,Baseline,-13,3,270,1070,Y,3,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,,-13,4.71,3.5,10.8,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Baseline,1,4.84,3.5,10.8,Y,4.84,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,4.49,3.5,10.8,,4.84,-0.34999999999999964,-7.2
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,5.94,3.5,10.8,,4.84,1.1000000000000005,22.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,6.47,3.5,10.8,,4.84,1.63,33.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 2 Day 1 A,23,4.61,3.5,10.8,,4.84,-0.22999999999999954,-4.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 2 Day 8 A,30,6.83,3.5,10.8,,4.84,1.9900000000000002,41.1
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 3 Day 1 A,44,6.33,3.5,10.8,,4.84,1.4900000000000002,30.8
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 3 Day 8 A,51,6.66,3.5,10.8,,4.84,1.8200000000000003,37.6
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 4 Day 1 A,64,6.07,3.5,10.8,,4.84,1.2300000000000004,25.4
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 4 Day 8 A,71,6.23,3.5,10.8,,4.84,1.3900000000000006,28.7
14A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,End of Treatment A,99,6.91,3.5,10.8,,4.84,2.0700000000000003,42.8
14A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,,-13,12.69,NA,NA,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Baseline,1,16.33,NA,NA,Y,16.33,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,23,17.53,NA,NA,,16.33,1.2000000000000028,7.3
14A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 3 Day 1 A,44,20.34,NA,NA,,16.33,4.010000000000002,24.6
14A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 4 Day 1 A,64,17.93,NA,NA,,16.33,1.6000000000000014,9.8
14A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,End of Treatment A,99,35.95,NA,NA,,16.33,19.620000000000005,120.1
14A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-13,1.22,0.44,7.11,,NA,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,0.79,0.44,7.11,Y,0.79,NA,NA
14A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 A,44,1.88,0.44,7.11,,0.79,1.0899999999999999,138
14A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 A,64,40.9,0.44,7.11,,0.79,40.11,5077.2
14A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,99,4.59,0.44,7.11,,0.79,3.8,481
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Baseline,1,13,NA,NA,Y,13,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 2 Day 1 B,30,18,NA,NA,,13,5,38.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,End of Treatment B,58,8,NA,NA,,13,-5,-38.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-11,16,0,55,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,14,0,55,Y,14,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,16,0,55,,14,2,14.3
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,16,19,0,55,,14,5,35.7
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,30,18,0,55,,14,4,28.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,58,15,0,55,,14,1,7.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 B,149,10,0,55,,14,-4,-28.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-11,3.9,3.8,5,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.9,3.8,5,Y,3.9,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,4,3.8,5,,3.9,0.10000000000000009,2.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,16,4.1,3.8,5,,3.9,0.19999999999999973,5.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,30,4,3.8,5,,3.9,0.10000000000000009,2.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment B,58,3.8,3.8,5,,3.9,-0.10000000000000009,-2.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 B,149,3.5,3.8,5,,3.9,-0.3999999999999999,-10.3
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-11,138,0,130,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,135,0,130,Y,135,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,143,0,130,,135,8,5.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,16,158,0,130,,135,23,17
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,30,183,0,130,,135,48,35.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,58,208,0,130,,135,73,54.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 B,149,312,0,130,,135,177,131.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-11,17,0,37,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,15,0,37,Y,15,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,15,0,37,,15,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,16,20,0,37,,15,5,33.3
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,30,17,0,37,,15,2,13.3
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,58,18,0,37,,15,3,20
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 B,149,15,0,37,,15,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-11,15,6,20,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Baseline,1,13,6,20,Y,13,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 B,8,16,6,20,,13,3,23.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 15 B,16,17,6,20,,13,4,30.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 B,30,13,6,20,,13,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,End of Treatment B,58,17,6,20,,13,4,30.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 B,149,19,6,20,,13,6,46.2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-11,22,18,29,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,22,18,29,Y,22,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,23,18,29,,22,1,4.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 15 B,16,22,18,29,,22,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 B,30,24,18,29,,22,2,9.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment B,58,22,18,29,,22,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 B,149,26,18,29,,22,4,18.2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-11,9.2,8.5,10.5,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.3,8.5,10.5,Y,9.3,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,9.2,8.5,10.5,,9.3,-0.10000000000000142,-1.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,16,9.4,8.5,10.5,,9.3,0.09999999999999964,1.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,30,9.6,8.5,10.5,,9.3,0.29999999999999893,3.2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment B,58,9.2,8.5,10.5,,9.3,-0.10000000000000142,-1.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 B,149,9.1,8.5,10.5,,9.3,-0.20000000000000107,-2.2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-11,108,98,109,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,108,98,109,Y,108,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,108,98,109,,108,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,16,106,98,109,,108,-2,-1.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,30,106,98,109,,108,-2,-1.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment B,58,105,98,109,,108,-3,-2.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 B,149,104,98,109,,108,-4,-3.7
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-11,1,0.6,1.3,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1,0.6,1.3,Y,1,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,1,0.6,1.3,,1,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,16,1,0.6,1.3,,1,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,30,1.1,0.6,1.3,,1,0.10000000000000009,10
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment B,58,1.1,0.6,1.3,,1,0.10000000000000009,10
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 B,149,1,0.6,1.3,,1,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-11,129,70,140,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,99,70,140,Y,99,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 B,8,116,70,140,,99,17,17.2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 15 B,16,101,70,140,,99,2,2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 B,30,117,70,140,,99,18,18.2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,End of Treatment B,58,141,70,140,,99,42,42.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 B,149,141,70,140,,99,42,42.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-11,231,130,250,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,218,130,250,Y,218,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,203,130,250,,218,-15,-6.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,16,227,130,250,,218,9,4.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,30,209,130,250,,218,-9,-4.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,58,299,130,250,,218,81,37.2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 B,149,281,130,250,,218,63,28.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-11,4.1,3.5,5.1,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4,3.5,5.1,Y,4,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,3.7,3.5,5.1,,4,-0.2999999999999998,-7.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,16,3.8,3.5,5.1,,4,-0.20000000000000018,-5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,30,3.6,3.5,5.1,,4,-0.3999999999999999,-10
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment B,58,4,3.5,5.1,,4,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 B,149,3.9,3.5,5.1,,4,-0.10000000000000009,-2.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-11,140,133,143,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,140,133,143,Y,140,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 B,8,142,133,143,,140,2,1.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 15 B,16,138,133,143,,140,-2,-1.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 B,30,140,133,143,,140,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,End of Treatment B,58,138,133,143,,140,-2,-1.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 B,149,140,133,143,,140,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-11,0.4,0,1.2,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.4,0,1.2,Y,0.4,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.2,0,1.2,,0.4,-0.2,-50
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,16,0.3,0,1.2,,0.4,-0.10000000000000003,-25
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,30,0.5,0,1.2,,0.4,0.09999999999999998,25
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment B,58,0.4,0,1.2,,0.4,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 B,149,0.4,0,1.2,,0.4,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-11,6.8,6.3,8.1,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.9,6.3,8.1,Y,6.9,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 B,8,6.9,6.3,8.1,,6.9,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 15 B,16,7.1,6.3,8.1,,6.9,0.1999999999999993,2.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 B,30,7.1,6.3,8.1,,6.9,0.1999999999999993,2.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment B,58,7.2,6.3,8.1,,6.9,0.2999999999999998,4.3
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 B,149,6.5,6.3,8.1,,6.9,-0.40000000000000036,-5.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,UREA,End of Treatment B,58,17,NA,NA,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-11,28.9,22.5,36.5,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,29,22.5,36.5,Y,29,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,41.6,22.5,36.5,,29,12.600000000000001,43.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 15 B,16,30,22.5,36.5,,29,1,3.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,30,37.4,22.5,36.5,,29,8.399999999999999,29
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,58,28.3,22.5,36.5,,29,-0.6999999999999993,-2.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-11,0.97,0.8,1.2,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,0.94,0.8,1.2,Y,0.94,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,1.76,0.8,1.2,,0.94,0.8200000000000001,87.2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 15 B,16,1.03,0.8,1.2,,0.94,0.09000000000000008,9.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,30,1.69,0.8,1.2,,0.94,0.75,79.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,58,0.91,0.8,1.2,,0.94,-0.029999999999999916,-3.2
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-11,12.9,11.1,15.2,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.6,11.1,15.2,Y,12.6,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,20.5,11.1,15.2,,12.6,7.9,62.7
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 15 B,16,13.5,11.1,15.2,,12.6,0.9000000000000004,7.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,30,19.8,11.1,15.2,,12.6,7.200000000000001,57.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment B,58,12.3,11.1,15.2,,12.6,-0.29999999999999893,-2.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,,-11,0,0,0.2,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 B,8,0.1,0,0.2,,0,0.1,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 15 B,16,0,0,0.2,,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 B,30,0,0,0.2,,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,End of Treatment B,58,0,0,0.2,,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 B,149,0,0,0.2,,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,,-11,0,0,0.7,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0,0,0.7,Y,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0,0,0.7,,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 15 B,16,0.1,0,0.7,,0,0.1,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 B,30,0,0,0.7,,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment B,58,0,0,0.7,,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 B,149,0,0,0.7,,0,0,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-11,3.35,3.95,5.54,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.43,3.95,5.54,Y,3.43,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,3.34,3.95,5.54,,3.43,-0.0900000000000003,-2.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,16,3.55,3.95,5.54,,3.43,0.11999999999999966,3.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,30,3.56,3.95,5.54,,3.43,0.1299999999999999,3.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,58,3.52,3.95,5.54,,3.43,0.08999999999999986,2.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,149,3.05,3.95,5.54,,3.43,-0.38000000000000034,-11.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-11,34.2,37.5,49.3,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,34,37.5,49.3,Y,34,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,34.1,37.5,49.3,,34,0.10000000000000142,0.3
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,16,35.6,37.5,49.3,,34,1.6000000000000014,4.7
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,30,34.8,37.5,49.3,,34,0.7999999999999972,2.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment B,58,34.8,37.5,49.3,,34,0.7999999999999972,2.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 B,149,29,37.5,49.3,,34,-5,-14.7
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-11,11,12.5,16.2,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.3,12.5,16.2,Y,11.3,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,11,12.5,16.2,,11.3,-0.3000000000000007,-2.7
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,16,11.5,12.5,16.2,,11.3,0.1999999999999993,1.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,30,11.3,12.5,16.2,,11.3,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment B,58,11.3,12.5,16.2,,11.3,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 B,149,9.2,12.5,16.2,,11.3,-2.1000000000000014,-18.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,,-11,0.4,0.9,3.2,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.7,0.9,3.2,Y,0.7,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,1.2,0.9,3.2,,0.7,0.5,71.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 15 B,16,1,0.9,3.2,,0.7,0.30000000000000004,42.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 B,30,0.5,0.9,3.2,,0.7,-0.19999999999999996,-28.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment B,58,0.5,0.9,3.2,,0.7,-0.19999999999999996,-28.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 B,149,0.7,0.9,3.2,,0.7,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,,-11,0.4,0,1.3,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.5,0,1.3,Y,0.5,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 B,8,1.2,0,1.3,,0.5,0.7,140
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 15 B,16,1.7,0,1.3,,0.5,1.2,240
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 B,30,0.7,0,1.3,,0.5,0.19999999999999996,40
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,End of Treatment B,58,0.4,0,1.3,,0.5,-0.09999999999999998,-20
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 B,149,0.4,0,1.3,,0.5,-0.09999999999999998,-20
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,,-11,4.7,1.5,7.5,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4,1.5,7.5,Y,4,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 B,8,4.7,1.5,7.5,,4,0.7000000000000002,17.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 15 B,16,5.6,1.5,7.5,,4,1.5999999999999996,40
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 B,30,4.7,1.5,7.5,,4,0.7000000000000002,17.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment B,58,3.5,1.5,7.5,,4,-0.5,-12.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 B,149,5.3,1.5,7.5,,4,1.2999999999999998,32.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-11,113,160,400,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,133,160,400,Y,133,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,123,160,400,,133,-10,-7.5
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,16,113,160,400,,133,-20,-15
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,30,113,160,400,,133,-20,-15
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment B,58,109,160,400,,133,-24,-18
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 B,149,100,160,400,,133,-33,-24.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,TESTR,Baseline,-11,2,221,716,Y,2,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,,-11,5.5,4,11,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.3,4,11,Y,5.3,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,7.2,4,11,,5.3,1.9000000000000004,35.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 15 B,16,8.5,4,11,,5.3,3.2,60.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 B,30,5.9,4,11,,5.3,0.6000000000000005,11.3
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment B,58,4.5,4,11,,5.3,-0.7999999999999998,-15.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 B,149,6.5,4,11,,5.3,1.2000000000000002,22.6
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,,-11,39.55,NA,NA,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,37.12,NA,NA,Y,37.12,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,30,50.06,NA,NA,,37.12,12.940000000000005,34.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment B,58,89.82,NA,NA,,37.12,52.699999999999996,142
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 B,149,200.37,NA,NA,,37.12,163.25,439.8
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),Baseline,-11,0.98,NA,NA,Y,0.98,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),Cycle 1 Day 8 B,8,0.94,NA,NA,,0.98,-0.040000000000000036,-4.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-11,0.57,0.6,4.8,,NA,NA,NA
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.4,0.6,4.8,Y,1.4,0,0
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,0.36,0.6,4.8,,1.4,-1.04,-74.3
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,16,1.15,0.6,4.8,,1.4,-0.25,-17.9
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,30,1.38,0.6,4.8,,1.4,-0.020000000000000018,-1.4
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,58,1.23,0.6,4.8,,1.4,-0.16999999999999993,-12.1
14B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 B,149,1.8,0.6,4.8,,1.4,0.40000000000000013,28.6
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,0,NA,NA,Y,0,0,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,29,3,NA,NA,,0,3,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,End of Treatment C,71,0,NA,NA,,0,0,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,1,11,0,45,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,11,0,45,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,13,0,45,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,15,22,0,45,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,16,0,45,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,29,16,0,45,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,71,19,0,45,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 C,134,17,0,45,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,1,4,3.5,5.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4,3.5,5.5,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,4.1,3.5,5.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,15,4,3.5,5.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,4.1,3.5,5.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,29,3.8,3.5,5.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,71,4,3.5,5.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 C,134,3.4,3.5,5.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,1,75,0,124,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,75,0,124,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,83,0,124,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,15,84,0,124,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,79,0,124,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,29,81,0,124,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,71,70,0,124,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 C,134,81,0,124,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,1,14,0,35,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,14,0,35,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,19,0,35,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,15,25,0,35,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,18,0,35,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,29,25,0,35,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,71,14,0,35,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 C,134,10,0,35,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,1,17,5,25,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,17,5,25,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,11,5,25,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,15,12,5,25,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,17,5,25,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,29,13,5,25,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,71,27,5,25,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 C,134,25,5,25,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,1,25,23,31,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,25,23,31,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,24,23,31,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,15,25,23,31,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,27,23,31,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,29,24,23,31,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment C,71,26,23,31,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 C,134,30,23,31,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,1,9,8.9,10.1,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9,8.9,10.1,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,8.7,8.9,10.1,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,15,8.5,8.9,10.1,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,8.8,8.9,10.1,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,29,8.4,8.9,10.1,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,71,8.6,8.9,10.1,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 C,134,8.5,8.9,10.1,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,1,105,96,108,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,105,96,108,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,105,96,108,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,15,105,96,108,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,104,96,108,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,29,103,96,108,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,71,102,96,108,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 C,134,102,96,108,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,1,1,0.4,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1,0.4,1.2,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,1,0.4,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,15,1.1,0.4,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,1,0.4,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,29,1.3,0.4,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,71,0.8,0.4,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 C,134,0.8,0.4,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,1,119,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,119,NA,NA,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,102,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,15,115,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,102,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,29,108,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,71,153,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 C,134,266,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,1,151,0,259,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,151,0,259,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,278,0,259,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,15,323,0,259,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,330,0,259,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,29,539,0,259,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,71,168,0,259,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,1,3.9,3.5,5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,3.9,3.5,5,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,3.9,3.5,5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,15,4.2,3.5,5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.4,3.5,5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,29,4.1,3.5,5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,71,3.9,3.5,5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 C,134,4.2,3.5,5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,1,140,135,145,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,140,135,145,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,139,135,145,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,15,140,135,145,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,139,135,145,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,29,137,135,145,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,71,137,135,145,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 C,134,139,135,145,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,1,0.5,0.1,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.5,0.1,1.2,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.3,0.1,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,15,0.3,0.1,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.5,0.1,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,29,0.2,0.1,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,71,0.5,0.1,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 C,134,0.4,0.1,1.2,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,1,7.4,6,8.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.4,6,8.5,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,7.7,6,8.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,15,7.7,6,8.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,7.9,6,8.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,29,7.3,6,8.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,71,7.1,6,8.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 C,134,6.1,6,8.5,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,1,27,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,27,NA,NA,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment C,71,24,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,1,1.1,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.1,NA,NA,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment C,71,1.1,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,1,13.4,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,13.4,NA,NA,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment C,71,13,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,1,0,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,NA,NA,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,15,0.08,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,29,0,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,71,0.01,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 C,134,0,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,1,0,0.03,0.44,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0,0.03,0.44,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0,0.03,0.44,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,15,0.02,0.03,0.44,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0,0.03,0.44,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,29,0.84,0.03,0.44,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,71,0.01,0.03,0.44,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 C,134,0,0.03,0.44,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,1,3.37,3.97,5.65,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.37,3.97,5.65,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,3.63,3.97,5.65,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,15,3.51,3.97,5.65,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.4,3.97,5.65,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,29,3.14,3.97,5.65,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,71,3.42,3.97,5.65,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 C,134,3.44,3.97,5.65,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,1,32.4,37.5,49.9,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,32.4,37.5,49.9,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,35.4,37.5,49.9,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,15,33.6,37.5,49.9,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,32.8,37.5,49.9,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,29,30.6,37.5,49.9,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,71,35,37.5,49.9,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 C,134,34.7,37.5,49.9,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,1,10.5,13,17,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,10.5,13,17,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,11.2,13,17,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,15,10.9,13,17,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,10.3,13,17,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,29,9.6,13,17,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,71,11,13,17,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 C,134,10.7,13,17,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,1,0.26,0.85,3,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.26,0.85,3,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,3.36,0.85,3,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,15,1.47,0.85,3,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,3.22,0.85,3,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,29,6.7,0.85,3,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,71,0.38,0.85,3,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 C,134,0.66,0.85,3,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,1,0.45,0.19,0.77,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.45,0.19,0.77,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,6.34,0.19,0.77,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,15,14.92,0.19,0.77,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,4.83,0.19,0.77,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,29,24.3,0.19,0.77,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,71,0.34,0.19,0.77,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 C,134,0.44,0.19,0.77,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,1,5.71,1.82,7.42,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,5.71,1.82,7.42,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,27.59,1.82,7.42,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,15,8.12,1.82,7.42,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,6.58,1.82,7.42,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,29,44.41,1.82,7.42,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,71,8.74,1.82,7.42,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 C,134,19.87,1.82,7.42,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,1,129,150,450,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,129,150,450,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,139,150,450,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,15,87,150,450,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,117,150,450,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,29,136,150,450,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,71,119,150,450,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 C,134,150,150,450,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,1,6.42,4,11,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,3.37,4,11,Y,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,37.28,4,11,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,15,25.74,4,11,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,14.63,4,11,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,29,83.79,4,11,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,71,9.93,4,11,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 C,134,22.08,4,11,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-25,2.98,NA,NA,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,3.53,NA,NA,Y,3.53,0,0
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,4.92,NA,NA,,3.53,1.3900000000000001,39.4
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,29,4.34,NA,NA,,3.53,0.81,22.9
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,71,8.81,NA,NA,,3.53,5.280000000000001,149.6
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 C,134,13.65,NA,NA,,3.53,10.120000000000001,286.7
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-25,2.87,0.39,4.6,,NA,NA,NA
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.24,0.39,4.6,Y,2.24,0,0
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,2.34,0.39,4.6,,2.24,0.09999999999999964,4.5
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,15,2.02,0.39,4.6,,2.24,-0.2200000000000002,-9.8
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,2.19,0.39,4.6,,2.24,-0.050000000000000266,-2.2
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,29,2.63,0.39,4.6,,2.24,0.3899999999999997,17.4
14C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,71,0.73,0.39,4.6,,2.24,-1.5100000000000002,-67.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Baseline,1,3,NA,NA,Y,3,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 2 Day 1 B,30,4,NA,NA,,3,1,33.3
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 3 Day 1 B,58,15,NA,NA,,3,12,400
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-6,23,0,55,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,38,0,55,Y,38,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,39,0,55,,38,1,2.6
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,16,38,0,55,,38,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,30,25,0,55,,38,-13,-34.2
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,58,34,0,55,,38,-4,-10.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-6,4.1,3.8,5,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4.2,3.8,5,Y,4.2,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,4.2,3.8,5,,4.2,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,16,4,3.8,5,,4.2,-0.20000000000000018,-4.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,30,4,3.8,5,,4.2,-0.20000000000000018,-4.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,58,4,3.8,5,,4.2,-0.20000000000000018,-4.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-6,159,0,130,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,173,0,130,Y,173,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,177,0,130,,173,4,2.3
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,16,185,0,130,,173,12,6.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,30,178,0,130,,173,5,2.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,58,327,0,130,,173,154,89
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-6,25,0,37,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,32,0,37,Y,32,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,33,0,37,,32,1,3.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,16,28,0,37,,32,-4,-12.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,30,26,0,37,,32,-6,-18.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,58,25,0,37,,32,-7,-21.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-6,19,6,20,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Baseline,1,21,6,20,Y,21,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 B,8,17,6,20,,21,-4,-19
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 15 B,16,26,6,20,,21,5,23.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 B,30,20,6,20,,21,-1,-4.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 B,58,20,6,20,,21,-1,-4.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,End of Treatment B,75,14,6,20,,21,-7,-33.3
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-6,29,18,29,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,27,18,29,Y,27,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,26,18,29,,27,-1,-3.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 15 B,16,25,18,29,,27,-2,-7.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 B,30,24,18,29,,27,-3,-11.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 B,58,22,18,29,,27,-5,-18.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment B,75,24,18,29,,27,-3,-11.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-6,9.3,8.5,10.5,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.5,8.5,10.5,Y,9.5,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,8.8,8.5,10.5,,9.5,-0.6999999999999993,-7.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,16,8.6,8.5,10.5,,9.5,-0.9000000000000004,-9.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,30,8.5,8.5,10.5,,9.5,-1,-10.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,58,7.5,8.5,10.5,,9.5,-2,-21.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment B,75,7.5,8.5,10.5,,9.5,-2,-21.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-6,107,98,109,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,108,98,109,Y,108,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,107,98,109,,108,-1,-0.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,16,110,98,109,,108,2,1.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,30,105,98,109,,108,-3,-2.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,58,111,98,109,,108,3,2.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment B,75,100,98,109,,108,-8,-7.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-6,0.9,0.6,1.3,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.8,0.6,1.3,Y,0.8,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,0.8,0.6,1.3,,0.8,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,16,0.9,0.6,1.3,,0.8,0.09999999999999998,12.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,30,0.8,0.6,1.3,,0.8,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,58,0.9,0.6,1.3,,0.8,0.09999999999999998,12.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment B,75,0.7,0.6,1.3,,0.8,-0.10000000000000009,-12.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-6,75,70,140,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,96,70,140,Y,96,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 B,8,102,70,140,,96,6,6.3
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 15 B,16,87,70,140,,96,-9,-9.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 B,30,83,70,140,,96,-13,-13.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 B,58,98,70,140,,96,2,2.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,End of Treatment B,75,105,70,140,,96,9,9.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-6,195,130,250,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,209,130,250,Y,209,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,201,130,250,,209,-8,-3.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,16,222,130,250,,209,13,6.2
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,30,213,130,250,,209,4,1.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,58,205,130,250,,209,-4,-1.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-6,4.4,3.5,5.1,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.4,3.5,5.1,Y,4.4,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.3,3.5,5.1,,4.4,-0.10000000000000053,-2.3
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,16,4.4,3.5,5.1,,4.4,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,30,4.4,3.5,5.1,,4.4,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,58,4.3,3.5,5.1,,4.4,-0.10000000000000053,-2.3
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment B,75,4.2,3.5,5.1,,4.4,-0.20000000000000018,-4.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-6,142,133,143,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,142,133,143,Y,142,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 B,8,141,133,143,,142,-1,-0.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 15 B,16,142,133,143,,142,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 B,30,138,133,143,,142,-4,-2.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 B,58,141,133,143,,142,-1,-0.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,End of Treatment B,75,132,133,143,,142,-10,-7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-6,0.4,0,1.2,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.5,0,1.2,Y,0.5,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.3,0,1.2,,0.5,-0.2,-40
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,16,0.4,0,1.2,,0.5,-0.09999999999999998,-20
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,30,0.6,0,1.2,,0.5,0.09999999999999998,20
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,58,0.4,0,1.2,,0.5,-0.09999999999999998,-20
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-6,6.7,6.3,8.1,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.1,6.3,8.1,Y,7.1,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 B,8,7,6.3,8.1,,7.1,-0.09999999999999964,-1.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 15 B,16,6.7,6.3,8.1,,7.1,-0.39999999999999947,-5.6
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 B,30,6.5,6.3,8.1,,7.1,-0.5999999999999996,-8.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 B,58,6.7,6.3,8.1,,7.1,-0.39999999999999947,-5.6
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-6,52.3,22.5,36.5,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,47.6,22.5,36.5,Y,47.6,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,47.4,22.5,36.5,,47.6,-0.20000000000000284,-0.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 15 B,16,48.7,22.5,36.5,,47.6,1.1000000000000014,2.3
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,30,50.1,22.5,36.5,,47.6,2.5,5.3
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 B,58,48.1,22.5,36.5,,47.6,0.5,1.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-6,1.15,0.8,1.2,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.14,0.8,1.2,Y,1.14,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,1.1,0.8,1.2,,1.14,-0.039999999999999813,-3.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 15 B,16,1.13,0.8,1.2,,1.14,-0.010000000000000009,-0.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,30,1.16,0.8,1.2,,1.14,0.020000000000000018,1.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 B,58,1.13,0.8,1.2,,1.14,-0.010000000000000009,-0.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,75,1.17,0.8,1.2,,1.14,0.030000000000000027,2.6
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-6,14.7,11.1,15.2,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,14.6,11.1,15.2,Y,14.6,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,14.3,11.1,15.2,,14.6,-0.29999999999999893,-2.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 15 B,16,14.5,11.1,15.2,,14.6,-0.09999999999999964,-0.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,30,14.8,11.1,15.2,,14.6,0.20000000000000107,1.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 B,58,14.5,11.1,15.2,,14.6,-0.09999999999999964,-0.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment B,75,14.9,11.1,15.2,,14.6,0.3000000000000007,2.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,,-6,0,0,0.2,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 B,8,0,0,0.2,,0,0,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 15 B,16,0,0,0.2,,0,0,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 B,30,0,0,0.2,,0,0,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 B,58,0,0,0.2,,0,0,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,End of Treatment B,75,0,0,0.2,,0,0,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,,-6,0.1,0,0.7,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.7,Y,0.1,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.1,0,0.7,,0.1,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 15 B,16,0.1,0,0.7,,0.1,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 B,30,0.1,0,0.7,,0.1,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 B,58,0,0,0.7,,0.1,-0.1,-100
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment B,75,0,0,0.7,,0.1,-0.1,-100
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-6,3.89,3.95,5.54,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.96,3.95,5.54,Y,3.96,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,3.87,3.95,5.54,,3.96,-0.08999999999999986,-2.3
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,16,3.74,3.95,5.54,,3.96,-0.21999999999999975,-5.6
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,30,3.69,3.95,5.54,,3.96,-0.27,-6.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,58,3.88,3.95,5.54,,3.96,-0.08000000000000007,-2
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,75,3.64,3.95,5.54,,3.96,-0.31999999999999984,-8.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-6,37.2,37.5,49.3,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,37,37.5,49.3,Y,37,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,36.5,37.5,49.3,,37,-0.5,-1.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,16,35.7,37.5,49.3,,37,-1.2999999999999972,-3.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,30,33.7,37.5,49.3,,37,-3.299999999999997,-8.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,58,35.5,37.5,49.3,,37,-1.5,-4.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment B,75,32.1,37.5,49.3,,37,-4.899999999999999,-13.2
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-6,11.9,12.5,16.2,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.9,12.5,16.2,Y,11.9,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,11.7,12.5,16.2,,11.9,-0.20000000000000107,-1.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,16,11.5,12.5,16.2,,11.9,-0.40000000000000036,-3.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,30,11.1,12.5,16.2,,11.9,-0.8000000000000007,-6.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,58,11.5,12.5,16.2,,11.9,-0.40000000000000036,-3.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment B,75,10.5,12.5,16.2,,11.9,-1.4000000000000004,-11.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,,-6,1.2,0.9,3.2,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.3,0.9,3.2,Y,1.3,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,1.1,0.9,3.2,,1.3,-0.19999999999999996,-15.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 15 B,16,1.2,0.9,3.2,,1.3,-0.10000000000000009,-7.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 B,30,0.9,0.9,3.2,,1.3,-0.4,-30.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 B,58,1,0.9,3.2,,1.3,-0.30000000000000004,-23.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment B,75,0.2,0.9,3.2,,1.3,-1.1,-84.6
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,,-6,0.5,0,1.3,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.5,0,1.3,Y,0.5,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 B,8,1,0,1.3,,0.5,0.5,100
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 15 B,16,1.4,0,1.3,,0.5,0.8999999999999999,180
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 B,30,0.6,0,1.3,,0.5,0.09999999999999998,20
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 B,58,0.3,0,1.3,,0.5,-0.2,-40
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,End of Treatment B,75,0.3,0,1.3,,0.5,-0.2,-40
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,,-6,3.2,1.5,7.5,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.1,1.5,7.5,Y,3.1,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 B,8,2.6,1.5,7.5,,3.1,-0.5,-16.1
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 15 B,16,2.7,1.5,7.5,,3.1,-0.3999999999999999,-12.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 B,30,2.3,1.5,7.5,,3.1,-0.8000000000000003,-25.8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 B,58,2.7,1.5,7.5,,3.1,-0.3999999999999999,-12.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment B,75,4.2,1.5,7.5,,3.1,1.1,35.5
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-6,181,160,400,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,193,160,400,Y,193,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,169,160,400,,193,-24,-12.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,16,144,160,400,,193,-49,-25.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,30,183,160,400,,193,-10,-5.2
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,58,170,160,400,,193,-23,-11.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment B,75,233,160,400,,193,40,20.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,TESTR,Baseline,-6,4,221,716,Y,4,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,,-6,5,4,11,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5,4,11,Y,5,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,4.8,4,11,,5,-0.20000000000000018,-4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 15 B,16,5.4,4,11,,5,0.40000000000000036,8
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 B,30,3.9,4,11,,5,-1.1,-22
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 B,58,4.1,4,11,,5,-0.9000000000000004,-18
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment B,75,4.7,4,11,,5,-0.2999999999999998,-6
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,,-6,43.83,NA,NA,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,54.87,NA,NA,Y,54.87,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,30,91.28,NA,NA,,54.87,36.410000000000004,66.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 B,58,167.32,NA,NA,,54.87,112.44999999999999,204.9
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-6,1.86,0.6,4.8,,NA,NA,NA
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.36,0.6,4.8,Y,1.36,0,0
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,1.61,0.6,4.8,,1.36,0.25,18.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,16,1.31,0.6,4.8,,1.36,-0.050000000000000044,-3.7
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,30,0.92,0.6,4.8,,1.36,-0.44000000000000006,-32.4
15B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,58,2.13,0.6,4.8,,1.36,0.7699999999999998,56.6
1A,A,NKTR-214 + Nivolumab,N,N,,CTC,Baseline,1,1934,NA,NA,Y,1934,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 A,22,1294,NA,NA,,1934,-640,-33.1
1A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 3 Day 1 A,43,691,NA,NA,,1934,-1243,-64.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-13,12,1,45,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,8,1,45,Y,8,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,44,1,45,,8,36,450
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,22,11,1,45,,8,3,37.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,29,14,1,45,,8,6,75
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 A,43,13,1,45,,8,5,62.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 8 A,51,16,1,45,,8,8,100
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,64,12,1,45,,8,4,50
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 A,178,7,1,45,,8,-1,-12.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-13,3.9,3.5,4.9,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.9,3.5,4.9,Y,3.9,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,3.5,3.5,4.9,,3.9,-0.3999999999999999,-10.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,22,3.7,3.5,4.9,,3.9,-0.19999999999999973,-5.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,29,3.2,3.5,4.9,,3.9,-0.6999999999999997,-17.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 A,43,2.6,3.5,4.9,,3.9,-1.2999999999999998,-33.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 8 A,51,3.2,3.5,4.9,,3.9,-0.6999999999999997,-17.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment A,64,3.1,3.5,4.9,,3.9,-0.7999999999999998,-20.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 A,178,4.1,3.5,4.9,,3.9,0.19999999999999973,5.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-13,397,38,126,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,449,38,126,Y,449,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,364,38,126,,449,-85,-18.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,22,722,38,126,,449,273,60.8
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,29,296,38,126,,449,-153,-34.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 A,43,320,38,126,,449,-129,-28.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 8 A,51,528,38,126,,449,79,17.6
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,64,422,38,126,,449,-27,-6
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 A,178,557,38,126,,449,108,24.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-13,20,1,35,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,22,1,35,Y,22,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,45,1,35,,22,23,104.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,22,75,1,35,,22,53,240.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,29,20,1,35,,22,-2,-9.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 A,43,22,1,35,,22,0,0
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 8 A,51,30,1,35,,22,8,36.4
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,64,32,1,35,,22,10,45.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 A,178,108,1,35,,22,86,390.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-13,17,6,23,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,15,6,23,Y,15,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,8,16,6,23,,15,1,6.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,22,21,6,23,,15,6,40
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 8 A,29,20,6,23,,15,5,33.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 A,43,15,6,23,,15,0,0
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 8 A,51,13,6,23,,15,-2,-13.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,End of Treatment A,64,19,6,23,,15,4,26.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 A,178,17,6,23,,15,2,13.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-13,26,22,30,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,24,22,30,Y,24,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,26,22,30,,24,2,8.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,22,23.7,22,30,,24,-0.3000000000000007,-1.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,29,25,22,30,,24,1,4.2
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 A,43,20,22,30,,24,-4,-16.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 8 A,51,25,22,30,,24,1,4.2
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment A,64,25,22,30,,24,1,4.2
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 A,178,18,22,30,,24,-6,-25
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-13,7.9,8.5,10.5,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8.3,8.5,10.5,Y,8.3,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,7.6,8.5,10.5,,8.3,-0.7000000000000011,-8.4
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,22,7.9,8.5,10.5,,8.3,-0.40000000000000036,-4.8
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,29,9.4,8.5,10.5,,8.3,1.0999999999999996,13.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 A,43,7.1,8.5,10.5,,8.3,-1.200000000000001,-14.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 8 A,51,7.1,8.5,10.5,,8.3,-1.200000000000001,-14.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment A,64,8.1,8.5,10.5,,8.3,-0.20000000000000107,-2.4
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 A,178,7.6,8.5,10.5,,8.3,-0.7000000000000011,-8.4
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-13,108,96,108,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,109,96,108,Y,109,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,109,96,108,,109,0,0
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,22,107,96,108,,109,-2,-1.8
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,29,110,96,108,,109,1,0.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 A,43,106,96,108,,109,-3,-2.8
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 8 A,51,106,96,108,,109,-3,-2.8
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment A,64,107,96,108,,109,-2,-1.8
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 A,178,103,96,108,,109,-6,-5.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-13,0.87,0.7,1.3,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.89,0.7,1.3,Y,0.89,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,0.87,0.7,1.3,,0.89,-0.020000000000000018,-2.2
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,22,0.82,0.7,1.3,,0.89,-0.07000000000000006,-7.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,29,0.96,0.7,1.3,,0.89,0.06999999999999995,7.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 A,43,0.68,0.7,1.3,,0.89,-0.20999999999999996,-23.6
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 8 A,51,0.83,0.7,1.3,,0.89,-0.06000000000000005,-6.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment A,64,0.85,0.7,1.3,,0.89,-0.040000000000000036,-4.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 A,178,0.85,0.7,1.3,,0.89,-0.040000000000000036,-4.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-13,104,60,100,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,110,60,100,Y,110,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 A,8,108,60,100,,110,-2,-1.8
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,22,114,60,100,,110,4,3.6
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,29,117,60,100,,110,7,6.4
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 A,43,131,60,100,,110,21,19.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 8 A,51,125,60,100,,110,15,13.6
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment A,64,121,60,100,,110,11,10
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 A,178,100,60,100,,110,-10,-9.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-13,305,100,220,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,394,100,220,Y,394,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,8,473,100,220,,394,79,20.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,22,1815,100,220,,394,1421,360.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,29,496,100,220,,394,102,25.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 8 A,51,1029,100,220,,394,635,161.2
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment A,64,976,100,220,,394,582,147.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-13,4.9,3.5,5.2,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.1,3.5,5.2,Y,4.1,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,4.2,3.5,5.2,,4.1,0.10000000000000053,2.4
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,22,4.4,3.5,5.2,,4.1,0.3000000000000007,7.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,29,5.2,3.5,5.2,,4.1,1.1000000000000005,26.8
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 A,43,4.1,3.5,5.2,,4.1,0,0
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 8 A,51,5,3.5,5.2,,4.1,0.9000000000000004,22
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment A,64,4.7,3.5,5.2,,4.1,0.6000000000000005,14.6
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 A,178,4.6,3.5,5.2,,4.1,0.5,12.2
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-13,142,135,145,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,143,135,145,Y,143,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,8,142,135,145,,143,-1,-0.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,22,140,135,145,,143,-3,-2.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,29,146,135,145,,143,3,2.1
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 A,43,137,135,145,,143,-6,-4.2
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 8 A,51,138,135,145,,143,-5,-3.5
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment A,64,145,135,145,,143,2,1.4
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 A,178,137,135,145,,143,-6,-4.2
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-13,0.4,0.1,1.2,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.6,0.1,1.2,Y,0.6,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.3,0.1,1.2,,0.6,-0.3,-50
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,22,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,29,0.2,0.1,1.2,,0.6,-0.39999999999999997,-66.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 A,43,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 8 A,51,0.6,0.1,1.2,,0.6,0,0
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment A,64,0.5,0.1,1.2,,0.6,-0.09999999999999998,-16.7
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 A,178,0.9,0.1,1.2,,0.6,0.30000000000000004,50
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-13,6.8,6,8.3,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7,6,8.3,Y,7,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,8,6.2,6,8.3,,7,-0.7999999999999998,-11.4
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,22,6.9,6,8.3,,7,-0.09999999999999964,-1.4
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,29,6.4,6,8.3,,7,-0.5999999999999996,-8.6
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 A,43,6,6,8.3,,7,-1,-14.3
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 8 A,51,6.4,6,8.3,,7,-0.5999999999999996,-8.6
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment A,64,6.8,6,8.3,,7,-0.20000000000000018,-2.9
1A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 A,178,7.2,6,8.3,,7,0.20000000000000018,2.9
1A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-13,25.9,25.4,34.9,Y,25.9,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-13,1.2,2,3,Y,1.2,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,-13,14.5,12.3,14.9,Y,14.5,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-13,0,0,0.2,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0,0,0.2,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0,0,0.2,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,8,0,0,0.2,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,22,0.1,0,0.2,,0,0.1,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,29,1.2,0,0.2,,0,1.2,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 A,43,0,0,0.2,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 8 A,51,0,0,0.2,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,End of Treatment A,64,0,0,0.2,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 A,178,0,0,0.2,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-13,0,0,0.6,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0,0,0.6,Y,0,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0,0,0.6,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.1,0,0.6,,0,0.1,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.2,0,0.6,,0,0.2,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,22,0.1,0,0.6,,0,0.1,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 8 A,29,0.6,0,0.6,,0,0.6,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 A,43,0,0,0.6,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 8 A,51,0.3,0,0.6,,0,0.3,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment A,64,0,0,0.6,,0,0,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 A,178,0.1,0,0.6,,0,0.1,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-13,4.7,4.5,6,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.71,4.5,6,Y,4.71,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,4.5,4.5,6,,4.71,-0.20999999999999996,-4.5
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,4.57,4.5,6,,4.71,-0.13999999999999968,-3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,4.36,4.5,6,,4.71,-0.34999999999999964,-7.4
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,22,4.35,4.5,6,,4.71,-0.3600000000000003,-7.6
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,29,3.95,4.5,6,,4.71,-0.7599999999999998,-16.1
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 A,43,3.95,4.5,6,,4.71,-0.7599999999999998,-16.1
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 8 A,51,3.28,4.5,6,,4.71,-1.4300000000000002,-30.4
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment A,64,3.81,4.5,6,,4.71,-0.8999999999999999,-19.1
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 A,178,5.35,4.5,6,,4.71,0.6399999999999997,13.6
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-13,36.6,42,52,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,35.3,42,52,Y,35.3,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,34,42,52,,35.3,-1.2999999999999972,-3.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,34.1,42,52,,35.3,-1.1999999999999957,-3.4
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,32.4,42,52,,35.3,-2.8999999999999986,-8.2
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,22,31.7,42,52,,35.3,-3.599999999999998,-10.2
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,29,29.2,42,52,,35.3,-6.099999999999998,-17.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 A,43,28.6,42,52,,35.3,-6.699999999999996,-19
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 8 A,51,23.6,42,52,,35.3,-11.699999999999996,-33.1
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment A,64,28.1,42,52,,35.3,-7.199999999999996,-20.4
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 A,178,39.4,42,52,,35.3,4.100000000000001,11.6
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-13,12,13.9,16.3,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.7,13.9,16.3,Y,11.7,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,11.1,13.9,16.3,,11.7,-0.5999999999999996,-5.1
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,11.2,13.9,16.3,,11.7,-0.5,-4.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,10.8,13.9,16.3,,11.7,-0.8999999999999986,-7.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,22,10.5,13.9,16.3,,11.7,-1.1999999999999993,-10.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,29,9.4,13.9,16.3,,11.7,-2.299999999999999,-19.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 A,43,9.2,13.9,16.3,,11.7,-2.5,-21.4
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 8 A,51,7.6,13.9,16.3,,11.7,-4.1,-35
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment A,64,9.1,13.9,16.3,,11.7,-2.5999999999999996,-22.2
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 A,178,13,13.9,16.3,,11.7,1.3000000000000007,11.1
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-13,0.5,1,4.5,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.6,1,4.5,Y,0.6,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.2,1,4.5,,0.6,-0.39999999999999997,-66.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.1,1,4.5,,0.6,-0.5,-83.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,1,1,4.5,,0.6,0.4,66.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,22,0.6,1,4.5,,0.6,0,0
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,29,1.5,1,4.5,,0.6,0.9,150
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 A,43,0.7,1,4.5,,0.6,0.09999999999999998,16.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 8 A,51,0.9,1,4.5,,0.6,0.30000000000000004,50
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment A,64,0.9,1,4.5,,0.6,0.30000000000000004,50
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 A,178,0.5,1,4.5,,0.6,-0.09999999999999998,-16.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-13,0.3,0.2,1,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.4,0.2,1,Y,0.4,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.2,0.2,1,,0.4,-0.2,-50
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.2,0.2,1,,0.4,-0.2,-50
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,8,0.2,0.2,1,,0.4,-0.2,-50
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,22,0.3,0.2,1,,0.4,-0.10000000000000003,-25
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,29,0.3,0.2,1,,0.4,-0.10000000000000003,-25
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 A,43,0.3,0.2,1,,0.4,-0.10000000000000003,-25
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 8 A,51,0.4,0.2,1,,0.4,0,0
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment A,64,0.3,0.2,1,,0.4,-0.10000000000000003,-25
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 A,178,0.5,0.2,1,,0.4,0.09999999999999998,25
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-13,3.4,1.9,8,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4.2,1.9,8,Y,4.2,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,3.1,1.9,8,,4.2,-1.1,-26.2
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,2.3,1.9,8,,4.2,-1.9000000000000004,-45.2
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,8,1.7,1.9,8,,4.2,-2.5,-59.5
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,22,2.8,1.9,8,,4.2,-1.4000000000000004,-33.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,29,2.97,1.9,8,,4.2,-1.23,-29.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 A,43,3.24,1.9,8,,4.2,-0.96,-22.9
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 8 A,51,3.17,1.9,8,,4.2,-1.0300000000000002,-24.5
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment A,64,2.8,1.9,8,,4.2,-1.4000000000000004,-33.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 A,178,3.64,1.9,8,,4.2,-0.56,-13.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-13,128,150,450,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,106,150,450,Y,106,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,112,150,450,,106,6,5.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,103,150,450,,106,-3,-2.8
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,100,150,450,,106,-6,-5.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,22,152,150,450,,106,46,43.4
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,29,162,150,450,,106,56,52.8
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 A,43,183,150,450,,106,77,72.6
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 8 A,51,119,150,450,,106,13,12.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment A,64,172,150,450,,106,66,62.3
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 A,178,137,150,450,,106,31,29.2
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,TESTR,Baseline,-13,6.51,300,1080,Y,6.51,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-13,4.2,4.5,11,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.2,4.5,11,Y,5.2,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,3.5,4.5,11,,5.2,-1.7000000000000002,-32.7
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,2.7,4.5,11,,5.2,-2.5,-48.1
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,3.1,4.5,11,,5.2,-2.1,-40.4
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,22,3.9,4.5,11,,5.2,-1.3000000000000003,-25
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,29,5.5,4.5,11,,5.2,0.2999999999999998,5.8
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 A,43,4.5,4.5,11,,5.2,-0.7000000000000002,-13.5
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 8 A,51,4.4,4.5,11,,5.2,-0.7999999999999998,-15.4
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment A,64,4,4.5,11,,5.2,-1.2000000000000002,-23.1
1A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 A,178,4.5,4.5,11,,5.2,-0.7000000000000002,-13.5
1A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-13,51.79,NA,NA,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,63.09,NA,NA,Y,63.09,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,22,72.34,NA,NA,,63.09,9.25,14.7
1A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 A,43,88.5,NA,NA,,63.09,25.409999999999997,40.3
1A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment A,64,139.3,NA,NA,,63.09,76.21000000000001,120.8
1A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 A,178,85.49,NA,NA,,63.09,22.39999999999999,35.5
1A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-13,0.78,0.4,4.2,,NA,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,0.94,0.4,4.2,Y,0.94,NA,NA
1A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,22,2.18,0.4,4.2,,0.94,1.2400000000000002,131.9
1A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 A,43,2.56,0.4,4.2,,0.94,1.62,172.3
1A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,64,1.47,0.4,4.2,,0.94,0.53,56.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Baseline,1,47,NA,NA,Y,47,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 2 Day 1 B,31,54,NA,NA,,47,7,14.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,End of Treatment B,59,99,NA,NA,,47,52,110.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-35,11,1,45,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,14,1,45,Y,14,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,15,1,45,,14,1,7.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,15,13,1,45,,14,-1,-7.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,31,14,1,45,,14,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,59,17,1,45,,14,3,21.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 B,171,10,1,45,,14,-4,-28.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 200 B,262,12,1,45,,14,-2,-14.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-35,3.8,3.5,4.9,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.7,3.5,4.9,Y,3.7,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,3.6,3.5,4.9,,3.7,-0.10000000000000009,-2.7
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,15,3.7,3.5,4.9,,3.7,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,31,3.7,3.5,4.9,,3.7,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment B,59,3.3,3.5,4.9,,3.7,-0.40000000000000036,-10.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 B,171,4,3.5,4.9,,3.7,0.2999999999999998,8.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 200 B,262,3.9,3.5,4.9,,3.7,0.19999999999999973,5.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-35,82,38,126,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,83,38,126,Y,83,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,78,38,126,,83,-5,-6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,15,82,38,126,,83,-1,-1.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,31,80,38,126,,83,-3,-3.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,59,121,38,126,,83,38,45.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 B,171,221,38,126,,83,138,166.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 200 B,262,105,38,126,,83,22,26.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-35,12,1,35,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,14,1,35,Y,14,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,15,1,35,,14,1,7.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,15,16,1,35,,14,2,14.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,31,21,1,35,,14,7,50
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,59,21,1,35,,14,7,50
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 200 B,262,12,1,35,,14,-2,-14.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-35,12,6,23,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Baseline,1,17,6,23,Y,17,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 B,8,20,6,23,,17,3,17.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 15 B,15,14,6,23,,17,-3,-17.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 B,31,10,6,23,,17,-7,-41.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,End of Treatment B,59,15,6,23,,17,-2,-11.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 B,171,14,6,23,,17,-3,-17.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Follow-up 200 B,262,19,6,23,,17,2,11.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-35,28.5,22,30,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,24.1,22,30,Y,24.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,26.1,22,30,,24.1,2,8.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 15 B,15,23.1,22,30,,24.1,-1,-4.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 B,31,22.9,22,30,,24.1,-1.2000000000000028,-5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment B,59,26.4,22,30,,24.1,2.299999999999997,9.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 B,171,20.3,22,30,,24.1,-3.8000000000000007,-15.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 200 B,262,26.3,22,30,,24.1,2.1999999999999993,9.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-35,9,8.5,10.5,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.1,8.5,10.5,Y,9.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,8.9,8.5,10.5,,9.1,-0.1999999999999993,-2.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,15,9,8.5,10.5,,9.1,-0.09999999999999964,-1.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,31,9,8.5,10.5,,9.1,-0.09999999999999964,-1.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment B,59,9.6,8.5,10.5,,9.1,0.5,5.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 B,171,8.3,8.5,10.5,,9.1,-0.7999999999999989,-8.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 200 B,262,8.7,8.5,10.5,,9.1,-0.40000000000000036,-4.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-35,102,96,108,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,103,96,108,Y,103,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,104,96,108,,103,1,1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,15,104,96,108,,103,1,1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,31,105,96,108,,103,2,1.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment B,59,105,96,108,,103,2,1.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 B,171,106,96,108,,103,3,2.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 200 B,262,104,96,108,,103,1,1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-35,0.88,0.7,1.3,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.74,0.7,1.3,Y,0.74,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,1.1,0.7,1.3,,0.74,0.3600000000000001,48.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,15,0.91,0.7,1.3,,0.74,0.17000000000000004,23
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,31,0.89,0.7,1.3,,0.74,0.15000000000000002,20.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment B,59,0.81,0.7,1.3,,0.74,0.07000000000000006,9.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 B,171,0.88,0.7,1.3,,0.74,0.14,18.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 200 B,262,1.02,0.7,1.3,,0.74,0.28,37.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-35,275,60,100,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,285,60,100,Y,285,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 B,8,162,60,100,,285,-123,-43.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 15 B,15,128,60,100,,285,-157,-55.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 B,31,140,60,100,,285,-145,-50.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,End of Treatment B,59,157,60,100,,285,-128,-44.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 B,171,120,60,100,,285,-165,-57.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Follow-up 200 B,262,218,60,100,,285,-67,-23.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-35,181,100,220,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,167,100,220,Y,167,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,182,100,220,,167,15,9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,15,237,100,220,,167,70,41.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,31,309,100,220,,167,142,85
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,59,296,100,220,,167,129,77.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-35,4.2,3.5,5.2,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.4,3.5,5.2,Y,4.4,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.2,3.5,5.2,,4.4,-0.20000000000000018,-4.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,15,4.8,3.5,5.2,,4.4,0.39999999999999947,9.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,31,4.7,3.5,5.2,,4.4,0.2999999999999998,6.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment B,59,5,3.5,5.2,,4.4,0.5999999999999996,13.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 B,171,6.5,3.5,5.2,,4.4,2.0999999999999996,47.7
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 200 B,262,4.7,3.5,5.2,,4.4,0.2999999999999998,6.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-35,140,135,145,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,139,135,145,Y,139,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 B,8,141,135,145,,139,2,1.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 15 B,15,140,135,145,,139,1,0.7
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 B,31,140,135,145,,139,1,0.7
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,End of Treatment B,59,141,135,145,,139,2,1.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 B,171,139,135,145,,139,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Follow-up 200 B,262,137,135,145,,139,-2,-1.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-35,0.3,0.1,1.2,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.2,0.1,1.2,Y,0.2,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.3,0.1,1.2,,0.2,0.09999999999999998,50
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,15,0.2,0.1,1.2,,0.2,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,31,0.2,0.1,1.2,,0.2,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment B,59,0.2,0.1,1.2,,0.2,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 B,171,0.3,0.1,1.2,,0.2,0.09999999999999998,50
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 200 B,262,0.3,0.1,1.2,,0.2,0.09999999999999998,50
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-35,6.8,6,8.3,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.4,6,8.3,Y,6.4,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 B,8,6.6,6,8.3,,6.4,0.1999999999999993,3.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 15 B,15,6.6,6,8.3,,6.4,0.1999999999999993,3.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 B,31,6.8,6,8.3,,6.4,0.39999999999999947,6.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment B,59,7,6,8.3,,6.4,0.5999999999999996,9.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 B,171,7.3,6,8.3,,6.4,0.8999999999999995,14.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 200 B,262,6.5,6,8.3,,6.4,0.09999999999999964,1.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-4,25.2,25.4,34.9,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,25.1,25.4,34.9,Y,25.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,25.6,25.4,34.9,,25.1,0.5,2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 15 B,15,25.9,25.4,34.9,,25.1,0.7999999999999972,3.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,31,26.7,25.4,34.9,,25.1,1.5999999999999979,6.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,59,28.5,25.4,34.9,,25.1,3.3999999999999986,13.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-4,0.9,2,3,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,2.6,2,3,Y,2.6,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,1,2,3,,2.6,-1.6,-61.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 15 B,15,0.9,2,3,,2.6,-1.7000000000000002,-65.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,31,1,2,3,,2.6,-1.6,-61.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,59,1,2,3,,2.6,-1.6,-61.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-4,12,12.3,14.9,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,27,12.3,14.9,Y,27,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,12.4,12.3,14.9,,27,-14.6,-54.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 15 B,15,12.3,12.3,14.9,,27,-14.7,-54.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,31,12.6,12.3,14.9,,27,-14.4,-53.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment B,59,12.8,12.3,14.9,,27,-14.2,-52.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,,-35,0,0,0.2,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.1,0,0.2,Y,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 B,8,0,0,0.2,,0.1,-0.1,-100
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 15 B,15,0.1,0,0.2,,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 B,31,0.1,0,0.2,,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,End of Treatment B,59,0,0,0.2,,0.1,-0.1,-100
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 B,171,0,0,0.2,,0.1,-0.1,-100
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Follow-up 200 B,262,0,0,0.2,,0.1,-0.1,-100
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,,-35,0.1,0,0.6,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.6,Y,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.1,0,0.6,,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 15 B,15,0.1,0,0.6,,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 B,31,0.1,0,0.6,,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment B,59,0.1,0,0.6,,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 B,171,0.1,0,0.6,,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 200 B,262,0.1,0,0.6,,0.1,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-35,3.75,4.5,6,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.73,4.5,6,Y,3.73,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,3.46,4.5,6,,3.73,-0.27,-7.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,15,3.46,4.5,6,,3.73,-0.27,-7.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,31,3.46,4.5,6,,3.73,-0.27,-7.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,59,3.46,4.5,6,,3.73,-0.27,-7.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,171,2.53,4.5,6,,3.73,-1.2000000000000002,-32.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 200 B,262,2.34,4.5,6,,3.73,-1.3900000000000001,-37.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-35,31.6,42,52,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,31.2,42,52,Y,31.2,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,29.2,42,52,,31.2,-2,-6.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,15,29.1,42,52,,31.2,-2.099999999999998,-6.7
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,31,29.2,42,52,,31.2,-2,-6.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment B,59,28.4,42,52,,31.2,-2.8000000000000007,-9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 B,171,25.7,42,52,,31.2,-5.5,-17.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 200 B,262,25.2,42,52,,31.2,-6,-19.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-35,10.7,13.9,16.3,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,10.6,13.9,16.3,Y,10.6,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,9.9,13.9,16.3,,10.6,-0.6999999999999993,-6.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,15,10,13.9,16.3,,10.6,-0.5999999999999996,-5.7
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,31,9.8,13.9,16.3,,10.6,-0.7999999999999989,-7.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment B,59,9.3,13.9,16.3,,10.6,-1.299999999999999,-12.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 B,171,8.8,13.9,16.3,,10.6,-1.799999999999999,-17
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 200 B,262,8.9,13.9,16.3,,10.6,-1.6999999999999993,-16
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,,-35,1.1,1,4.5,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.4,1,4.5,Y,1.4,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,1.2,1,4.5,,1.4,-0.19999999999999996,-14.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 15 B,15,1,1,4.5,,1.4,-0.3999999999999999,-28.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 B,31,1.1,1,4.5,,1.4,-0.2999999999999998,-21.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment B,59,1,1,4.5,,1.4,-0.3999999999999999,-28.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 B,171,0.7,1,4.5,,1.4,-0.7,-50
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 200 B,262,1,1,4.5,,1.4,-0.3999999999999999,-28.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,,-35,0.7,0.2,1,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.4,0.2,1,Y,0.4,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 B,8,1.6,0.2,1,,0.4,1.2000000000000002,300
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 15 B,15,2.9,0.2,1,,0.4,2.5,625
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 B,31,0.8,0.2,1,,0.4,0.4,100
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,End of Treatment B,59,0.6,0.2,1,,0.4,0.19999999999999996,50
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 B,171,0.4,0.2,1,,0.4,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Follow-up 200 B,262,0.5,0.2,1,,0.4,0.09999999999999998,25
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,,-35,6.8,1.9,8,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4.5,1.9,8,Y,4.5,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 B,8,4.48,1.9,8,,4.5,-0.019999999999999574,-0.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 15 B,15,5.49,1.9,8,,4.5,0.9900000000000002,22
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 B,31,6.5,1.9,8,,4.5,2,44.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment B,59,5.5,1.9,8,,4.5,1,22.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 B,171,4.4,1.9,8,,4.5,-0.09999999999999964,-2.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 200 B,262,5,1.9,8,,4.5,0.5,11.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-35,221,150,450,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,197,150,450,Y,197,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,169,150,450,,197,-28,-14.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,15,261,150,450,,197,64,32.5
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,31,260,150,450,,197,63,32
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment B,59,341,150,450,,197,144,73.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 B,171,161,150,450,,197,-36,-18.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 200 B,262,187,150,450,,197,-10,-5.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,TESTR,Baseline,-35,19.46,300,1080,Y,19.46,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,,-35,8.8,4.5,11,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,6.5,4.5,11,Y,6.5,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,7,4.5,11,,6.5,0.5,7.7
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 15 B,15,9.8,4.5,11,,6.5,3.3000000000000007,50.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 B,31,8.6,4.5,11,,6.5,2.0999999999999996,32.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment B,59,7.3,4.5,11,,6.5,0.7999999999999998,12.3
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 B,171,6.2,4.5,11,,6.5,-0.2999999999999998,-4.6
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 200 B,262,6.7,4.5,11,,6.5,0.20000000000000018,3.1
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,,-35,7.34,NA,NA,,NA,NA,NA
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,20.78,NA,NA,Y,20.78,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,31,41.34,NA,NA,,20.78,20.560000000000002,98.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment B,59,88.72,NA,NA,,20.78,67.94,326.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 B,171,17.27,NA,NA,,20.78,-3.5100000000000016,-16.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 200 B,262,5.78,NA,NA,,20.78,-15,-72.2
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.65,0.4,4.2,Y,1.65,0,0
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,0.76,0.4,4.2,,1.65,-0.8899999999999999,-53.9
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,15,0.96,0.4,4.2,,1.65,-0.69,-41.8
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,31,0.95,0.4,4.2,,1.65,-0.7,-42.4
1B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,62,0.95,0.4,4.2,,1.65,-0.7,-42.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,1,NA,NA,Y,1,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,29,98,NA,NA,,1,97,9700
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 C,64,22,NA,NA,,1,21,2100
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 3 Day 1 C,92,82,NA,NA,,1,81,8100
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,End of Treatment C,122,187,NA,NA,,1,186,18600
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-32,10,3,61,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,9,3,61,Y,9,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,8,3,61,,9,-1,-11.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,15,12,3,61,,9,3,33.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,10,3,61,,9,1,11.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,29,21,3,61,,9,12,133.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,29,21,3,61,,9,12,133.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,36,42,3,61,,9,33,366.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,50,9,3,61,,9,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 C,64,8,3,61,,9,-1,-11.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,80,16,3,61,,9,7,77.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-32,4.4,3.8,5.5,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4,3.8,5.5,Y,4,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,4,3.8,5.5,,4,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,15,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,29,216,3.8,5.5,,4,212,5300
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,29,3.9,3.8,5.5,,4,-0.10000000000000009,-2.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,36,3.5,3.8,5.5,,4,-0.5,-12.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,50,3.5,3.8,5.5,,4,-0.5,-12.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,64,3.6,3.8,5.5,,4,-0.3999999999999999,-10
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,80,4.2,3.8,5.5,,4,0.20000000000000018,5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-32,91,33,98,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,113,33,98,Y,113,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,113,33,98,,113,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,15,119,33,98,,113,6,5.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,131,33,98,,113,18,15.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,29,216,33,98,,113,103,91.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,29,216,33,98,,113,103,91.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,36,350,33,98,,113,237,209.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,50,252,33,98,,113,139,123
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,64,204,33,98,,113,91,80.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,80,193,33,98,,113,80,70.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-32,15,5,38,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,13,5,38,Y,13,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,15,5,38,,13,2,15.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,15,21,5,38,,13,8,61.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,28,5,38,,13,15,115.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,29,40,5,38,,13,27,207.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,29,40,5,38,,13,27,207.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,36,34,5,38,,13,21,161.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,50,20,5,38,,13,7,53.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,64,11,5,38,,13,-2,-15.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,80,32,5,38,,13,19,146.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-32,22.4,7,25,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,17,7,25,Y,17,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,21,7,25,,17,4,23.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,15,18,7,25,,17,1,5.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,23,7,25,,17,6,35.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,29,26,7,25,,17,9,52.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,29,26,7,25,,17,9,52.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,36,18,7,25,,17,1,5.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,50,22,7,25,,17,5,29.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 C,64,22,7,25,,17,5,29.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,80,26,7,25,,17,9,52.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-32,25,21,31,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,27,21,31,Y,27,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,26,21,31,,27,-1,-3.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,15,23,21,31,,27,-4,-14.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,25,21,31,,27,-2,-7.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,29,23,21,31,,27,-4,-14.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment C,29,23,21,31,,27,-4,-14.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,36,25,21,31,,27,-2,-7.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,50,24,21,31,,27,-3,-11.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 C,64,24,21,31,,27,-3,-11.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,80,27,21,31,,27,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-32,8.4,8.7,10.1,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.1,8.7,10.1,Y,9.1,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,8.6,8.7,10.1,,9.1,-0.5,-5.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,15,8.6,8.7,10.1,,9.1,-0.5,-5.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,8.9,8.7,10.1,,9.1,-0.1999999999999993,-2.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,29,8.9,8.7,10.1,,9.1,-0.1999999999999993,-2.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,29,8.9,8.7,10.1,,9.1,-0.1999999999999993,-2.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,36,8.9,8.7,10.1,,9.1,-0.1999999999999993,-2.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,50,8.6,8.7,10.1,,9.1,-0.5,-5.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,64,9.1,8.7,10.1,,9.1,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,80,9,8.7,10.1,,9.1,-0.09999999999999964,-1.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-32,104,99,107,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,103,99,107,Y,103,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,104,99,107,,103,1,1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,15,104,99,107,,103,1,1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,99,99,107,,103,-4,-3.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,29,102,99,107,,103,-1,-1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,29,102,99,107,,103,-1,-1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,36,101,99,107,,103,-2,-1.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,50,98,99,107,,103,-5,-4.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,64,100,99,107,,103,-3,-2.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,80,103,99,107,,103,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-32,0.79,0.7,1.3,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.89,0.7,1.3,Y,0.89,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,0.88,0.7,1.3,,0.89,-0.010000000000000009,-1.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,15,0.83,0.7,1.3,,0.89,-0.06000000000000005,-6.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,0.92,0.7,1.3,,0.89,0.030000000000000027,3.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,29,0.81,0.7,1.3,,0.89,-0.07999999999999996,-9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,29,0.81,0.7,1.3,,0.89,-0.07999999999999996,-9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,36,0.72,0.7,1.3,,0.89,-0.17000000000000004,-19.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,50,0.76,0.7,1.3,,0.89,-0.13,-14.6
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,64,0.86,0.7,1.3,,0.89,-0.030000000000000027,-3.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,80,0.84,0.7,1.3,,0.89,-0.050000000000000044,-5.6
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-32,104,63,130,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,117,63,130,Y,117,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,94,63,130,,117,-23,-19.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,15,78,63,130,,117,-39,-33.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,110,63,130,,117,-7,-6
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,29,115,63,130,,117,-2,-1.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,29,115,63,130,,117,-2,-1.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,36,96,63,130,,117,-21,-17.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,50,98,63,130,,117,-19,-16.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 C,64,96,63,130,,117,-21,-17.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,80,98,63,130,,117,-19,-16.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,165,100,210,Y,165,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,183,100,210,,165,18,10.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,15,207,100,210,,165,42,25.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,247,100,210,,165,82,49.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,29,288,100,210,,165,123,74.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,29,288,100,210,,165,123,74.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,36,269,100,210,,165,104,63
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,50,284,100,210,,165,119,72.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 C,64,168,100,210,,165,3,1.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,80,421,100,210,,165,256,155.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-32,3.8,3.5,5.1,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.8,3.5,5.1,Y,4.8,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,4.3,3.5,5.1,,4.8,-0.5,-10.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,15,3.8,3.5,5.1,,4.8,-1,-20.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.2,3.5,5.1,,4.8,-0.5999999999999996,-12.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,29,4,3.5,5.1,,4.8,-0.7999999999999998,-16.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,29,4,3.5,5.1,,4.8,-0.7999999999999998,-16.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,36,3.9,3.5,5.1,,4.8,-0.8999999999999999,-18.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,50,4.3,3.5,5.1,,4.8,-0.5,-10.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,64,3.9,3.5,5.1,,4.8,-0.8999999999999999,-18.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,80,4.4,3.5,5.1,,4.8,-0.39999999999999947,-8.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-32,140,136,145,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,140,136,145,Y,140,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,139,136,145,,140,-1,-0.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,15,137,136,145,,140,-3,-2.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,137,136,145,,140,-3,-2.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,29,140,136,145,,140,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,29,140,136,145,,140,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,36,139,136,145,,140,-1,-0.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,50,135,136,145,,140,-5,-3.6
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 C,64,137,136,145,,140,-3,-2.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,80,143,136,145,,140,3,2.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-32,6.7,0.1,1.4,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.2,0.1,1.4,Y,0.2,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.2,0.1,1.4,,0.2,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,15,0.3,0.1,1.4,,0.2,0.09999999999999998,50
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.3,0.1,1.4,,0.2,0.09999999999999998,50
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,29,0.2,0.1,1.4,,0.2,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,29,0.2,0.1,1.4,,0.2,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,36,0.3,0.1,1.4,,0.2,0.09999999999999998,50
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,50,0.4,0.1,1.4,,0.2,0.2,100
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,64,0.3,0.1,1.4,,0.2,0.09999999999999998,50
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,80,0.3,0.1,1.4,,0.2,0.09999999999999998,50
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-32,6.7,6.3,8.1,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.2,6.3,8.1,Y,7.2,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,7.2,6.3,8.1,,7.2,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,15,7.4,6.3,8.1,,7.2,0.20000000000000018,2.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,7.6,6.3,8.1,,7.2,0.39999999999999947,5.6
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,29,7.5,6.3,8.1,,7.2,0.2999999999999998,4.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,29,7.5,6.3,8.1,,7.2,0.2999999999999998,4.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,36,7.1,6.3,8.1,,7.2,-0.10000000000000053,-1.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,50,7.5,6.3,8.1,,7.2,0.2999999999999998,4.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 C,64,7.5,6.3,8.1,,7.2,0.2999999999999998,4.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,80,7.8,6.3,8.1,,7.2,0.5999999999999996,8.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-10,27,25.5,36,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,26.1,25.5,36,Y,26.1,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-10,1.05,0.9,1.3,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,0.99,0.9,1.3,Y,0.99,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-10,10.8,12.1,15.2,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,10.2,12.1,15.2,Y,10.2,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-32,0.09,0,0.1,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.1,Y,0,0,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0,0,0.1,,0,0,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,15,0,0,0.1,,0,0,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0,0,0.1,,0,0,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,29,0.1,0,0.1,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,29,0.1,0,0.1,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 C,36,0.1,0,0.1,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,50,0.1,0,0.1,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 C,64,0,0,0.1,,0,0,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,80,0,0,0.1,,0,0,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-32,0,0,0.4,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0,0,0.4,Y,0,0,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0.1,0,0.4,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,15,0.1,0,0.4,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0,0,0.4,,0,0,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,29,0.1,0,0.4,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,29,0.1,0,0.4,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 C,36,0.1,0,0.4,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,50,0.1,0,0.4,,0,0.1,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 C,64,0.2,0,0.4,,0,0.2,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,80,0.2,0,0.4,,0,0.2,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-32,2.56,4,6,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,2.39,4,6,Y,2.39,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,2.31,4,6,,2.39,-0.08000000000000007,-3.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,15,2.35,4,6,,2.39,-0.040000000000000036,-1.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,2.29,4,6,,2.39,-0.10000000000000009,-4.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,29,3.01,4,6,,2.39,0.6199999999999997,25.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,29,3.01,4,6,,2.39,0.6199999999999997,25.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,36,2.51,4,6,,2.39,0.11999999999999966,5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,50,3.02,4,6,,2.39,0.6299999999999999,26.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,64,2.51,4,6,,2.39,0.11999999999999966,5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,80,2.94,4,6,,2.39,0.5499999999999998,23
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-32,27.9,43.5,48,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,25.7,43.5,48,Y,25.7,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,25,43.5,48,,25.7,-0.6999999999999993,-2.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,15,25.1,43.5,48,,25.7,-0.5999999999999979,-2.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,24,43.5,48,,25.7,-1.6999999999999993,-6.6
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,29,29.8,43.5,48,,25.7,4.100000000000001,16
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,29,29.8,43.5,48,,25.7,4.100000000000001,16
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,36,25.1,43.5,48,,25.7,-0.5999999999999979,-2.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,50,29.9,43.5,48,,25.7,4.199999999999999,16.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,64,25.4,43.5,48,,25.7,-0.3000000000000007,-1.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,80,28.9,43.5,48,,25.7,3.1999999999999993,12.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-32,9.1,13.9,16.3,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,8.3,13.9,16.3,Y,8.3,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,7.9,13.9,16.3,,8.3,-0.40000000000000036,-4.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,15,7.9,13.9,16.3,,8.3,-0.40000000000000036,-4.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,7.6,13.9,16.3,,8.3,-0.7000000000000011,-8.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,29,9.5,13.9,16.3,,8.3,1.1999999999999993,14.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,29,9.5,13.9,16.3,,8.3,1.1999999999999993,14.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,36,8,13.9,16.3,,8.3,-0.3000000000000007,-3.6
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,50,9.2,13.9,16.3,,8.3,0.8999999999999986,10.8
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,64,7.7,13.9,16.3,,8.3,-0.6000000000000005,-7.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,80,8.9,13.9,16.3,,8.3,0.5999999999999996,7.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-32,0.82,0.9,2.6,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.9,0.9,2.6,Y,0.9,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,1.1,0.9,2.6,,0.9,0.20000000000000007,22.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,15,1.2,0.9,2.6,,0.9,0.29999999999999993,33.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,1,0.9,2.6,,0.9,0.09999999999999998,11.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,29,1.8,0.9,2.6,,0.9,0.9,100
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,29,1.8,0.9,2.6,,0.9,0.9,100
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 C,36,2,0.9,2.6,,0.9,1.1,122.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,50,1.7,0.9,2.6,,0.9,0.7999999999999999,88.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 C,64,1.1,0.9,2.6,,0.9,0.20000000000000007,22.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,80,1.5,0.9,2.6,,0.9,0.6,66.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-32,0.76,0.1,0.9,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.4,0.1,0.9,Y,0.4,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,1,0.1,0.9,,0.4,0.6,150
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,15,2.8,0.1,0.9,,0.4,2.4,600
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,2.8,0.1,0.9,,0.4,2.4,600
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,29,8.1,0.1,0.9,,0.4,7.699999999999999,1925
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,29,8.1,0.1,0.9,,0.4,7.699999999999999,1925
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 C,36,9.4,0.1,0.9,,0.4,9,2250
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,50,1.4,0.1,0.9,,0.4,0.9999999999999999,250
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 C,64,0.7,0.1,0.9,,0.4,0.29999999999999993,75
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,80,0.6,0.1,0.9,,0.4,0.19999999999999996,50
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-32,8.3,1.8,6.5,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4.6,1.8,6.5,Y,4.6,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,4.6,1.8,6.5,,4.6,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,15,6.9,1.8,6.5,,4.6,2.3000000000000007,50
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,8.2,1.8,6.5,,4.6,3.5999999999999996,78.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,29,11.9,1.8,6.5,,4.6,7.300000000000001,158.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,29,11.9,1.8,6.5,,4.6,7.300000000000001,158.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 C,36,12.8,1.8,6.5,,4.6,8.200000000000001,178.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,50,13.3,1.8,6.5,,4.6,8.700000000000001,189.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 C,64,6.7,1.8,6.5,,4.6,2.1000000000000005,45.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,80,4.7,1.8,6.5,,4.6,0.10000000000000053,2.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-32,192,150,450,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,293,150,450,Y,293,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,287,150,450,,293,-6,-2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,15,403,150,450,,293,110,37.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,558,150,450,,293,265,90.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,29,652,150,450,,293,359,122.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,29,652,150,450,,293,359,122.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,36,448,150,450,,293,155,52.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,50,608,150,450,,293,315,107.5
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,64,405,150,450,,293,112,38.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,80,216,150,450,,293,-77,-26.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-32,10.03,4,11,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,6,4,11,Y,6,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,6.9,4,11,,6,0.9000000000000004,15
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,15,11,4,11,,6,5,83.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,12.1,4,11,,6,6.1,101.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,29,23.9,4,11,,6,17.9,298.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,29,23.9,4,11,,6,17.9,298.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,36,26.7,4,11,,6,20.7,345
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,50,18.1,4,11,,6,12.100000000000001,201.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 C,64,9.2,4,11,,6,3.1999999999999993,53.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,80,7.7,4,11,,6,1.7000000000000002,28.3
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-32,183.22,NA,NA,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,215.63,NA,NA,Y,215.63,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,398.35,NA,NA,,215.63,182.72000000000003,84.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,29,379.32,NA,NA,,215.63,163.69,75.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,29,379.32,NA,NA,,215.63,163.69,75.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,64,390.55,NA,NA,,215.63,174.92000000000002,81.1
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-10,1.56,0.4,4,,NA,NA,NA
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.37,0.4,4,Y,1.37,0,0
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,1.54,0.4,4,,1.37,0.16999999999999993,12.4
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,15,2.19,0.4,4,,1.37,0.8199999999999998,59.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,1.66,0.4,4,,1.37,0.2899999999999998,21.2
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,29,1.9,0.4,4,,1.37,0.5299999999999998,38.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,29,1.9,0.4,4,,1.37,0.5299999999999998,38.7
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,36,1.33,0.4,4,,1.37,-0.040000000000000036,-2.9
1C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,64,1.48,0.4,4,,1.37,0.10999999999999988,8
2A,A,NKTR-214 + Nivolumab,N,N,,CTC,Baseline,1,5,NA,NA,Y,5,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-12,18,12,60,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,19,12,60,Y,19,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,77,12,60,,19,58,305.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,23,30,12,60,,19,11,57.9
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,30,58,12,60,,19,39,205.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,31,57,12,60,,19,38,200
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,37,24,12,60,,19,5,26.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 A,43,19,12,60,,19,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 8 A,50,18,12,60,,19,-1,-5.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,67,15,12,60,,19,-4,-21.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 A,156,17,12,60,,19,-2,-10.5
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-12,4,3.5,4.8,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.9,3.5,4.8,Y,3.9,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,3.4,3.5,4.8,,3.9,-0.5,-12.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,23,3.6,3.5,4.8,,3.9,-0.2999999999999998,-7.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,30,3,3.5,4.8,,3.9,-0.8999999999999999,-23.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,31,3.4,3.5,4.8,,3.9,-0.5,-12.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,37,3.6,3.5,4.8,,3.9,-0.2999999999999998,-7.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 A,43,3.7,3.5,4.8,,3.9,-0.19999999999999973,-5.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 8 A,50,2.9,3.5,4.8,,3.9,-1,-25.6
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment A,67,3.7,3.5,4.8,,3.9,-0.19999999999999973,-5.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 A,156,4.1,3.5,4.8,,3.9,0.19999999999999973,5.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-12,209,31,95,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,192,31,95,Y,192,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,174,31,95,,192,-18,-9.4
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,23,154,31,95,,192,-38,-19.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,30,187,31,95,,192,-5,-2.6
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,31,188,31,95,,192,-4,-2.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,37,154,31,95,,192,-38,-19.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 A,43,141,31,95,,192,-51,-26.6
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 8 A,50,154,31,95,,192,-38,-19.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,67,155,31,95,,192,-37,-19.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 A,156,141,31,95,,192,-51,-26.6
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-12,24,18,63,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,26,18,63,Y,26,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,61,18,63,,26,35,134.6
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,23,27,18,63,,26,1,3.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,30,49,18,63,,26,23,88.5
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,31,41,18,63,,26,15,57.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,37,23,18,63,,26,-3,-11.5
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 A,43,22,18,63,,26,-4,-15.4
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 8 A,50,21,18,63,,26,-5,-19.2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,67,21,18,63,,26,-5,-19.2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 A,156,26,18,63,,26,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-12,11,6,22,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,10,6,22,Y,10,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,8,7,6,22,,10,-3,-30
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,23,10,6,22,,10,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,31,5,6,22,,10,-5,-50
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,37,10,6,22,,10,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 A,43,8,6,22,,10,-2,-20
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 8 A,50,5,6,22,,10,-5,-50
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,End of Treatment A,67,10,6,22,,10,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 A,156,7,6,22,,10,-3,-30
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-12,29,22,27,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,27,22,27,Y,27,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,27,22,27,,27,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,23,29,22,27,,27,2,7.4
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,30,26,22,27,,27,-1,-3.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,31,26,22,27,,27,-1,-3.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,37,27,22,27,,27,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 A,43,27,22,27,,27,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 8 A,50,25,22,27,,27,-2,-7.4
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment A,67,27,22,27,,27,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 A,156,23,22,27,,27,-4,-14.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-12,9.6,8.8,10.3,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.7,8.8,10.3,Y,9.7,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,8.6,8.8,10.3,,9.7,-1.0999999999999996,-11.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,23,9.8,8.8,10.3,,9.7,0.10000000000000142,1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,30,9,8.8,10.3,,9.7,-0.6999999999999993,-7.2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,31,9.4,8.8,10.3,,9.7,-0.29999999999999893,-3.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,37,9,8.8,10.3,,9.7,-0.6999999999999993,-7.2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 A,43,9.4,8.8,10.3,,9.7,-0.29999999999999893,-3.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 8 A,50,8.6,8.8,10.3,,9.7,-1.0999999999999996,-11.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment A,67,9.1,8.8,10.3,,9.7,-0.5999999999999996,-6.2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 A,156,8.7,8.8,10.3,,9.7,-1,-10.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-12,100,97,108,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,100,97,108,Y,100,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,98,97,108,,100,-2,-2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,23,104,97,108,,100,4,4
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,30,102,97,108,,100,2,2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,31,99,97,108,,100,-1,-1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,37,101,97,108,,100,1,1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 A,43,103,97,108,,100,3,3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 8 A,50,100,97,108,,100,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment A,67,103,97,108,,100,3,3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 A,156,92,97,108,,100,-8,-8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-12,0.55,0.61,1.24,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.59,0.61,1.24,Y,0.59,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,0.63,0.61,1.24,,0.59,0.040000000000000036,6.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,23,0.59,0.61,1.24,,0.59,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,30,0.75,0.61,1.24,,0.59,0.16000000000000003,27.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,31,0.73,0.61,1.24,,0.59,0.14,23.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,37,0.62,0.61,1.24,,0.59,0.030000000000000027,5.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 A,43,0.65,0.61,1.24,,0.59,0.06000000000000005,10.2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 8 A,50,0.81,0.61,1.24,,0.59,0.22000000000000008,37.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment A,67,0.62,0.61,1.24,,0.59,0.030000000000000027,5.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 A,156,0.5,0.61,1.24,,0.59,-0.08999999999999997,-15.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-12,100,70,199,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,107,70,199,Y,107,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 A,8,98,70,199,,107,-9,-8.4
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,23,105,70,199,,107,-2,-1.9
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,30,106,70,199,,107,-1,-0.9
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,31,92,70,199,,107,-15,-14
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,37,88,70,199,,107,-19,-17.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 A,43,99,70,199,,107,-8,-7.5
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 8 A,50,94,70,199,,107,-13,-12.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment A,67,105,70,199,,107,-2,-1.9
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 A,156,84,70,199,,107,-23,-21.5
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,-12,162,102,199,Y,162,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,8,195,102,199,,162,33,20.4
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,23,146,102,199,,162,-16,-9.9
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,30,202,102,199,,162,40,24.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 A,43,189,102,199,,162,27,16.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 8 A,50,205,102,199,,162,43,26.5
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment A,67,193,102,199,,162,31,19.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-12,3.8,3.5,5.1,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.5,3.5,5.1,Y,4.5,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,3.8,3.5,5.1,,4.5,-0.7000000000000002,-15.6
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,23,4.6,3.5,5.1,,4.5,0.09999999999999964,2.2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,30,4.2,3.5,5.1,,4.5,-0.2999999999999998,-6.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,31,4.3,3.5,5.1,,4.5,-0.20000000000000018,-4.4
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,37,4,3.5,5.1,,4.5,-0.5,-11.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 A,43,4.6,3.5,5.1,,4.5,0.09999999999999964,2.2
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 8 A,50,4.5,3.5,5.1,,4.5,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment A,67,4,3.5,5.1,,4.5,-0.5,-11.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 A,156,3.7,3.5,5.1,,4.5,-0.7999999999999998,-17.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-12,139,135,145,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,135,135,145,Y,135,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,8,134,135,145,,135,-1,-0.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,23,139,135,145,,135,4,3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,30,136,135,145,,135,1,0.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,31,133,135,145,,135,-2,-1.5
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,37,134,135,145,,135,-1,-0.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 A,43,135,135,145,,135,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 8 A,50,130,135,145,,135,-5,-3.7
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment A,67,135,135,145,,135,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 A,156,124,135,145,,135,-11,-8.1
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-12,6.7,0.2,1.3,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.5,0.2,1.3,Y,0.5,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.8,0.2,1.3,,0.5,0.30000000000000004,60
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,23,0.5,0.2,1.3,,0.5,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,30,0.4,0.2,1.3,,0.5,-0.09999999999999998,-20
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,31,0.4,0.2,1.3,,0.5,-0.09999999999999998,-20
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,37,0.8,0.2,1.3,,0.5,0.30000000000000004,60
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 A,43,0.4,0.2,1.3,,0.5,-0.09999999999999998,-20
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 8 A,50,0.5,0.2,1.3,,0.5,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment A,67,0.7,0.2,1.3,,0.5,0.19999999999999996,40
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 A,156,0.6,0.2,1.3,,0.5,0.09999999999999998,20
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-12,6.7,6,8.4,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.3,6,8.4,Y,6.3,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,8,5.7,6,8.4,,6.3,-0.5999999999999996,-9.5
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,23,6.2,6,8.4,,6.3,-0.09999999999999964,-1.6
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,30,5.3,6,8.4,,6.3,-1,-15.9
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,31,6,6,8.4,,6.3,-0.2999999999999998,-4.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,37,6,6,8.4,,6.3,-0.2999999999999998,-4.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 A,43,6,6,8.4,,6.3,-0.2999999999999998,-4.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 8 A,50,5.4,6,8.4,,6.3,-0.8999999999999995,-14.3
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment A,67,6,6,8.4,,6.3,-0.2999999999999998,-4.8
2A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 A,156,6,6,8.4,,6.3,-0.2999999999999998,-4.8
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-12,22.4,22.6,34.5,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,22,22.6,34.5,Y,22,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 A,8,22.2,22.6,34.5,,22,0.1999999999999993,0.9
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 A,23,22.1,22.6,34.5,,22,0.10000000000000142,0.5
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 8 A,30,22.6,22.6,34.5,,22,0.6000000000000014,2.7
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 A,43,22.9,22.6,34.5,,22,0.8999999999999986,4.1
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 8 A,50,25.8,22.6,34.5,,22,3.8000000000000007,17.3
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment A,67,23,22.6,34.5,,22,1,4.5
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-12,1,0.9,1.3,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1,0.9,1.3,Y,1,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 A,8,1.1,0.9,1.3,,1,0.10000000000000009,10
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 A,23,1.1,0.9,1.3,,1,0.10000000000000009,10
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 8 A,30,1.2,0.9,1.3,,1,0.19999999999999996,20
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 A,43,1,0.9,1.3,,1,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 8 A,50,1.2,0.9,1.3,,1,0.19999999999999996,20
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment A,67,1.1,0.9,1.3,,1,0.10000000000000009,10
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-12,12.8,NA,NA,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.5,NA,NA,Y,12.5,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 A,8,13.5,NA,NA,,12.5,1,8
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 A,23,13.5,NA,NA,,12.5,1,8
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 8 A,30,14.4,NA,NA,,12.5,1.9000000000000004,15.2
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 A,43,13,NA,NA,,12.5,0.5,4
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 8 A,50,14.7,NA,NA,,12.5,2.1999999999999993,17.6
2A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment A,67,13.5,NA,NA,,12.5,1,8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-12,0.02,0,0.1,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.02,0,0.1,Y,0.02,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0.02,0,0.1,,0.02,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0.01,0,0.1,,0.02,-0.01,-50
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,8,0,0,0.1,,0.02,-0.02,-100
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,23,0.06,0,0.1,,0.02,0.039999999999999994,200
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,30,0,0,0.1,,0.02,-0.02,-100
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,31,0.31,0,0.1,,0.02,0.29,1450
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,37,0.02,0,0.1,,0.02,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 A,43,0.07,0,0.1,,0.02,0.05,250
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 8 A,50,0.19,0,0.1,,0.02,0.17,850
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,End of Treatment A,67,0.06,0,0.1,,0.02,0.039999999999999994,200
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 A,156,0.02,0,0.1,,0.02,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-12,0.11,0,0.4,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.14,0,0.4,Y,0.14,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.1,0,0.4,,0.14,-0.04000000000000001,-28.6
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.13,0,0.4,,0.14,-0.010000000000000009,-7.1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.35,0,0.4,,0.14,0.20999999999999996,150
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,23,0.55,0,0.4,,0.14,0.41000000000000003,292.9
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 8 A,30,11.55,0,0.4,,0.14,11.41,8150
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,31,18.42,0,0.4,,0.14,18.28,13057.1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,37,9.86,0,0.4,,0.14,9.719999999999999,6942.9
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 A,43,1.74,0,0.4,,0.14,1.6,1142.9
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 8 A,50,8.93,0,0.4,,0.14,8.79,6278.6
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment A,67,2.07,0,0.4,,0.14,1.9299999999999997,1378.6
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 A,156,0.01,0,0.4,,0.14,-0.13,-92.9
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-12,3.83,4.4,5.9,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.67,4.4,5.9,Y,3.67,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,3.52,4.4,5.9,,3.67,-0.1499999999999999,-4.1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,3.57,4.4,5.9,,3.67,-0.10000000000000009,-2.7
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,3.29,4.4,5.9,,3.67,-0.3799999999999999,-10.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,23,3.57,4.4,5.9,,3.67,-0.10000000000000009,-2.7
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,30,3.3,4.4,5.9,,3.67,-0.3700000000000001,-10.1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,31,3.52,4.4,5.9,,3.67,-0.1499999999999999,-4.1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,37,3.75,4.4,5.9,,3.67,0.08000000000000007,2.2
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 A,43,3.59,4.4,5.9,,3.67,-0.08000000000000007,-2.2
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 8 A,50,3.43,4.4,5.9,,3.67,-0.23999999999999977,-6.5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment A,67,3.64,4.4,5.9,,3.67,-0.029999999999999805,-0.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 A,156,3.01,4.4,5.9,,3.67,-0.6600000000000001,-18
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-12,35.3,41,53,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,34.5,41,53,Y,34.5,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,31.6,41,53,,34.5,-2.8999999999999986,-8.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,32.5,41,53,,34.5,-2,-5.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,30.4,41,53,,34.5,-4.100000000000001,-11.9
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,23,31.8,41,53,,34.5,-2.6999999999999993,-7.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,30,29,41,53,,34.5,-5.5,-15.9
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,31,30.9,41,53,,34.5,-3.6000000000000014,-10.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,37,33.9,41,53,,34.5,-0.6000000000000014,-1.7
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 A,43,32.3,41,53,,34.5,-2.200000000000003,-6.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 8 A,50,30.1,41,53,,34.5,-4.399999999999999,-12.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment A,67,32.4,41,53,,34.5,-2.1000000000000014,-6.1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 A,156,28,41,53,,34.5,-6.5,-18.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-12,11.9,13.6,17.5,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.5,13.6,17.5,Y,11.5,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,10.8,13.6,17.5,,11.5,-0.6999999999999993,-6.1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,11.1,13.6,17.5,,11.5,-0.40000000000000036,-3.5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,10.2,13.6,17.5,,11.5,-1.3000000000000007,-11.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,23,10.7,13.6,17.5,,11.5,-0.8000000000000007,-7
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,30,10,13.6,17.5,,11.5,-1.5,-13
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,31,10.4,13.6,17.5,,11.5,-1.0999999999999996,-9.6
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,37,11.1,13.6,17.5,,11.5,-0.40000000000000036,-3.5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 A,43,10.6,13.6,17.5,,11.5,-0.9000000000000004,-7.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 8 A,50,10.3,13.6,17.5,,11.5,-1.1999999999999993,-10.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment A,67,10.6,13.6,17.5,,11.5,-0.9000000000000004,-7.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 A,156,9.8,13.6,17.5,,11.5,-1.6999999999999993,-14.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-12,0.97,1,3.4,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.95,1,3.4,Y,0.95,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.3,1,3.4,,0.95,-0.6499999999999999,-68.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.16,1,3.4,,0.95,-0.7899999999999999,-83.2
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,1.76,1,3.4,,0.95,0.81,85.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,23,1.61,1,3.4,,0.95,0.6600000000000001,69.5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,30,2.31,1,3.4,,0.95,1.36,143.2
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,31,6.14,1,3.4,,0.95,5.1899999999999995,546.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,37,2.48,1,3.4,,0.95,1.53,161.1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 A,43,1.75,1,3.4,,0.95,0.8,84.2
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 8 A,50,4.56,1,3.4,,0.95,3.6099999999999994,380
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment A,67,1.29,1,3.4,,0.95,0.3400000000000001,35.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 A,156,1.31,1,3.4,,0.95,0.3600000000000001,37.9
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-12,0.5,0.2,0.8,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.57,0.2,0.8,Y,0.57,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.54,0.2,0.8,,0.57,-0.029999999999999916,-5.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.57,0.2,0.8,,0.57,0,0
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,8,0.68,0.2,0.8,,0.57,0.1100000000000001,19.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,23,0.63,0.2,0.8,,0.57,0.06000000000000005,10.5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,30,0.63,0.2,0.8,,0.57,0.06000000000000005,10.5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,31,0.31,0.2,0.8,,0.57,-0.25999999999999995,-45.6
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,37,0.68,0.2,0.8,,0.57,0.1100000000000001,19.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 A,43,0.42,0.2,0.8,,0.57,-0.14999999999999997,-26.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 8 A,50,0.76,0.2,0.8,,0.57,0.19000000000000006,33.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment A,67,0.37,0.2,0.8,,0.57,-0.19999999999999996,-35.1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 A,156,0.49,0.2,0.8,,0.57,-0.07999999999999996,-14
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-12,3.11,1.8,6.8,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.39,1.8,6.8,Y,3.39,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,3.56,1.8,6.8,,3.39,0.16999999999999993,5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,4.33,1.8,6.8,,3.39,0.94,27.7
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,8,3.16,1.8,6.8,,3.39,-0.22999999999999998,-6.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,23,2.36,1.8,6.8,,3.39,-1.0300000000000002,-30.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,30,6.51,1.8,6.8,,3.39,3.1199999999999997,92
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,31,5.22,1.8,6.8,,3.39,1.8299999999999996,54
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,37,2.73,1.8,6.8,,3.39,-0.6600000000000001,-19.5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 A,43,2.97,1.8,6.8,,3.39,-0.41999999999999993,-12.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 8 A,50,4.56,1.8,6.8,,3.39,1.1699999999999995,34.5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment A,67,2.02,1.8,6.8,,3.39,-1.37,-40.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 A,156,2.55,1.8,6.8,,3.39,-0.8400000000000003,-24.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-12,183,140,450,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,197,140,450,Y,197,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,154,140,450,,197,-43,-21.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,117,140,450,,197,-80,-40.6
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,151,140,450,,197,-46,-23.4
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,23,201,140,450,,197,4,2
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,30,161,140,450,,197,-36,-18.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,31,199,140,450,,197,2,1
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,37,271,140,450,,197,74,37.6
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 A,43,235,140,450,,197,38,19.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 8 A,50,220,140,450,,197,23,11.7
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment A,67,224,140,450,,197,27,13.7
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 A,156,119,140,450,,197,-78,-39.6
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,TESTR,Baseline,-12,8,240,871,Y,8,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-12,4.7,3.4,10,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.1,3.4,10,Y,5.1,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,4.5,3.4,10,,5.1,-0.5999999999999996,-11.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,5.2,3.4,10,,5.1,0.10000000000000053,2
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,6,3.4,10,,5.1,0.9000000000000004,17.6
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,23,5.2,3.4,10,,5.1,0.10000000000000053,2
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,30,21,3.4,10,,5.1,15.9,311.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,31,30.7,3.4,10,,5.1,25.6,502
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,37,15.9,3.4,10,,5.1,10.8,211.8
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 A,43,7,3.4,10,,5.1,1.9000000000000004,37.3
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 8 A,50,19,3.4,10,,5.1,13.9,272.5
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment A,67,5.8,3.4,10,,5.1,0.7000000000000002,13.7
2A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 A,156,4.4,3.4,10,,5.1,-0.6999999999999993,-13.7
2A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-12,0.37,NA,NA,,NA,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,0.51,NA,NA,Y,0.51,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,23,0.44,NA,NA,,0.51,-0.07,-13.7
2A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 A,43,0.64,NA,NA,,0.51,0.13,25.5
2A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment A,67,0.77,NA,NA,,0.51,0.26,51
2A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 A,156,0.59,NA,NA,,0.51,0.07999999999999996,15.7
2A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,-12,1.35,0.45,4.12,Y,1.35,NA,NA
2A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,23,0.01,0.45,4.12,,1.35,-1.34,-99.3
2A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 A,43,16.07,0.45,4.12,,1.35,14.72,1090.4
2A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,67,16.74,0.45,4.12,,1.35,15.389999999999999,1140
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Baseline,1,31,NA,NA,Y,31,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-20,11,1,45,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,10,1,45,Y,10,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,12,1,45,,10,2,20
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,15,12,1,45,,10,2,20
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,60,16,1,45,,10,6,60
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-20,3.9,3.5,4.9,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.5,3.5,4.9,Y,3.5,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,3.2,3.5,4.9,,3.5,-0.2999999999999998,-8.6
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,15,3.5,3.5,4.9,,3.5,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment B,60,3,3.5,4.9,,3.5,-0.5,-14.3
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-20,449,38,126,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,712,38,126,Y,712,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,577,38,126,,712,-135,-19
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,15,655,38,126,,712,-57,-8
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,60,751,38,126,,712,39,5.5
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-20,13,1,35,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,18,1,35,Y,18,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,14,1,35,,18,-4,-22.2
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,15,16,1,35,,18,-2,-11.1
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,60,19,1,35,,18,1,5.6
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-20,21,6,23,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Baseline,1,25,6,23,Y,25,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 B,8,21,6,23,,25,-4,-16
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 15 B,15,22,6,23,,25,-3,-12
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,End of Treatment B,60,19,6,23,,25,-6,-24
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-20,30,22,30,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,25,22,30,Y,25,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,22,22,30,,25,-3,-12
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 15 B,15,26,22,30,,25,1,4
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment B,60,24,22,30,,25,-1,-4
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-20,10.4,8.5,10.5,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.5,8.5,10.5,Y,9.5,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,8.9,8.5,10.5,,9.5,-0.5999999999999996,-6.3
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,15,9.4,8.5,10.5,,9.5,-0.09999999999999964,-1.1
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment B,60,8.8,8.5,10.5,,9.5,-0.6999999999999993,-7.4
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-20,103,96,108,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,103,96,108,Y,103,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,104,96,108,,103,1,1
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,15,105,96,108,,103,2,1.9
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment B,60,105,96,108,,103,2,1.9
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-20,1.3,0.7,1.3,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1.28,0.7,1.3,Y,1.28,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,1.35,0.7,1.3,,1.28,0.07000000000000006,5.5
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,15,1.43,0.7,1.3,,1.28,0.1499999999999999,11.7
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment B,60,1.25,0.7,1.3,,1.28,-0.030000000000000027,-2.3
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-20,109,60,100,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,198,60,100,Y,198,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 B,8,284,60,100,,198,86,43.4
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 15 B,15,119,60,100,,198,-79,-39.9
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,End of Treatment B,60,188,60,100,,198,-10,-5.1
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-20,164,100,220,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,254,100,220,Y,254,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,175,100,220,,254,-79,-31.1
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,60,243,100,220,,254,-11,-4.3
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-20,4.6,3.5,5.2,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.7,3.5,5.2,Y,4.7,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.1,3.5,5.2,,4.7,-0.6000000000000005,-12.8
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,15,4.1,3.5,5.2,,4.7,-0.6000000000000005,-12.8
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment B,60,4.6,3.5,5.2,,4.7,-0.10000000000000053,-2.1
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-20,140,135,145,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,137,135,145,Y,137,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 B,8,136,135,145,,137,-1,-0.7
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 15 B,15,142,135,145,,137,5,3.6
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,End of Treatment B,60,141,135,145,,137,4,2.9
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-20,0.4,0.1,1.2,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.2,0.1,1.2,Y,0.2,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.1,0.1,1.2,,0.2,-0.1,-50
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,15,0.1,0.1,1.2,,0.2,-0.1,-50
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment B,60,0.3,0.1,1.2,,0.2,0.09999999999999998,50
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-20,7.7,6,8.3,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.8,6,8.3,Y,6.8,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 B,8,6.5,6,8.3,,6.8,-0.2999999999999998,-4.4
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 15 B,15,6.9,6,8.3,,6.8,0.10000000000000053,1.5
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment B,60,6.4,6,8.3,,6.8,-0.39999999999999947,-5.9
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-20,28.8,25.4,34.9,Y,28.8,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,26.3,25.4,34.9,,28.8,-2.5,-8.7
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-20,1,2,3,Y,1,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,1,2,3,,1,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,-20,13,12.3,14.9,Y,13,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,12.5,12.3,14.9,,13,-0.5,-3.8
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,,-20,0.1,0,0.2,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.1,0,0.2,Y,0.1,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 B,8,0.1,0,0.2,,0.1,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 15 B,15,0.1,0,0.2,,0.1,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,End of Treatment B,60,0,0,0.2,,0.1,-0.1,-100
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,,-20,0.3,0,0.6,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.3,0,0.6,Y,0.3,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.3,0,0.6,,0.3,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 15 B,15,0.4,0,0.6,,0.3,0.10000000000000003,33.3
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment B,60,0.3,0,0.6,,0.3,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-20,5.26,4.5,6,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.78,4.5,6,Y,4.78,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,4.45,4.5,6,,4.78,-0.33000000000000007,-6.9
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,15,4.52,4.5,6,,4.78,-0.2600000000000007,-5.4
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,60,3.79,4.5,6,,4.78,-0.9900000000000002,-20.7
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-20,44.7,42,52,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,40.7,42,52,Y,40.7,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,37.4,42,52,,40.7,-3.3000000000000043,-8.1
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,15,37.8,42,52,,40.7,-2.9000000000000057,-7.1
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment B,60,31,42,52,,40.7,-9.700000000000003,-23.8
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-20,14.4,13.9,16.3,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,13.3,13.9,16.3,Y,13.3,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,12.1,13.9,16.3,,13.3,-1.200000000000001,-9
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,15,12.3,13.9,16.3,,13.3,-1,-7.5
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment B,60,10.5,13.9,16.3,,13.3,-2.8000000000000007,-21.1
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,,-20,2.6,1,4.5,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.9,1,4.5,Y,1.9,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,1.6,1,4.5,,1.9,-0.2999999999999998,-15.8
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 15 B,15,2.1,1,4.5,,1.9,0.20000000000000018,10.5
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment B,60,0.5,1,4.5,,1.9,-1.4,-73.7
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,,-20,0.7,0.2,1,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.6,0.2,1,Y,0.6,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 B,8,2.6,0.2,1,,0.6,2,333.3
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 15 B,15,5.8,0.2,1,,0.6,5.2,866.7
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,End of Treatment B,60,0.4,0.2,1,,0.6,-0.19999999999999996,-33.3
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,,-20,5.3,1.9,8,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4.7,1.9,8,Y,4.7,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 B,8,5.67,1.9,8,,4.7,0.9699999999999998,20.6
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 15 B,15,7.6,1.9,8,,4.7,2.8999999999999995,61.7
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment B,60,3.7,1.9,8,,4.7,-1,-21.3
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-20,307,150,450,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,229,150,450,Y,229,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,228,150,450,,229,-1,-0.4
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,15,208,150,450,,229,-21,-9.2
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment B,60,122,150,450,,229,-107,-46.7
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,TESTR,Baseline,-20,14.89,300,1080,Y,14.89,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,,-20,9.1,4.5,11,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,7.6,4.5,11,Y,7.6,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,10.5,4.5,11,,7.6,2.9000000000000004,38.2
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 15 B,15,16,4.5,11,,7.6,8.4,110.5
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment B,60,4.9,4.5,11,,7.6,-2.6999999999999993,-35.5
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,,-20,31.95,NA,NA,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,49.98,NA,NA,Y,49.98,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment B,60,217.23,NA,NA,,49.98,167.25,334.6
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-20,1.18,0.4,4.2,,NA,NA,NA
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.08,0.4,4.2,Y,1.08,0,0
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,1.76,0.4,4.2,,1.08,0.6799999999999999,63
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,15,1.24,0.4,4.2,,1.08,0.15999999999999992,14.8
2B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,60,0.54,0.4,4.2,,1.08,-0.54,-50
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,60,NA,NA,Y,60,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,29,50,NA,NA,,60,-10,-16.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 C,57,141,NA,NA,,60,81,135
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-24,7,3,61,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,6,3,61,Y,6,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,6,3,61,,6,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,15,9,3,61,,6,3,50
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,7,3,61,,6,1,16.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,29,11,3,61,,6,5,83.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,37,8,3,61,,6,2,33.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-24,3.6,3.8,5.5,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.5,3.8,5.5,Y,3.5,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,3.1,3.8,5.5,,3.5,-0.3999999999999999,-11.4
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,15,3.3,3.8,5.5,,3.5,-0.20000000000000018,-5.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,3.2,3.8,5.5,,3.5,-0.2999999999999998,-8.6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,29,2.9,3.8,5.5,,3.5,-0.6000000000000001,-17.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,37,3,3.8,5.5,,3.5,-0.5,-14.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-24,100,33,98,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,96,33,98,Y,96,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,108,33,98,,96,12,12.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,15,111,33,98,,96,15,15.6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,116,33,98,,96,20,20.8
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,29,112,33,98,,96,16,16.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,37,146,33,98,,96,50,52.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-24,13,5,38,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,13,5,38,Y,13,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,13,5,38,,13,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,15,13,5,38,,13,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,15,5,38,,13,2,15.4
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,29,13,5,38,,13,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,37,19,5,38,,13,6,46.2
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-24,17,7,25,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,14,7,25,Y,14,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,14,7,25,,14,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,15,15,7,25,,14,1,7.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,21,7,25,,14,7,50
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,29,15,7,25,,14,1,7.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,37,21,7,25,,14,7,50
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-24,24,21,31,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,26,21,31,Y,26,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,25,21,31,,26,-1,-3.8
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,15,26,21,31,,26,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,24,21,31,,26,-2,-7.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,29,26,21,31,,26,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,37,24,21,31,,26,-2,-7.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-24,8.1,8.7,10.1,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8,8.7,10.1,Y,8,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,8.8,8.7,10.1,,8,0.8000000000000007,10
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,15,9,8.7,10.1,,8,1,12.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,7.9,8.7,10.1,,8,-0.09999999999999964,-1.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,29,7.5,8.7,10.1,,8,-0.5,-6.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,37,8.1,8.7,10.1,,8,0.09999999999999964,1.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-24,101,99,107,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,100,99,107,Y,100,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,102,99,107,,100,2,2
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,15,103,99,107,,100,3,3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,102,99,107,,100,2,2
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,29,103,99,107,,100,3,3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,37,98,99,107,,100,-2,-2
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-24,0.68,0.7,1.3,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.67,0.7,1.3,Y,0.67,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,0.68,0.7,1.3,,0.67,0.010000000000000009,1.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,15,0.64,0.7,1.3,,0.67,-0.030000000000000027,-4.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,0.63,0.7,1.3,,0.67,-0.040000000000000036,-6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,29,0.55,0.7,1.3,,0.67,-0.12,-17.9
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,37,0.62,0.7,1.3,,0.67,-0.050000000000000044,-7.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-24,115,63,130,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,130,63,130,Y,130,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,147,63,130,,130,17,13.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,15,119,63,130,,130,-11,-8.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,135,63,130,,130,5,3.8
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,29,108,63,130,,130,-22,-16.9
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,37,143,63,130,,130,13,10
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-24,299,100,210,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,385,100,210,Y,385,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,283,100,210,,385,-102,-26.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,15,330,100,210,,385,-55,-14.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,415,100,210,,385,30,7.8
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,29,332,100,210,,385,-53,-13.8
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,37,413,100,210,,385,28,7.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-24,3.4,3.5,5.1,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,5.3,3.5,5.1,Y,5.3,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,4.2,3.5,5.1,,5.3,-1.0999999999999996,-20.8
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,15,4.8,3.5,5.1,,5.3,-0.5,-9.4
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.3,3.5,5.1,,5.3,-1,-18.9
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,29,3.5,3.5,5.1,,5.3,-1.7999999999999998,-34
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,37,4.1,3.5,5.1,,5.3,-1.2000000000000002,-22.6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-24,136,136,145,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,137,136,145,Y,137,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,136,136,145,,137,-1,-0.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,15,139,136,145,,137,2,1.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,137,136,145,,137,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,29,139,136,145,,137,2,1.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,37,133,136,145,,137,-4,-2.9
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-24,0.5,0.1,1.4,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.3,0.1,1.4,Y,0.3,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.3,0.1,1.4,,0.3,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,15,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,29,0.3,0.1,1.4,,0.3,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,37,0.2,0.1,1.4,,0.3,-0.09999999999999998,-33.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-24,6.5,6.3,8.1,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.6,6.3,8.1,Y,6.6,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,6.2,6.3,8.1,,6.6,-0.39999999999999947,-6.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,15,6.6,6.3,8.1,,6.6,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,6.3,6.3,8.1,,6.6,-0.2999999999999998,-4.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,29,5.8,6.3,8.1,,6.6,-0.7999999999999998,-12.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,37,6.3,6.3,8.1,,6.6,-0.2999999999999998,-4.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-24,27,25.5,36,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,26.5,25.5,36,Y,26.5,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,8,30.8,25.5,36,,26.5,4.300000000000001,16.2
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-24,1.1,0.9,1.3,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.01,0.9,1.3,Y,1.01,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,8,1.07,0.9,1.3,,1.01,0.06000000000000005,5.9
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-24,11.3,12.1,15.2,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,10.8,12.1,15.2,Y,10.8,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,8,11.4,12.1,15.2,,10.8,0.5999999999999996,5.6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-7,0,0,0.1,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.1,Y,0,0,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0,0,0.1,,0,0,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,15,0.1,0,0.1,,0,0.1,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.1,,0,0.1,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,29,0.1,0,0.1,,0,0.1,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 C,37,0.1,0,0.1,,0,0.1,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-7,0,0,0.4,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0,0,0.4,Y,0,0,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0,0,0.4,,0,0,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,15,0,0,0.4,,0,0,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0,0,0.4,,0,0,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,29,0.1,0,0.4,,0,0.1,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 C,37,0,0,0.4,,0,0,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-7,3.29,4,6,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.15,4,6,Y,3.15,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,2.6,4,6,,3.15,-0.5499999999999998,-17.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,15,2.5,4,6,,3.15,-0.6499999999999999,-20.6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,2.19,4,6,,3.15,-0.96,-30.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,29,2.98,4,6,,3.15,-0.16999999999999993,-5.4
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,37,2.96,4,6,,3.15,-0.18999999999999995,-6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-7,31.2,43.5,48,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,30,43.5,48,Y,30,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,25.5,43.5,48,,30,-4.5,-15
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,15,24.8,43.5,48,,30,-5.199999999999999,-17.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,21.5,43.5,48,,30,-8.5,-28.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,29,27.7,43.5,48,,30,-2.3000000000000007,-7.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,37,27.5,43.5,48,,30,-2.5,-8.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-7,9.9,13.9,16.3,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,9.3,13.9,16.3,Y,9.3,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,7.8,13.9,16.3,,9.3,-1.5000000000000009,-16.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,15,7.5,13.9,16.3,,9.3,-1.8000000000000007,-19.4
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,6.5,13.9,16.3,,9.3,-2.8000000000000007,-30.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,29,9,13.9,16.3,,9.3,-0.3000000000000007,-3.2
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,37,8.9,13.9,16.3,,9.3,-0.40000000000000036,-4.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-7,0.7,0.9,2.6,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.7,0.9,2.6,Y,0.7,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,0.7,0.9,2.6,,0.7,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,15,0.9,0.9,2.6,,0.7,0.20000000000000007,28.6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,1,0.9,2.6,,0.7,0.30000000000000004,42.9
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,29,0.8,0.9,2.6,,0.7,0.10000000000000009,14.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 C,37,1,0.9,2.6,,0.7,0.30000000000000004,42.9
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-7,0.9,0.1,0.9,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.8,0.1,0.9,Y,0.8,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,1.4,0.1,0.9,,0.8,0.5999999999999999,75
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,15,2.7,0.1,0.9,,0.8,1.9000000000000001,237.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,4.8,0.1,0.9,,0.8,4,500
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,29,3.3,0.1,0.9,,0.8,2.5,312.5
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 C,37,4.8,0.1,0.9,,0.8,4,500
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-7,4.5,1.8,6.5,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,5.2,1.8,6.5,Y,5.2,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,4.8,1.8,6.5,,5.2,-0.40000000000000036,-7.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,15,7,1.8,6.5,,5.2,1.7999999999999998,34.6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,8.6,1.8,6.5,,5.2,3.3999999999999995,65.4
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,29,6.4,1.8,6.5,,5.2,1.2000000000000002,23.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 C,37,13.5,1.8,6.5,,5.2,8.3,159.6
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-7,285,150,450,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,334,150,450,Y,334,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,297,150,450,,334,-37,-11.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,15,255,150,450,,334,-79,-23.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,341,150,450,,334,7,2.1
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,29,253,150,450,,334,-81,-24.3
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,37,294,150,450,,334,-40,-12
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-7,5.9,4,11,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,7,4,11,Y,7,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,7.2,4,11,,7,0.20000000000000018,2.9
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,15,12.7,4,11,,7,5.699999999999999,81.4
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,16.1,4,11,,7,9.100000000000001,130
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,29,13.7,4,11,,7,6.699999999999999,95.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,37,21.7,4,11,,7,14.7,210
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-7,899.18,NA,NA,,NA,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,1236.45,NA,NA,Y,1236.45,0,0
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,980.7,NA,NA,,1236.45,-255.75,-20.7
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,29,800.92,NA,NA,,1236.45,-435.5300000000001,-35.2
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,-24,0.69,0.4,4,Y,0.69,NA,NA
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,15,1.13,0.4,4,,0.69,0.43999999999999995,63.8
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,0.78,0.4,4,,0.69,0.09000000000000008,13
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,29,0.74,0.4,4,,0.69,0.050000000000000044,7.2
2C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,37,1.39,0.4,4,,0.69,0.7,101.4
3A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 A,36,4,NA,NA,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 3 Day 1 A,57,5,NA,NA,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,,CTC,End of Treatment A,80,14,NA,NA,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-15,65,0,59,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,26,0,59,Y,26,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,9,100,0,59,,26,74,284.6
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,22,21,0,59,,26,-5,-19.2
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,44,26,0,59,,26,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 A,57,21,0,59,,26,-5,-19.2
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,80,15,0,59,,26,-11,-42.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-15,3.8,3.5,4.7,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.5,3.5,4.7,Y,3.5,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,9,3,3.5,4.7,,3.5,-0.5,-14.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,22,3,3.5,4.7,,3.5,-0.5,-14.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,44,2.8,3.5,4.7,,3.5,-0.7000000000000002,-20
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 A,57,2.8,3.5,4.7,,3.5,-0.7000000000000002,-20
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment A,80,2.9,3.5,4.7,,3.5,-0.6000000000000001,-17.1
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-15,209,56,119,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,139,56,119,Y,139,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,9,157,56,119,,139,18,12.9
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,22,117,56,119,,139,-22,-15.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,44,122,56,119,,139,-17,-12.2
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 A,57,106,56,119,,139,-33,-23.7
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,80,99,56,119,,139,-40,-28.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-15,54,0,41,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,19,0,41,Y,19,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,9,65,0,41,,19,46,242.1
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,22,20,0,41,,19,1,5.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,44,21,0,41,,19,2,10.5
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 A,57,22,0,41,,19,3,15.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,80,22,0,41,,19,3,15.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-15,19,6,20,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,14,6,20,Y,14,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,9,8,6,20,,14,-6,-42.9
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,22,15,6,20,,14,1,7.1
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 8 A,44,12,6,20,,14,-2,-14.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 A,57,18,6,20,,14,4,28.6
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,End of Treatment A,80,16,6,20,,14,2,14.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-15,27,21,32,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,25,21,32,Y,25,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,9,29,21,32,,25,4,16
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,22,30,21,32,,25,5,20
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,44,28,21,32,,25,3,12
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 A,57,30,21,32,,25,5,20
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment A,80,31,21,32,,25,6,24
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-15,9.1,8.6,10.2,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.3,8.6,10.2,Y,9.3,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,9,8.9,8.6,10.2,,9.3,-0.40000000000000036,-4.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,22,9.2,8.6,10.2,,9.3,-0.10000000000000142,-1.1
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,44,9.3,8.6,10.2,,9.3,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 A,57,9.4,8.6,10.2,,9.3,0.09999999999999964,1.1
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment A,80,11,8.6,10.2,,9.3,1.6999999999999993,18.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-15,103,97,108,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,105,97,108,Y,105,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,9,105,97,108,,105,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,22,101,97,108,,105,-4,-3.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,44,101,97,108,,105,-4,-3.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 A,57,100,97,108,,105,-5,-4.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment A,80,99,97,108,,105,-6,-5.7
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-15,0.88,0.7,1.3,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.9,0.7,1.3,Y,0.9,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,9,0.88,0.7,1.3,,0.9,-0.020000000000000018,-2.2
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,22,0.85,0.7,1.3,,0.9,-0.050000000000000044,-5.6
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,44,0.92,0.7,1.3,,0.9,0.020000000000000018,2.2
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 A,57,0.91,0.7,1.3,,0.9,0.010000000000000009,1.1
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment A,80,1.05,0.7,1.3,,0.9,0.15000000000000002,16.7
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-15,107,70,99,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,150,70,99,Y,150,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 A,9,118,70,99,,150,-32,-21.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,22,141,70,99,,150,-9,-6
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,44,133,70,99,,150,-17,-11.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 A,57,129,70,99,,150,-21,-14
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment A,80,113,70,99,,150,-37,-24.7
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-15,278,0,250,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,264,0,250,Y,264,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,9,250,0,250,,264,-14,-5.3
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,22,243,0,250,,264,-21,-8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,44,287,0,250,,264,23,8.7
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 A,57,280,0,250,,264,16,6.1
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment A,80,293,0,250,,264,29,11
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-15,4,3.4,5,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4,3.4,5,Y,4,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,9,3.9,3.4,5,,4,-0.10000000000000009,-2.5
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,22,4.1,3.4,5,,4,0.09999999999999964,2.5
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,44,4.3,3.4,5,,4,0.2999999999999998,7.5
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 A,57,4.5,3.4,5,,4,0.5,12.5
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment A,80,4.3,3.4,5,,4,0.2999999999999998,7.5
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-15,141,136,145,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,142,136,145,Y,142,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,9,142,136,145,,142,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,22,140,136,145,,142,-2,-1.4
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,44,138,136,145,,142,-4,-2.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 A,57,138,136,145,,142,-4,-2.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment A,80,139,136,145,,142,-3,-2.1
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-15,0.5,0.3,1.2,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.4,0.3,1.2,Y,0.4,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,9,0.4,0.3,1.2,,0.4,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,22,0.5,0.3,1.2,,0.4,0.09999999999999998,25
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,44,0.5,0.3,1.2,,0.4,0.09999999999999998,25
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 A,57,0.4,0.3,1.2,,0.4,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment A,80,0.3,0.3,1.2,,0.4,-0.10000000000000003,-25
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-15,8.4,6.4,8.2,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,8.2,6.4,8.2,Y,8.2,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,9,7.4,6.4,8.2,,8.2,-0.7999999999999989,-9.8
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,22,8.2,6.4,8.2,,8.2,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,44,7.3,6.4,8.2,,8.2,-0.8999999999999995,-11
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 A,57,7.9,6.4,8.2,,8.2,-0.29999999999999893,-3.7
3A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment A,80,8,6.4,8.2,,8.2,-0.1999999999999993,-2.4
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-15,32.6,22.5,34.5,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,32.8,22.5,34.5,Y,32.8,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 A,9,31.4,22.5,34.5,,32.8,-1.3999999999999986,-4.3
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 A,22,34.2,22.5,34.5,,32.8,1.4000000000000057,4.3
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 8 A,44,34.3,22.5,34.5,,32.8,1.5,4.6
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 A,57,33.7,22.5,34.5,,32.8,0.9000000000000057,2.7
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment A,80,36.8,22.5,34.5,,32.8,4,12.2
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-15,1.14,0.8,1.2,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.13,0.8,1.2,Y,1.13,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 A,9,1.07,0.8,1.2,,1.13,-0.05999999999999983,-5.3
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 A,22,1.14,0.8,1.2,,1.13,0.010000000000000009,0.9
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 8 A,44,1.12,0.8,1.2,,1.13,-0.009999999999999787,-0.9
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 A,57,1.22,0.8,1.2,,1.13,0.09000000000000008,8
3A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment A,80,1.17,0.8,1.2,,1.13,0.040000000000000036,3.5
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-15,0.04,0,0.1,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.03,0,0.1,Y,0.03,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0.02,0,0.1,,0.03,-0.009999999999999998,-33.3
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0.03,0,0.1,,0.03,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,9,0.03,0,0.1,,0.03,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,22,0.04,0,0.1,,0.03,0.010000000000000002,33.3
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,44,0.03,0,0.1,,0.03,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 A,57,0.06,0,0.1,,0.03,0.03,100
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,End of Treatment A,80,0.06,0,0.1,,0.03,0.03,100
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-15,0.11,0,0.5,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.5,Y,0.1,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.12,0,0.5,,0.1,0.01999999999999999,20
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.16,0,0.5,,0.1,0.06,60
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,9,0.46,0,0.5,,0.1,0.36,360
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,22,0.12,0,0.5,,0.1,0.01999999999999999,20
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 8 A,44,0.57,0,0.5,,0.1,0.47,470
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 A,57,0.32,0,0.5,,0.1,0.22,220
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment A,80,0.68,0,0.5,,0.1,0.5800000000000001,580
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-15,5.18,4.5,6,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,5.04,4.5,6,Y,5.04,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,5.09,4.5,6,,5.04,0.04999999999999982,1
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,5.04,4.5,6,,5.04,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,9,4.78,4.5,6,,5.04,-0.2599999999999998,-5.2
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,22,4.96,4.5,6,,5.04,-0.08000000000000007,-1.6
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,44,4.88,4.5,6,,5.04,-0.16000000000000014,-3.2
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 A,57,4.91,4.5,6,,5.04,-0.1299999999999999,-2.6
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment A,80,4.87,4.5,6,,5.04,-0.16999999999999993,-3.4
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-15,41.9,41,53,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,40.6,41,53,Y,40.6,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,41.3,41,53,,40.6,0.6999999999999957,1.7
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,40.6,41,53,,40.6,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,9,38.9,41,53,,40.6,-1.7000000000000028,-4.2
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,22,40.7,41,53,,40.6,0.10000000000000142,0.2
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,44,39.3,41,53,,40.6,-1.3000000000000043,-3.2
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 A,57,39.3,41,53,,40.6,-1.3000000000000043,-3.2
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment A,80,37.8,41,53,,40.6,-2.8000000000000043,-6.9
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-15,13.5,13.5,17.5,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,12.8,13.5,17.5,Y,12.8,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,13,13.5,17.5,,12.8,0.1999999999999993,1.6
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,12.8,13.5,17.5,,12.8,0,0
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,9,12.2,13.5,17.5,,12.8,-0.6000000000000014,-4.7
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,22,12.4,13.5,17.5,,12.8,-0.40000000000000036,-3.1
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,44,12.2,13.5,17.5,,12.8,-0.6000000000000014,-4.7
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 A,57,12,13.5,17.5,,12.8,-0.8000000000000007,-6.3
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment A,80,11.7,13.5,17.5,,12.8,-1.1000000000000014,-8.6
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-15,1.25,1,4.8,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.03,1,4.8,Y,1.03,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.36,1,4.8,,1.03,-0.67,-65
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.27,1,4.8,,1.03,-0.76,-73.8
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,9,1.83,1,4.8,,1.03,0.8,77.7
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,22,1.23,1,4.8,,1.03,0.19999999999999996,19.4
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,44,1.52,1,4.8,,1.03,0.49,47.6
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 A,57,1.09,1,4.8,,1.03,0.06000000000000005,5.8
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment A,80,1.01,1,4.8,,1.03,-0.020000000000000018,-1.9
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-15,0.99,0.1,0.9,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.68,0.1,0.9,Y,0.68,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.76,0.1,0.9,,0.68,0.07999999999999996,11.8
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,1.04,0.1,0.9,,0.68,0.36,52.9
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,9,0.83,0.1,0.9,,0.68,0.1499999999999999,22.1
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,22,0.84,0.1,0.9,,0.68,0.15999999999999992,23.5
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,44,1.04,0.1,0.9,,0.68,0.36,52.9
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 A,57,1.01,0.1,0.9,,0.68,0.32999999999999996,48.5
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment A,80,0.96,0.1,0.9,,0.68,0.2799999999999999,41.2
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-15,6.33,1.8,7.7,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4.47,1.8,7.7,Y,4.47,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,6.52,1.8,7.7,,4.47,2.05,45.9
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,7.4,1.8,7.7,,4.47,2.9300000000000006,65.5
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,9,3.12,1.8,7.7,,4.47,-1.3499999999999996,-30.2
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,22,5.95,1.8,7.7,,4.47,1.4800000000000004,33.1
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,44,4.33,1.8,7.7,,4.47,-0.13999999999999968,-3.1
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 A,57,4.85,1.8,7.7,,4.47,0.3799999999999999,8.5
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment A,80,5.41,1.8,7.7,,4.47,0.9400000000000004,21
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-15,285,150,400,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,289,150,400,Y,289,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,273,150,400,,289,-16,-5.5
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,237,150,400,,289,-52,-18
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,9,207,150,400,,289,-82,-28.4
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,22,393,150,400,,289,104,36
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,44,244,150,400,,289,-45,-15.6
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 A,57,456,150,400,,289,167,57.8
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment A,80,444,150,400,,289,155,53.6
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-15,8.75,3.5,10.8,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,6.36,3.5,10.8,Y,6.36,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,7.82,3.5,10.8,,6.36,1.46,23
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,8.93,3.5,10.8,,6.36,2.5699999999999994,40.4
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,9,6.33,3.5,10.8,,6.36,-0.03000000000000025,-0.5
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,22,8.2,3.5,10.8,,6.36,1.839999999999999,28.9
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,44,7.53,3.5,10.8,,6.36,1.17,18.4
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 A,57,7.35,3.5,10.8,,6.36,0.9899999999999993,15.6
3A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment A,80,8.14,3.5,10.8,,6.36,1.7800000000000002,28
3A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-15,83.47,NA,NA,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,97.93,NA,NA,Y,97.93,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,22,90.59,NA,NA,,97.93,-7.340000000000003,-7.5
3A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 A,57,234.73,NA,NA,,97.93,136.79999999999998,139.7
3A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment A,80,323.02,NA,NA,,97.93,225.08999999999997,229.8
3A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-15,2.18,0.44,7.11,,NA,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.36,0.44,7.11,Y,1.36,NA,NA
3A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,22,0.68,0.44,7.11,,1.36,-0.68,-50
3A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 A,57,0.91,0.44,7.11,,1.36,-0.45000000000000007,-33.1
3A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,80,2.42,0.44,7.11,,1.36,1.0599999999999998,77.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Baseline,1,43,NA,NA,Y,43,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 2 Day 1 B,29,16,NA,NA,,43,-27,-62.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 3 Day 1 B,57,24,NA,NA,,43,-19,-44.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 4 Day 1 B,85,60,NA,NA,,43,17,39.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 6 Day 1 B,141,330,NA,NA,,43,287,667.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,End of Treatment B,149,369,NA,NA,,43,326,758.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,-24,36,3,61,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,32,3,61,Y,32,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,27,3,61,,32,-5,-15.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,16,35,3,61,,32,3,9.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,29,26,3,61,,32,-6,-18.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,57,27,3,61,,32,-5,-15.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 B,85,30,3,61,,32,-2,-6.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,85,30,3,61,,32,-2,-6.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 B,113,33,3,61,,32,1,3.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,113,33,3,61,,32,1,3.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,141,93,3,61,,32,61,190.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,-24,4.3,3.8,5.5,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Baseline,1,4.4,3.8,5.5,Y,4.4,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,4.3,3.8,5.5,,4.4,-0.10000000000000053,-2.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,16,4.4,3.8,5.5,,4.4,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,29,4.2,3.8,5.5,,4.4,-0.20000000000000018,-4.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,57,4.5,3.8,5.5,,4.4,0.09999999999999964,2.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 4 Day 1 B,85,4.5,3.8,5.5,,4.4,0.09999999999999964,2.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,85,4.5,3.8,5.5,,4.4,0.09999999999999964,2.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 5 Day 1 B,113,4.1,3.8,5.5,,4.4,-0.3000000000000007,-6.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,113,4.1,3.8,5.5,,4.4,-0.3000000000000007,-6.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),End of Treatment B,141,3.9,3.8,5.5,,4.4,-0.5000000000000004,-11.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,-24,76,33,98,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,78,33,98,Y,78,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,81,33,98,,78,3,3.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,16,88,33,98,,78,10,12.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,29,96,33,98,,78,18,23.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,57,106,33,98,,78,28,35.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 B,85,83,33,98,,78,5,6.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,85,83,33,98,,78,5,6.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 B,113,112,33,98,,78,34,43.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,113,112,33,98,,78,34,43.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,141,86,33,98,,78,8,10.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-24,47,5,38,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,33,5,38,Y,33,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,30,5,38,,33,-3,-9.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,16,36,5,38,,33,3,9.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,29,29,5,38,,33,-4,-12.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,57,46,5,38,,33,13,39.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 B,85,37,5,38,,33,4,12.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,85,37,5,38,,33,4,12.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 B,113,67,5,38,,33,34,103
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,113,67,5,38,,33,34,103
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,141,110,5,38,,33,77,233.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,,-24,10,7,25,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Baseline,1,9,7,25,Y,9,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 8 B,8,8,7,25,,9,-1,-11.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 15 B,16,10,7,25,,9,1,11.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 2 Day 1 B,29,18,7,25,,9,9,100
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 3 Day 1 B,57,9,7,25,,9,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 4 Day 1 B,85,18,7,25,,9,9,100
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,,85,18,7,25,,9,9,100
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 5 Day 1 B,113,20,7,25,,9,11,122.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,,113,20,7,25,,9,11,122.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,End of Treatment B,141,26,7,25,,9,17,188.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,,-24,24,21,31,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Baseline,1,24,21,31,Y,24,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,24,21,31,,24,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 15 B,16,26,21,31,,24,2,8.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 2 Day 1 B,29,24,21,31,,24,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 3 Day 1 B,57,22,21,31,,24,-2,-8.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 4 Day 1 B,85,25,21,31,,24,1,4.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,,85,25,21,31,,24,1,4.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 5 Day 1 B,113,21,21,31,,24,-3,-12.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,,113,21,21,31,,24,-3,-12.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,End of Treatment B,141,22,21,31,,24,-2,-8.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,-24,9.7,8.7,10.1,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Baseline,1,9.4,8.7,10.1,Y,9.4,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,9.6,8.7,10.1,,9.4,0.1999999999999993,2.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,16,9.5,8.7,10.1,,9.4,0.09999999999999964,1.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,29,8.8,8.7,10.1,,9.4,-0.5999999999999996,-6.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,57,9.4,8.7,10.1,,9.4,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 B,85,9.6,8.7,10.1,,9.4,0.1999999999999993,2.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,85,9.6,8.7,10.1,,9.4,0.1999999999999993,2.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 B,113,9,8.7,10.1,,9.4,-0.40000000000000036,-4.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,113,9,8.7,10.1,,9.4,-0.40000000000000036,-4.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),End of Treatment B,141,9.1,8.7,10.1,,9.4,-0.3000000000000007,-3.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,-24,101,99,107,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Baseline,1,103,99,107,Y,103,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,102,99,107,,103,-1,-1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,16,102,99,107,,103,-1,-1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,29,100,99,107,,103,-3,-2.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,57,99,99,107,,103,-4,-3.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 B,85,99,99,107,,103,-4,-3.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,85,99,99,107,,103,-4,-3.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 B,113,99,99,107,,103,-4,-3.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,113,99,99,107,,103,-4,-3.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),End of Treatment B,141,100,99,107,,103,-3,-2.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,-24,0.75,0.7,1.3,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Baseline,1,0.82,0.7,1.3,Y,0.82,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,0.83,0.7,1.3,,0.82,0.010000000000000009,1.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,16,0.85,0.7,1.3,,0.82,0.030000000000000027,3.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,29,0.83,0.7,1.3,,0.82,0.010000000000000009,1.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,57,0.89,0.7,1.3,,0.82,0.07000000000000006,8.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 B,85,1.03,0.7,1.3,,0.82,0.21000000000000008,25.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,85,1.03,0.7,1.3,,0.82,0.21000000000000008,25.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 B,113,1.11,0.7,1.3,,0.82,0.29000000000000015,35.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,113,1.11,0.7,1.3,,0.82,0.29000000000000015,35.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),End of Treatment B,141,0.89,0.7,1.3,,0.82,0.07000000000000006,8.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,,-24,95,63,130,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Baseline,1,118,63,130,Y,118,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 8 B,8,103,63,130,,118,-15,-12.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 15 B,16,110,63,130,,118,-8,-6.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 2 Day 1 B,29,96,63,130,,118,-22,-18.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 3 Day 1 B,57,101,63,130,,118,-17,-14.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 4 Day 1 B,85,112,63,130,,118,-6,-5.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,,85,112,63,130,,118,-6,-5.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 5 Day 1 B,113,101,63,130,,118,-17,-14.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,,113,101,63,130,,118,-17,-14.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,End of Treatment B,141,79,63,130,,118,-39,-33.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-24,288,100,210,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,198,100,210,Y,198,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,210,100,210,,198,12,6.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,16,205,100,210,,198,7,3.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,29,219,100,210,,198,21,10.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,57,368,100,210,,198,170,85.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 B,85,360,100,210,,198,162,81.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,85,360,100,210,,198,162,81.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 B,113,545,100,210,,198,347,175.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,113,545,100,210,,198,347,175.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,141,606,100,210,,198,408,206.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,-24,3.6,3.5,5.1,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Baseline,1,3.7,3.5,5.1,Y,3.7,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.2,3.5,5.1,,3.7,0.5,13.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,16,4.2,3.5,5.1,,3.7,0.5,13.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,29,4.1,3.5,5.1,,3.7,0.39999999999999947,10.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,57,4.3,3.5,5.1,,3.7,0.5999999999999996,16.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 B,85,4.6,3.5,5.1,,3.7,0.8999999999999995,24.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,85,4.6,3.5,5.1,,3.7,0.8999999999999995,24.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 B,113,4.2,3.5,5.1,,3.7,0.5,13.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,113,4.2,3.5,5.1,,3.7,0.5,13.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),End of Treatment B,141,4.7,3.5,5.1,,3.7,1,27
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,,-24,137,136,145,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Baseline,1,138,136,145,Y,138,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 8 B,8,137,136,145,,138,-1,-0.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 15 B,16,136,136,145,,138,-2,-1.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 2 Day 1 B,29,134,136,145,,138,-4,-2.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 3 Day 1 B,57,133,136,145,,138,-5,-3.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 4 Day 1 B,85,135,136,145,,138,-3,-2.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,,85,135,136,145,,138,-3,-2.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 5 Day 1 B,113,132,136,145,,138,-6,-4.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,,113,132,136,145,,138,-6,-4.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,End of Treatment B,141,131,136,145,,138,-7,-5.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,-24,0.4,0.1,1.4,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Baseline,1,0.6,0.1,1.4,Y,0.6,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.5,0.1,1.4,,0.6,-0.09999999999999998,-16.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,16,0.5,0.1,1.4,,0.6,-0.09999999999999998,-16.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,29,0.4,0.1,1.4,,0.6,-0.19999999999999996,-33.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,57,0.9,0.1,1.4,,0.6,0.30000000000000004,50
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 4 Day 1 B,85,0.4,0.1,1.4,,0.6,-0.19999999999999996,-33.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,85,0.4,0.1,1.4,,0.6,-0.19999999999999996,-33.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 5 Day 1 B,113,1,0.1,1.4,,0.6,0.4,66.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,113,1,0.1,1.4,,0.6,0.4,66.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,End of Treatment B,141,0.7,0.1,1.4,,0.6,0.09999999999999998,16.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,,-24,7,6.3,8.1,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Baseline,1,6.9,6.3,8.1,Y,6.9,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 8 B,8,7.1,6.3,8.1,,6.9,0.1999999999999993,2.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 15 B,16,7.2,6.3,8.1,,6.9,0.2999999999999998,4.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 2 Day 1 B,29,6.8,6.3,8.1,,6.9,-0.10000000000000053,-1.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 3 Day 1 B,57,7.2,6.3,8.1,,6.9,0.2999999999999998,4.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 4 Day 1 B,85,7.6,6.3,8.1,,6.9,0.6999999999999993,10.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,,85,7.6,6.3,8.1,,6.9,0.6999999999999993,10.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 5 Day 1 B,113,6.9,6.3,8.1,,6.9,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,,113,6.9,6.3,8.1,,6.9,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,End of Treatment B,141,6.1,6.3,8.1,,6.9,-0.8000000000000007,-11.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-24,23.9,25.5,36,Y,23.9,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-24,0.96,0.9,1.3,Y,0.96,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Baseline,-24,9.9,12.1,15.2,Y,9.9,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,,-24,0,0,0.1,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Baseline,1,0,0,0.1,Y,0,0,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 8 B,8,0,0,0.1,,0,0,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 15 B,16,0,0,0.1,,0,0,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 2 Day 1 B,29,0,0,0.1,,0,0,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 3 Day 1 B,57,0,0,0.1,,0,0,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 4 Day 1 B,85,0,0,0.1,,0,0,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,,85,0,0,0.1,,0,0,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 5 Day 1 B,113,0,0,0.1,,0,0,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,,113,0,0,0.1,,0,0,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,End of Treatment B,141,0.1,0,0.1,,0,0.1,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,,-24,0.2,0,0.4,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Baseline,1,0.2,0,0.4,Y,0.2,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.4,0,0.4,,0.2,0.2,100
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 15 B,16,0.6,0,0.4,,0.2,0.39999999999999997,200
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 2 Day 1 B,29,1.2,0,0.4,,0.2,1,500
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 3 Day 1 B,57,0.5,0,0.4,,0.2,0.3,150
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 4 Day 1 B,85,0,0,0.4,,0.2,-0.2,-100
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,,85,0,0,0.4,,0.2,-0.2,-100
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 5 Day 1 B,113,0.1,0,0.4,,0.2,-0.1,-50
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,,113,0.1,0,0.4,,0.2,-0.1,-50
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,End of Treatment B,141,0.4,0,0.4,,0.2,0.2,100
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),,-24,4.03,4,6,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Baseline,1,4.13,4,6,Y,4.13,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,4.25,4,6,,4.13,0.1200000000000001,2.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,16,4.08,4,6,,4.13,-0.04999999999999982,-1.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,29,3.9,4,6,,4.13,-0.22999999999999998,-5.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,57,4.36,4,6,,4.13,0.23000000000000043,5.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 B,85,4.6,4,6,,4.13,0.46999999999999975,11.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),,85,4.6,4,6,,4.13,0.46999999999999975,11.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 B,113,4.21,4,6,,4.13,0.08000000000000007,1.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),,113,4.21,4,6,,4.13,0.08000000000000007,1.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),End of Treatment B,141,3.96,4,6,,4.13,-0.16999999999999993,-4.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),,-24,38.1,43.5,48,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Baseline,1,37.5,43.5,48,Y,37.5,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,39,43.5,48,,37.5,1.5,4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,16,37.3,43.5,48,,37.5,-0.20000000000000284,-0.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,29,35.5,43.5,48,,37.5,-2,-5.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,57,39.3,43.5,48,,37.5,1.7999999999999972,4.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 B,85,41.4,43.5,48,,37.5,3.8999999999999986,10.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),,85,41.4,43.5,48,,37.5,3.8999999999999986,10.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 B,113,38.1,43.5,48,,37.5,0.6000000000000014,1.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),,113,38.1,43.5,48,,37.5,0.6000000000000014,1.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),End of Treatment B,141,36.3,43.5,48,,37.5,-1.2000000000000028,-3.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),,-24,13.1,13.9,16.3,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Baseline,1,13.1,13.9,16.3,Y,13.1,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,13.3,13.9,16.3,,13.1,0.20000000000000107,1.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,16,12.9,13.9,16.3,,13.1,-0.1999999999999993,-1.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,29,12.3,13.9,16.3,,13.1,-0.7999999999999989,-6.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,57,13.5,13.9,16.3,,13.1,0.40000000000000036,3.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 B,85,14.3,13.9,16.3,,13.1,1.200000000000001,9.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),,85,14.3,13.9,16.3,,13.1,1.200000000000001,9.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 B,113,13.1,13.9,16.3,,13.1,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),,113,13.1,13.9,16.3,,13.1,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),End of Treatment B,141,12.5,13.9,16.3,,13.1,-0.5999999999999996,-4.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,,-24,1.8,0.9,2.6,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Baseline,1,1.9,0.9,2.6,Y,1.9,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,1.8,0.9,2.6,,1.9,-0.09999999999999987,-5.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 15 B,16,2.1,0.9,2.6,,1.9,0.20000000000000018,10.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 2 Day 1 B,29,2.1,0.9,2.6,,1.9,0.20000000000000018,10.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 3 Day 1 B,57,2.1,0.9,2.6,,1.9,0.20000000000000018,10.5
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 4 Day 1 B,85,2.2,0.9,2.6,,1.9,0.30000000000000027,15.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,,85,2.2,0.9,2.6,,1.9,0.30000000000000027,15.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 5 Day 1 B,113,1.8,0.9,2.6,,1.9,-0.09999999999999987,-5.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,,113,1.8,0.9,2.6,,1.9,-0.09999999999999987,-5.3
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,End of Treatment B,141,2.2,0.9,2.6,,1.9,0.30000000000000027,15.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,,-24,0.6,0.1,0.9,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Baseline,1,0.6,0.1,0.9,Y,0.6,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 8 B,8,1,0.1,0.9,,0.6,0.4,66.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 15 B,16,1.3,0.1,0.9,,0.6,0.7000000000000001,116.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 2 Day 1 B,29,0.5,0.1,0.9,,0.6,-0.09999999999999998,-16.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 3 Day 1 B,57,0.5,0.1,0.9,,0.6,-0.09999999999999998,-16.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 4 Day 1 B,85,0.9,0.1,0.9,,0.6,0.30000000000000004,50
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,,85,0.9,0.1,0.9,,0.6,0.30000000000000004,50
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 5 Day 1 B,113,0.9,0.1,0.9,,0.6,0.30000000000000004,50
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,,113,0.9,0.1,0.9,,0.6,0.30000000000000004,50
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,End of Treatment B,141,0.6,0.1,0.9,,0.6,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,,-24,4,1.8,6.5,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Baseline,1,3.9,1.8,6.5,Y,3.9,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 8 B,8,3.9,1.8,6.5,,3.9,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 15 B,16,3.3,1.8,6.5,,3.9,-0.6000000000000001,-15.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 2 Day 1 B,29,3.9,1.8,6.5,,3.9,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 3 Day 1 B,57,4.4,1.8,6.5,,3.9,0.5000000000000004,12.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 4 Day 1 B,85,9.6,1.8,6.5,,3.9,5.699999999999999,146.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,,85,9.6,1.8,6.5,,3.9,5.699999999999999,146.2
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 5 Day 1 B,113,6.2,1.8,6.5,,3.9,2.3000000000000003,59
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,,113,6.2,1.8,6.5,,3.9,2.3000000000000003,59
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,End of Treatment B,141,7.4,1.8,6.5,,3.9,3.5000000000000004,89.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),,-24,250,150,450,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Baseline,1,206,150,450,Y,206,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,228,150,450,,206,22,10.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,16,197,150,450,,206,-9,-4.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,29,267,150,450,,206,61,29.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,57,211,150,450,,206,5,2.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 1 B,85,276,150,450,,206,70,34
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),,85,276,150,450,,206,70,34
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 5 Day 1 B,113,186,150,450,,206,-20,-9.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),,113,186,150,450,,206,-20,-9.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),End of Treatment B,141,140,150,450,,206,-66,-32
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,TESTR,Baseline,-24,7.1,181,758,Y,7.1,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,,-24,6.6,4,11,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Baseline,1,6.6,4,11,Y,6.6,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,7.1,4,11,,6.6,0.5,7.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 15 B,16,7.3,4,11,,6.6,0.7000000000000002,10.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 2 Day 1 B,29,7.9,4,11,,6.6,1.3000000000000007,19.7
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 3 Day 1 B,57,7.5,4,11,,6.6,0.9000000000000004,13.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 4 Day 1 B,85,12.8,4,11,,6.6,6.200000000000001,93.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,,85,12.8,4,11,,6.6,6.200000000000001,93.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 5 Day 1 B,113,9,4,11,,6.6,2.4000000000000004,36.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,,113,9,4,11,,6.6,2.4000000000000004,36.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,End of Treatment B,141,10.4,4,11,,6.6,3.8000000000000007,57.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,,-24,68.33,NA,NA,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Baseline,1,66.81,NA,NA,Y,66.81,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,29,34.14,NA,NA,,66.81,-32.67,-48.9
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 4 Day 1 B,85,189.83,NA,NA,,66.81,123.02000000000001,184.1
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 5 Day 1 B,113,295.81,NA,NA,,66.81,229,342.8
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,End of Treatment B,141,1178.51,NA,NA,,66.81,1111.7,1664
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-24,1.22,0.4,4,,NA,NA,NA
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.25,0.4,4,Y,1.25,0,0
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,1.28,0.4,4,,1.25,0.030000000000000027,2.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,16,1.45,0.4,4,,1.25,0.19999999999999996,16
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,29,1.02,0.4,4,,1.25,-0.22999999999999998,-18.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,57,1.42,0.4,4,,1.25,0.16999999999999993,13.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 B,85,1.08,0.4,4,,1.25,-0.16999999999999993,-13.6
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 B,113,1.22,0.4,4,,1.25,-0.030000000000000027,-2.4
3B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,141,1.9,0.4,4,,1.25,0.6499999999999999,52
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,,CTC,Baseline,1,8,NA,NA,Y,8,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,,CTC,Cycle 3 Day 1 C,88,5,NA,NA,,8,-3,-37.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,,CTC,Cycle 5 Day 1 C,144,16,NA,NA,,8,8,100
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,,CTC,Cycle 6 Day 1 C,172,39,NA,NA,,8,31,387.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,,CTC,Cycle 7 Day 1 C,214,63,NA,NA,,8,55,687.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),,-10,16,1,45,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,19,1,45,Y,19,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,21,1,45,,19,2,10.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,16,28,1,45,,19,9,47.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,20,1,45,,19,1,5.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,30,18,1,45,,19,-1,-5.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,37,17,1,45,,19,-2,-10.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 C,60,13,1,45,,19,-6,-31.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 C,88,18,1,45,,19,-1,-5.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 C,116,15,1,45,,19,-4,-21.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 C,144,15,1,45,,19,-4,-21.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 6 Day 1 C,186,19,1,45,,19,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 7 Day 1 C,214,14,1,45,,19,-5,-26.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,235,15,1,45,,19,-4,-21.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 C,316,23,1,45,,19,4,21.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),,-10,4,3.5,4.9,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Baseline,1,4.1,3.5,4.9,Y,4.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),I-P Lead In C,8,3.9,3.5,4.9,,4.1,-0.19999999999999973,-4.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),I-P Lead In C,16,3.9,3.5,4.9,,4.1,-0.19999999999999973,-4.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),I-P Lead In C,22,3.9,3.5,4.9,,4.1,-0.19999999999999973,-4.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,30,4.1,3.5,4.9,,4.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,37,4,3.5,4.9,,4.1,-0.09999999999999964,-2.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,60,3.9,3.5,4.9,,4.1,-0.19999999999999973,-4.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 1 C,88,4.1,3.5,4.9,,4.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 4 Day 1 C,116,3.8,3.5,4.9,,4.1,-0.2999999999999998,-7.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 5 Day 1 C,144,3.9,3.5,4.9,,4.1,-0.19999999999999973,-4.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 6 Day 1 C,186,3.8,3.5,4.9,,4.1,-0.2999999999999998,-7.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 7 Day 1 C,214,4,3.5,4.9,,4.1,-0.09999999999999964,-2.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),End of Treatment C,235,3.9,3.5,4.9,,4.1,-0.19999999999999973,-4.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Follow-up 110 C,316,3.9,3.5,4.9,,4.1,-0.19999999999999973,-4.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),,-10,46,38,126,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,50,38,126,Y,50,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,50,38,126,,50,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,16,47,38,126,,50,-3,-6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,51,38,126,,50,1,2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,30,50,38,126,,50,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,37,52,38,126,,50,2,4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,60,57,38,126,,50,7,14
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 C,88,55,38,126,,50,5,10
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 C,116,49,38,126,,50,-1,-2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 C,144,57,38,126,,50,7,14
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 6 Day 1 C,186,61,38,126,,50,11,22
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 7 Day 1 C,214,56,38,126,,50,6,12
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,235,55,38,126,,50,5,10
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 C,316,62,38,126,,50,12,24
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-10,20,1,35,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,21,1,35,Y,21,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,22,1,35,,21,1,4.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,16,27,1,35,,21,6,28.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,20,1,35,,21,-1,-4.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,30,20,1,35,,21,-1,-4.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,37,22,1,35,,21,1,4.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,60,18,1,35,,21,-3,-14.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 C,88,22,1,35,,21,1,4.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 C,116,18,1,35,,21,-3,-14.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 C,144,23,1,35,,21,2,9.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 6 Day 1 C,186,21,1,35,,21,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 7 Day 1 C,214,19,1,35,,21,-2,-9.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,235,20,1,35,,21,-1,-4.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 C,316,24,1,35,,21,3,14.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,,-10,30,6,23,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Baseline,1,22,6,23,Y,22,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,I-P Lead In C,8,15,6,23,,22,-7,-31.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,I-P Lead In C,16,17,6,23,,22,-5,-22.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,I-P Lead In C,22,18,6,23,,22,-4,-18.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Cycle 1 Day 1 C,30,22,6,23,,22,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Cycle 1 Day 8 C,37,22,6,23,,22,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Cycle 2 Day 1 C,60,16,6,23,,22,-6,-27.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Cycle 3 Day 1 C,88,17,6,23,,22,-5,-22.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Cycle 4 Day 1 C,116,19,6,23,,22,-3,-13.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Cycle 5 Day 1 C,144,16,6,23,,22,-6,-27.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Cycle 6 Day 1 C,186,20,6,23,,22,-2,-9.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Cycle 7 Day 1 C,214,15,6,23,,22,-7,-31.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,End of Treatment C,235,22,6,23,,22,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,BUN,Follow-up 110 C,316,16,6,23,,22,-6,-27.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,,-10,27.4,22,30,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Baseline,1,24.1,22,30,Y,24.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,I-P Lead In C,8,29.2,22,30,,24.1,5.099999999999998,21.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,I-P Lead In C,16,31,22,30,,24.1,6.899999999999999,28.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,I-P Lead In C,22,29.1,22,30,,24.1,5,20.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 1 Day 1 C,30,28.9,22,30,,24.1,4.799999999999997,19.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 1 Day 8 C,37,30.4,22,30,,24.1,6.299999999999997,26.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 2 Day 1 C,60,32.8,22,30,,24.1,8.699999999999996,36.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 3 Day 1 C,88,28.3,22,30,,24.1,4.199999999999999,17.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 4 Day 1 C,116,26.4,22,30,,24.1,2.299999999999997,9.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 5 Day 1 C,144,33,22,30,,24.1,8.899999999999999,36.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 6 Day 1 C,186,29,22,30,,24.1,4.899999999999999,20.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 7 Day 1 C,214,30.5,22,30,,24.1,6.399999999999999,26.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,End of Treatment C,235,30.8,22,30,,24.1,6.699999999999999,27.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Bicarbonate,Follow-up 110 C,316,30.3,22,30,,24.1,6.199999999999999,25.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),,-10,9.6,8.5,10.5,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Baseline,1,9.7,8.5,10.5,Y,9.7,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),I-P Lead In C,8,9.7,8.5,10.5,,9.7,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),I-P Lead In C,16,9.4,8.5,10.5,,9.7,-0.29999999999999893,-3.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),I-P Lead In C,22,9.2,8.5,10.5,,9.7,-0.5,-5.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,30,10,8.5,10.5,,9.7,0.3000000000000007,3.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,37,9.7,8.5,10.5,,9.7,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,60,9.7,8.5,10.5,,9.7,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 C,88,9.4,8.5,10.5,,9.7,-0.29999999999999893,-3.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 C,116,9.3,8.5,10.5,,9.7,-0.3999999999999986,-4.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 C,144,9.8,8.5,10.5,,9.7,0.10000000000000142,1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 6 Day 1 C,186,9.7,8.5,10.5,,9.7,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 7 Day 1 C,214,9.3,8.5,10.5,,9.7,-0.3999999999999986,-4.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),End of Treatment C,235,9.5,8.5,10.5,,9.7,-0.1999999999999993,-2.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Follow-up 110 C,316,9.9,8.5,10.5,,9.7,0.20000000000000107,2.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),,-10,105,96,108,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Baseline,1,107,96,108,Y,107,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),I-P Lead In C,8,103,96,108,,107,-4,-3.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),I-P Lead In C,16,98,96,108,,107,-9,-8.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),I-P Lead In C,22,103,96,108,,107,-4,-3.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,30,105,96,108,,107,-2,-1.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,37,104,96,108,,107,-3,-2.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,60,105,96,108,,107,-2,-1.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 C,88,104,96,108,,107,-3,-2.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 C,116,107,96,108,,107,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 C,144,104,96,108,,107,-3,-2.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 6 Day 1 C,186,106,96,108,,107,-1,-0.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 7 Day 1 C,214,102,96,108,,107,-5,-4.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),End of Treatment C,235,102,96,108,,107,-5,-4.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Follow-up 110 C,316,102,96,108,,107,-5,-4.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),,-10,1.14,0.7,1.3,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Baseline,1,1.13,0.7,1.3,Y,1.13,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),I-P Lead In C,8,1,0.7,1.3,,1.13,-0.1299999999999999,-11.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),I-P Lead In C,16,1,0.7,1.3,,1.13,-0.1299999999999999,-11.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),I-P Lead In C,22,1.05,0.7,1.3,,1.13,-0.07999999999999985,-7.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,30,1.1,0.7,1.3,,1.13,-0.029999999999999805,-2.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,37,1.02,0.7,1.3,,1.13,-0.10999999999999988,-9.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,60,0.98,0.7,1.3,,1.13,-0.1499999999999999,-13.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 C,88,0.94,0.7,1.3,,1.13,-0.18999999999999995,-16.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 C,116,1.01,0.7,1.3,,1.13,-0.11999999999999988,-10.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 C,144,0.95,0.7,1.3,,1.13,-0.17999999999999994,-15.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 6 Day 1 C,186,0.99,0.7,1.3,,1.13,-0.1399999999999999,-12.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 7 Day 1 C,214,0.93,0.7,1.3,,1.13,-0.19999999999999984,-17.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),End of Treatment C,235,0.97,0.7,1.3,,1.13,-0.15999999999999992,-14.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Follow-up 110 C,316,0.93,0.7,1.3,,1.13,-0.19999999999999984,-17.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,,-10,87,60,100,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Baseline,1,80,60,100,Y,80,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,I-P Lead In C,8,106,60,100,,80,26,32.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,I-P Lead In C,16,93,60,100,,80,13,16.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,I-P Lead In C,22,96,60,100,,80,16,20
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 1 Day 1 C,30,131,60,100,,80,51,63.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 1 Day 8 C,37,110,60,100,,80,30,37.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 2 Day 1 C,60,94,60,100,,80,14,17.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 3 Day 1 C,88,96,60,100,,80,16,20
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 4 Day 1 C,116,100,60,100,,80,20,25
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 5 Day 1 C,144,73,60,100,,80,-7,-8.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 6 Day 1 C,186,122,60,100,,80,42,52.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 7 Day 1 C,214,84,60,100,,80,4,5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,End of Treatment C,235,88,60,100,,80,8,10
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Glucose,Follow-up 110 C,316,129,60,100,,80,49,61.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-10,158,100,220,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,169,100,220,Y,169,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,172,100,220,,169,3,1.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,16,253,100,220,,169,84,49.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,210,100,220,,169,41,24.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,30,219,100,220,,169,50,29.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,37,231,100,220,,169,62,36.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 C,60,162,100,220,,169,-7,-4.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 C,88,178,100,220,,169,9,5.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 C,116,156,100,220,,169,-13,-7.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 C,144,203,100,220,,169,34,20.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 6 Day 1 C,186,193,100,220,,169,24,14.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 7 Day 1 C,214,180,100,220,,169,11,6.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,235,171,100,220,,169,2,1.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),,-10,3.7,3.5,5.2,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Baseline,1,4,3.5,5.2,Y,4,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),I-P Lead In C,8,3.9,3.5,5.2,,4,-0.10000000000000009,-2.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),I-P Lead In C,16,3.2,3.5,5.2,,4,-0.7999999999999998,-20
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),I-P Lead In C,22,3.8,3.5,5.2,,4,-0.20000000000000018,-5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,30,3.7,3.5,5.2,,4,-0.2999999999999998,-7.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,37,3.6,3.5,5.2,,4,-0.3999999999999999,-10
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,60,3.8,3.5,5.2,,4,-0.20000000000000018,-5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 C,88,3.7,3.5,5.2,,4,-0.2999999999999998,-7.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 C,116,3.8,3.5,5.2,,4,-0.20000000000000018,-5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 C,144,4.1,3.5,5.2,,4,0.09999999999999964,2.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 6 Day 1 C,186,4.2,3.5,5.2,,4,0.20000000000000018,5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 7 Day 1 C,214,3.7,3.5,5.2,,4,-0.2999999999999998,-7.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),End of Treatment C,235,3.8,3.5,5.2,,4,-0.20000000000000018,-5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Follow-up 110 C,316,3.6,3.5,5.2,,4,-0.3999999999999999,-10
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,,-10,143,135,145,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Baseline,1,144,135,145,Y,144,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,I-P Lead In C,8,143,135,145,,144,-1,-0.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,I-P Lead In C,16,132,135,145,,144,-12,-8.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,I-P Lead In C,22,143,135,145,,144,-1,-0.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 1 Day 1 C,30,144,135,145,,144,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 1 Day 8 C,37,143,135,145,,144,-1,-0.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 2 Day 1 C,60,144,135,145,,144,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 3 Day 1 C,88,143,135,145,,144,-1,-0.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 4 Day 1 C,116,143,135,145,,144,-1,-0.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 5 Day 1 C,144,141,135,145,,144,-3,-2.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 6 Day 1 C,186,143,135,145,,144,-1,-0.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 7 Day 1 C,214,141,135,145,,144,-3,-2.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,End of Treatment C,235,143,135,145,,144,-1,-0.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Sodium,Follow-up 110 C,316,141,135,145,,144,-3,-2.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,,-10,0.2,0.1,1.2,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Baseline,1,0.2,0.1,1.2,Y,0.2,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,I-P Lead In C,8,0.2,0.1,1.2,,0.2,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,I-P Lead In C,16,0.2,0.1,1.2,,0.2,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,I-P Lead In C,22,0.4,0.1,1.2,,0.2,0.2,100
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,30,0.3,0.1,1.2,,0.2,0.09999999999999998,50
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,37,0.3,0.1,1.2,,0.2,0.09999999999999998,50
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,60,0.3,0.1,1.2,,0.2,0.09999999999999998,50
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 3 Day 1 C,88,0.2,0.1,1.2,,0.2,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 4 Day 1 C,116,0.2,0.1,1.2,,0.2,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 5 Day 1 C,144,0.2,0.1,1.2,,0.2,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 6 Day 1 C,186,0.2,0.1,1.2,,0.2,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 7 Day 1 C,214,0.2,0.1,1.2,,0.2,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,End of Treatment C,235,0.3,0.1,1.2,,0.2,0.09999999999999998,50
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Follow-up 110 C,316,0.3,0.1,1.2,,0.2,0.09999999999999998,50
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,,-10,7.1,6,8.3,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Baseline,1,7.1,6,8.3,Y,7.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,I-P Lead In C,8,6.9,6,8.3,,7.1,-0.1999999999999993,-2.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,I-P Lead In C,16,6.7,6,8.3,,7.1,-0.39999999999999947,-5.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,I-P Lead In C,22,6.6,6,8.3,,7.1,-0.5,-7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 1 Day 1 C,30,7,6,8.3,,7.1,-0.09999999999999964,-1.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 1 Day 8 C,37,6.9,6,8.3,,7.1,-0.1999999999999993,-2.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 2 Day 1 C,60,6.8,6,8.3,,7.1,-0.2999999999999998,-4.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 3 Day 1 C,88,7.2,6,8.3,,7.1,0.10000000000000053,1.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 4 Day 1 C,116,6.7,6,8.3,,7.1,-0.39999999999999947,-5.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 5 Day 1 C,144,7,6,8.3,,7.1,-0.09999999999999964,-1.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 6 Day 1 C,186,7,6,8.3,,7.1,-0.09999999999999964,-1.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 7 Day 1 C,214,7,6,8.3,,7.1,-0.09999999999999964,-1.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,End of Treatment C,235,7.1,6,8.3,,7.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,Total Protein,Follow-up 110 C,316,7.2,6,8.3,,7.1,0.10000000000000053,1.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Chemistry,UREA,Follow-up 110 C,316,16,6,23,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),,-10,24.4,25.4,34.9,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,24.4,25.4,34.9,Y,24.4,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,8,25.3,25.4,34.9,,24.4,0.9000000000000021,3.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,16,25.8,25.4,34.9,,24.4,1.4000000000000021,5.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,22,24,25.4,34.9,,24.4,-0.3999999999999986,-1.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 1 C,30,26.5,25.4,34.9,,24.4,2.1000000000000014,8.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 C,37,25.9,25.4,34.9,,24.4,1.5,6.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 C,60,26,25.4,34.9,,24.4,1.6000000000000014,6.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 C,88,26.4,25.4,34.9,,24.4,2,8.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 C,116,27.4,25.4,34.9,,24.4,3,12.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 5 Day 1 C,144,25,25.4,34.9,,24.4,0.6000000000000014,2.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 6 Day 1 C,186,25.9,25.4,34.9,,24.4,1.5,6.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 7 Day 1 C,214,26.7,25.4,34.9,,24.4,2.3000000000000007,9.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment C,235,25.4,25.4,34.9,,24.4,1,4.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-10,0.9,2,3,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,0.9,2,3,Y,0.9,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,8,0.9,2,3,,0.9,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,16,0.9,2,3,,0.9,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,22,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 1 C,30,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 C,37,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 C,60,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 C,88,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 C,116,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 5 Day 1 C,144,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 6 Day 1 C,186,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 7 Day 1 C,214,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment C,235,1,2,3,,0.9,0.09999999999999998,11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),,-10,12.3,12.3,14.9,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Baseline,1,11.6,12.3,14.9,Y,11.6,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),I-P Lead In C,8,12.1,12.3,14.9,,11.6,0.5,4.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),I-P Lead In C,16,12.3,12.3,14.9,,11.6,0.7000000000000011,6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),I-P Lead In C,22,12.5,12.3,14.9,,11.6,0.9000000000000004,7.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 1 Day 1 C,30,12.5,12.3,14.9,,11.6,0.9000000000000004,7.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 C,37,12.9,12.3,14.9,,11.6,1.3000000000000007,11.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 C,60,12.4,12.3,14.9,,11.6,0.8000000000000007,6.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 C,88,12.9,12.3,14.9,,11.6,1.3000000000000007,11.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 4 Day 1 C,116,12.6,12.3,14.9,,11.6,1,8.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 5 Day 1 C,144,12.2,12.3,14.9,,11.6,0.5999999999999996,5.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 6 Day 1 C,186,12.5,12.3,14.9,,11.6,0.9000000000000004,7.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 7 Day 1 C,214,12.5,12.3,14.9,,11.6,0.9000000000000004,7.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),End of Treatment C,235,12.5,12.3,14.9,,11.6,0.9000000000000004,7.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,,-10,0,0,0.2,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,I-P Lead In C,8,0.1,0,0.2,,0,0.1,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,I-P Lead In C,16,0,0,0.2,,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.2,,0,0.1,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 1 C,30,0.1,0,0.2,,0,0.1,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 8 C,37,0.1,0,0.2,,0,0.1,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Cycle 2 Day 1 C,60,0,0,0.2,,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Cycle 3 Day 1 C,88,0,0,0.2,,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Cycle 4 Day 1 C,116,0,0,0.2,,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Cycle 5 Day 1 C,144,0,0,0.2,,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Cycle 6 Day 1 C,186,0,0,0.2,,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Cycle 7 Day 1 C,214,0,0,0.2,,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,End of Treatment C,235,0,0,0.2,,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Basophils,Follow-up 110 C,316,0,0,0.2,,0,0,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,,-10,0.2,0,0.6,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Baseline,1,0.1,0,0.6,Y,0.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,I-P Lead In C,8,0.2,0,0.6,,0.1,0.1,100
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,I-P Lead In C,16,0.1,0,0.6,,0.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,I-P Lead In C,22,0.1,0,0.6,,0.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 1 C,30,0.3,0,0.6,,0.1,0.19999999999999998,200
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 8 C,37,0.4,0,0.6,,0.1,0.30000000000000004,300
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 2 Day 1 C,60,0.3,0,0.6,,0.1,0.19999999999999998,200
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 3 Day 1 C,88,0.1,0,0.6,,0.1,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 4 Day 1 C,116,0.2,0,0.6,,0.1,0.1,100
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 5 Day 1 C,144,0.8,0,0.6,,0.1,0.7000000000000001,700
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 6 Day 1 C,186,2.9,0,0.6,,0.1,2.8,2800
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 7 Day 1 C,214,0.6,0,0.6,,0.1,0.5,500
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,End of Treatment C,235,0.3,0,0.6,,0.1,0.19999999999999998,200
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Eosinophils,Follow-up 110 C,316,0.7,0,0.6,,0.1,0.6,600
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),,-10,3.96,4.5,6,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Baseline,1,4.13,4.5,6,Y,4.13,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,4.12,4.5,6,,4.13,-0.009999999999999787,-0.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),I-P Lead In C,16,3.85,4.5,6,,4.13,-0.2799999999999998,-6.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.7,4.5,6,,4.13,-0.4299999999999997,-10.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,30,3.81,4.5,6,,4.13,-0.31999999999999984,-7.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,37,3.58,4.5,6,,4.13,-0.5499999999999998,-13.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,60,3.59,4.5,6,,4.13,-0.54,-13.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 C,88,3.91,4.5,6,,4.13,-0.21999999999999975,-5.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 C,116,3.67,4.5,6,,4.13,-0.45999999999999996,-11.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 C,144,4,4.5,6,,4.13,-0.1299999999999999,-3.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 6 Day 1 C,186,3.91,4.5,6,,4.13,-0.21999999999999975,-5.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 7 Day 1 C,214,3.79,4.5,6,,4.13,-0.33999999999999986,-8.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),End of Treatment C,235,3.83,4.5,6,,4.13,-0.2999999999999998,-7.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Follow-up 110 C,316,4,4.5,6,,4.13,-0.1299999999999999,-3.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),,-10,35,42,52,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Baseline,1,36.3,42,52,Y,36.3,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),I-P Lead In C,8,36,42,52,,36.3,-0.29999999999999716,-0.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),I-P Lead In C,16,33,42,52,,36.3,-3.299999999999997,-9.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),I-P Lead In C,22,32.3,42,52,,36.3,-4,-11
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,30,33.3,42,52,,36.3,-3,-8.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,37,31.8,42,52,,36.3,-4.4999999999999964,-12.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,60,32,42,52,,36.3,-4.299999999999997,-11.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 C,88,34.9,42,52,,36.3,-1.3999999999999986,-3.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 C,116,32.2,42,52,,36.3,-4.099999999999994,-11.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 C,144,34.9,42,52,,36.3,-1.3999999999999986,-3.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 6 Day 1 C,186,34.4,42,52,,36.3,-1.8999999999999986,-5.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 7 Day 1 C,214,33.3,42,52,,36.3,-3,-8.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),End of Treatment C,235,34,42,52,,36.3,-2.299999999999997,-6.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Follow-up 110 C,316,35.8,42,52,,36.3,-0.5,-1.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),,-10,12.2,13.9,16.3,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Baseline,1,12.3,13.9,16.3,Y,12.3,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,12.2,13.9,16.3,,12.3,-0.10000000000000142,-0.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),I-P Lead In C,16,11.5,13.9,16.3,,12.3,-0.8000000000000007,-6.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,10.9,13.9,16.3,,12.3,-1.4000000000000004,-11.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,30,11.3,13.9,16.3,,12.3,-1,-8.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,37,10.8,13.9,16.3,,12.3,-1.5,-12.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,60,10.7,13.9,16.3,,12.3,-1.6000000000000014,-13
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 C,88,11.7,13.9,16.3,,12.3,-0.6000000000000014,-4.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 C,116,10.9,13.9,16.3,,12.3,-1.4000000000000004,-11.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 C,144,11.7,13.9,16.3,,12.3,-0.6000000000000014,-4.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 6 Day 1 C,186,11.3,13.9,16.3,,12.3,-1,-8.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 7 Day 1 C,214,11.3,13.9,16.3,,12.3,-1,-8.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),End of Treatment C,235,11.4,13.9,16.3,,12.3,-0.9000000000000004,-7.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Follow-up 110 C,316,12.3,13.9,16.3,,12.3,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,,-10,1.9,1,4.5,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Baseline,1,1.5,1,4.5,Y,1.5,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,I-P Lead In C,8,1.3,1,4.5,,1.5,-0.19999999999999996,-13.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,I-P Lead In C,16,1.7,1,4.5,,1.5,0.19999999999999996,13.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,I-P Lead In C,22,1.4,1,4.5,,1.5,-0.10000000000000009,-6.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 1 C,30,2,1,4.5,,1.5,0.5,33.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 8 C,37,1.6,1,4.5,,1.5,0.10000000000000009,6.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 2 Day 1 C,60,1.4,1,4.5,,1.5,-0.10000000000000009,-6.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 3 Day 1 C,88,1.3,1,4.5,,1.5,-0.19999999999999996,-13.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 4 Day 1 C,116,1.3,1,4.5,,1.5,-0.19999999999999996,-13.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 5 Day 1 C,144,1.3,1,4.5,,1.5,-0.19999999999999996,-13.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 6 Day 1 C,186,1.9,1,4.5,,1.5,0.3999999999999999,26.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 7 Day 1 C,214,1.1,1,4.5,,1.5,-0.3999999999999999,-26.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,End of Treatment C,235,1.3,1,4.5,,1.5,-0.19999999999999996,-13.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Lymphocytes,Follow-up 110 C,316,0.7,1,4.5,,1.5,-0.8,-53.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,,-10,0.4,0.2,1,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Baseline,1,0.4,0.2,1,Y,0.4,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,I-P Lead In C,8,1.2,0.2,1,,0.4,0.7999999999999999,200
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,I-P Lead In C,16,2.9,0.2,1,,0.4,2.5,625
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,I-P Lead In C,22,1.1,0.2,1,,0.4,0.7000000000000001,175
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 1 C,30,2.5,0.2,1,,0.4,2.1,525
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 8 C,37,2.4,0.2,1,,0.4,2,500
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 2 Day 1 C,60,0.3,0.2,1,,0.4,-0.10000000000000003,-25
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 3 Day 1 C,88,0.1,0.2,1,,0.4,-0.30000000000000004,-75
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 4 Day 1 C,116,0.3,0.2,1,,0.4,-0.10000000000000003,-25
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 5 Day 1 C,144,0.3,0.2,1,,0.4,-0.10000000000000003,-25
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 6 Day 1 C,186,0.5,0.2,1,,0.4,0.09999999999999998,25
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 7 Day 1 C,214,0.4,0.2,1,,0.4,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,End of Treatment C,235,0.4,0.2,1,,0.4,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Monocytes,Follow-up 110 C,316,0.4,0.2,1,,0.4,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,,-10,3.1,1.9,8,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Baseline,1,2.9,1.9,8,Y,2.9,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,I-P Lead In C,8,3.97,1.9,8,,2.9,1.0700000000000003,36.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,I-P Lead In C,16,2.93,1.9,8,,2.9,0.03000000000000025,1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,I-P Lead In C,22,2.8,1.9,8,,2.9,-0.10000000000000009,-3.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 1 C,30,6.77,1.9,8,,2.9,3.8699999999999997,133.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 8 C,37,3.9,1.9,8,,2.9,1,34.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 2 Day 1 C,60,2.7,1.9,8,,2.9,-0.19999999999999973,-6.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 3 Day 1 C,88,2.7,1.9,8,,2.9,-0.19999999999999973,-6.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 4 Day 1 C,116,2.2,1.9,8,,2.9,-0.6999999999999997,-24.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 5 Day 1 C,144,3.7,1.9,8,,2.9,0.8000000000000003,27.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 6 Day 1 C,186,3.76,1.9,8,,2.9,0.8599999999999999,29.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 7 Day 1 C,214,3.9,1.9,8,,2.9,1,34.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,End of Treatment C,235,3.4,1.9,8,,2.9,0.5,17.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Neutrophils,Follow-up 110 C,316,2.6,1.9,8,,2.9,-0.2999999999999998,-10.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),,-10,214,150,450,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Baseline,1,206,150,450,Y,206,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),I-P Lead In C,8,213,150,450,,206,7,3.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),I-P Lead In C,16,137,150,450,,206,-69,-33.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),I-P Lead In C,22,233,150,450,,206,27,13.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,30,289,150,450,,206,83,40.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,37,169,150,450,,206,-37,-18
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,60,188,150,450,,206,-18,-8.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 1 C,88,203,150,450,,206,-3,-1.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 1 C,116,176,150,450,,206,-30,-14.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 5 Day 1 C,144,189,150,450,,206,-17,-8.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 6 Day 1 C,186,224,150,450,,206,18,8.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 7 Day 1 C,214,206,150,450,,206,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),End of Treatment C,235,217,150,450,,206,11,5.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Follow-up 110 C,316,213,150,450,,206,7,3.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,,-10,5.7,4.5,11,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Baseline,1,4.9,4.5,11,Y,4.9,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,I-P Lead In C,8,6.4,4.5,11,,4.9,1.5,30.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,I-P Lead In C,16,7.7,4.5,11,,4.9,2.8,57.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,I-P Lead In C,22,5.5,4.5,11,,4.9,0.5999999999999996,12.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 1 C,30,11.1,4.5,11,,4.9,6.199999999999999,126.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 8 C,37,8.3,4.5,11,,4.9,3.4000000000000004,69.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 2 Day 1 C,60,4.6,4.5,11,,4.9,-0.3000000000000007,-6.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 3 Day 1 C,88,4.4,4.5,11,,4.9,-0.5,-10.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 4 Day 1 C,116,3.9,4.5,11,,4.9,-1.0000000000000004,-20.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 5 Day 1 C,144,6.2,4.5,11,,4.9,1.2999999999999998,26.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 6 Day 1 C,186,9.4,4.5,11,,4.9,4.5,91.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 7 Day 1 C,214,6,4.5,11,,4.9,1.0999999999999996,22.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,End of Treatment C,235,5.4,4.5,11,,4.9,0.5,10.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Hematology,White Blood Cells,Follow-up 110 C,316,4.3,4.5,11,,4.9,-0.6000000000000005,-12.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,,-10,35.43,NA,NA,,NA,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Baseline,1,39.15,NA,NA,Y,39.15,0,0
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,I-P Lead In C,22,32.77,NA,NA,,39.15,-6.3799999999999955,-16.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,30,37.66,NA,NA,,39.15,-1.490000000000002,-3.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,60,32.78,NA,NA,,39.15,-6.3699999999999974,-16.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 3 Day 1 C,88,36.06,NA,NA,,39.15,-3.0899999999999963,-7.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 4 Day 1 C,116,25.42,NA,NA,,39.15,-13.729999999999997,-35.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 5 Day 1 C,144,38.99,NA,NA,,39.15,-0.1599999999999966,-0.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 6 Day 1 C,186,62.58,NA,NA,,39.15,23.43,59.8
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 7 Day 1 C,214,79.45,NA,NA,,39.15,40.300000000000004,102.9
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,End of Treatment C,235,85.98,NA,NA,,39.15,46.830000000000005,119.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Follow-up 110 C,316,157.9,NA,NA,,39.15,118.75,303.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,-10,0.86,0.4,4.2,Y,0.86,NA,NA
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,1.2,0.4,4.2,,0.86,0.33999999999999997,39.5
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,30,0.79,0.4,4.2,,0.86,-0.06999999999999995,-8.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,37,0.61,0.4,4.2,,0.86,-0.25,-29.1
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,60,1.18,0.4,4.2,,0.86,0.31999999999999995,37.2
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 C,88,1,0.4,4.2,,0.86,0.14,16.3
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 C,116,0.74,NA,NA,,0.86,-0.12,-14
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 C,144,1.21,0.4,4.2,,0.86,0.35,40.7
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 6 Day 1 C,186,1.14,0.4,4.2,,0.86,0.2799999999999999,32.6
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 7 Day 1 C,214,1.01,0.4,4.2,,0.86,0.15000000000000002,17.4
3C,C,CDX-301 + INO-5151 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,235,0.74,0.4,4.2,,0.86,-0.12,-14
4A,A,NKTR-214 + Nivolumab,N,N,,CTC,Baseline,1,4,NA,NA,Y,4,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 5 Day 1 A,85,1,NA,NA,,4,-3,-75
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-8,26,12,60,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,25,12,60,Y,25,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,75,12,60,,25,50,200
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,22,25,12,60,,25,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,30,29,12,60,,25,4,16
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 A,41,19,12,60,,25,-6,-24
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 8 A,48,28,12,60,,25,3,12
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,64,19,12,60,,25,-6,-24
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 8 A,72,20,12,60,,25,-5,-20
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 A,85,23,12,60,,25,-2,-8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 A,143,21,12,60,,25,-4,-16
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-8,4.1,3.5,4.8,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4.3,3.5,4.8,Y,4.3,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,3.7,3.5,4.8,,4.3,-0.5999999999999996,-14
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,22,4.1,3.5,4.8,,4.3,-0.20000000000000018,-4.7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,30,3.9,3.5,4.8,,4.3,-0.3999999999999999,-9.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 A,41,4,3.5,4.8,,4.3,-0.2999999999999998,-7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 8 A,48,3.8,3.5,4.8,,4.3,-0.5,-11.6
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment A,64,3.9,3.5,4.8,,4.3,-0.3999999999999999,-9.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 4 Day 8 A,72,4.4,3.5,4.8,,4.3,0.10000000000000053,2.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 5 Day 1 A,85,4.1,3.5,4.8,,4.3,-0.20000000000000018,-4.7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 A,143,4.3,3.5,4.8,,4.3,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-8,58,31,95,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,56,31,95,Y,56,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,75,31,95,,56,19,33.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,22,57,31,95,,56,1,1.8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,30,60,31,95,,56,4,7.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 A,41,54,31,95,,56,-2,-3.6
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 8 A,48,61,31,95,,56,5,8.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,64,49,31,95,,56,-7,-12.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 8 A,72,55,31,95,,56,-1,-1.8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 A,85,54,31,95,,56,-2,-3.6
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 A,143,74,31,95,,56,18,32.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-8,27,18,63,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,29,18,63,Y,29,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,56,18,63,,29,27,93.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,22,28,18,63,,29,-1,-3.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,30,25,18,63,,29,-4,-13.8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 A,41,24,18,63,,29,-5,-17.2
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 8 A,48,25,18,63,,29,-4,-13.8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,64,22,18,63,,29,-7,-24.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 8 A,72,26,18,63,,29,-3,-10.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 A,85,28,18,63,,29,-1,-3.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 A,143,25,18,63,,29,-4,-13.8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-8,10,6,22,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,12,6,22,Y,12,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,8,9,6,22,,12,-3,-25
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,22,12,6,22,,12,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 8 A,30,10,6,22,,12,-2,-16.7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 A,41,13,6,22,,12,1,8.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 8 A,48,12,6,22,,12,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,End of Treatment A,64,22,6,22,,12,10,83.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 4 Day 8 A,72,18,6,22,,12,6,50
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 5 Day 1 A,85,11,6,22,,12,-1,-8.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 A,143,11,6,22,,12,-1,-8.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-8,20,22,27,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,22,22,27,Y,22,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,27,22,27,,22,5,22.7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,22,21,22,27,,22,-1,-4.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,30,27,22,27,,22,5,22.7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 A,41,22,22,27,,22,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 8 A,48,26,22,27,,22,4,18.2
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment A,64,19,22,27,,22,-3,-13.6
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 4 Day 8 A,72,23,22,27,,22,1,4.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 5 Day 1 A,85,22,22,27,,22,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 A,143,25,22,27,,22,3,13.6
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-8,9,8.8,10.3,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.3,8.8,10.3,Y,9.3,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,9.2,8.8,10.3,,9.3,-0.10000000000000142,-1.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,22,9.2,8.8,10.3,,9.3,-0.10000000000000142,-1.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,30,9.3,8.8,10.3,,9.3,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 A,41,9.2,8.8,10.3,,9.3,-0.10000000000000142,-1.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 8 A,48,8.9,8.8,10.3,,9.3,-0.40000000000000036,-4.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment A,64,8.3,8.8,10.3,,9.3,-1,-10.8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 4 Day 8 A,72,9.3,8.8,10.3,,9.3,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 A,85,9.4,8.8,10.3,,9.3,0.09999999999999964,1.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 A,143,9.3,8.8,10.3,,9.3,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-8,107,97,108,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,108,97,108,Y,108,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,107,97,108,,108,-1,-0.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,22,106,97,108,,108,-2,-1.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,30,104,97,108,,108,-4,-3.7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 A,41,109,97,108,,108,1,0.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 8 A,48,109,97,108,,108,1,0.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment A,64,116,97,108,,108,8,7.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 4 Day 8 A,72,103,97,108,,108,-5,-4.6
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 A,85,105,97,108,,108,-3,-2.8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 A,143,100,97,108,,108,-8,-7.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-8,0.89,0.61,1.24,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.94,0.61,1.24,Y,0.94,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,1.06,0.61,1.24,,0.94,0.1200000000000001,12.8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,22,0.94,0.61,1.24,,0.94,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,30,1.11,0.61,1.24,,0.94,0.17000000000000015,18.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 A,41,1.04,0.61,1.24,,0.94,0.10000000000000009,10.6
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 8 A,48,1.1,0.61,1.24,,0.94,0.16000000000000014,17
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment A,64,2.21,0.61,1.24,,0.94,1.27,135.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 4 Day 8 A,72,1.46,0.61,1.24,,0.94,0.52,55.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 A,85,1.08,0.61,1.24,,0.94,0.14000000000000012,14.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 A,143,1.01,0.61,1.24,,0.94,0.07000000000000006,7.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-8,133,70,199,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,122,70,199,Y,122,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,22,138,70,199,,122,16,13.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,30,174,70,199,,122,52,42.6
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 A,41,135,70,199,,122,13,10.7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 8 A,48,116,70,199,,122,-6,-4.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment A,64,101,70,199,,122,-21,-17.2
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 4 Day 8 A,72,119,70,199,,122,-3,-2.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 5 Day 1 A,85,145,70,199,,122,23,18.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 A,143,118,70,199,,122,-4,-3.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-8,142,102,199,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,163,102,199,Y,163,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,8,207,102,199,,163,44,27
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,22,139,102,199,,163,-24,-14.7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,30,175,102,199,,163,12,7.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 A,41,133,102,199,,163,-30,-18.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 8 A,48,178,102,199,,163,15,9.2
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment A,64,163,102,199,,163,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 8 A,72,150,102,199,,163,-13,-8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 A,85,144,102,199,,163,-19,-11.7
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 A,143,160,102,199,,163,-3,-1.8
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-8,3.8,3.5,5.1,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4,3.5,5.1,Y,4,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,3.9,3.5,5.1,,4,-0.10000000000000009,-2.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,22,3.8,3.5,5.1,,4,-0.20000000000000018,-5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,30,3.9,3.5,5.1,,4,-0.10000000000000009,-2.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 A,41,3.9,3.5,5.1,,4,-0.10000000000000009,-2.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 8 A,48,4,3.5,5.1,,4,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment A,64,4.4,3.5,5.1,,4,0.40000000000000036,10
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 4 Day 8 A,72,4.2,3.5,5.1,,4,0.20000000000000018,5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 A,85,3.6,3.5,5.1,,4,-0.3999999999999999,-10
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 A,143,3.9,3.5,5.1,,4,-0.10000000000000009,-2.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-8,140,135,145,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,140,135,145,Y,140,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,8,145,135,145,,140,5,3.6
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,22,137,135,145,,140,-3,-2.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,30,143,135,145,,140,3,2.1
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 A,41,140,135,145,,140,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 8 A,48,140,135,145,,140,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment A,64,140,135,145,,140,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 4 Day 8 A,72,136,135,145,,140,-4,-2.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 5 Day 1 A,85,136,135,145,,140,-4,-2.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 A,143,133,135,145,,140,-7,-5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-8,0.5,0.2,1.3,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.5,0.2,1.3,Y,0.5,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.7,0.2,1.3,,0.5,0.19999999999999996,40
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,22,0.6,0.2,1.3,,0.5,0.09999999999999998,20
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,30,0.7,0.2,1.3,,0.5,0.19999999999999996,40
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 A,41,0.7,0.2,1.3,,0.5,0.19999999999999996,40
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 8 A,48,0.5,0.2,1.3,,0.5,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment A,64,0.4,0.2,1.3,,0.5,-0.09999999999999998,-20
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 4 Day 8 A,72,0.4,0.2,1.3,,0.5,-0.09999999999999998,-20
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 5 Day 1 A,85,0.4,0.2,1.3,,0.5,-0.09999999999999998,-20
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 A,143,0.4,0.2,1.3,,0.5,-0.09999999999999998,-20
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-8,6.7,6,8.4,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.8,6,8.4,Y,6.8,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,8,6.5,6,8.4,,6.8,-0.2999999999999998,-4.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,22,7.1,6,8.4,,6.8,0.2999999999999998,4.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,30,6.7,6,8.4,,6.8,-0.09999999999999964,-1.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 A,41,6.9,6,8.4,,6.8,0.10000000000000053,1.5
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 8 A,48,6.3,6,8.4,,6.8,-0.5,-7.4
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment A,64,6.4,6,8.4,,6.8,-0.39999999999999947,-5.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 4 Day 8 A,72,7.5,6,8.4,,6.8,0.7000000000000002,10.3
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 5 Day 1 A,85,7.2,6,8.4,,6.8,0.40000000000000036,5.9
4A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 A,143,7.1,6,8.4,,6.8,0.2999999999999998,4.4
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-8,29.6,22.6,34.5,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,28.6,22.6,34.5,Y,28.6,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 A,8,27.5,22.6,34.5,,28.6,-1.1000000000000014,-3.8
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 A,22,30.1,22.6,34.5,,28.6,1.5,5.2
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 8 A,30,28.6,22.6,34.5,,28.6,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 A,41,29.2,22.6,34.5,,28.6,0.5999999999999979,2.1
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 8 A,48,27.4,22.6,34.5,,28.6,-1.2000000000000028,-4.2
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 A,64,30.1,22.6,34.5,,28.6,1.5,5.2
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment A,64,30.1,22.6,34.5,,28.6,1.5,5.2
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 8 A,72,30.1,22.6,34.5,,28.6,1.5,5.2
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Follow-up 110 A,143,30.6,22.6,34.5,,28.6,2,7
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-8,1,0.9,1.3,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1,0.9,1.3,Y,1,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 A,8,1.1,0.9,1.3,,1,0.10000000000000009,10
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 A,22,1.1,0.9,1.3,,1,0.10000000000000009,10
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 8 A,30,1.1,0.9,1.3,,1,0.10000000000000009,10
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 A,41,1.1,0.9,1.3,,1,0.10000000000000009,10
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 8 A,48,1.1,0.9,1.3,,1,0.10000000000000009,10
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 A,64,1.1,0.9,1.3,,1,0.10000000000000009,10
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment A,64,1.1,0.9,1.3,,1,0.10000000000000009,10
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 8 A,72,1.1,0.9,1.3,,1,0.10000000000000009,10
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Follow-up 110 A,143,1,0.9,1.3,,1,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-8,13.1,NA,NA,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.4,NA,NA,Y,12.4,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 A,8,13.4,NA,NA,,12.4,1,8.1
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 A,22,13.3,NA,NA,,12.4,0.9000000000000004,7.3
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 8 A,30,13.7,NA,NA,,12.4,1.299999999999999,10.5
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 A,41,13.8,NA,NA,,12.4,1.4000000000000004,11.3
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 8 A,48,13.6,NA,NA,,12.4,1.1999999999999993,9.7
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 4 Day 1 A,64,13.6,NA,NA,,12.4,1.1999999999999993,9.7
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment A,64,13.6,NA,NA,,12.4,1.1999999999999993,9.7
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 4 Day 8 A,72,13.6,NA,NA,,12.4,1.1999999999999993,9.7
4A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Follow-up 110 A,143,13.2,NA,NA,,12.4,0.7999999999999989,6.5
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-8,0.03,0,0.1,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.01,0,0.1,Y,0.01,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0.02,0,0.1,,0.01,0.01,100
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0.01,0,0.1,,0.01,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,8,0.02,0,0.1,,0.01,0.01,100
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,22,0.04,0,0.1,,0.01,0.03,300
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,30,0.03,0,0.1,,0.01,0.019999999999999997,200
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 A,41,0.05,0,0.1,,0.01,0.04,400
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 8 A,48,0.04,0,0.1,,0.01,0.03,300
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 4 Day 1 A,64,0.03,0,0.1,,0.01,0.019999999999999997,200
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,End of Treatment A,64,0.03,0,0.1,,0.01,0.019999999999999997,200
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 4 Day 8 A,72,0.02,0,0.1,,0.01,0.01,100
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 5 Day 1 A,85,0.02,0,0.1,,0.01,0.01,100
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 A,143,0.03,0,0.1,,0.01,0.019999999999999997,200
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-8,0.1,0,0.4,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.15,0,0.4,Y,0.15,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.13,0,0.4,,0.15,-0.01999999999999999,-13.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.17,0,0.4,,0.15,0.020000000000000018,13.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.69,0,0.4,,0.15,0.5399999999999999,360
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,22,0.2,0,0.4,,0.15,0.05000000000000002,33.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 8 A,30,3.14,0,0.4,,0.15,2.99,1993.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 A,41,0.32,0,0.4,,0.15,0.17,113.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 8 A,48,3.68,0,0.4,,0.15,3.5300000000000002,2353.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 4 Day 1 A,64,0.35,0,0.4,,0.15,0.19999999999999998,133.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment A,64,0.35,0,0.4,,0.15,0.19999999999999998,133.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 4 Day 8 A,72,1.1,0,0.4,,0.15,0.9500000000000001,633.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 5 Day 1 A,85,0.5,0,0.4,,0.15,0.35,233.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 A,143,0.28,0,0.4,,0.15,0.13000000000000003,86.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-8,4.63,4.4,5.9,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.66,4.4,5.9,Y,4.66,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,4.4,4.4,5.9,,4.66,-0.2599999999999998,-5.6
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,4.58,4.4,5.9,,4.66,-0.08000000000000007,-1.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,4.04,4.4,5.9,,4.66,-0.6200000000000001,-13.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,22,4.16,4.4,5.9,,4.66,-0.5,-10.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,30,3.72,4.4,5.9,,4.66,-0.94,-20.2
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 A,41,3.74,4.4,5.9,,4.66,-0.9199999999999999,-19.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 8 A,48,3.51,4.4,5.9,,4.66,-1.1500000000000004,-24.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 A,64,3.12,4.4,5.9,,4.66,-1.54,-33
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment A,64,3.12,4.4,5.9,,4.66,-1.54,-33
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 8 A,72,3.58,4.4,5.9,,4.66,-1.08,-23.2
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 A,85,3.34,4.4,5.9,,4.66,-1.3200000000000003,-28.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 A,143,3.87,4.4,5.9,,4.66,-0.79,-17
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-8,41.4,41,53,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,42,41,53,Y,42,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,39.7,41,53,,42,-2.299999999999997,-5.5
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,40.8,41,53,,42,-1.2000000000000028,-2.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,37.5,41,53,,42,-4.5,-10.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,22,37.8,41,53,,42,-4.200000000000003,-10
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,30,33.6,41,53,,42,-8.399999999999999,-20
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 A,41,33.7,41,53,,42,-8.299999999999997,-19.8
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 8 A,48,32,41,53,,42,-10,-23.8
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 A,64,28.8,41,53,,42,-13.2,-31.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment A,64,28.8,41,53,,42,-13.2,-31.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 8 A,72,32.8,41,53,,42,-9.200000000000003,-21.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 A,85,30.2,41,53,,42,-11.8,-28.1
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 A,143,35.6,41,53,,42,-6.399999999999999,-15.2
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-8,13.9,13.6,17.5,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,13.9,13.6,17.5,Y,13.9,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,13.3,13.6,17.5,,13.9,-0.5999999999999996,-4.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,13.7,13.6,17.5,,13.9,-0.20000000000000107,-1.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,11.9,13.6,17.5,,13.9,-2,-14.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,22,12.4,13.6,17.5,,13.9,-1.5,-10.8
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,30,10.9,13.6,17.5,,13.9,-3,-21.6
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 A,41,11,13.6,17.5,,13.9,-2.9000000000000004,-20.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 8 A,48,10.6,13.6,17.5,,13.9,-3.3000000000000007,-23.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 A,64,9.4,13.6,17.5,,13.9,-4.5,-32.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment A,64,9.4,13.6,17.5,,13.9,-4.5,-32.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 8 A,72,10.9,13.6,17.5,,13.9,-3,-21.6
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 A,85,10.3,13.6,17.5,,13.9,-3.5999999999999996,-25.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 A,143,11.6,13.6,17.5,,13.9,-2.3000000000000007,-16.5
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-8,2.18,1,3.4,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,2.1,1,3.4,Y,2.1,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.86,1,3.4,,2.1,-1.2400000000000002,-59
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.39,1,3.4,,2.1,-1.71,-81.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,3.7,1,3.4,,2.1,1.6,76.2
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,22,2.31,1,3.4,,2.1,0.20999999999999996,10
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,30,3.84,1,3.4,,2.1,1.7399999999999998,82.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 A,41,1.92,1,3.4,,2.1,-0.18000000000000016,-8.6
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 8 A,48,4.77,1,3.4,,2.1,2.6699999999999995,127.1
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 4 Day 1 A,64,1.85,1,3.4,,2.1,-0.25,-11.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment A,64,1.85,1,3.4,,2.1,-0.25,-11.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 4 Day 8 A,72,2.36,1,3.4,,2.1,0.2599999999999998,12.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 5 Day 1 A,85,2.25,1,3.4,,2.1,0.1499999999999999,7.1
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 A,143,1.66,1,3.4,,2.1,-0.44000000000000017,-21
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-8,0.41,0.2,0.8,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.47,0.2,0.8,Y,0.47,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.49,0.2,0.8,,0.47,0.020000000000000018,4.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.75,0.2,0.8,,0.47,0.28,59.6
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,8,0.82,0.2,0.8,,0.47,0.35,74.5
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,22,0.44,0.2,0.8,,0.47,-0.02999999999999997,-6.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,30,0.76,0.2,0.8,,0.47,0.29000000000000004,61.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 A,41,0.4,0.2,0.8,,0.47,-0.06999999999999995,-14.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 8 A,48,0.8,0.2,0.8,,0.47,0.33000000000000007,70.2
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 4 Day 1 A,64,0.4,0.2,0.8,,0.47,-0.06999999999999995,-14.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment A,64,0.4,0.2,0.8,,0.47,-0.06999999999999995,-14.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 4 Day 8 A,72,0.51,0.2,0.8,,0.47,0.040000000000000036,8.5
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 5 Day 1 A,85,0.37,0.2,0.8,,0.47,-0.09999999999999998,-21.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 A,143,0.45,0.2,0.8,,0.47,-0.019999999999999962,-4.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-8,2.97,1.8,6.8,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.55,1.8,6.8,Y,3.55,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,4.09,1.8,6.8,,3.55,0.54,15.2
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,5.5,1.8,6.8,,3.55,1.9500000000000002,54.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,8,3.15,1.8,6.8,,3.55,-0.3999999999999999,-11.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,22,3.24,1.8,6.8,,3.55,-0.3099999999999996,-8.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,30,2.06,1.8,6.8,,3.55,-1.4899999999999998,-42
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 A,41,3.53,1.8,6.8,,3.55,-0.020000000000000018,-0.6
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 8 A,48,2.29,1.8,6.8,,3.55,-1.2599999999999998,-35.5
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 4 Day 1 A,64,3.93,1.8,6.8,,3.55,0.38000000000000034,10.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment A,64,3.93,1.8,6.8,,3.55,0.38000000000000034,10.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 4 Day 8 A,72,3.42,1.8,6.8,,3.55,-0.1299999999999999,-3.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 5 Day 1 A,85,4.57,1.8,6.8,,3.55,1.0200000000000005,28.7
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 A,143,3.65,1.8,6.8,,3.55,0.10000000000000009,2.8
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-8,132,140,450,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,135,140,450,Y,135,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,120,140,450,,135,-15,-11.1
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,110,140,450,,135,-25,-18.5
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,113,140,450,,135,-22,-16.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,22,207,140,450,,135,72,53.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,30,117,140,450,,135,-18,-13.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 A,41,189,140,450,,135,54,40
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 8 A,48,119,140,450,,135,-16,-11.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 4 Day 1 A,64,132,140,450,,135,-3,-2.2
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment A,64,132,140,450,,135,-3,-2.2
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 4 Day 8 A,72,141,140,450,,135,6,4.4
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 5 Day 1 A,85,151,140,450,,135,16,11.9
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 A,143,128,140,450,,135,-7,-5.2
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,TESTR,Baseline,-8,37,240,871,Y,37,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-8,5.7,3.4,10,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,6.3,3.4,10,Y,6.3,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,5.6,3.4,10,,6.3,-0.7000000000000002,-11.1
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,6.9,3.4,10,,6.3,0.6000000000000005,9.5
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,8.4,3.4,10,,6.3,2.1000000000000005,33.3
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,22,6.3,3.4,10,,6.3,0,0
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,30,9.9,3.4,10,,6.3,3.6000000000000005,57.1
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 A,41,6.2,3.4,10,,6.3,-0.09999999999999964,-1.6
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 8 A,48,11.6,3.4,10,,6.3,5.3,84.1
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 4 Day 1 A,64,6.6,3.4,10,,6.3,0.2999999999999998,4.8
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment A,64,6.6,3.4,10,,6.3,0.2999999999999998,4.8
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 4 Day 8 A,72,7.4,3.4,10,,6.3,1.1000000000000005,17.5
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 5 Day 1 A,85,7.8,3.4,10,,6.3,1.5,23.8
4A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 A,143,6.1,3.4,10,,6.3,-0.20000000000000018,-3.2
4A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-8,29.21,NA,NA,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,32.7,NA,NA,Y,32.7,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,22,30.29,NA,NA,,32.7,-2.4100000000000037,-7.4
4A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 A,41,35.06,NA,NA,,32.7,2.3599999999999994,7.2
4A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 4 Day 1 A,64,32.37,NA,NA,,32.7,-0.3300000000000054,-1
4A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment A,64,32.37,NA,NA,,32.7,-0.3300000000000054,-1
4A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 5 Day 1 A,85,40.44,NA,NA,,32.7,7.739999999999995,23.7
4A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 A,143,43.99,NA,NA,,32.7,11.29,34.5
4A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-8,0.56,0.45,4.12,,NA,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.26,0.45,4.12,Y,1.26,NA,NA
4A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,22,0.53,0.45,4.12,,1.26,-0.73,-57.9
4A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 A,41,0.14,0.45,4.12,,1.26,-1.12,-88.9
4A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 A,64,1.1,0.45,4.12,,1.26,-0.15999999999999992,-12.7
4A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,64,1.1,0.45,4.12,,1.26,-0.15999999999999992,-12.7
4A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 A,85,1.54,0.45,4.12,,1.26,0.28,22.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Baseline,1,4,NA,NA,Y,4,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 3 Day 1 B,57,4,NA,NA,,4,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 4 Day 1 B,87,10,NA,NA,,4,6,150
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,End of Treatment B,110,21,NA,NA,,4,17,425
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-7,17,0,55,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,12,0,55,Y,12,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,16,0,55,,12,4,33.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,15,19,0,55,,12,7,58.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,29,18,0,55,,12,6,50
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,57,22,0,55,,12,10,83.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 B,87,17,0,55,,12,5,41.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,110,16,0,55,,12,4,33.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 B,194,13,0,55,,12,1,8.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-7,4.2,3.8,5,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4,3.8,5,Y,4,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,4.1,3.8,5,,4,0.09999999999999964,2.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,15,4.1,3.8,5,,4,0.09999999999999964,2.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,29,4.1,3.8,5,,4,0.09999999999999964,2.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,57,4.1,3.8,5,,4,0.09999999999999964,2.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 4 Day 1 B,87,4.2,3.8,5,,4,0.20000000000000018,5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment B,110,4.1,3.8,5,,4,0.09999999999999964,2.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 B,194,3.8,3.8,5,,4,-0.20000000000000018,-5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-7,132,0,130,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,126,0,130,Y,126,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,123,0,130,,126,-3,-2.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,15,119,0,130,,126,-7,-5.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,29,111,0,130,,126,-15,-11.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,57,127,0,130,,126,1,0.8
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 B,87,150,0,130,,126,24,19
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,110,159,0,130,,126,33,26.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 B,194,171,0,130,,126,45,35.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-7,13,0,37,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,12,0,37,Y,12,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,15,0,37,,12,3,25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,15,17,0,37,,12,5,41.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,29,15,0,37,,12,3,25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,57,15,0,37,,12,3,25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 B,87,14,0,37,,12,2,16.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,110,13,0,37,,12,1,8.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 B,194,13,0,37,,12,1,8.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-7,18,6,20,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Baseline,1,13,6,20,Y,13,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 B,8,13,6,20,,13,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 15 B,15,15,6,20,,13,2,15.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 B,29,13,6,20,,13,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 B,57,18,6,20,,13,5,38.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 4 Day 1 B,87,19,6,20,,13,6,46.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,End of Treatment B,110,17,6,20,,13,4,30.8
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 B,194,16,6,20,,13,3,23.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-7,29,18,29,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,24,18,29,Y,24,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,29,18,29,,24,5,20.8
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 15 B,15,27,18,29,,24,3,12.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 B,29,22,18,29,,24,-2,-8.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 B,57,23,18,29,,24,-1,-4.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 4 Day 1 B,87,26,18,29,,24,2,8.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment B,110,28,18,29,,24,4,16.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 B,194,26,18,29,,24,2,8.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-7,9.1,8.5,10.5,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9,8.5,10.5,Y,9,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,9.1,8.5,10.5,,9,0.09999999999999964,1.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,15,9.2,8.5,10.5,,9,0.1999999999999993,2.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,29,9.1,8.5,10.5,,9,0.09999999999999964,1.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,57,8.9,8.5,10.5,,9,-0.09999999999999964,-1.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 B,87,9.5,8.5,10.5,,9,0.5,5.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment B,110,8.8,8.5,10.5,,9,-0.1999999999999993,-2.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 B,194,8.8,8.5,10.5,,9,-0.1999999999999993,-2.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-7,106,98,109,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,107,98,109,Y,107,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,106,98,109,,107,-1,-0.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,15,105,98,109,,107,-2,-1.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,29,107,98,109,,107,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,57,106,98,109,,107,-1,-0.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 B,87,106,98,109,,107,-1,-0.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment B,110,105,98,109,,107,-2,-1.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 B,194,106,98,109,,107,-1,-0.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-7,0.8,0.6,1.3,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.7,0.6,1.3,Y,0.7,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,0.8,0.6,1.3,,0.7,0.10000000000000009,14.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,15,0.8,0.6,1.3,,0.7,0.10000000000000009,14.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,29,0.7,0.6,1.3,,0.7,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,57,0.8,0.6,1.3,,0.7,0.10000000000000009,14.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 B,87,0.8,0.6,1.3,,0.7,0.10000000000000009,14.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment B,110,0.8,0.6,1.3,,0.7,0.10000000000000009,14.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 B,194,0.8,0.6,1.3,,0.7,0.10000000000000009,14.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-7,120,70,140,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,89,70,140,Y,89,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 B,8,100,70,140,,89,11,12.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 15 B,15,109,70,140,,89,20,22.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 B,29,98,70,140,,89,9,10.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 B,57,131,70,140,,89,42,47.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 4 Day 1 B,87,107,70,140,,89,18,20.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,End of Treatment B,110,137,70,140,,89,48,53.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 B,194,109,70,140,,89,20,22.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-7,187,130,250,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,206,130,250,Y,206,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,190,130,250,,206,-16,-7.8
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,15,211,130,250,,206,5,2.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,29,206,130,250,,206,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,57,189,130,250,,206,-17,-8.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 B,87,247,130,250,,206,41,19.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,110,240,130,250,,206,34,16.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-7,4.6,3.5,5.1,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,3.8,3.5,5.1,Y,3.8,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.5,3.5,5.1,,3.8,0.7000000000000002,18.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,15,4.8,3.5,5.1,,3.8,1,26.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,29,4.3,3.5,5.1,,3.8,0.5,13.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,57,4.1,3.5,5.1,,3.8,0.2999999999999998,7.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 B,87,4.9,3.5,5.1,,3.8,1.1000000000000005,28.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment B,110,4.5,3.5,5.1,,3.8,0.7000000000000002,18.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 B,194,4.1,3.5,5.1,,3.8,0.2999999999999998,7.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-7,143,133,143,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,141,133,143,Y,141,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 B,8,142,133,143,,141,1,0.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 15 B,15,141,133,143,,141,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 B,29,140,133,143,,141,-1,-0.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 B,57,139,133,143,,141,-2,-1.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 4 Day 1 B,87,142,133,143,,141,1,0.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,End of Treatment B,110,142,133,143,,141,1,0.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 B,194,139,133,143,,141,-2,-1.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-7,0.4,0,1.2,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.4,0,1.2,Y,0.4,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.3,0,1.2,,0.4,-0.10000000000000003,-25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,15,0.3,0,1.2,,0.4,-0.10000000000000003,-25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,29,0.3,0,1.2,,0.4,-0.10000000000000003,-25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,57,0.2,0,1.2,,0.4,-0.2,-50
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 4 Day 1 B,87,0.3,0,1.2,,0.4,-0.10000000000000003,-25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment B,110,0.3,0,1.2,,0.4,-0.10000000000000003,-25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 B,194,0.4,0,1.2,,0.4,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-7,7.1,6.3,8.1,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.9,6.3,8.1,Y,6.9,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 B,8,7.2,6.3,8.1,,6.9,0.2999999999999998,4.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 15 B,15,7.2,6.3,8.1,,6.9,0.2999999999999998,4.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 B,29,7.1,6.3,8.1,,6.9,0.1999999999999993,2.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 B,57,7.2,6.3,8.1,,6.9,0.2999999999999998,4.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 4 Day 1 B,87,7.2,6.3,8.1,,6.9,0.2999999999999998,4.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment B,110,7,6.3,8.1,,6.9,0.09999999999999964,1.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 B,194,6.4,6.3,8.1,,6.9,-0.5,-7.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-7,26.8,22.5,36.5,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,21,22.5,36.5,Y,21,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,27.6,22.5,36.5,,21,6.600000000000001,31.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 15 B,15,26.9,22.5,36.5,,21,5.899999999999999,28.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,29,27.1,22.5,36.5,,21,6.100000000000001,29
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 B,57,25.4,22.5,36.5,,21,4.399999999999999,21
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 B,87,25.7,22.5,36.5,,21,4.699999999999999,22.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,110,26.9,22.5,36.5,,21,5.899999999999999,28.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-7,0.93,0.8,1.2,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,0.94,0.8,1.2,Y,0.94,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,0.94,0.8,1.2,,0.94,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 15 B,15,0.97,0.8,1.2,,0.94,0.030000000000000027,3.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,29,0.92,0.8,1.2,,0.94,-0.019999999999999907,-2.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 B,57,0.91,0.8,1.2,,0.94,-0.029999999999999916,-3.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 B,87,0.96,0.8,1.2,,0.94,0.020000000000000018,2.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,110,0.92,0.8,1.2,,0.94,-0.019999999999999907,-2.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-7,12.4,11.1,15.2,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.5,11.1,15.2,Y,12.5,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,12.6,11.1,15.2,,12.5,0.09999999999999964,0.8
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 15 B,15,12.9,11.1,15.2,,12.5,0.40000000000000036,3.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,29,12.4,11.1,15.2,,12.5,-0.09999999999999964,-0.8
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 B,57,12.3,11.1,15.2,,12.5,-0.1999999999999993,-1.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 4 Day 1 B,87,12.6,11.1,15.2,,12.5,0.09999999999999964,0.8
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment B,110,12.1,11.1,15.2,,12.5,-0.40000000000000036,-3.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,,-7,0,0,0.2,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 B,8,0,0,0.2,,0,0,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 15 B,15,0,0,0.2,,0,0,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 B,29,0,0,0.2,,0,0,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 B,57,0,0,0.2,,0,0,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 4 Day 1 B,87,0,0,0.2,,0,0,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,End of Treatment B,110,0,0,0.2,,0,0,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 B,194,0,0,0.2,,0,0,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,,-7,0.1,0,0.7,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.7,Y,0.1,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.1,0,0.7,,0.1,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 15 B,15,0.1,0,0.7,,0.1,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 B,29,0.1,0,0.7,,0.1,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 B,57,0.1,0,0.7,,0.1,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 4 Day 1 B,87,0.1,0,0.7,,0.1,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment B,110,0.1,0,0.7,,0.1,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 B,194,0,0,0.7,,0.1,-0.1,-100
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-7,4.85,3.95,5.54,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.7,3.95,5.54,Y,4.7,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,4.82,3.95,5.54,,4.7,0.1200000000000001,2.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,15,4.65,3.95,5.54,,4.7,-0.04999999999999982,-1.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,29,4.81,3.95,5.54,,4.7,0.10999999999999943,2.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,57,4.82,3.95,5.54,,4.7,0.1200000000000001,2.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 B,87,4.58,3.95,5.54,,4.7,-0.1200000000000001,-2.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,110,4.63,3.95,5.54,,4.7,-0.07000000000000028,-1.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,194,3.94,3.95,5.54,,4.7,-0.7600000000000002,-16.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-7,46,37.5,49.3,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,42.4,37.5,49.3,Y,42.4,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,43.9,37.5,49.3,,42.4,1.5,3.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,15,43.5,37.5,49.3,,42.4,1.1000000000000014,2.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,29,44.7,37.5,49.3,,42.4,2.3000000000000043,5.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,57,45.2,37.5,49.3,,42.4,2.8000000000000043,6.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 B,87,43.7,37.5,49.3,,42.4,1.3000000000000043,3.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment B,110,43.5,37.5,49.3,,42.4,1.1000000000000014,2.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 B,194,37.3,37.5,49.3,,42.4,-5.100000000000001,-12
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-7,14.8,12.5,16.2,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,14.2,12.5,16.2,Y,14.2,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,14.3,12.5,16.2,,14.2,0.10000000000000142,0.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,15,14,12.5,16.2,,14.2,-0.1999999999999993,-1.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,29,14.3,12.5,16.2,,14.2,0.10000000000000142,0.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,57,14.2,12.5,16.2,,14.2,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 B,87,13.7,12.5,16.2,,14.2,-0.5,-3.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment B,110,14,12.5,16.2,,14.2,-0.1999999999999993,-1.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 B,194,11.8,12.5,16.2,,14.2,-2.3999999999999986,-16.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,,-7,0.9,0.9,3.2,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.8,0.9,3.2,Y,0.8,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,0.8,0.9,3.2,,0.8,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 15 B,15,0.9,0.9,3.2,,0.8,0.09999999999999998,12.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 B,29,0.9,0.9,3.2,,0.8,0.09999999999999998,12.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 B,57,0.8,0.9,3.2,,0.8,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 4 Day 1 B,87,0.8,0.9,3.2,,0.8,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment B,110,0.7,0.9,3.2,,0.8,-0.10000000000000009,-12.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 B,194,0.7,0.9,3.2,,0.8,-0.10000000000000009,-12.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,,-7,0.6,0,1.3,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.8,0,1.3,Y,0.8,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 B,8,1.6,0,1.3,,0.8,0.8,100
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 15 B,15,2.4,0,1.3,,0.8,1.5999999999999999,200
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 B,29,1.2,0,1.3,,0.8,0.3999999999999999,50
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 B,57,0.7,0,1.3,,0.8,-0.10000000000000009,-12.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 4 Day 1 B,87,0.8,0,1.3,,0.8,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,End of Treatment B,110,0.6,0,1.3,,0.8,-0.20000000000000007,-25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 B,194,1,0,1.3,,0.8,0.19999999999999996,25
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,,-7,3.3,1.5,7.5,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4.3,1.5,7.5,Y,4.3,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 B,8,2.7,1.5,7.5,,4.3,-1.5999999999999996,-37.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 15 B,15,3.8,1.5,7.5,,4.3,-0.5,-11.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 B,29,3.4,1.5,7.5,,4.3,-0.8999999999999999,-20.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 B,57,3.8,1.5,7.5,,4.3,-0.5,-11.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 4 Day 1 B,87,3.9,1.5,7.5,,4.3,-0.3999999999999999,-9.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment B,110,3.5,1.5,7.5,,4.3,-0.7999999999999998,-18.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 B,194,6.8,1.5,7.5,,4.3,2.5,58.1
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-7,246,160,400,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,218,160,400,Y,218,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,233,160,400,,218,15,6.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,15,199,160,400,,218,-19,-8.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,29,250,160,400,,218,32,14.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,57,272,160,400,,218,54,24.8
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 4 Day 1 B,87,231,160,400,,218,13,6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment B,110,216,160,400,,218,-2,-0.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 B,194,225,160,400,,218,7,3.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,,-7,4.9,4,11,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,6,4,11,Y,6,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,5.2,4,11,,6,-0.7999999999999998,-13.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 15 B,15,7.3,4,11,,6,1.2999999999999998,21.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 B,29,5.5,4,11,,6,-0.5,-8.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 B,57,5.5,4,11,,6,-0.5,-8.3
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 4 Day 1 B,87,5.7,4,11,,6,-0.2999999999999998,-5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment B,110,5,4,11,,6,-1,-16.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 B,194,8.8,4,11,,6,2.8000000000000007,46.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,,-7,1.57,NA,NA,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,1.44,NA,NA,Y,1.44,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,29,1.76,NA,NA,,1.44,0.32000000000000006,22.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 B,57,2.67,NA,NA,,1.44,1.23,85.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 4 Day 1 B,87,5.35,NA,NA,,1.44,3.9099999999999997,271.5
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment B,110,7.34,NA,NA,,1.44,5.9,409.7
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 B,194,11.71,NA,NA,,1.44,10.270000000000001,713.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),Baseline,-7,1.06,NA,NA,Y,1.06,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-7,0.53,0.6,4.8,,NA,NA,NA
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,0.67,0.6,4.8,Y,0.67,0,0
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,0.84,0.6,4.8,,0.67,0.16999999999999993,25.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,15,0.8,0.6,4.8,,0.67,0.13,19.4
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,29,1.08,0.6,4.8,,0.67,0.41000000000000003,61.2
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,57,1.19,0.6,4.8,,0.67,0.5199999999999999,77.6
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 B,87,0.87,0.6,4.8,,0.67,0.19999999999999996,29.9
4B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,110,0.81,0.6,4.8,,0.67,0.14,20.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,0,NA,NA,Y,0,0,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,29,1,NA,NA,,0,1,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 C,57,0,NA,NA,,0,0,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 C,64,1,NA,NA,,0,1,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 3 Day 1 C,94,0,NA,NA,,0,0,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 4 Day 1 C,115,0,NA,NA,,0,0,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 4 Day 1 C,122,0,NA,NA,,0,0,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 4 Day 1 C,136,3,NA,NA,,0,3,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,End of Treatment C,172,5,NA,NA,,0,5,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-21,29,1,45,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,21,1,45,Y,21,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,25,1,45,,21,4,19
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,15,37,1,45,,21,16,76.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,28,1,45,,21,7,33.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,29,26,1,45,,21,5,23.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,36,34,1,45,,21,13,61.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 C,64,18,1,45,,21,-3,-14.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 C,94,15,1,45,,21,-6,-28.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 C,136,13,1,45,,21,-8,-38.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,172,16,1,45,,21,-5,-23.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 C,261,26,1,45,,21,5,23.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-21,3.9,3.5,4.9,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.8,3.5,4.9,Y,3.8,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,15,4,3.5,4.9,,3.8,0.20000000000000018,5.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,4.1,3.5,4.9,,3.8,0.2999999999999998,7.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,29,3.8,3.5,4.9,,3.8,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,36,3.9,3.5,4.9,,3.8,0.10000000000000009,2.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,64,4.2,3.5,4.9,,3.8,0.40000000000000036,10.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 C,94,3.8,3.5,4.9,,3.8,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 4 Day 1 C,136,3.9,3.5,4.9,,3.8,0.10000000000000009,2.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,172,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 C,261,4.1,3.5,4.9,,3.8,0.2999999999999998,7.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-21,101,38,126,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,68,38,126,Y,68,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,64,38,126,,68,-4,-5.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,15,81,38,126,,68,13,19.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,70,38,126,,68,2,2.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,29,69,38,126,,68,1,1.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,36,79,38,126,,68,11,16.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,64,66,38,126,,68,-2,-2.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 C,94,51,38,126,,68,-17,-25
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 C,136,62,38,126,,68,-6,-8.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,172,68,38,126,,68,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 C,261,109,38,126,,68,41,60.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-21,23,1,35,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,27,1,35,Y,27,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,28,1,35,,27,1,3.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,15,44,1,35,,27,17,63
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,31,1,35,,27,4,14.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,29,31,1,35,,27,4,14.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,36,39,1,35,,27,12,44.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,64,26,1,35,,27,-1,-3.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 C,94,22,1,35,,27,-5,-18.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 C,136,22,1,35,,27,-5,-18.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,172,20,1,35,,27,-7,-25.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 C,261,24,1,35,,27,-3,-11.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-21,12,6,23,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,13,6,23,Y,13,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,15,6,23,,13,2,15.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,15,16,6,23,,13,3,23.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,13,6,23,,13,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,29,12,6,23,,13,-1,-7.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,36,19,6,23,,13,6,46.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 C,64,12,6,23,,13,-1,-7.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 C,94,12,6,23,,13,-1,-7.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 4 Day 1 C,136,14,6,23,,13,1,7.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,172,12,6,23,,13,-1,-7.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 C,261,16,6,23,,13,3,23.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-21,25.6,22,30,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,27.5,22,30,Y,27.5,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,28.4,22,30,,27.5,0.8999999999999986,3.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,15,28.4,22,30,,27.5,0.8999999999999986,3.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,27.5,22,30,,27.5,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,29,27.3,22,30,,27.5,-0.1999999999999993,-0.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,36,27.5,22,30,,27.5,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 C,64,29.2,22,30,,27.5,1.6999999999999993,6.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 C,94,29.1,22,30,,27.5,1.6000000000000014,5.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 4 Day 1 C,136,29.1,22,30,,27.5,1.6000000000000014,5.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment C,172,27,22,30,,27.5,-0.5,-1.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 C,261,29.2,22,30,,27.5,1.6999999999999993,6.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-21,8.8,8.5,10.5,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8.8,8.5,10.5,Y,8.8,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,8.4,8.5,10.5,,8.8,-0.40000000000000036,-4.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,15,9.1,8.5,10.5,,8.8,0.29999999999999893,3.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,9.2,8.5,10.5,,8.8,0.3999999999999986,4.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,29,8.9,8.5,10.5,,8.8,0.09999999999999964,1.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,36,8.5,8.5,10.5,,8.8,-0.3000000000000007,-3.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,64,9,8.5,10.5,,8.8,0.1999999999999993,2.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 C,94,8.5,8.5,10.5,,8.8,-0.3000000000000007,-3.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 C,136,8.8,8.5,10.5,,8.8,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,172,8,8.5,10.5,,8.8,-0.8000000000000007,-9.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 C,261,9.1,8.5,10.5,,8.8,0.29999999999999893,3.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-21,104,96,108,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,104,96,108,Y,104,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,105,96,108,,104,1,1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,15,103,96,108,,104,-1,-1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,103,96,108,,104,-1,-1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,29,106,96,108,,104,2,1.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,36,104,96,108,,104,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,64,104,96,108,,104,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 C,94,107,96,108,,104,3,2.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 C,136,104,96,108,,104,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,172,102,96,108,,104,-2,-1.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 C,261,103,96,108,,104,-1,-1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-21,0.76,0.7,1.3,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.82,0.7,1.3,Y,0.82,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,0.93,0.7,1.3,,0.82,0.1100000000000001,13.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,15,0.88,0.7,1.3,,0.82,0.06000000000000005,7.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,0.83,0.7,1.3,,0.82,0.010000000000000009,1.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,29,0.82,0.7,1.3,,0.82,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,36,0.88,0.7,1.3,,0.82,0.06000000000000005,7.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,64,0.84,0.7,1.3,,0.82,0.020000000000000018,2.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 C,94,0.85,0.7,1.3,,0.82,0.030000000000000027,3.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 C,136,0.78,0.7,1.3,,0.82,-0.039999999999999925,-4.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,172,0.79,0.7,1.3,,0.82,-0.029999999999999916,-3.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 C,261,0.8,0.7,1.3,,0.82,-0.019999999999999907,-2.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-21,89,60,100,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,95,60,100,Y,95,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,99,60,100,,95,4,4.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,15,96,60,100,,95,1,1.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,89,60,100,,95,-6,-6.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,29,93,60,100,,95,-2,-2.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,36,103,60,100,,95,8,8.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 C,64,101,60,100,,95,6,6.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 C,94,106,60,100,,95,11,11.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 4 Day 1 C,136,101,60,100,,95,6,6.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,172,103,60,100,,95,8,8.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 C,261,106,60,100,,95,11,11.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-21,172,100,220,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,170,100,220,Y,170,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,169,100,220,,170,-1,-0.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,15,244,100,220,,170,74,43.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,225,100,220,,170,55,32.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,29,224,100,220,,170,54,31.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,36,249,100,220,,170,79,46.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 C,64,175,100,220,,170,5,2.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 C,94,147,100,220,,170,-23,-13.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 C,136,161,100,220,,170,-9,-5.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,172,172,100,220,,170,2,1.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 C,261,170,100,220,,170,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-21,3.9,3.5,5.2,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4,3.5,5.2,Y,4,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,4.4,3.5,5.2,,4,0.40000000000000036,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,15,4.4,3.5,5.2,,4,0.40000000000000036,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.2,3.5,5.2,,4,0.20000000000000018,5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,29,4.4,3.5,5.2,,4,0.40000000000000036,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,36,4.7,3.5,5.2,,4,0.7000000000000002,17.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,64,4.5,3.5,5.2,,4,0.5,12.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 C,94,4.4,3.5,5.2,,4,0.40000000000000036,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 C,136,4.4,3.5,5.2,,4,0.40000000000000036,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,172,4.4,3.5,5.2,,4,0.40000000000000036,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 C,261,4.8,3.5,5.2,,4,0.7999999999999998,20
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-21,140,135,145,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,140,135,145,Y,140,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,140,135,145,,140,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,15,139,135,145,,140,-1,-0.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,139,135,145,,140,-1,-0.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,29,139,135,145,,140,-1,-0.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,36,139,135,145,,140,-1,-0.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 C,64,140,135,145,,140,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 C,94,140,135,145,,140,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 4 Day 1 C,136,140,135,145,,140,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,172,136,135,145,,140,-4,-2.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 C,261,139,135,145,,140,-1,-0.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-21,0.6,0.1,1.2,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.4,0.1,1.2,Y,0.4,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.4,0.1,1.2,,0.4,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,15,0.5,0.1,1.2,,0.4,0.09999999999999998,25
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.5,0.1,1.2,,0.4,0.09999999999999998,25
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,29,0.4,0.1,1.2,,0.4,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,36,0.3,0.1,1.2,,0.4,-0.10000000000000003,-25
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,64,0.4,0.1,1.2,,0.4,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 C,94,0.3,0.1,1.2,,0.4,-0.10000000000000003,-25
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 4 Day 1 C,136,0.3,0.1,1.2,,0.4,-0.10000000000000003,-25
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,172,0.2,0.1,1.2,,0.4,-0.2,-50
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 C,261,0.3,0.1,1.2,,0.4,-0.10000000000000003,-25
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-21,6.2,6,8.3,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.1,6,8.3,Y,6.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,5.9,6,8.3,,6.1,-0.1999999999999993,-3.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,15,6.1,6,8.3,,6.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,6.2,6,8.3,,6.1,0.10000000000000053,1.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,29,5.9,6,8.3,,6.1,-0.1999999999999993,-3.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,36,6.1,6,8.3,,6.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 C,64,6.5,6,8.3,,6.1,0.40000000000000036,6.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 C,94,6,6,8.3,,6.1,-0.09999999999999964,-1.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 4 Day 1 C,136,6.3,6,8.3,,6.1,0.20000000000000018,3.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,172,6.2,6,8.3,,6.1,0.10000000000000053,1.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 C,261,6.6,6,8.3,,6.1,0.5,8.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-21,25.6,25.4,34.9,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,25.7,25.4,34.9,Y,25.7,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,8,25.4,25.4,34.9,,25.7,-0.3000000000000007,-1.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,15,26.9,25.4,34.9,,25.7,1.1999999999999993,4.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,22,25.2,25.4,34.9,,25.7,-0.5,-1.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 1 C,29,26.6,25.4,34.9,,25.7,0.9000000000000021,3.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 C,36,26.8,25.4,34.9,,25.7,1.1000000000000014,4.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 C,64,25.8,25.4,34.9,,25.7,0.10000000000000142,0.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 C,94,25.7,25.4,34.9,,25.7,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 C,136,25.1,25.4,34.9,,25.7,-0.5999999999999979,-2.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Follow-up 110 C,261,24.3,25.4,34.9,,25.7,-1.3999999999999986,-5.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-21,1,2,3,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1,2,3,Y,1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,8,1.1,2,3,,1,0.10000000000000009,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,15,1.2,2,3,,1,0.19999999999999996,20
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,22,1.1,2,3,,1,0.10000000000000009,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 1 C,29,1.1,2,3,,1,0.10000000000000009,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 C,36,1.1,2,3,,1,0.10000000000000009,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 C,64,1,2,3,,1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 C,94,1.1,2,3,,1,0.10000000000000009,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 C,136,1.1,2,3,,1,0.10000000000000009,10
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Follow-up 110 C,261,1,2,3,,1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-21,12.8,12.3,14.9,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.9,12.3,14.9,Y,12.9,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,8,13.4,12.3,14.9,,12.9,0.5,3.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,15,14.1,12.3,14.9,,12.9,1.1999999999999993,9.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,22,13.7,12.3,14.9,,12.9,0.7999999999999989,6.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 1 C,29,13.4,12.3,14.9,,12.9,0.5,3.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 C,36,13.7,12.3,14.9,,12.9,0.7999999999999989,6.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 C,64,13,12.3,14.9,,12.9,0.09999999999999964,0.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 C,94,13.3,12.3,14.9,,12.9,0.40000000000000036,3.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 4 Day 1 C,136,13.6,12.3,14.9,,12.9,0.6999999999999993,5.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Follow-up 110 C,261,12.4,12.3,14.9,,12.9,-0.5,-3.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-21,0.1,0,0.2,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.1,0,0.2,Y,0.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0.2,0,0.2,,0.1,0.1,100
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,15,0.1,0,0.2,,0.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.2,,0.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,29,0.1,0,0.2,,0.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 C,36,0.1,0,0.2,,0.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 C,64,0,0,0.2,,0.1,-0.1,-100
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 C,94,0,0,0.2,,0.1,-0.1,-100
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 4 Day 1 C,136,0,0,0.2,,0.1,-0.1,-100
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,172,0.1,0,0.2,,0.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 C,261,0.1,0,0.2,,0.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-21,0.2,0,0.6,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.2,0,0.6,Y,0.2,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,15,0.1,0,0.6,,0.2,-0.1,-50
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0.1,0,0.6,,0.2,-0.1,-50
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,29,0.2,0,0.6,,0.2,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 C,36,0.3,0,0.6,,0.2,0.09999999999999998,50
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 C,64,0.2,0,0.6,,0.2,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 C,94,0.1,0,0.6,,0.2,-0.1,-50
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 4 Day 1 C,136,0.2,0,0.6,,0.2,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,172,0.2,0,0.6,,0.2,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 C,261,0.2,0,0.6,,0.2,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-21,3.92,4.5,6,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.78,4.5,6,Y,3.78,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,3.65,4.5,6,,3.78,-0.1299999999999999,-3.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,15,3.8,4.5,6,,3.78,0.020000000000000018,0.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.66,4.5,6,,3.78,-0.11999999999999966,-3.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,29,3.64,4.5,6,,3.78,-0.13999999999999968,-3.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,36,3.61,4.5,6,,3.78,-0.16999999999999993,-4.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,64,3.68,4.5,6,,3.78,-0.09999999999999964,-2.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 C,94,3.59,4.5,6,,3.78,-0.18999999999999995,-5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 C,136,3.63,4.5,6,,3.78,-0.1499999999999999,-4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,172,3.45,4.5,6,,3.78,-0.3299999999999996,-8.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 C,261,4.42,4.5,6,,3.78,0.6400000000000001,16.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-21,37.1,42,52,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,36.1,42,52,Y,36.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,34.9,42,52,,36.1,-1.2000000000000028,-3.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,15,36.1,42,52,,36.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,35,42,52,,36.1,-1.1000000000000014,-3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,29,34.7,42,52,,36.1,-1.3999999999999986,-3.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,36,34.4,42,52,,36.1,-1.7000000000000028,-4.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,64,34.2,42,52,,36.1,-1.8999999999999986,-5.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 C,94,32.7,42,52,,36.1,-3.3999999999999986,-9.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 C,136,31.8,42,52,,36.1,-4.300000000000001,-11.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,172,28.9,42,52,,36.1,-7.200000000000003,-19.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 C,261,40.3,42,52,,36.1,4.199999999999996,11.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-21,12.8,13.9,16.3,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,12.1,13.9,16.3,Y,12.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,12,13.9,16.3,,12.1,-0.09999999999999964,-0.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,15,12.2,13.9,16.3,,12.1,0.09999999999999964,0.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,11.9,13.9,16.3,,12.1,-0.1999999999999993,-1.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,29,11.5,13.9,16.3,,12.1,-0.5999999999999996,-5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,36,11.5,13.9,16.3,,12.1,-0.5999999999999996,-5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,64,11.5,13.9,16.3,,12.1,-0.5999999999999996,-5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 C,94,10.9,13.9,16.3,,12.1,-1.1999999999999993,-9.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 C,136,10.5,13.9,16.3,,12.1,-1.5999999999999996,-13.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,172,9.5,13.9,16.3,,12.1,-2.5999999999999996,-21.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 C,261,13.7,13.9,16.3,,12.1,1.5999999999999996,13.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-21,1.2,1,4.5,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.1,1,4.5,Y,1.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,1.1,1,4.5,,1.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,15,1.1,1,4.5,,1.1,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,0.9,1,4.5,,1.1,-0.20000000000000007,-18.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,29,1.2,1,4.5,,1.1,0.09999999999999987,9.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 C,36,1.2,1,4.5,,1.1,0.09999999999999987,9.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 C,64,0.8,1,4.5,,1.1,-0.30000000000000004,-27.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 C,94,0.7,1,4.5,,1.1,-0.40000000000000013,-36.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 4 Day 1 C,136,0.8,1,4.5,,1.1,-0.30000000000000004,-27.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,172,0.9,1,4.5,,1.1,-0.20000000000000007,-18.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 C,261,0.9,1,4.5,,1.1,-0.20000000000000007,-18.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-21,0.3,0.2,1,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.4,0.2,1,Y,0.4,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,1.3,0.2,1,,0.4,0.9,225
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,15,1.7,0.2,1,,0.4,1.2999999999999998,325
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,2.4,0.2,1,,0.4,2,500
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,29,1.8,0.2,1,,0.4,1.4,350
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 C,36,2.8,0.2,1,,0.4,2.4,600
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 C,64,0.3,0.2,1,,0.4,-0.10000000000000003,-25
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 C,94,0.3,0.2,1,,0.4,-0.10000000000000003,-25
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 4 Day 1 C,136,0.4,0.2,1,,0.4,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,172,0.4,0.2,1,,0.4,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 C,261,0.4,0.2,1,,0.4,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-21,3.6,1.9,8,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.3,1.9,8,Y,3.3,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,3.66,1.9,8,,3.3,0.3600000000000003,10.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,15,1.87,1.9,8,,3.3,-1.4299999999999997,-43.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,3.92,1.9,8,,3.3,0.6200000000000001,18.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,29,3.1,1.9,8,,3.3,-0.19999999999999973,-6.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 C,36,4.24,1.9,8,,3.3,0.9400000000000004,28.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 C,64,1.9,1.9,8,,3.3,-1.4,-42.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 C,94,2.9,1.9,8,,3.3,-0.3999999999999999,-12.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 4 Day 1 C,136,2.6,1.9,8,,3.3,-0.6999999999999997,-21.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,172,3.4,1.9,8,,3.3,0.10000000000000009,3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 C,261,4.5,1.9,8,,3.3,1.2000000000000002,36.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-21,257,150,450,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,207,150,450,Y,207,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,198,150,450,,207,-9,-4.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,15,143,150,450,,207,-64,-30.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,236,150,450,,207,29,14
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,29,253,150,450,,207,46,22.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,36,190,150,450,,207,-17,-8.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,64,153,150,450,,207,-54,-26.1
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 C,94,207,150,450,,207,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 4 Day 1 C,136,212,150,450,,207,5,2.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,172,233,150,450,,207,26,12.6
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 C,261,223,150,450,,207,16,7.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-21,5.5,4.5,11,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5,4.5,11,Y,5,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,6.1,4.5,11,,5,1.0999999999999996,22
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,15,4.8,4.5,11,,5,-0.20000000000000018,-4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,7,4.5,11,,5,2,40
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,29,6.2,4.5,11,,5,1.2000000000000002,24
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,36,7.7,4.5,11,,5,2.7,54
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 C,64,3.2,4.5,11,,5,-1.7999999999999998,-36
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 C,94,4.1,4.5,11,,5,-0.9000000000000004,-18
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 4 Day 1 C,136,4,4.5,11,,5,-1,-20
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,172,4.9,4.5,11,,5,-0.09999999999999964,-2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 C,261,6.1,4.5,11,,5,1.0999999999999996,22
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-21,5.3,NA,NA,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,4.56,NA,NA,Y,4.56,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,7.27,NA,NA,,4.56,2.71,59.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,29,7.88,NA,NA,,4.56,3.3200000000000003,72.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,64,13.34,NA,NA,,4.56,8.780000000000001,192.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 C,94,20.6,NA,NA,,4.56,16.040000000000003,351.8
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 4 Day 1 C,136,31.44,NA,NA,,4.56,26.880000000000003,589.5
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,172,53.6,NA,NA,,4.56,49.04,1075.4
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 C,261,250.75,NA,NA,,4.56,246.19,5398.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-21,1.39,0.4,4.2,,NA,NA,NA
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.38,0.4,4.2,Y,1.38,0,0
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,1.28,0.4,4.2,,1.38,-0.09999999999999987,-7.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,15,1.26,0.4,4.2,,1.38,-0.11999999999999988,-8.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,1.08,0.4,4.2,,1.38,-0.2999999999999998,-21.7
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,29,1.1,0.4,4.2,,1.38,-0.2799999999999998,-20.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,36,1.1,0.4,4.2,,1.38,-0.2799999999999998,-20.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,64,1.23,0.4,4.2,,1.38,-0.1499999999999999,-10.9
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 C,94,0.7,0.4,4.2,,1.38,-0.6799999999999999,-49.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 C,136,1.7,0.4,4.2,,1.38,0.32000000000000006,23.2
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,172,1.21,0.4,4.2,,1.38,-0.16999999999999993,-12.3
4C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 C,261,1.13,0.4,4.2,,1.38,-0.25,-18.1
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Baseline,1,0,NA,NA,Y,0,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 2 Day 1 A,22,0,NA,NA,,0,0,NA
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 3 Day 1 A,43,1,NA,NA,,0,1,NA
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 4 Day 1 A,64,3,NA,NA,,0,3,NA
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 6 Day 1 A,115,5,NA,NA,,0,5,NA
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 7 Day 1 A,136,5,NA,NA,,0,5,NA
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 8 Day 1 A,155,12,NA,NA,,0,12,NA
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 9 Day 1 A,176,16,NA,NA,,0,16,NA
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,Cycle 11 Day 1 A,218,9,NA,NA,,0,9,NA
5A,A,NKTR-214 + Nivolumab,N,Y,,CTC,End of Treatment A,274,1,NA,NA,,0,1,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),,-19,32,1,45,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,25,1,45,Y,25,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,87,1,45,,25,62,248
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,22,26,1,45,,25,1,4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,30,50,1,45,,25,25,100
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 A,43,23,1,45,,25,-2,-8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 8 A,51,25,1,45,,25,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 8 A,71,21,1,45,,25,-4,-16
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 A,92,20,1,45,,25,-5,-20
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 8 A,99,28,1,45,,25,3,12
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 6 Day 1 A,115,16,1,45,,25,-9,-36
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 6 Day 8 A,122,12,1,45,,25,-13,-52
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 7 Day 1 A,136,17,1,45,,25,-8,-32
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 7 Day 8 A,143,14,1,45,,25,-11,-44
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 8 Day 1 A,155,14,1,45,,25,-11,-44
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 8 Day 8 A,162,14,1,45,,25,-11,-44
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 9 Day 1 A,176,15,1,45,,25,-10,-40
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 9 Day 8 A,183,14,1,45,,25,-11,-44
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 10 Day 1 A,197,13,1,45,,25,-12,-48
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 11 Day 1 A,218,14,1,45,,25,-11,-44
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 12 Day 1 A,241,13,1,45,,25,-12,-48
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 12 Day 8 A,249,14,1,45,,25,-11,-44
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,274,10,1,45,,25,-15,-60
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 A,348,12,1,45,,25,-13,-52
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),,-19,3.9,3.5,4.9,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Baseline,1,3.8,3.5,4.9,Y,3.8,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,3.2,3.5,4.9,,3.8,-0.5999999999999996,-15.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,22,3.8,3.5,4.9,,3.8,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,30,3.3,3.5,4.9,,3.8,-0.5,-13.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 1 A,43,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 8 A,51,3.5,3.5,4.9,,3.8,-0.2999999999999998,-7.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 4 Day 8 A,71,3.5,3.5,4.9,,3.8,-0.2999999999999998,-7.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 5 Day 1 A,92,3.9,3.5,4.9,,3.8,0.10000000000000009,2.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 5 Day 8 A,99,3.3,3.5,4.9,,3.8,-0.5,-13.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 6 Day 1 A,115,3.8,3.5,4.9,,3.8,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 6 Day 8 A,122,3.8,3.5,4.9,,3.8,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 7 Day 1 A,136,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 7 Day 8 A,143,3.5,3.5,4.9,,3.8,-0.2999999999999998,-7.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 8 Day 1 A,155,3.9,3.5,4.9,,3.8,0.10000000000000009,2.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 8 Day 8 A,162,3.5,3.5,4.9,,3.8,-0.2999999999999998,-7.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 9 Day 1 A,176,3.8,3.5,4.9,,3.8,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 9 Day 8 A,183,3.2,3.5,4.9,,3.8,-0.5999999999999996,-15.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 10 Day 1 A,197,3.6,3.5,4.9,,3.8,-0.19999999999999973,-5.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 11 Day 1 A,218,3.5,3.5,4.9,,3.8,-0.2999999999999998,-7.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 12 Day 1 A,241,3.6,3.5,4.9,,3.8,-0.19999999999999973,-5.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 12 Day 8 A,249,3.4,3.5,4.9,,3.8,-0.3999999999999999,-10.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),End of Treatment A,274,3.8,3.5,4.9,,3.8,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Follow-up 110 A,348,3.8,3.5,4.9,,3.8,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),,-19,59,38,126,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,62,38,126,Y,62,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,69,38,126,,62,7,11.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,22,60,38,126,,62,-2,-3.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,30,66,38,126,,62,4,6.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 A,43,59,38,126,,62,-3,-4.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 8 A,51,64,38,126,,62,2,3.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 8 A,71,62,38,126,,62,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 A,92,69,38,126,,62,7,11.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 8 A,99,66,38,126,,62,4,6.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 6 Day 1 A,115,73,38,126,,62,11,17.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 6 Day 8 A,122,77,38,126,,62,15,24.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 7 Day 1 A,136,73,38,126,,62,11,17.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 7 Day 8 A,143,66,38,126,,62,4,6.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 8 Day 1 A,155,72,38,126,,62,10,16.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 8 Day 8 A,162,69,38,126,,62,7,11.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 9 Day 1 A,176,85,38,126,,62,23,37.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 9 Day 8 A,183,71,38,126,,62,9,14.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 10 Day 1 A,197,87,38,126,,62,25,40.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 11 Day 1 A,218,89,38,126,,62,27,43.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 12 Day 1 A,241,84,38,126,,62,22,35.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 12 Day 8 A,249,89,38,126,,62,27,43.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,274,107,38,126,,62,45,72.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 A,348,71,38,126,,62,9,14.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-19,25,1,35,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,17,1,35,Y,17,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,46,1,35,,17,29,170.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,22,18,1,35,,17,1,5.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,30,29,1,35,,17,12,70.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 A,43,17,1,35,,17,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 8 A,51,17,1,35,,17,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 8 A,71,12,1,35,,17,-5,-29.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 A,92,15,1,35,,17,-2,-11.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 8 A,99,15,1,35,,17,-2,-11.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 6 Day 1 A,115,14,1,35,,17,-3,-17.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 6 Day 8 A,122,11,1,35,,17,-6,-35.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 7 Day 1 A,136,13,1,35,,17,-4,-23.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 7 Day 8 A,143,11,1,35,,17,-6,-35.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 8 Day 1 A,155,13,1,35,,17,-4,-23.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 8 Day 8 A,162,10,1,35,,17,-7,-41.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 9 Day 1 A,176,12,1,35,,17,-5,-29.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 9 Day 8 A,183,10,1,35,,17,-7,-41.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 10 Day 1 A,197,12,1,35,,17,-5,-29.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 11 Day 1 A,218,13,1,35,,17,-4,-23.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 12 Day 1 A,241,14,1,35,,17,-3,-17.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 12 Day 8 A,249,10,1,35,,17,-7,-41.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,274,12,1,35,,17,-5,-29.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 A,348,11,1,35,,17,-6,-35.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,,-19,13,6,23,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Baseline,1,14,6,23,Y,14,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 1 Day 8 A,8,14,6,23,,14,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 2 Day 1 A,22,14,6,23,,14,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 2 Day 8 A,30,17,6,23,,14,3,21.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 3 Day 1 A,43,17,6,23,,14,3,21.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 3 Day 8 A,51,8,6,23,,14,-6,-42.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 4 Day 8 A,71,7,6,23,,14,-7,-50
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 5 Day 1 A,92,15,6,23,,14,1,7.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 5 Day 8 A,99,9,6,23,,14,-5,-35.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 6 Day 1 A,115,14,6,23,,14,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 6 Day 8 A,122,16,6,23,,14,2,14.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 7 Day 1 A,136,16,6,23,,14,2,14.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 7 Day 8 A,143,11,6,23,,14,-3,-21.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 8 Day 1 A,155,18,6,23,,14,4,28.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 8 Day 8 A,162,14,6,23,,14,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 9 Day 1 A,176,14,6,23,,14,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 9 Day 8 A,183,16,6,23,,14,2,14.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 10 Day 1 A,197,17,6,23,,14,3,21.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 11 Day 1 A,218,12,6,23,,14,-2,-14.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 12 Day 1 A,241,14,6,23,,14,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Cycle 12 Day 8 A,249,13,6,23,,14,-1,-7.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,End of Treatment A,274,18,6,23,,14,4,28.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,BUN,Follow-up 110 A,348,17,6,23,,14,3,21.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,,-19,28,22,30,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Baseline,1,24,22,30,Y,24,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,27,22,30,,24,3,12.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 2 Day 1 A,22,25,22,30,,24,1,4.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 2 Day 8 A,30,28,22,30,,24,4,16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 3 Day 1 A,43,25,22,30,,24,1,4.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 3 Day 8 A,51,25,22,30,,24,1,4.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 4 Day 8 A,71,25,22,30,,24,1,4.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 5 Day 1 A,92,27,22,30,,24,3,12.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 5 Day 8 A,99,25,22,30,,24,1,4.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 6 Day 1 A,115,25,22,30,,24,1,4.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 6 Day 8 A,122,22,22,30,,24,-2,-8.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 7 Day 1 A,136,24,22,30,,24,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 7 Day 8 A,143,24,22,30,,24,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 8 Day 1 A,155,25.8,22,30,,24,1.8000000000000007,7.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 8 Day 8 A,162,24.4,22,30,,24,0.3999999999999986,1.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 9 Day 1 A,176,23.9,22,30,,24,-0.10000000000000142,-0.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 9 Day 8 A,183,21.4,22,30,,24,-2.6000000000000014,-10.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 10 Day 1 A,197,24.4,22,30,,24,0.3999999999999986,1.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 11 Day 1 A,218,24.5,22,30,,24,0.5,2.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 12 Day 1 A,241,27.9,22,30,,24,3.8999999999999986,16.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 12 Day 8 A,249,26.4,22,30,,24,2.3999999999999986,10
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,End of Treatment A,274,23.5,22,30,,24,-0.5,-2.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Bicarbonate,Follow-up 110 A,348,26,22,30,,24,2,8.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),,-19,9.9,8.5,10.5,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Baseline,1,9.4,8.5,10.5,Y,9.4,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,8.8,8.5,10.5,,9.4,-0.5999999999999996,-6.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,22,9.2,8.5,10.5,,9.4,-0.20000000000000107,-2.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,30,9,8.5,10.5,,9.4,-0.40000000000000036,-4.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 A,43,9.3,8.5,10.5,,9.4,-0.09999999999999964,-1.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 8 A,51,8.9,8.5,10.5,,9.4,-0.5,-5.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 4 Day 8 A,71,8.9,8.5,10.5,,9.4,-0.5,-5.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 A,92,9,8.5,10.5,,9.4,-0.40000000000000036,-4.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 5 Day 8 A,99,9.1,8.5,10.5,,9.4,-0.3000000000000007,-3.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 6 Day 1 A,115,9.4,8.5,10.5,,9.4,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 6 Day 8 A,122,8.9,8.5,10.5,,9.4,-0.5,-5.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 7 Day 1 A,136,8.9,8.5,10.5,,9.4,-0.5,-5.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 7 Day 8 A,143,8.5,8.5,10.5,,9.4,-0.9000000000000004,-9.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 8 Day 1 A,155,9.5,8.5,10.5,,9.4,0.09999999999999964,1.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 8 Day 8 A,162,9.1,8.5,10.5,,9.4,-0.3000000000000007,-3.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 9 Day 1 A,176,9.1,8.5,10.5,,9.4,-0.3000000000000007,-3.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 9 Day 8 A,183,8.7,8.5,10.5,,9.4,-0.7000000000000011,-7.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 10 Day 1 A,197,8.9,8.5,10.5,,9.4,-0.5,-5.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 11 Day 1 A,218,8.6,8.5,10.5,,9.4,-0.8000000000000007,-8.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 12 Day 1 A,241,9,8.5,10.5,,9.4,-0.40000000000000036,-4.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 12 Day 8 A,249,8.6,8.5,10.5,,9.4,-0.8000000000000007,-8.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),End of Treatment A,274,8.6,8.5,10.5,,9.4,-0.8000000000000007,-8.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Follow-up 110 A,348,9.5,8.5,10.5,,9.4,0.09999999999999964,1.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),,-19,106,96,108,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Baseline,1,106,96,108,Y,106,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,104,96,108,,106,-2,-1.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,22,105,96,108,,106,-1,-0.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,30,103,96,108,,106,-3,-2.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 A,43,104,96,108,,106,-2,-1.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 8 A,51,96,96,108,,106,-10,-9.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 4 Day 8 A,71,102,96,108,,106,-4,-3.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 A,92,101,96,108,,106,-5,-4.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 5 Day 8 A,99,104,96,108,,106,-2,-1.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 6 Day 1 A,115,103,96,108,,106,-3,-2.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 6 Day 8 A,122,105,96,108,,106,-1,-0.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 7 Day 1 A,136,103,96,108,,106,-3,-2.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 7 Day 8 A,143,104,96,108,,106,-2,-1.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 8 Day 1 A,155,103,96,108,,106,-3,-2.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 8 Day 8 A,162,101,96,108,,106,-5,-4.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 9 Day 1 A,176,103,96,108,,106,-3,-2.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 9 Day 8 A,183,106,96,108,,106,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 10 Day 1 A,197,105,96,108,,106,-1,-0.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 11 Day 1 A,218,105,96,108,,106,-1,-0.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 12 Day 1 A,241,103,96,108,,106,-3,-2.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 12 Day 8 A,249,103,96,108,,106,-3,-2.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),End of Treatment A,274,106,96,108,,106,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Follow-up 110 A,348,102,96,108,,106,-4,-3.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),,-19,1.06,0.7,1.3,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Baseline,1,1.07,0.7,1.3,Y,1.07,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,1.05,0.7,1.3,,1.07,-0.020000000000000018,-1.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,22,1.01,0.7,1.3,,1.07,-0.06000000000000005,-5.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,30,1.07,0.7,1.3,,1.07,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 A,43,1.03,0.7,1.3,,1.07,-0.040000000000000036,-3.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 8 A,51,1.14,0.7,1.3,,1.07,0.06999999999999984,6.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 4 Day 8 A,71,1.24,0.7,1.3,,1.07,0.16999999999999993,15.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 A,92,1.08,0.7,1.3,,1.07,0.010000000000000009,0.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 5 Day 8 A,99,1.12,0.7,1.3,,1.07,0.050000000000000044,4.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 6 Day 1 A,115,1.1,0.7,1.3,,1.07,0.030000000000000027,2.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 6 Day 8 A,122,1.1,0.7,1.3,,1.07,0.030000000000000027,2.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 7 Day 1 A,136,1.12,0.7,1.3,,1.07,0.050000000000000044,4.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 7 Day 8 A,143,1.15,0.7,1.3,,1.07,0.07999999999999985,7.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 8 Day 1 A,155,1.13,0.7,1.3,,1.07,0.05999999999999983,5.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 8 Day 8 A,162,1.17,0.7,1.3,,1.07,0.09999999999999987,9.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 9 Day 1 A,176,1.11,0.7,1.3,,1.07,0.040000000000000036,3.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 9 Day 8 A,183,1.12,0.7,1.3,,1.07,0.050000000000000044,4.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 10 Day 1 A,197,1.07,0.7,1.3,,1.07,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 11 Day 1 A,218,1.09,0.7,1.3,,1.07,0.020000000000000018,1.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 12 Day 1 A,241,1.08,0.7,1.3,,1.07,0.010000000000000009,0.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 12 Day 8 A,249,1.14,0.7,1.3,,1.07,0.06999999999999984,6.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),End of Treatment A,274,1.14,0.7,1.3,,1.07,0.06999999999999984,6.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Follow-up 110 A,348,1.25,0.7,1.3,,1.07,0.17999999999999994,16.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,,-19,99,60,100,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Baseline,1,92,60,100,Y,92,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 1 Day 8 A,8,95,60,100,,92,3,3.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 2 Day 1 A,22,94,60,100,,92,2,2.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 2 Day 8 A,30,99,60,100,,92,7,7.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 3 Day 1 A,43,98,60,100,,92,6,6.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 3 Day 8 A,51,93,60,100,,92,1,1.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 4 Day 8 A,71,93,60,100,,92,1,1.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 5 Day 1 A,92,108,60,100,,92,16,17.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 5 Day 8 A,99,101,60,100,,92,9,9.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 6 Day 1 A,115,94,60,100,,92,2,2.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 6 Day 8 A,122,105,60,100,,92,13,14.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 7 Day 1 A,136,90,60,100,,92,-2,-2.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 7 Day 8 A,143,91,60,100,,92,-1,-1.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 8 Day 1 A,155,88,60,100,,92,-4,-4.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 8 Day 8 A,162,132,60,100,,92,40,43.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 9 Day 1 A,176,83,60,100,,92,-9,-9.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 9 Day 8 A,183,92,60,100,,92,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 10 Day 1 A,197,86,60,100,,92,-6,-6.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 11 Day 1 A,218,129,60,100,,92,37,40.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 12 Day 1 A,241,93,60,100,,92,1,1.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Cycle 12 Day 8 A,249,106,60,100,,92,14,15.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,End of Treatment A,274,114,60,100,,92,22,23.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Glucose,Follow-up 110 A,348,96,60,100,,92,4,4.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-19,230,100,220,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,186,100,220,Y,186,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,22,200,100,220,,186,14,7.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,30,214,100,220,,186,28,15.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 A,43,200,100,220,,186,14,7.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 A,92,177,100,220,,186,-9,-4.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 8 A,99,188,100,220,,186,2,1.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 6 Day 1 A,115,199,100,220,,186,13,7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 6 Day 8 A,122,192,100,220,,186,6,3.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 7 Day 1 A,136,188,100,220,,186,2,1.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 7 Day 8 A,143,185,100,220,,186,-1,-0.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 8 Day 1 A,155,179,100,220,,186,-7,-3.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 8 Day 8 A,162,170,100,220,,186,-16,-8.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 9 Day 1 A,176,183,100,220,,186,-3,-1.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 9 Day 8 A,183,183,100,220,,186,-3,-1.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 10 Day 1 A,197,183,100,220,,186,-3,-1.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),,-19,4.7,3.5,5.2,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Baseline,1,4.1,3.5,5.2,Y,4.1,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,3.8,3.5,5.2,,4.1,-0.2999999999999998,-7.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,22,4,3.5,5.2,,4.1,-0.09999999999999964,-2.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,30,4,3.5,5.2,,4.1,-0.09999999999999964,-2.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 A,43,4.5,3.5,5.2,,4.1,0.40000000000000036,9.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 8 A,51,3.7,3.5,5.2,,4.1,-0.39999999999999947,-9.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 4 Day 8 A,71,3.7,3.5,5.2,,4.1,-0.39999999999999947,-9.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 A,92,3.7,3.5,5.2,,4.1,-0.39999999999999947,-9.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 5 Day 8 A,99,3.9,3.5,5.2,,4.1,-0.19999999999999973,-4.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 6 Day 1 A,115,4.7,3.5,5.2,,4.1,0.6000000000000005,14.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 6 Day 8 A,122,4,3.5,5.2,,4.1,-0.09999999999999964,-2.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 7 Day 1 A,136,3.7,3.5,5.2,,4.1,-0.39999999999999947,-9.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 7 Day 8 A,143,4,3.5,5.2,,4.1,-0.09999999999999964,-2.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 8 Day 1 A,155,4.8,3.5,5.2,,4.1,0.7000000000000002,17.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 8 Day 8 A,162,4.1,3.5,5.2,,4.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 9 Day 1 A,176,4.4,3.5,5.2,,4.1,0.3000000000000007,7.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 9 Day 8 A,183,4.2,3.5,5.2,,4.1,0.10000000000000053,2.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 10 Day 1 A,197,4.3,3.5,5.2,,4.1,0.20000000000000018,4.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 11 Day 1 A,218,4.4,3.5,5.2,,4.1,0.3000000000000007,7.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 12 Day 1 A,241,4.1,3.5,5.2,,4.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 12 Day 8 A,249,4.2,3.5,5.2,,4.1,0.10000000000000053,2.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),End of Treatment A,274,4.2,3.5,5.2,,4.1,0.10000000000000053,2.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Follow-up 110 A,348,4.6,3.5,5.2,,4.1,0.5,12.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,,-19,143,135,145,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Baseline,1,140,135,145,Y,140,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 1 Day 8 A,8,139,135,145,,140,-1,-0.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 2 Day 1 A,22,138,135,145,,140,-2,-1.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 2 Day 8 A,30,138,135,145,,140,-2,-1.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 3 Day 1 A,43,137,135,145,,140,-3,-2.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 3 Day 8 A,51,128,135,145,,140,-12,-8.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 4 Day 8 A,71,137,135,145,,140,-3,-2.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 5 Day 1 A,92,134,135,145,,140,-6,-4.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 5 Day 8 A,99,139,135,145,,140,-1,-0.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 6 Day 1 A,115,138,135,145,,140,-2,-1.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 6 Day 8 A,122,137,135,145,,140,-3,-2.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 7 Day 1 A,136,140,135,145,,140,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 7 Day 8 A,143,140,135,145,,140,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 8 Day 1 A,155,140,135,145,,140,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 8 Day 8 A,162,138,135,145,,140,-2,-1.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 9 Day 1 A,176,140,135,145,,140,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 9 Day 8 A,183,141,135,145,,140,1,0.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 10 Day 1 A,197,138,135,145,,140,-2,-1.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 11 Day 1 A,218,138,135,145,,140,-2,-1.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 12 Day 1 A,241,140,135,145,,140,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Cycle 12 Day 8 A,249,138,135,145,,140,-2,-1.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,End of Treatment A,274,138,135,145,,140,-2,-1.4
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Sodium,Follow-up 110 A,348,136,135,145,,140,-4,-2.9
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,,-19,0.7,0.1,1.2,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Baseline,1,0.6,0.1,1.2,Y,0.6,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.5,0.1,1.2,,0.6,-0.09999999999999998,-16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,22,0.6,0.1,1.2,,0.6,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,30,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 3 Day 1 A,43,0.7,0.1,1.2,,0.6,0.09999999999999998,16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 3 Day 8 A,51,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 4 Day 8 A,71,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 5 Day 1 A,92,0.6,0.1,1.2,,0.6,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 5 Day 8 A,99,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 6 Day 1 A,115,0.7,0.1,1.2,,0.6,0.09999999999999998,16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 6 Day 8 A,122,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 7 Day 1 A,136,0.6,0.1,1.2,,0.6,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 7 Day 8 A,143,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 8 Day 1 A,155,0.6,0.1,1.2,,0.6,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 8 Day 8 A,162,0.5,0.1,1.2,,0.6,-0.09999999999999998,-16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 9 Day 1 A,176,0.6,0.1,1.2,,0.6,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 9 Day 8 A,183,0.3,0.1,1.2,,0.6,-0.3,-50
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 10 Day 1 A,197,0.5,0.1,1.2,,0.6,-0.09999999999999998,-16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 11 Day 1 A,218,0.6,0.1,1.2,,0.6,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 12 Day 1 A,241,0.6,0.1,1.2,,0.6,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 12 Day 8 A,249,0.5,0.1,1.2,,0.6,-0.09999999999999998,-16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,End of Treatment A,274,0.6,0.1,1.2,,0.6,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Bilirubin,Follow-up 110 A,348,0.5,0.1,1.2,,0.6,-0.09999999999999998,-16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,,-19,6.6,6,8.3,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Baseline,1,6.5,6,8.3,Y,6.5,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 1 Day 8 A,8,5.9,6,8.3,,6.5,-0.5999999999999996,-9.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 2 Day 1 A,22,6.6,6,8.3,,6.5,0.09999999999999964,1.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 2 Day 8 A,30,6.2,6,8.3,,6.5,-0.2999999999999998,-4.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 3 Day 1 A,43,6.5,6,8.3,,6.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 3 Day 8 A,51,6.3,6,8.3,,6.5,-0.20000000000000018,-3.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 4 Day 8 A,71,6.4,6,8.3,,6.5,-0.09999999999999964,-1.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 5 Day 1 A,92,6.8,6,8.3,,6.5,0.2999999999999998,4.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 5 Day 8 A,99,6.4,6,8.3,,6.5,-0.09999999999999964,-1.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 6 Day 1 A,115,7,6,8.3,,6.5,0.5,7.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 6 Day 8 A,122,6.9,6,8.3,,6.5,0.40000000000000036,6.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 7 Day 1 A,136,6.9,6,8.3,,6.5,0.40000000000000036,6.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 7 Day 8 A,143,6.4,6,8.3,,6.5,-0.09999999999999964,-1.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 8 Day 1 A,155,7.2,6,8.3,,6.5,0.7000000000000002,10.8
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 8 Day 8 A,162,6.5,6,8.3,,6.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 9 Day 1 A,176,7,6,8.3,,6.5,0.5,7.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 9 Day 8 A,183,6.3,6,8.3,,6.5,-0.20000000000000018,-3.1
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 10 Day 1 A,197,7,6,8.3,,6.5,0.5,7.7
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 11 Day 1 A,218,6.8,6,8.3,,6.5,0.2999999999999998,4.6
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 12 Day 1 A,241,6.9,6,8.3,,6.5,0.40000000000000036,6.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 12 Day 8 A,249,6.6,6,8.3,,6.5,0.09999999999999964,1.5
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,End of Treatment A,274,7.1,6,8.3,,6.5,0.5999999999999996,9.2
5A,A,NKTR-214 + Nivolumab,N,Y,Chemistry,Total Protein,Follow-up 110 A,348,6.9,6,8.3,,6.5,0.40000000000000036,6.2
5A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-19,33.5,25.4,34.9,Y,33.5,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-19,1.6,2,3,Y,1.6,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Baseline,-19,18.4,12.3,14.9,Y,18.4,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,,-19,0.1,0,0.2,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Baseline,1,0.1,0,0.2,Y,0.1,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 2 A,2,0,0,0.2,,0.1,-0.1,-100
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 3 A,3,0,0,0.2,,0.1,-0.1,-100
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 8 A,8,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 2 Day 1 A,22,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 2 Day 8 A,30,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 3 Day 1 A,43,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 3 Day 8 A,51,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 4 Day 1 A,64,1.4,0,0.2,,0.1,1.2999999999999998,1300
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 4 Day 8 A,71,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 5 Day 1 A,92,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 5 Day 8 A,99,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 6 Day 1 A,115,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 6 Day 8 A,122,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 7 Day 1 A,136,0,0,0.2,,0.1,-0.1,-100
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 7 Day 8 A,143,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 8 Day 1 A,155,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 8 Day 8 A,162,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 9 Day 1 A,176,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 9 Day 8 A,183,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 10 Day 1 A,197,1.1,0,0.2,,0.1,1,1000
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 11 Day 1 A,218,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 12 Day 1 A,241,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Cycle 12 Day 8 A,249,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,End of Treatment A,274,0.1,0,0.2,,0.1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Basophils,Follow-up 110 A,348,0,0,0.2,,0.1,-0.1,-100
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,,-19,0.2,0,0.6,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Baseline,1,0.2,0,0.6,Y,0.2,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.2,0,0.6,,0.2,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.2,0,0.6,,0.2,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.5,0,0.6,,0.2,0.3,150
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 2 Day 1 A,22,0.7,0,0.6,,0.2,0.49999999999999994,250
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 2 Day 8 A,30,5.1,0,0.6,,0.2,4.8999999999999995,2450
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 3 Day 1 A,43,0.7,0,0.6,,0.2,0.49999999999999994,250
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 3 Day 8 A,51,7.2,0,0.6,,0.2,7,3500
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 4 Day 1 A,64,1.3,0,0.6,,0.2,1.1,550
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 4 Day 8 A,71,7.2,0,0.6,,0.2,7,3500
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 5 Day 1 A,92,1.3,0,0.6,,0.2,1.1,550
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 5 Day 8 A,99,2.7,0,0.6,,0.2,2.5,1250
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 6 Day 1 A,115,1.4,0,0.6,,0.2,1.2,600
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 6 Day 8 A,122,3.7,0,0.6,,0.2,3.5,1750
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 7 Day 1 A,136,0.6,0,0.6,,0.2,0.39999999999999997,200
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 7 Day 8 A,143,3,0,0.6,,0.2,2.8,1400
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 8 Day 1 A,155,0.7,0,0.6,,0.2,0.49999999999999994,250
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 8 Day 8 A,162,4.9,0,0.6,,0.2,4.7,2350
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 9 Day 1 A,176,0.8,0,0.6,,0.2,0.6000000000000001,300
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 9 Day 8 A,183,5.2,0,0.6,,0.2,5,2500
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 10 Day 1 A,197,1,0,0.6,,0.2,0.8,400
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 11 Day 1 A,218,0.9,0,0.6,,0.2,0.7,350
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 12 Day 1 A,241,0.9,0,0.6,,0.2,0.7,350
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 12 Day 8 A,249,3.7,0,0.6,,0.2,3.5,1750
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,End of Treatment A,274,0.7,0,0.6,,0.2,0.49999999999999994,250
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Eosinophils,Follow-up 110 A,348,0.3,0,0.6,,0.2,0.09999999999999998,50
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),,-19,4.34,4.5,6,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Baseline,1,4.16,4.5,6,Y,4.16,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,4.17,4.5,6,,4.16,0.009999999999999787,0.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,4.17,4.5,6,,4.16,0.009999999999999787,0.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,4.08,4.5,6,,4.16,-0.08000000000000007,-1.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,22,4.14,4.5,6,,4.16,-0.020000000000000462,-0.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,30,3.96,4.5,6,,4.16,-0.20000000000000018,-4.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 A,43,4.09,4.5,6,,4.16,-0.07000000000000028,-1.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 8 A,51,3.88,4.5,6,,4.16,-0.28000000000000025,-6.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 A,64,4.15,4.5,6,,4.16,-0.009999999999999787,-0.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 8 A,71,3.77,4.5,6,,4.16,-0.3900000000000001,-9.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 A,92,3.91,4.5,6,,4.16,-0.25,-6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 8 A,99,3.81,4.5,6,,4.16,-0.3500000000000001,-8.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 6 Day 1 A,115,3.98,4.5,6,,4.16,-0.18000000000000016,-4.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 6 Day 8 A,122,3.93,4.5,6,,4.16,-0.22999999999999998,-5.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 7 Day 1 A,136,3.92,4.5,6,,4.16,-0.2400000000000002,-5.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 7 Day 8 A,143,3.7,4.5,6,,4.16,-0.45999999999999996,-11.1
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 8 Day 1 A,155,3.99,4.5,6,,4.16,-0.16999999999999993,-4.1
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 8 Day 8 A,162,3.91,4.5,6,,4.16,-0.25,-6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 9 Day 1 A,176,4.05,4.5,6,,4.16,-0.11000000000000032,-2.6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 9 Day 8 A,183,3.84,4.5,6,,4.16,-0.3200000000000003,-7.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 10 Day 1 A,197,4.04,4.5,6,,4.16,-0.1200000000000001,-2.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 11 Day 1 A,218,3.97,4.5,6,,4.16,-0.18999999999999995,-4.6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 12 Day 1 A,241,3.92,4.5,6,,4.16,-0.2400000000000002,-5.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 12 Day 8 A,249,3.85,4.5,6,,4.16,-0.31000000000000005,-7.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),End of Treatment A,274,4.11,4.5,6,,4.16,-0.04999999999999982,-1.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Follow-up 110 A,348,4.09,4.5,6,,4.16,-0.07000000000000028,-1.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),,-19,40.3,42,52,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Baseline,1,38.5,42,52,Y,38.5,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,38.8,42,52,,38.5,0.29999999999999716,0.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,38.6,42,52,,38.5,0.10000000000000142,0.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,37.4,42,52,,38.5,-1.1000000000000014,-2.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,22,38,42,52,,38.5,-0.5,-1.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,30,36.1,42,52,,38.5,-2.3999999999999986,-6.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 A,43,37.1,42,52,,38.5,-1.3999999999999986,-3.6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 8 A,51,35.3,42,52,,38.5,-3.200000000000003,-8.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 A,64,38.1,42,52,,38.5,-0.3999999999999986,-1
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 8 A,71,34.8,42,52,,38.5,-3.700000000000003,-9.6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 A,92,36.1,42,52,,38.5,-2.3999999999999986,-6.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 5 Day 8 A,99,35.3,42,52,,38.5,-3.200000000000003,-8.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 6 Day 1 A,115,36.8,42,52,,38.5,-1.7000000000000028,-4.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 6 Day 8 A,122,36.3,42,52,,38.5,-2.200000000000003,-5.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 7 Day 1 A,136,36.6,42,52,,38.5,-1.8999999999999986,-4.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 7 Day 8 A,143,34.7,42,52,,38.5,-3.799999999999997,-9.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 8 Day 1 A,155,37.7,42,52,,38.5,-0.7999999999999972,-2.1
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 8 Day 8 A,162,36.7,42,52,,38.5,-1.7999999999999972,-4.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 9 Day 1 A,176,38.4,42,52,,38.5,-0.10000000000000142,-0.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 9 Day 8 A,183,36.9,42,52,,38.5,-1.6000000000000014,-4.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 10 Day 1 A,197,38.2,42,52,,38.5,-0.29999999999999716,-0.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 11 Day 1 A,218,36.9,42,52,,38.5,-1.6000000000000014,-4.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 12 Day 1 A,241,37,42,52,,38.5,-1.5,-3.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 12 Day 8 A,249,35.5,42,52,,38.5,-3,-7.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),End of Treatment A,274,38.2,42,52,,38.5,-0.29999999999999716,-0.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Follow-up 110 A,348,38.7,42,52,,38.5,0.20000000000000284,0.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),,-19,14.1,13.9,16.3,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Baseline,1,13.4,13.9,16.3,Y,13.4,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,13.4,13.9,16.3,,13.4,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,13.4,13.9,16.3,,13.4,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,12.9,13.9,16.3,,13.4,-0.5,-3.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,22,13,13.9,16.3,,13.4,-0.40000000000000036,-3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,30,12.6,13.9,16.3,,13.4,-0.8000000000000007,-6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 A,43,12.7,13.9,16.3,,13.4,-0.7000000000000011,-5.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 8 A,51,11.8,13.9,16.3,,13.4,-1.5999999999999996,-11.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 A,64,12.7,13.9,16.3,,13.4,-0.7000000000000011,-5.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 8 A,71,12,13.9,16.3,,13.4,-1.4000000000000004,-10.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 A,92,12.6,13.9,16.3,,13.4,-0.8000000000000007,-6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 5 Day 8 A,99,12.2,13.9,16.3,,13.4,-1.200000000000001,-9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 6 Day 1 A,115,12.9,13.9,16.3,,13.4,-0.5,-3.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 6 Day 8 A,122,12.7,13.9,16.3,,13.4,-0.7000000000000011,-5.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 7 Day 1 A,136,12.7,13.9,16.3,,13.4,-0.7000000000000011,-5.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 7 Day 8 A,143,12.1,13.9,16.3,,13.4,-1.3000000000000007,-9.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 8 Day 1 A,155,13,13.9,16.3,,13.4,-0.40000000000000036,-3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 8 Day 8 A,162,12.7,13.9,16.3,,13.4,-0.7000000000000011,-5.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 9 Day 1 A,176,13.2,13.9,16.3,,13.4,-0.20000000000000107,-1.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 9 Day 8 A,183,12.6,13.9,16.3,,13.4,-0.8000000000000007,-6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 10 Day 1 A,197,13.3,13.9,16.3,,13.4,-0.09999999999999964,-0.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 11 Day 1 A,218,12.8,13.9,16.3,,13.4,-0.5999999999999996,-4.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 12 Day 1 A,241,12.7,13.9,16.3,,13.4,-0.7000000000000011,-5.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 12 Day 8 A,249,12.4,13.9,16.3,,13.4,-1,-7.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),End of Treatment A,274,12.8,13.9,16.3,,13.4,-0.5999999999999996,-4.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Follow-up 110 A,348,13.2,13.9,16.3,,13.4,-0.20000000000000107,-1.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,,-19,1,1,4.5,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Baseline,1,1,1,4.5,Y,1,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.2,1,4.5,,1,-0.8,-80
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.1,1,4.5,,1,-0.9,-90
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,2.1,1,4.5,,1,1.1,110
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 2 Day 1 A,22,1.4,1,4.5,,1,0.3999999999999999,40
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 2 Day 8 A,30,2.8,1,4.5,,1,1.7999999999999998,180
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 3 Day 1 A,43,1,1,4.5,,1,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 3 Day 8 A,51,3,1,4.5,,1,2,200
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 4 Day 1 A,64,1.8,1,4.5,,1,0.8,80
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 4 Day 8 A,71,3,1,4.5,,1,2,200
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 5 Day 1 A,92,1.3,1,4.5,,1,0.30000000000000004,30
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 5 Day 8 A,99,2.8,1,4.5,,1,1.7999999999999998,180
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 6 Day 1 A,115,1.4,1,4.5,,1,0.3999999999999999,40
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 6 Day 8 A,122,2,1,4.5,,1,1,100
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 7 Day 1 A,136,1.3,1,4.5,,1,0.30000000000000004,30
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 7 Day 8 A,143,2.4,1,4.5,,1,1.4,140
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 8 Day 1 A,155,1.5,1,4.5,,1,0.5,50
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 8 Day 8 A,162,2.6,1,4.5,,1,1.6,160
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 9 Day 1 A,176,1.7,1,4.5,,1,0.7,70
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 9 Day 8 A,183,2,1,4.5,,1,1,100
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 10 Day 1 A,197,1.5,1,4.5,,1,0.5,50
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 11 Day 1 A,218,1.3,1,4.5,,1,0.30000000000000004,30
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 12 Day 1 A,241,1.1,1,4.5,,1,0.10000000000000009,10
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 12 Day 8 A,249,2.5,1,4.5,,1,1.5,150
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,End of Treatment A,274,1.6,1,4.5,,1,0.6000000000000001,60
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Lymphocytes,Follow-up 110 A,348,1.5,1,4.5,,1,0.5,50
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,,-19,0.5,0.2,1,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Baseline,1,0.5,0.2,1,Y,0.5,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.6,0.2,1,,0.5,0.09999999999999998,20
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.8,0.2,1,,0.5,0.30000000000000004,60
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 8 A,8,0.7,0.2,1,,0.5,0.19999999999999996,40
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 2 Day 1 A,22,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 2 Day 8 A,30,0.7,0.2,1,,0.5,0.19999999999999996,40
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 3 Day 1 A,43,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 3 Day 8 A,51,0.6,0.2,1,,0.5,0.09999999999999998,20
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 4 Day 1 A,64,0.4,0.2,1,,0.5,-0.09999999999999998,-20
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 4 Day 8 A,71,0.7,0.2,1,,0.5,0.19999999999999996,40
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 5 Day 1 A,92,0.4,0.2,1,,0.5,-0.09999999999999998,-20
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 5 Day 8 A,99,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 6 Day 1 A,115,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 6 Day 8 A,122,0.4,0.2,1,,0.5,-0.09999999999999998,-20
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 7 Day 1 A,136,0.3,0.2,1,,0.5,-0.2,-40
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 7 Day 8 A,143,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 8 Day 1 A,155,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 8 Day 8 A,162,0.3,0.2,1,,0.5,-0.2,-40
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 9 Day 1 A,176,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 9 Day 8 A,183,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 10 Day 1 A,197,0.6,0.2,1,,0.5,0.09999999999999998,20
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 11 Day 1 A,218,0.3,0.2,1,,0.5,-0.2,-40
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 12 Day 1 A,241,0.3,0.2,1,,0.5,-0.2,-40
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Cycle 12 Day 8 A,249,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,End of Treatment A,274,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Monocytes,Follow-up 110 A,348,0.5,0.2,1,,0.5,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,,-19,3.6,1.9,8,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Baseline,1,3,1.9,8,Y,3,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 2 A,2,5,1.9,8,,3,2,66.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 3 A,3,5.1,1.9,8,,3,2.0999999999999996,70
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 8 A,8,2,1.9,8,,3,-1,-33.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 2 Day 1 A,22,2.7,1.9,8,,3,-0.2999999999999998,-10
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 2 Day 8 A,30,1.9,1.9,8,,3,-1.1,-36.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 3 Day 1 A,43,3,1.9,8,,3,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 3 Day 8 A,51,2.02,1.9,8,,3,-0.98,-32.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 4 Day 1 A,64,3.4,1.9,8,,3,0.3999999999999999,13.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 4 Day 8 A,71,2.5,1.9,8,,3,-0.5,-16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 5 Day 1 A,92,2.6,1.9,8,,3,-0.3999999999999999,-13.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 5 Day 8 A,99,2.1,1.9,8,,3,-0.8999999999999999,-30
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 6 Day 1 A,115,2.9,1.9,8,,3,-0.10000000000000009,-3.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 6 Day 8 A,122,2.2,1.9,8,,3,-0.7999999999999998,-26.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 7 Day 1 A,136,2.4,1.9,8,,3,-0.6000000000000001,-20
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 7 Day 8 A,143,2.8,1.9,8,,3,-0.20000000000000018,-6.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 8 Day 1 A,155,3.3,1.9,8,,3,0.2999999999999998,10
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 8 Day 8 A,162,2.3,1.9,8,,3,-0.7000000000000002,-23.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 9 Day 1 A,176,3.1,1.9,8,,3,0.10000000000000009,3.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 9 Day 8 A,183,2.22,1.9,8,,3,-0.7799999999999998,-26
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 10 Day 1 A,197,3.7,1.9,8,,3,0.7000000000000002,23.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 11 Day 1 A,218,3.2,1.9,8,,3,0.20000000000000018,6.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 12 Day 1 A,241,2.6,1.9,8,,3,-0.3999999999999999,-13.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 12 Day 8 A,249,2.4,1.9,8,,3,-0.6000000000000001,-20
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,End of Treatment A,274,3.5,1.9,8,,3,0.5,16.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Neutrophils,Follow-up 110 A,348,4.1,1.9,8,,3,1.0999999999999996,36.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),,-19,266,150,450,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Baseline,1,261,150,450,Y,261,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,222,150,450,,261,-39,-14.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,186,150,450,,261,-75,-28.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,215,150,450,,261,-46,-17.6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,22,314,150,450,,261,53,20.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,30,262,150,450,,261,1,0.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 1 A,43,298,150,450,,261,37,14.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 8 A,51,309,150,450,,261,48,18.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 1 A,64,366,150,450,,261,105,40.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 8 A,71,284,150,450,,261,23,8.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 5 Day 1 A,92,246,150,450,,261,-15,-5.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 5 Day 8 A,99,286,150,450,,261,25,9.6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 6 Day 1 A,115,282,150,450,,261,21,8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 6 Day 8 A,122,274,150,450,,261,13,5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 7 Day 1 A,136,270,150,450,,261,9,3.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 7 Day 8 A,143,284,150,450,,261,23,8.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 8 Day 1 A,155,331,150,450,,261,70,26.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 8 Day 8 A,162,238,150,450,,261,-23,-8.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 9 Day 1 A,176,300,150,450,,261,39,14.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 9 Day 8 A,183,247,150,450,,261,-14,-5.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 10 Day 1 A,197,340,150,450,,261,79,30.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 11 Day 1 A,218,320,150,450,,261,59,22.6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 12 Day 1 A,241,306,150,450,,261,45,17.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 12 Day 8 A,249,275,150,450,,261,14,5.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),End of Treatment A,274,322,150,450,,261,61,23.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Follow-up 110 A,348,299,150,450,,261,38,14.6
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,TESTR,Baseline,-19,4.91,300,1080,Y,4.91,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,,-19,5.3,4.5,11,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Baseline,1,4.7,4.5,11,Y,4.7,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,6,4.5,11,,4.7,1.2999999999999998,27.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,6.3,4.5,11,,4.7,1.5999999999999996,34
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,5.5,4.5,11,,4.7,0.7999999999999998,17
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 2 Day 1 A,22,5.4,4.5,11,,4.7,0.7000000000000002,14.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 2 Day 8 A,30,10.6,4.5,11,,4.7,5.8999999999999995,125.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 3 Day 1 A,43,5.3,4.5,11,,4.7,0.5999999999999996,12.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 3 Day 8 A,51,12.6,4.5,11,,4.7,7.8999999999999995,168.1
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 4 Day 1 A,64,7.1,4.5,11,,4.7,2.3999999999999995,51.1
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 4 Day 8 A,71,13.6,4.5,11,,4.7,8.899999999999999,189.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 5 Day 1 A,92,5.8,4.5,11,,4.7,1.0999999999999996,23.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 5 Day 8 A,99,8.2,4.5,11,,4.7,3.499999999999999,74.5
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 6 Day 1 A,115,6.3,4.5,11,,4.7,1.5999999999999996,34
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 6 Day 8 A,122,8.4,4.5,11,,4.7,3.7,78.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 7 Day 1 A,136,4.7,4.5,11,,4.7,0,0
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 7 Day 8 A,143,8,4.5,11,,4.7,3.3,70.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 8 Day 1 A,155,6,4.5,11,,4.7,1.2999999999999998,27.7
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 8 Day 8 A,162,10,4.5,11,,4.7,5.3,112.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 9 Day 1 A,176,6.2,4.5,11,,4.7,1.5,31.9
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 9 Day 8 A,183,12.6,4.5,11,,4.7,7.8999999999999995,168.1
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 10 Day 1 A,197,6.9,4.5,11,,4.7,2.2,46.8
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 11 Day 1 A,218,5.8,4.5,11,,4.7,1.0999999999999996,23.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 12 Day 1 A,241,5,4.5,11,,4.7,0.2999999999999998,6.4
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 12 Day 8 A,249,9.6,4.5,11,,4.7,4.8999999999999995,104.3
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,End of Treatment A,274,6.4,4.5,11,,4.7,1.7000000000000002,36.2
5A,A,NKTR-214 + Nivolumab,N,Y,Hematology,White Blood Cells,Follow-up 110 A,348,6.5,4.5,11,,4.7,1.7999999999999998,38.3
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Baseline,-19,1.57,NA,NA,Y,1.57,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,22,2.58,NA,NA,,1.57,1.01,64.3
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 3 Day 1 A,43,4.65,NA,NA,,1.57,3.08,196.2
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 4 Day 1 A,64,6.41,NA,NA,,1.57,4.84,308.3
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 5 Day 1 A,92,6.45,NA,NA,,1.57,4.88,310.8
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 6 Day 1 A,115,6.69,NA,NA,,1.57,5.12,326.1
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 8 Day 1 A,155,13.44,NA,NA,,1.57,11.87,756.1
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 9 Day 1 A,176,13.84,NA,NA,,1.57,12.27,781.5
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 10 Day 1 A,197,17.9,NA,NA,,1.57,16.33,1040.1
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 11 Day 1 A,218,18.75,NA,NA,,1.57,17.18,1094.3
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 12 Day 1 A,241,23.98,NA,NA,,1.57,22.41,1427.4
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,End of Treatment A,274,9.19,NA,NA,,1.57,7.619999999999999,485.4
5A,A,NKTR-214 + Nivolumab,N,Y,Prostate-specific antigen,PSA,Follow-up 110 A,348,3.44,NA,NA,,1.57,1.8699999999999999,119.1
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 6 Day 1 A,115,1.15,0.8,1.5,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 8 Day 1 A,155,0.98,0.8,1.5,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 10 Day 1 A,197,1.1,0.8,1.5,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-19,0.84,0.4,4.2,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.1,0.4,4.2,Y,1.1,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,22,0.02,0.4,4.2,,1.1,-1.08,-98.2
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 A,43,0.03,0.4,4.2,,1.1,-1.07,-97.3
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 A,64,34.99,0.4,4.2,,1.1,33.89,3080.9
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 A,92,14.04,0.4,4.2,,1.1,12.94,1176.4
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 6 Day 1 A,115,4.5,0.4,4.2,,1.1,3.4,309.1
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 7 Day 1 A,136,3.84,0.4,4.2,,1.1,2.7399999999999998,249.1
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 8 Day 1 A,155,5.91,0.4,4.2,,1.1,4.8100000000000005,437.3
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 9 Day 1 A,176,2.98,0.4,4.2,,1.1,1.88,170.9
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 10 Day 1 A,197,4.33,0.4,4.2,,1.1,3.23,293.6
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 11 Day 1 A,218,3.82,0.4,4.2,,1.1,2.7199999999999998,247.3
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 12 Day 1 A,241,0.79,0.4,4.2,,1.1,-0.31000000000000005,-28.2
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,274,0.61,0.4,4.2,,1.1,-0.4900000000000001,-44.5
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Triiodothyronine (T3),Cycle 6 Day 1 A,115,3.1,2.5,3.9,,NA,NA,NA
5A,A,NKTR-214 + Nivolumab,N,Y,Thyroid Function Testing,Triiodothyronine (T3),Cycle 10 Day 1 A,197,2.94,2.5,3.9,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,,CTC,Baseline,1,0,NA,NA,Y,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,,CTC,Cycle 2 Day 1 B,30,0,NA,NA,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,,CTC,Cycle 3 Day 1 B,58,0,NA,NA,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,,CTC,Cycle 4 Day 1 B,86,0,NA,NA,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,,CTC,Cycle 5 Day 1 B,114,0,NA,NA,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,,CTC,Cycle 6 Day 1 B,142,1,NA,NA,,0,1,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,,CTC,Cycle 9 Day 1 B,249,1,NA,NA,,0,1,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,,CTC,Cycle 10 Day 1 B,277,1,NA,NA,,0,1,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,,CTC,Cycle 11 Day 1 B,305,0,NA,NA,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),,-11,11,1,45,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,8,1,45,Y,8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,9,6,1,45,,8,-2,-25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,16,8,1,45,,8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,30,9,1,45,,8,1,12.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,58,6,1,45,,8,-2,-25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 B,86,8,1,45,,8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 B,114,13,1,45,,8,5,62.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 6 Day 1 B,142,8,1,45,,8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 7 Day 1 B,170,8,1,45,,8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 8 Day 1 B,221,6,1,45,,8,-2,-25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 9 Day 1 B,249,6,1,45,,8,-2,-25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 10 Day 1 B,277,11,1,45,,8,3,37.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 11 Day 1 B,305,18,1,45,,8,10,125
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,359,44,1,45,,8,36,450
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 B,422,42,1,45,,8,34,425
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),,-11,4.1,3.5,4.9,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Baseline,1,3.8,3.5,4.9,Y,3.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,9,3.8,3.5,4.9,,3.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,16,3.8,3.5,4.9,,3.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,30,4,3.5,4.9,,3.8,0.20000000000000018,5.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,58,3.8,3.5,4.9,,3.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 4 Day 1 B,86,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 5 Day 1 B,114,4,3.5,4.9,,3.8,0.20000000000000018,5.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 6 Day 1 B,142,3.6,3.5,4.9,,3.8,-0.19999999999999973,-5.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 7 Day 1 B,170,3.8,3.5,4.9,,3.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 8 Day 1 B,221,3.4,3.5,4.9,,3.8,-0.3999999999999999,-10.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 9 Day 1 B,249,3.9,3.5,4.9,,3.8,0.10000000000000009,2.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 10 Day 1 B,277,4.3,3.5,4.9,,3.8,0.5,13.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Cycle 11 Day 1 B,305,3.8,3.5,4.9,,3.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),End of Treatment B,359,2.9,3.5,4.9,,3.8,-0.8999999999999999,-23.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Albumin (g/dL),Follow-up 110 B,422,3,3.5,4.9,,3.8,-0.7999999999999998,-21.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),,-11,109,38,126,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,102,38,126,Y,102,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,9,92,38,126,,102,-10,-9.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,16,85,38,126,,102,-17,-16.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,30,98,38,126,,102,-4,-3.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,58,79,38,126,,102,-23,-22.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 B,86,80,38,126,,102,-22,-21.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 B,114,85,38,126,,102,-17,-16.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 6 Day 1 B,142,83,38,126,,102,-19,-18.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 7 Day 1 B,170,83,38,126,,102,-19,-18.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 8 Day 1 B,221,67,38,126,,102,-35,-34.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 9 Day 1 B,249,87,38,126,,102,-15,-14.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 10 Day 1 B,277,96,38,126,,102,-6,-5.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 11 Day 1 B,305,95,38,126,,102,-7,-6.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,359,89,38,126,,102,-13,-12.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 B,422,84,38,126,,102,-18,-17.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-11,15,1,35,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,13,1,35,Y,13,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,9,12,1,35,,13,-1,-7.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,16,15,1,35,,13,2,15.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,30,13,1,35,,13,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,58,12,1,35,,13,-1,-7.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 B,86,12,1,35,,13,-1,-7.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 B,114,14,1,35,,13,1,7.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 6 Day 1 B,142,13,1,35,,13,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 7 Day 1 B,170,11,1,35,,13,-2,-15.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 8 Day 1 B,221,9,1,35,,13,-4,-30.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 9 Day 1 B,249,10,1,35,,13,-3,-23.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 10 Day 1 B,277,15,1,35,,13,2,15.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 11 Day 1 B,305,18,1,35,,13,5,38.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,359,37,1,35,,13,24,184.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 B,422,28,1,35,,13,15,115.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,,-11,27,6,23,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Baseline,1,13,6,23,Y,13,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 1 Day 8 B,9,22,6,23,,13,9,69.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 1 Day 15 B,16,24,6,23,,13,11,84.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 2 Day 1 B,30,26,6,23,,13,13,100
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 3 Day 1 B,58,22,6,23,,13,9,69.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 4 Day 1 B,86,21,6,23,,13,8,61.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 5 Day 1 B,114,25,6,23,,13,12,92.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 6 Day 1 B,142,19,6,23,,13,6,46.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 7 Day 1 B,170,30,6,23,,13,17,130.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 8 Day 1 B,221,16,6,23,,13,3,23.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 9 Day 1 B,249,24,6,23,,13,11,84.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 10 Day 1 B,277,21,6,23,,13,8,61.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Cycle 11 Day 1 B,305,19,6,23,,13,6,46.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,End of Treatment B,359,22,6,23,,13,9,69.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,BUN,Follow-up 110 B,422,12,6,23,,13,-1,-7.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,,-11,29,22,30,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Baseline,1,25.8,22,30,Y,25.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 1 Day 8 B,9,26,22,30,,25.8,0.1999999999999993,0.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 1 Day 15 B,16,26,22,30,,25.8,0.1999999999999993,0.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 2 Day 1 B,30,24,22,30,,25.8,-1.8000000000000007,-7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 3 Day 1 B,58,23,22,30,,25.8,-2.8000000000000007,-10.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 4 Day 1 B,86,24.3,22,30,,25.8,-1.5,-5.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 5 Day 1 B,114,24.9,22,30,,25.8,-0.9000000000000021,-3.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 6 Day 1 B,142,26.5,22,30,,25.8,0.6999999999999993,2.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 7 Day 1 B,170,30,22,30,,25.8,4.199999999999999,16.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 8 Day 1 B,221,26.2,22,30,,25.8,0.3999999999999986,1.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 9 Day 1 B,249,23.5,22,30,,25.8,-2.3000000000000007,-8.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 10 Day 1 B,277,21.8,22,30,,25.8,-4,-15.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Cycle 11 Day 1 B,305,1.57,22,30,,25.8,-24.23,-93.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,End of Treatment B,359,28.2,22,30,,25.8,2.3999999999999986,9.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Bicarbonate,Follow-up 110 B,422,23,22,30,,25.8,-2.8000000000000007,-10.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),,-11,10.1,8.5,10.5,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Baseline,1,9.6,8.5,10.5,Y,9.6,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,9,9.4,8.5,10.5,,9.6,-0.1999999999999993,-2.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,16,9.3,8.5,10.5,,9.6,-0.29999999999999893,-3.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,30,9.3,8.5,10.5,,9.6,-0.29999999999999893,-3.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,58,9.1,8.5,10.5,,9.6,-0.5,-5.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 B,86,9.3,8.5,10.5,,9.6,-0.29999999999999893,-3.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 B,114,9.6,8.5,10.5,,9.6,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 6 Day 1 B,142,9.1,8.5,10.5,,9.6,-0.5,-5.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 7 Day 1 B,170,8.9,8.5,10.5,,9.6,-0.6999999999999993,-7.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 8 Day 1 B,221,8.6,8.5,10.5,,9.6,-1,-10.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 9 Day 1 B,249,9.7,8.5,10.5,,9.6,0.09999999999999964,1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 10 Day 1 B,277,9.8,8.5,10.5,,9.6,0.20000000000000107,2.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Cycle 11 Day 1 B,305,9.4,8.5,10.5,,9.6,-0.1999999999999993,-2.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),End of Treatment B,359,8.1,8.5,10.5,,9.6,-1.5,-15.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Calcium (mmol/L),Follow-up 110 B,422,5.8,8.5,10.5,,9.6,-3.8,-39.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),,-11,106,96,108,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Baseline,1,105,96,108,Y,105,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,9,110,96,108,,105,5,4.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,16,110,96,108,,105,5,4.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,30,110,96,108,,105,5,4.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,58,112,96,108,,105,7,6.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 B,86,109,96,108,,105,4,3.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 B,114,106,96,108,,105,1,1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 6 Day 1 B,142,105,96,108,,105,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 7 Day 1 B,170,108,96,108,,105,3,2.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 8 Day 1 B,221,105,96,108,,105,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 9 Day 1 B,249,107,96,108,,105,2,1.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 10 Day 1 B,277,110,96,108,,105,5,4.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Cycle 11 Day 1 B,305,107,96,108,,105,2,1.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),End of Treatment B,359,107,96,108,,105,2,1.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Chloride (mmol/L),Follow-up 110 B,422,113,96,108,,105,8,7.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),,-11,1.47,0.7,1.3,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Baseline,1,1.37,0.7,1.3,Y,1.37,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,9,1.47,0.7,1.3,,1.37,0.09999999999999987,7.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,16,1.42,0.7,1.3,,1.37,0.04999999999999982,3.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,30,1.34,0.7,1.3,,1.37,-0.030000000000000027,-2.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,58,1.36,0.7,1.3,,1.37,-0.010000000000000009,-0.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 B,86,1.39,0.7,1.3,,1.37,0.019999999999999796,1.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 B,114,1.49,0.7,1.3,,1.37,0.11999999999999988,8.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 6 Day 1 B,142,1.26,0.7,1.3,,1.37,-0.1100000000000001,-8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 7 Day 1 B,170,1.44,0.7,1.3,,1.37,0.06999999999999984,5.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 8 Day 1 B,221,1.17,0.7,1.3,,1.37,-0.20000000000000018,-14.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 9 Day 1 B,249,1.45,0.7,1.3,,1.37,0.07999999999999985,5.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 10 Day 1 B,277,1.6,0.7,1.3,,1.37,0.22999999999999998,16.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Cycle 11 Day 1 B,305,1.57,0.7,1.3,,1.37,0.19999999999999996,14.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),End of Treatment B,359,1.03,0.7,1.3,,1.37,-0.3400000000000001,-24.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Creatinine (umol/L),Follow-up 110 B,422,0.86,0.7,1.3,,1.37,-0.5100000000000001,-37.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,,-11,101,60,100,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Baseline,1,77,60,100,Y,77,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 1 Day 8 B,9,100,60,100,,77,23,29.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 1 Day 15 B,16,102,60,100,,77,25,32.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 2 Day 1 B,30,120,60,100,,77,43,55.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 3 Day 1 B,58,101,60,100,,77,24,31.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 4 Day 1 B,86,129,60,100,,77,52,67.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 5 Day 1 B,114,138,60,100,,77,61,79.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 6 Day 1 B,142,113,60,100,,77,36,46.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 7 Day 1 B,170,129,60,100,,77,52,67.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 8 Day 1 B,221,95,60,100,,77,18,23.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 9 Day 1 B,249,112,60,100,,77,35,45.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 10 Day 1 B,277,134,60,100,,77,57,74
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Cycle 11 Day 1 B,305,108,60,100,,77,31,40.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,End of Treatment B,359,114,60,100,,77,37,48.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Glucose,Follow-up 110 B,422,111,60,100,,77,34,44.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-11,196,100,220,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,176,100,220,Y,176,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,9,199,100,220,,176,23,13.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,16,221,100,220,,176,45,25.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,30,213,100,220,,176,37,21
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,58,172,100,220,,176,-4,-2.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 B,86,170,100,220,,176,-6,-3.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 B,114,168,100,220,,176,-8,-4.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 6 Day 1 B,142,153,100,220,,176,-23,-13.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 7 Day 1 B,170,175,100,220,,176,-1,-0.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 8 Day 1 B,221,175,100,220,,176,-1,-0.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 9 Day 1 B,249,180,100,220,,176,4,2.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 10 Day 1 B,277,228,100,220,,176,52,29.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 11 Day 1 B,305,173,100,220,,176,-3,-1.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,359,243,100,220,,176,67,38.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),,-11,5.2,3.5,5.2,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Baseline,1,4.8,3.5,5.2,Y,4.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,9,4.8,3.5,5.2,,4.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,16,5,3.5,5.2,,4.8,0.20000000000000018,4.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,30,4.6,3.5,5.2,,4.8,-0.20000000000000018,-4.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,58,5,3.5,5.2,,4.8,0.20000000000000018,4.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 B,86,5.2,3.5,5.2,,4.8,0.40000000000000036,8.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 B,114,4.9,3.5,5.2,,4.8,0.10000000000000053,2.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 6 Day 1 B,142,4.9,3.5,5.2,,4.8,0.10000000000000053,2.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 7 Day 1 B,170,4.2,3.5,5.2,,4.8,-0.5999999999999996,-12.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 8 Day 1 B,221,4.1,3.5,5.2,,4.8,-0.7000000000000002,-14.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 9 Day 1 B,249,5,3.5,5.2,,4.8,0.20000000000000018,4.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 10 Day 1 B,277,4.9,3.5,5.2,,4.8,0.10000000000000053,2.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Cycle 11 Day 1 B,305,4.8,3.5,5.2,,4.8,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),End of Treatment B,359,4.7,3.5,5.2,,4.8,-0.09999999999999964,-2.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Potassium (mmol/L),Follow-up 110 B,422,3.8,3.5,5.2,,4.8,-1,-20.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,,-11,142,135,145,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Baseline,1,137,135,145,Y,137,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 1 Day 8 B,9,147,135,145,,137,10,7.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 1 Day 15 B,16,146,135,145,,137,9,6.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 2 Day 1 B,30,143,135,145,,137,6,4.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 3 Day 1 B,58,144,135,145,,137,7,5.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 4 Day 1 B,86,140,135,145,,137,3,2.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 5 Day 1 B,114,137,135,145,,137,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 6 Day 1 B,142,140,135,145,,137,3,2.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 7 Day 1 B,170,139,135,145,,137,2,1.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 8 Day 1 B,221,138,135,145,,137,1,0.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 9 Day 1 B,249,141,135,145,,137,4,2.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 10 Day 1 B,277,144,135,145,,137,7,5.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Cycle 11 Day 1 B,305,142,135,145,,137,5,3.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,End of Treatment B,359,143,135,145,,137,6,4.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Sodium,Follow-up 110 B,422,146,135,145,,137,9,6.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,,-11,0.2,0.1,1.2,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Baseline,1,0.2,0.1,1.2,Y,0.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,9,0.1,0.1,1.2,,0.2,-0.1,-50
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,16,0.1,0.1,1.2,,0.2,-0.1,-50
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,30,0.2,0.1,1.2,,0.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,58,0.1,0.1,1.2,,0.2,-0.1,-50
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 4 Day 1 B,86,0.3,0.1,1.2,,0.2,0.09999999999999998,50
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 5 Day 1 B,114,0.2,0.1,1.2,,0.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 6 Day 1 B,142,0.2,0.1,1.2,,0.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 7 Day 1 B,170,0.2,0.1,1.2,,0.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 8 Day 1 B,221,0.2,0.1,1.2,,0.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 9 Day 1 B,249,0.3,0.1,1.2,,0.2,0.09999999999999998,50
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 10 Day 1 B,277,0.3,0.1,1.2,,0.2,0.09999999999999998,50
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Cycle 11 Day 1 B,305,0.2,0.1,1.2,,0.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,End of Treatment B,359,0.2,0.1,1.2,,0.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Bilirubin,Follow-up 110 B,422,0.2,0.1,1.2,,0.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,,-11,7.4,6,8.3,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Baseline,1,7,6,8.3,Y,7,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 1 Day 8 B,9,7,6,8.3,,7,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 1 Day 15 B,16,7.2,6,8.3,,7,0.20000000000000018,2.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 2 Day 1 B,30,7.4,6,8.3,,7,0.40000000000000036,5.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 3 Day 1 B,58,7,6,8.3,,7,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 4 Day 1 B,86,6.8,6,8.3,,7,-0.20000000000000018,-2.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 5 Day 1 B,114,7.3,6,8.3,,7,0.2999999999999998,4.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 6 Day 1 B,142,6.8,6,8.3,,7,-0.20000000000000018,-2.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 7 Day 1 B,170,6.8,6,8.3,,7,-0.20000000000000018,-2.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 8 Day 1 B,221,6.2,6,8.3,,7,-0.7999999999999998,-11.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 9 Day 1 B,249,7.2,6,8.3,,7,0.20000000000000018,2.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 10 Day 1 B,277,7.8,6,8.3,,7,0.7999999999999998,11.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Cycle 11 Day 1 B,305,6.9,6,8.3,,7,-0.09999999999999964,-1.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,End of Treatment B,359,5.7,6,8.3,,7,-1.2999999999999998,-18.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Chemistry,Total Protein,Follow-up 110 B,422,5.8,6,8.3,,7,-1.2000000000000002,-17.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),,-11,27.1,25.4,34.9,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,31.3,25.4,34.9,Y,31.3,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,30,26.1,25.4,34.9,,31.3,-5.199999999999999,-16.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 B,58,28.9,25.4,34.9,,31.3,-2.400000000000002,-7.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 4 Day 1 B,86,25.5,25.4,34.9,,31.3,-5.800000000000001,-18.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 5 Day 1 B,114,28.3,25.4,34.9,,31.3,-3,-9.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 6 Day 1 B,142,28,25.4,34.9,,31.3,-3.3000000000000007,-10.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 7 Day 1 B,170,28.9,25.4,34.9,,31.3,-2.400000000000002,-7.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 8 Day 1 B,221,27.5,25.4,34.9,,31.3,-3.8000000000000007,-12.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 9 Day 1 B,249,27.4,25.4,34.9,,31.3,-3.900000000000002,-12.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 10 Day 1 B,277,27.5,25.4,34.9,,31.3,-3.8000000000000007,-12.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 11 Day 1 B,305,28.9,25.4,34.9,,31.3,-2.400000000000002,-7.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,352,28,25.4,34.9,,31.3,-3.3000000000000007,-10.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-11,1,2,3,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1,2,3,Y,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,30,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 B,58,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 4 Day 1 B,86,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 5 Day 1 B,114,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 6 Day 1 B,142,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 7 Day 1 B,170,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 8 Day 1 B,221,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 9 Day 1 B,249,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 10 Day 1 B,277,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 11 Day 1 B,305,1,2,3,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,352,1.3,2,3,,1,0.30000000000000004,30
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),,-11,12.4,12.3,14.9,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Baseline,1,13.2,12.3,14.9,Y,13.2,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,30,13.1,12.3,14.9,,13.2,-0.09999999999999964,-0.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 B,58,12.8,12.3,14.9,,13.2,-0.3999999999999986,-3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 4 Day 1 B,86,12.9,12.3,14.9,,13.2,-0.29999999999999893,-2.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 5 Day 1 B,114,12.6,12.3,14.9,,13.2,-0.5999999999999996,-4.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 6 Day 1 B,142,12.5,12.3,14.9,,13.2,-0.6999999999999993,-5.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 7 Day 1 B,170,12.9,12.3,14.9,,13.2,-0.29999999999999893,-2.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 8 Day 1 B,221,12.7,12.3,14.9,,13.2,-0.5,-3.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 9 Day 1 B,249,12.8,12.3,14.9,,13.2,-0.3999999999999986,-3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 10 Day 1 B,277,12.8,12.3,14.9,,13.2,-0.3999999999999986,-3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),Cycle 11 Day 1 B,305,13,12.3,14.9,,13.2,-0.1999999999999993,-1.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Coagulation,Prothrombin Time (PT),End of Treatment B,352,15.6,12.3,14.9,,13.2,2.4000000000000004,18.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,,-11,0,0,0.2,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 8 B,9,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 1 Day 15 B,16,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 2 Day 1 B,30,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 3 Day 1 B,58,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 4 Day 1 B,86,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 5 Day 1 B,114,0.6,0,0.2,,0,0.6,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 6 Day 1 B,142,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 7 Day 1 B,170,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 8 Day 1 B,221,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 9 Day 1 B,249,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 10 Day 1 B,277,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Cycle 11 Day 1 B,305,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,End of Treatment B,359,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Basophils,Follow-up 110 B,422,0,0,0.2,,0,0,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,,-11,0.1,0,0.6,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Baseline,1,0.1,0,0.6,Y,0.1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 8 B,9,0.2,0,0.6,,0.1,0.1,100
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 1 Day 15 B,16,0.3,0,0.6,,0.1,0.19999999999999998,200
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 2 Day 1 B,30,0.3,0,0.6,,0.1,0.19999999999999998,200
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 3 Day 1 B,58,0.3,0,0.6,,0.1,0.19999999999999998,200
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 4 Day 1 B,86,0.3,0,0.6,,0.1,0.19999999999999998,200
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 5 Day 1 B,114,0.4,0,0.6,,0.1,0.30000000000000004,300
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 6 Day 1 B,142,0.4,0,0.6,,0.1,0.30000000000000004,300
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 7 Day 1 B,170,0.3,0,0.6,,0.1,0.19999999999999998,200
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 8 Day 1 B,221,0.3,0,0.6,,0.1,0.19999999999999998,200
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 9 Day 1 B,249,0.3,0,0.6,,0.1,0.19999999999999998,200
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 10 Day 1 B,277,0.2,0,0.6,,0.1,0.1,100
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Cycle 11 Day 1 B,305,0.2,0,0.6,,0.1,0.1,100
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,End of Treatment B,359,0.1,0,0.6,,0.1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Eosinophils,Follow-up 110 B,422,0.2,0,0.6,,0.1,0.1,100
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),,-11,3.77,4.5,6,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Baseline,1,3.57,4.5,6,Y,3.57,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,9,3.51,4.5,6,,3.57,-0.06000000000000005,-1.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,16,3.38,4.5,6,,3.57,-0.18999999999999995,-5.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,30,3.04,4.5,6,,3.57,-0.5299999999999998,-14.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,58,2.54,4.5,6,,3.57,-1.0299999999999998,-28.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 B,86,3.26,4.5,6,,3.57,-0.31000000000000005,-8.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 B,114,3.34,4.5,6,,3.57,-0.22999999999999998,-6.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 6 Day 1 B,142,3.11,4.5,6,,3.57,-0.45999999999999996,-12.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 7 Day 1 B,170,2.39,4.5,6,,3.57,-1.1799999999999997,-33.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 8 Day 1 B,221,3.06,4.5,6,,3.57,-0.5099999999999998,-14.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 9 Day 1 B,249,3.32,4.5,6,,3.57,-0.25,-7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 10 Day 1 B,277,3.02,4.5,6,,3.57,-0.5499999999999998,-15.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Cycle 11 Day 1 B,305,2.88,4.5,6,,3.57,-0.69,-19.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),End of Treatment B,359,3.69,4.5,6,,3.57,0.1200000000000001,3.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,422,3.01,4.5,6,,3.57,-0.56,-15.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),,-11,34.3,42,52,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Baseline,1,31.7,42,52,Y,31.7,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,9,31.4,42,52,,31.7,-0.3000000000000007,-0.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,16,30.1,42,52,,31.7,-1.5999999999999979,-5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,30,26.7,42,52,,31.7,-5,-15.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,58,23.7,42,52,,31.7,-8,-25.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 B,86,29.8,42,52,,31.7,-1.8999999999999986,-6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 B,114,30.8,42,52,,31.7,-0.8999999999999986,-2.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 6 Day 1 B,142,28.6,42,52,,31.7,-3.099999999999998,-9.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 7 Day 1 B,170,22.2,42,52,,31.7,-9.5,-30
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 8 Day 1 B,221,27.3,42,52,,31.7,-4.399999999999999,-13.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 9 Day 1 B,249,31.9,42,52,,31.7,0.1999999999999993,0.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 10 Day 1 B,277,28.9,42,52,,31.7,-2.8000000000000007,-8.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Cycle 11 Day 1 B,305,27.7,42,52,,31.7,-4,-12.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),End of Treatment B,359,33.7,42,52,,31.7,2.0000000000000036,6.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hematocrit (RATIO),Follow-up 110 B,422,27,42,52,,31.7,-4.699999999999999,-14.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),,-11,11.2,13.9,16.3,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Baseline,1,10.7,13.9,16.3,Y,10.7,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,9,10.4,13.9,16.3,,10.7,-0.29999999999999893,-2.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,16,10.2,13.9,16.3,,10.7,-0.5,-4.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,30,9,13.9,16.3,,10.7,-1.6999999999999993,-15.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,58,7.9,13.9,16.3,,10.7,-2.799999999999999,-26.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 B,86,9.8,13.9,16.3,,10.7,-0.8999999999999986,-8.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 B,114,10.4,13.9,16.3,,10.7,-0.29999999999999893,-2.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 6 Day 1 B,142,9.6,13.9,16.3,,10.7,-1.0999999999999996,-10.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 7 Day 1 B,170,7.5,13.9,16.3,,10.7,-3.1999999999999993,-29.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 8 Day 1 B,221,9.1,13.9,16.3,,10.7,-1.5999999999999996,-15
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 9 Day 1 B,249,10.5,13.9,16.3,,10.7,-0.1999999999999993,-1.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 10 Day 1 B,277,9.5,13.9,16.3,,10.7,-1.1999999999999993,-11.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Cycle 11 Day 1 B,305,9.1,13.9,16.3,,10.7,-1.5999999999999996,-15
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),End of Treatment B,359,11.2,13.9,16.3,,10.7,0.5,4.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Hemoglobin (g/dL),Follow-up 110 B,422,9.3,13.9,16.3,,10.7,-1.3999999999999986,-13.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,,-11,1,1,4.5,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Baseline,1,1,1,4.5,Y,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 8 B,9,1.2,1,4.5,,1,0.19999999999999996,20
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 1 Day 15 B,16,1.3,1,4.5,,1,0.30000000000000004,30
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 2 Day 1 B,30,1,1,4.5,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 3 Day 1 B,58,0.9,1,4.5,,1,-0.09999999999999998,-10
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 4 Day 1 B,86,0.6,1,4.5,,1,-0.4,-40
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 5 Day 1 B,114,1.1,1,4.5,,1,0.10000000000000009,10
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 6 Day 1 B,142,0.9,1,4.5,,1,-0.09999999999999998,-10
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 7 Day 1 B,170,0.9,1,4.5,,1,-0.09999999999999998,-10
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 8 Day 1 B,221,1,1,4.5,,1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 9 Day 1 B,249,0.7,1,4.5,,1,-0.30000000000000004,-30
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 10 Day 1 B,277,0.8,1,4.5,,1,-0.19999999999999996,-20
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Cycle 11 Day 1 B,305,0.8,1,4.5,,1,-0.19999999999999996,-20
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,End of Treatment B,359,0.9,1,4.5,,1,-0.09999999999999998,-10
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Lymphocytes,Follow-up 110 B,422,0.7,1,4.5,,1,-0.30000000000000004,-30
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,,-11,0.4,0.2,1,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Baseline,1,0.4,0.2,1,Y,0.4,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 8 B,9,1.4,0.2,1,,0.4,0.9999999999999999,250
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 1 Day 15 B,16,2.8,0.2,1,,0.4,2.4,600
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 2 Day 1 B,30,0.6,0.2,1,,0.4,0.19999999999999996,50
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 3 Day 1 B,58,0.4,0.2,1,,0.4,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 4 Day 1 B,86,0.3,0.2,1,,0.4,-0.10000000000000003,-25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 5 Day 1 B,114,0.5,0.2,1,,0.4,0.09999999999999998,25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 6 Day 1 B,142,0.3,0.2,1,,0.4,-0.10000000000000003,-25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 7 Day 1 B,170,0.3,0.2,1,,0.4,-0.10000000000000003,-25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 8 Day 1 B,221,0.4,0.2,1,,0.4,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 9 Day 1 B,249,0.4,0.2,1,,0.4,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 10 Day 1 B,277,0.4,0.2,1,,0.4,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Cycle 11 Day 1 B,305,0.5,0.2,1,,0.4,0.09999999999999998,25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,End of Treatment B,359,0.7,0.2,1,,0.4,0.29999999999999993,75
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Monocytes,Follow-up 110 B,422,0.5,0.2,1,,0.4,0.09999999999999998,25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,,-11,2.5,1.9,8,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Baseline,1,2.7,1.9,8,Y,2.7,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 8 B,9,2.5,1.9,8,,2.7,-0.20000000000000018,-7.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 1 Day 15 B,16,4,1.9,8,,2.7,1.2999999999999998,48.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 2 Day 1 B,30,3.8,1.9,8,,2.7,1.0999999999999996,40.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 3 Day 1 B,58,2.6,1.9,8,,2.7,-0.10000000000000009,-3.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 4 Day 1 B,86,3.1,1.9,8,,2.7,0.3999999999999999,14.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 5 Day 1 B,114,3.5,1.9,8,,2.7,0.7999999999999998,29.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 6 Day 1 B,142,2.9,1.9,8,,2.7,0.19999999999999973,7.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 7 Day 1 B,170,2.8,1.9,8,,2.7,0.09999999999999964,3.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 8 Day 1 B,221,4.3,1.9,8,,2.7,1.5999999999999996,59.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 9 Day 1 B,249,3.9,1.9,8,,2.7,1.1999999999999997,44.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 10 Day 1 B,277,3.7,1.9,8,,2.7,1,37
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Cycle 11 Day 1 B,305,4.1,1.9,8,,2.7,1.3999999999999995,51.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,End of Treatment B,359,8.7,1.9,8,,2.7,5.999999999999999,222.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Neutrophils,Follow-up 110 B,422,6,1.9,8,,2.7,3.3,122.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),,-11,182,150,450,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Baseline,1,193,150,450,Y,193,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,9,181,150,450,,193,-12,-6.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,16,170,150,450,,193,-23,-11.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,30,308,150,450,,193,115,59.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,58,244,150,450,,193,51,26.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 1 B,86,236,150,450,,193,43,22.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 5 Day 1 B,114,172,150,450,,193,-21,-10.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 6 Day 1 B,142,177,150,450,,193,-16,-8.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 7 Day 1 B,170,203,150,450,,193,10,5.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 8 Day 1 B,221,258,150,450,,193,65,33.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 9 Day 1 B,249,248,150,450,,193,55,28.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 10 Day 1 B,277,237,150,450,,193,44,22.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Cycle 11 Day 1 B,305,224,150,450,,193,31,16.1
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),End of Treatment B,359,293,150,450,,193,100,51.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,Platelets (10^9/L),Follow-up 110 B,422,210,150,450,,193,17,8.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,TESTR,Baseline,-11,14.36,300,1080,Y,14.36,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,,-11,4,4.5,11,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Baseline,1,4.1,4.5,11,Y,4.1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 8 B,9,5.2,4.5,11,,4.1,1.1000000000000005,26.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 1 Day 15 B,16,8.4,4.5,11,,4.1,4.300000000000001,104.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 2 Day 1 B,30,5.7,4.5,11,,4.1,1.6000000000000005,39
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 3 Day 1 B,58,4.1,4.5,11,,4.1,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 4 Day 1 B,86,4.3,4.5,11,,4.1,0.20000000000000018,4.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 5 Day 1 B,114,5.4,4.5,11,,4.1,1.3000000000000007,31.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 6 Day 1 B,142,4.5,4.5,11,,4.1,0.40000000000000036,9.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 7 Day 1 B,170,4.4,4.5,11,,4.1,0.3000000000000007,7.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 8 Day 1 B,221,6.1,4.5,11,,4.1,2,48.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 9 Day 1 B,249,5.4,4.5,11,,4.1,1.3000000000000007,31.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 10 Day 1 B,277,5.3,4.5,11,,4.1,1.2000000000000002,29.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Cycle 11 Day 1 B,305,5.6,4.5,11,,4.1,1.5,36.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,End of Treatment B,359,10.3,4.5,11,,4.1,6.200000000000001,151.2
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Hematology,White Blood Cells,Follow-up 110 B,422,7.4,4.5,11,,4.1,3.3000000000000007,80.5
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,,-11,31.92,NA,NA,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Baseline,1,46.6,NA,NA,Y,46.6,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,30,59.14,NA,NA,,46.6,12.54,26.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 3 Day 1 B,58,36.9,NA,NA,,46.6,-9.700000000000003,-20.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 4 Day 1 B,86,32.35,NA,NA,,46.6,-14.25,-30.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 5 Day 1 B,114,13.35,NA,NA,,46.6,-33.25,-71.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 6 Day 1 B,142,28.1,NA,NA,,46.6,-18.5,-39.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 7 Day 1 B,170,34.48,NA,NA,,46.6,-12.120000000000005,-26
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 8 Day 1 B,221,34.06,NA,NA,,46.6,-12.54,-26.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 9 Day 1 B,249,40.22,NA,NA,,46.6,-6.380000000000003,-13.7
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 10 Day 1 B,277,51.17,NA,NA,,46.6,4.57,9.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Cycle 11 Day 1 B,305,44.59,NA,NA,,46.6,-2.009999999999998,-4.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,End of Treatment B,359,86.16,NA,NA,,46.6,39.559999999999995,84.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Prostate-specific antigen,PSA,Follow-up 110 B,422,66.6,NA,NA,,46.6,19.999999999999993,42.9
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-11,0.33,0.4,4.2,,NA,NA,NA
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,0.72,0.4,4.2,Y,0.72,0,0
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,30,0.48,0.4,4.2,,0.72,-0.24,-33.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,58,0.96,0.4,4.2,,0.72,0.24,33.3
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 B,86,0.55,0.4,4.2,,0.72,-0.16999999999999993,-23.6
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 10 Day 1 B,277,0.58,0.4,4.2,,0.72,-0.14,-19.4
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 11 Day 1 B,305,0.54,0.4,4.2,,0.72,-0.17999999999999994,-25
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,359,0.7,0.4,4.2,,0.72,-0.020000000000000018,-2.8
5B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 B,389,0.54,0.4,4.2,,0.72,-0.17999999999999994,-25
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,21,NA,NA,Y,21,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,29,81,NA,NA,,21,60,285.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,End of Treatment C,64,159,NA,NA,,21,138,657.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-7,11,1,45,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,7,1,45,Y,7,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,15,12,1,45,,7,5,71.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,11,1,45,,7,4,57.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,29,8,1,45,,7,1,14.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,37,20,1,45,,7,13,185.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,64,74,1,45,,7,67,957.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-7,3.9,3.5,4.9,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.7,3.5,4.9,Y,3.7,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,15,3.7,3.5,4.9,,3.7,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,3.6,3.5,4.9,,3.7,-0.10000000000000009,-2.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,29,3.6,3.5,4.9,,3.7,-0.10000000000000009,-2.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,37,3.3,3.5,4.9,,3.7,-0.40000000000000036,-10.8
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,64,3,3.5,4.9,,3.7,-0.7000000000000002,-18.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-7,101,38,126,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,113,38,126,Y,113,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,15,135,38,126,,113,22,19.5
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,130,38,126,,113,17,15
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,29,133,38,126,,113,20,17.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,37,145,38,126,,113,32,28.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,64,205,38,126,,113,92,81.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-7,15,1,35,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,14,1,35,Y,14,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,15,22,1,35,,14,8,57.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,21,1,35,,14,7,50
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,29,20,1,35,,14,6,42.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,37,51,1,35,,14,37,264.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,64,69,1,35,,14,55,392.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-7,27,6,23,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,28,6,23,Y,28,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,15,23,6,23,,28,-5,-17.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,21,6,23,,28,-7,-25
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,29,22,6,23,,28,-6,-21.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,37,17,6,23,,28,-11,-39.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,64,19,6,23,,28,-9,-32.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-7,24,22,30,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,22.2,22,30,Y,22.2,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,15,22.4,22,30,,22.2,0.1999999999999993,0.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,20.4,22,30,,22.2,-1.8000000000000007,-8.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,29,20.1,22,30,,22.2,-2.099999999999998,-9.5
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,37,22.9,22,30,,22.2,0.6999999999999993,3.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-7,8.7,8.5,10.5,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8.4,8.5,10.5,Y,8.4,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,15,8.5,8.5,10.5,,8.4,0.09999999999999964,1.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,8.2,8.5,10.5,,8.4,-0.20000000000000107,-2.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,29,8.2,8.5,10.5,,8.4,-0.20000000000000107,-2.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,37,8.3,8.5,10.5,,8.4,-0.09999999999999964,-1.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,64,8.3,8.5,10.5,,8.4,-0.09999999999999964,-1.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-7,100,96,108,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,102,96,108,Y,102,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,15,101,96,108,,102,-1,-1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,103,96,108,,102,1,1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,29,100,96,108,,102,-2,-2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,37,99,96,108,,102,-3,-2.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,64,100,96,108,,102,-2,-2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-7,1.56,0.7,1.3,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1.67,0.7,1.3,Y,1.67,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,15,1.59,0.7,1.3,,1.67,-0.07999999999999985,-4.8
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,1.59,0.7,1.3,,1.67,-0.07999999999999985,-4.8
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,29,1.65,0.7,1.3,,1.67,-0.020000000000000018,-1.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,37,1.68,0.7,1.3,,1.67,0.010000000000000009,0.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,64,1.36,0.7,1.3,,1.67,-0.30999999999999983,-18.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-7,126,60,100,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,111,60,100,Y,111,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,15,110,60,100,,111,-1,-0.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,119,60,100,,111,8,7.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,29,112,60,100,,111,1,0.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,37,114,60,100,,111,3,2.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,64,107,60,100,,111,-4,-3.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-7,190,100,220,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,179,100,220,Y,179,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,15,310,100,220,,179,131,73.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,274,100,220,,179,95,53.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,29,317,100,220,,179,138,77.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,37,380,100,220,,179,201,112.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-7,5,3.5,5.2,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.7,3.5,5.2,Y,4.7,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,15,5.1,3.5,5.2,,4.7,0.39999999999999947,8.5
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.8,3.5,5.2,,4.7,0.09999999999999964,2.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,29,4.7,3.5,5.2,,4.7,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,37,4.9,3.5,5.2,,4.7,0.20000000000000018,4.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,64,5.8,3.5,5.2,,4.7,1.0999999999999996,23.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-7,132,135,145,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,132,135,145,Y,132,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,15,132,135,145,,132,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,132,135,145,,132,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,29,130,135,145,,132,-2,-1.5
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,37,130,135,145,,132,-2,-1.5
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,64,129,135,145,,132,-3,-2.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-7,0.4,0.1,1.2,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.4,0.1,1.2,Y,0.4,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,15,0.4,0.1,1.2,,0.4,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.4,0.1,1.2,,0.4,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,29,0.5,0.1,1.2,,0.4,0.09999999999999998,25
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,37,0.5,0.1,1.2,,0.4,0.09999999999999998,25
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,64,0.4,0.1,1.2,,0.4,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-7,6.6,6,8.3,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.3,6,8.3,Y,6.3,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,15,6.4,6,8.3,,6.3,0.10000000000000053,1.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,6.2,6,8.3,,6.3,-0.09999999999999964,-1.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,29,6.4,6,8.3,,6.3,0.10000000000000053,1.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,37,6.5,6,8.3,,6.3,0.20000000000000018,3.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,64,6.4,6,8.3,,6.3,0.10000000000000053,1.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-7,31.3,25.4,34.9,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,30,25.4,34.9,Y,30,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,8,29.9,25.4,34.9,,30,-0.10000000000000142,-0.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,22,31.3,25.4,34.9,,30,1.3000000000000007,4.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 1 C,29,32.5,NA,NA,,30,2.5,8.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment C,54,34.9,25.4,34.9,,30,4.899999999999999,16.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-7,1.1,2,3,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.2,2,3,Y,1.2,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,8,1.2,2,3,,1.2,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,22,1.2,2,3,,1.2,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 1 C,29,1.3,NA,NA,,1.2,0.10000000000000009,8.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment C,54,1.4,2,3,,1.2,0.19999999999999996,16.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-7,14.1,12.3,14.9,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,14.6,12.3,14.9,Y,14.6,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,8,14.2,12.3,14.9,,14.6,-0.40000000000000036,-2.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,22,14.1,12.3,14.9,,14.6,-0.5,-3.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 1 C,29,15.7,NA,NA,,14.6,1.0999999999999996,7.5
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment C,54,16.6,12.3,14.9,,14.6,2.0000000000000018,13.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-7,0.1,0,0.2,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.1,0,0.2,Y,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0.1,0,0.2,,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,15,0,0,0.2,,0.1,-0.1,-100
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.2,,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,29,0,0,0.2,,0.1,-0.1,-100
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 C,37,0.1,0,0.2,,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,64,0.1,0,0.2,,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-7,0.1,0,0.6,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.6,Y,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0.2,0,0.6,,0.1,0.1,100
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,15,0.1,0,0.6,,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0.1,0,0.6,,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,29,0.1,0,0.6,,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 C,37,0.1,0,0.6,,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,64,0.1,0,0.6,,0.1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-7,3.23,4.5,6,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.23,4.5,6,Y,3.23,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,3.23,4.5,6,,3.23,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,15,3.36,4.5,6,,3.23,0.1299999999999999,4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.23,4.5,6,,3.23,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,29,3.1,4.5,6,,3.23,-0.1299999999999999,-4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,37,3.08,4.5,6,,3.23,-0.1499999999999999,-4.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,64,3.05,4.5,6,,3.23,-0.18000000000000016,-5.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-7,28.3,42,52,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,28.3,42,52,Y,28.3,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,28.1,42,52,,28.3,-0.1999999999999993,-0.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,15,29.2,42,52,,28.3,0.8999999999999986,3.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,28.1,42,52,,28.3,-0.1999999999999993,-0.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,29,26.5,42,52,,28.3,-1.8000000000000007,-6.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,37,26.4,42,52,,28.3,-1.9000000000000021,-6.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,64,25.5,42,52,,28.3,-2.8000000000000007,-9.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-7,9.5,13.9,16.3,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,9.5,13.9,16.3,Y,9.5,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,9.3,13.9,16.3,,9.5,-0.1999999999999993,-2.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,15,9.7,13.9,16.3,,9.5,0.1999999999999993,2.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,9.3,13.9,16.3,,9.5,-0.1999999999999993,-2.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,29,9,13.9,16.3,,9.5,-0.5,-5.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,37,8.8,13.9,16.3,,9.5,-0.6999999999999993,-7.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,64,8.5,13.9,16.3,,9.5,-1,-10.5
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-7,1,1,4.5,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1,1,4.5,Y,1,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,1.1,1,4.5,,1,0.10000000000000009,10
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,15,1.2,1,4.5,,1,0.19999999999999996,20
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,1.1,1,4.5,,1,0.10000000000000009,10
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,29,1.2,1,4.5,,1,0.19999999999999996,20
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 C,37,1.2,1,4.5,,1,0.19999999999999996,20
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,64,0.8,1,4.5,,1,-0.19999999999999996,-20
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-7,0.5,0.2,1,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.5,0.2,1,Y,0.5,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,1.4,0.2,1,,0.5,0.8999999999999999,180
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,15,2.7,0.2,1,,0.5,2.2,440
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,3.8,0.2,1,,0.5,3.3,660
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,29,4.9,0.2,1,,0.5,4.4,880
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 C,37,9.2,0.2,1,,0.5,8.7,1740
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,64,0.5,0.2,1,,0.5,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-7,3.6,1.9,8,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.6,1.9,8,Y,3.6,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,3.4,1.9,8,,3.6,-0.20000000000000018,-5.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,15,3.3,1.9,8,,3.6,-0.30000000000000027,-8.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,5,1.9,8,,3.6,1.4,38.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,29,4.7,1.9,8,,3.6,1.1,30.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 C,37,8.51,1.9,8,,3.6,4.91,136.4
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,64,5.4,1.9,8,,3.6,1.8000000000000003,50
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-7,246,150,450,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,246,150,450,Y,246,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,216,150,450,,246,-30,-12.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,15,168,150,450,,246,-78,-31.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,258,150,450,,246,12,4.9
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,29,254,150,450,,246,8,3.3
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,37,303,150,450,,246,57,23.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,64,427,150,450,,246,181,73.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-7,5.3,4.5,11,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.3,4.5,11,Y,5.3,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,6,4.5,11,,5.3,0.7000000000000002,13.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,15,7.3,4.5,11,,5.3,2,37.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,9.9,4.5,11,,5.3,4.6000000000000005,86.8
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,29,10.9,4.5,11,,5.3,5.6000000000000005,105.7
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,37,18.1,4.5,11,,5.3,12.8,241.5
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,64,6.9,4.5,11,,5.3,1.6000000000000005,30.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-7,21.92,NA,NA,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,24.56,NA,NA,Y,24.56,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,35.9,NA,NA,,24.56,11.34,46.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,29,33.92,NA,NA,,24.56,9.360000000000003,38.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,64,65.85,NA,NA,,24.56,41.28999999999999,168.1
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-7,2.02,0.4,4.2,,NA,NA,NA
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.43,0.4,4.2,Y,2.43,0,0
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,2.82,0.4,4.2,,2.43,0.3899999999999997,16
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,15,2.22,0.4,4.2,,2.43,-0.20999999999999996,-8.6
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,1.72,0.4,4.2,,2.43,-0.7100000000000002,-29.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,29,1.75,0.4,4.2,,2.43,-0.6800000000000002,-28
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,37,1.55,0.4,4.2,,2.43,-0.8800000000000001,-36.2
5C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,54,1.38,0.4,4.2,,2.43,-1.0500000000000003,-43.2
6A,A,NKTR-214 + Nivolumab,N,N,,CTC,End of Treatment A,65,0,NA,NA,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-12,15,0,59,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,15,0,59,Y,15,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,37,0,59,,15,22,146.7
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,23,20,0,59,,15,5,33.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,30,39,0,59,,15,24,160
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 A,44,22,0,59,,15,7,46.7
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 8 A,51,26,0,59,,15,11,73.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,65,23,0,59,,15,8,53.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-12,3.9,3.5,4.7,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.6,3.5,4.7,Y,3.6,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,3.3,3.5,4.7,,3.6,-0.30000000000000027,-8.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,23,3.5,3.5,4.7,,3.6,-0.10000000000000009,-2.8
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,30,3.2,3.5,4.7,,3.6,-0.3999999999999999,-11.1
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 A,44,3.6,3.5,4.7,,3.6,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 8 A,51,2.9,3.5,4.7,,3.6,-0.7000000000000002,-19.4
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment A,65,3.7,3.5,4.7,,3.6,0.10000000000000009,2.8
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-12,72,53,128,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,69,53,128,Y,69,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,118,53,128,,69,49,71
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,23,67,53,128,,69,-2,-2.9
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,30,148,53,128,,69,79,114.5
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 A,44,99,53,128,,69,30,43.5
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 8 A,51,143,53,128,,69,74,107.2
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,65,99,53,128,,69,30,43.5
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-12,15,0,41,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,12,0,41,Y,12,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,9,0,41,,12,-3,-25
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,23,10,0,41,,12,-2,-16.7
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,30,12,0,41,,12,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 A,44,14,0,41,,12,2,16.7
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 8 A,51,9,0,41,,12,-3,-25
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,65,14,0,41,,12,2,16.7
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-12,13,6,20,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,23,6,20,Y,23,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,8,14,6,20,,23,-9,-39.1
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,23,20,6,20,,23,-3,-13
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 8 A,30,12,6,20,,23,-11,-47.8
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 A,44,18,6,20,,23,-5,-21.7
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 8 A,51,8,6,20,,23,-15,-65.2
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,End of Treatment A,65,15,6,20,,23,-8,-34.8
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-12,30,21,32,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,32,21,32,Y,32,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,29,21,32,,32,-3,-9.4
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,23,33,21,32,,32,1,3.1
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,30,29,21,32,,32,-3,-9.4
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 A,44,30,21,32,,32,-2,-6.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 8 A,51,34,21,32,,32,2,6.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment A,65,30,21,32,,32,-2,-6.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-12,8.5,8.6,10.2,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,8.4,8.6,10.2,Y,8.4,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,9,8.6,10.2,,8.4,0.5999999999999996,7.1
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,23,8.9,8.6,10.2,,8.4,0.5,6
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,30,9.7,8.6,10.2,,8.4,1.299999999999999,15.5
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 A,44,9.3,8.6,10.2,,8.4,0.9000000000000004,10.7
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 8 A,51,9.7,8.6,10.2,,8.4,1.299999999999999,15.5
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment A,65,9.1,8.6,10.2,,8.4,0.6999999999999993,8.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-12,103,97,108,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,100,97,108,Y,100,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,99,97,108,,100,-1,-1
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,23,100,97,108,,100,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,30,103,97,108,,100,3,3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 A,44,100,97,108,,100,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 8 A,51,103,97,108,,100,3,3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment A,65,102,97,108,,100,2,2
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-12,0.87,0.7,1.3,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.8,0.7,1.3,Y,0.8,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,0.75,0.7,1.3,,0.8,-0.050000000000000044,-6.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,23,0.96,0.7,1.3,,0.8,0.15999999999999992,20
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,30,0.92,0.7,1.3,,0.8,0.12,15
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 A,44,0.94,0.7,1.3,,0.8,0.1399999999999999,17.5
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 8 A,51,0.83,0.7,1.3,,0.8,0.029999999999999916,3.8
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment A,65,0.82,0.7,1.3,,0.8,0.019999999999999907,2.5
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-12,102,70,99,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,98,70,99,Y,98,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 A,8,135,70,99,,98,37,37.8
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,23,90,70,99,,98,-8,-8.2
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,30,147,70,99,,98,49,50
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 A,44,99,70,99,,98,1,1
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 8 A,51,114,70,99,,98,16,16.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment A,65,117,70,99,,98,19,19.4
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-12,179,0,250,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,196,0,250,Y,196,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,8,163,0,250,,196,-33,-16.8
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,23,123,0,250,,196,-73,-37.2
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,30,135,0,250,,196,-61,-31.1
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 A,44,149,0,250,,196,-47,-24
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 8 A,51,178,0,250,,196,-18,-9.2
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-12,4.1,3.4,5,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,3.8,3.4,5,Y,3.8,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,4,3.4,5,,3.8,0.20000000000000018,5.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,23,4.6,3.4,5,,3.8,0.7999999999999998,21.1
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,30,4.1,3.4,5,,3.8,0.2999999999999998,7.9
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 A,44,4,3.4,5,,3.8,0.20000000000000018,5.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 8 A,51,4,3.4,5,,3.8,0.20000000000000018,5.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment A,65,4,3.4,5,,3.8,0.20000000000000018,5.3
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-12,141,136,145,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,138,136,145,Y,138,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,8,138,136,145,,138,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,23,139,136,145,,138,1,0.7
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,30,142,136,145,,138,4,2.9
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 A,44,138,136,145,,138,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 8 A,51,141,136,145,,138,3,2.2
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment A,65,140,136,145,,138,2,1.4
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-12,0.2,0.3,1.2,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.2,0.3,1.2,Y,0.2,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.2,0.3,1.2,,0.2,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,23,0.2,0.3,1.2,,0.2,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,30,0.3,0.3,1.2,,0.2,0.09999999999999998,50
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 A,44,0.2,0.3,1.2,,0.2,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 8 A,51,0.1,0.3,1.2,,0.2,-0.1,-50
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment A,65,0.2,0.3,1.2,,0.2,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-12,7.6,6.4,8.2,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.1,6.4,8.2,Y,7.1,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,8,7.2,6.4,8.2,,7.1,0.10000000000000053,1.4
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,23,7.2,6.4,8.2,,7.1,0.10000000000000053,1.4
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,30,6.9,6.4,8.2,,7.1,-0.1999999999999993,-2.8
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 A,44,7.5,6.4,8.2,,7.1,0.40000000000000036,5.6
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 8 A,51,6.6,6.4,8.2,,7.1,-0.5,-7
6A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment A,65,7.8,6.4,8.2,,7.1,0.7000000000000002,9.9
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-12,33.7,22.5,34.5,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,31.4,22.5,34.5,Y,31.4,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 A,8,27.7,22.5,34.5,,31.4,-3.6999999999999993,-11.8
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 A,23,29,22.5,34.5,,31.4,-2.3999999999999986,-7.6
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 8 A,30,26.8,22.5,34.5,,31.4,-4.599999999999998,-14.6
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 A,44,32.8,22.5,34.5,,31.4,1.3999999999999986,4.5
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 8 A,51,29.9,22.5,34.5,,31.4,-1.5,-4.8
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-12,0.92,0.8,1.2,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,0.96,0.8,1.2,Y,0.96,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 A,8,1.06,0.8,1.2,,0.96,0.10000000000000009,10.4
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 A,23,0.91,0.8,1.2,,0.96,-0.04999999999999993,-5.2
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 8 A,30,1.01,0.8,1.2,,0.96,0.050000000000000044,5.2
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 A,44,0.96,0.8,1.2,,0.96,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 8 A,51,0.99,0.8,1.2,,0.96,0.030000000000000027,3.1
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-12,0.1,0,0.1,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.06,0,0.1,Y,0.06,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0.03,0,0.1,,0.06,-0.03,-50
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0.02,0,0.1,,0.06,-0.039999999999999994,-66.7
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,8,0.06,0,0.1,,0.06,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,23,0.03,0,0.1,,0.06,-0.03,-50
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,30,0.12,0,0.1,,0.06,0.06,100
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 A,44,0.07,0,0.1,,0.06,0.010000000000000009,16.7
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 8 A,51,0.11,0,0.1,,0.06,0.05,83.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,End of Treatment A,65,0.05,0,0.1,,0.06,-0.009999999999999995,-16.7
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-12,0.31,0,0.5,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.62,0,0.5,Y,0.62,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.51,0,0.5,,0.62,-0.10999999999999999,-17.7
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.74,0,0.5,,0.62,0.12,19.4
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.59,0,0.5,,0.62,-0.030000000000000027,-4.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,23,0.04,0,0.5,,0.62,-0.58,-93.5
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 8 A,30,3.86,0,0.5,,0.62,3.2399999999999998,522.6
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 A,44,1.08,0,0.5,,0.62,0.4600000000000001,74.2
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 8 A,51,12.79,0,0.5,,0.62,12.17,1962.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment A,65,0.87,0,0.5,,0.62,0.25,40.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-12,4.47,4.5,6,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.98,4.5,6,Y,3.98,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,3.84,4.5,6,,3.98,-0.14000000000000012,-3.5
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,4.01,4.5,6,,3.98,0.029999999999999805,0.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,3.98,4.5,6,,3.98,0,0
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,23,4.25,4.5,6,,3.98,0.27,6.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,30,4.47,4.5,6,,3.98,0.48999999999999977,12.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 A,44,4.6,4.5,6,,3.98,0.6199999999999997,15.6
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 8 A,51,4.51,4.5,6,,3.98,0.5299999999999998,13.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment A,65,4.67,4.5,6,,3.98,0.69,17.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-12,40.3,41,53,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,36.2,41,53,Y,36.2,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,35.2,41,53,,36.2,-1,-2.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,36.3,41,53,,36.2,0.09999999999999432,0.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,35.8,41,53,,36.2,-0.4000000000000057,-1.1
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,23,38.8,41,53,,36.2,2.5999999999999943,7.2
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,30,40.3,41,53,,36.2,4.099999999999994,11.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 A,44,42,41,53,,36.2,5.799999999999997,16
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 8 A,51,39.8,41,53,,36.2,3.5999999999999943,9.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment A,65,42.2,41,53,,36.2,6,16.6
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-12,13,13.5,17.5,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.3,13.5,17.5,Y,11.3,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,11,13.5,17.5,,11.3,-0.3000000000000007,-2.7
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,11.4,13.5,17.5,,11.3,0.09999999999999964,0.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,11.2,13.5,17.5,,11.3,-0.10000000000000142,-0.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,23,12.3,13.5,17.5,,11.3,1,8.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,30,12.7,13.5,17.5,,11.3,1.3999999999999986,12.4
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 A,44,13,13.5,17.5,,11.3,1.6999999999999993,15
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 8 A,51,12.9,13.5,17.5,,11.3,1.5999999999999996,14.2
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment A,65,13.3,13.5,17.5,,11.3,2,17.7
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-12,1.32,1,4.8,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.03,1,4.8,Y,1.03,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.45,1,4.8,,1.03,-0.5800000000000001,-56.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.26,1,4.8,,1.03,-0.77,-74.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,3.32,1,4.8,,1.03,2.29,222.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,23,1.27,1,4.8,,1.03,0.24,23.3
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,30,6.03,1,4.8,,1.03,5,485.4
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 A,44,1.25,1,4.8,,1.03,0.21999999999999997,21.4
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 8 A,51,4.6,1,4.8,,1.03,3.5699999999999994,346.6
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment A,65,1.11,1,4.8,,1.03,0.08000000000000007,7.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-12,0.51,0.1,0.9,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.44,0.1,0.9,Y,0.44,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.52,0.1,0.9,,0.44,0.08000000000000002,18.2
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.61,0.1,0.9,,0.44,0.16999999999999998,38.6
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,8,0.49,0.1,0.9,,0.44,0.04999999999999999,11.4
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,23,0.33,0.1,0.9,,0.44,-0.10999999999999999,-25
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,30,0.12,0.1,0.9,,0.44,-0.32,-72.7
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 A,44,0.28,0.1,0.9,,0.44,-0.15999999999999998,-36.4
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 8 A,51,0.69,0.1,0.9,,0.44,0.24999999999999994,56.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment A,65,0.27,0.1,0.9,,0.44,-0.16999999999999998,-38.6
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-12,6.06,1.8,7.7,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.8,1.8,7.7,Y,3.8,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,4.6,1.8,7.7,,3.8,0.7999999999999998,21.1
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,5.38,1.8,7.7,,3.8,1.58,41.6
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,8,7.63,1.8,7.7,,3.8,3.83,100.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,23,6.92,1.8,7.7,,3.8,3.12,82.1
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,30,3.51,1.8,7.7,,3.8,-0.29000000000000004,-7.6
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 A,44,4.05,1.8,7.7,,3.8,0.25,6.6
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 8 A,51,4.33,1.8,7.7,,3.8,0.5300000000000002,13.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment A,65,3.72,1.8,7.7,,3.8,-0.07999999999999963,-2.1
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-12,241,150,400,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,231,150,400,Y,231,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,200,150,400,,231,-31,-13.4
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,174,150,400,,231,-57,-24.7
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,229,150,400,,231,-2,-0.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,23,286,150,400,,231,55,23.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,30,185,150,400,,231,-46,-19.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 A,44,283,150,400,,231,52,22.5
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 8 A,51,213,150,400,,231,-18,-7.8
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment A,65,285,150,400,,231,54,23.4
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-12,8.34,3.5,10.8,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.96,3.5,10.8,Y,5.96,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,6.13,3.5,10.8,,5.96,0.16999999999999993,2.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,7.03,3.5,10.8,,5.96,1.0700000000000003,18
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,12.27,3.5,10.8,,5.96,6.31,105.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,23,8.61,3.5,10.8,,5.96,2.6499999999999995,44.5
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,30,13.65,3.5,10.8,,5.96,7.69,129
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 A,44,6.74,3.5,10.8,,5.96,0.7800000000000002,13.1
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 8 A,51,22.64,3.5,10.8,,5.96,16.68,279.9
6A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment A,65,6.03,3.5,10.8,,5.96,0.07000000000000028,1.2
6A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-12,29.19,NA,NA,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,32.19,NA,NA,Y,32.19,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,23,46.22,NA,NA,,32.19,14.030000000000001,43.6
6A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 A,44,31.18,NA,NA,,32.19,-1.009999999999998,-3.1
6A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment A,65,44.67,NA,NA,,32.19,12.480000000000004,38.8
6A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-12,4,0.44,7.11,,NA,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.62,0.44,7.11,Y,1.62,NA,NA
6A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,23,1.57,0.44,7.11,,1.62,-0.050000000000000044,-3.1
6A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 A,44,1.39,0.44,7.11,,1.62,-0.2300000000000002,-14.2
6A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,65,0.48,0.44,7.11,,1.62,-1.1400000000000001,-70.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Baseline,1,0,NA,NA,Y,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 2 Day 1 B,30,0,NA,NA,,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 3 Day 1 B,58,0,NA,NA,,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 4 Day 1 B,86,0,NA,NA,,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 5 Day 1 B,114,0,NA,NA,,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 6 Day 1 B,142,0,NA,NA,,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 7 Day 1 B,173,0,NA,NA,,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 8 Day 1 B,199,0,NA,NA,,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 9 Day 1 B,226,0,NA,NA,,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,End of Treatment B,248,0,NA,NA,,0,0,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,-13,27,12,60,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,24,12,60,Y,24,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,30,12,60,,24,6,25
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,15,35,12,60,,24,11,45.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,30,31,12,60,,24,7,29.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,58,25,12,60,,24,1,4.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 B,86,30,12,60,,24,6,25
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 B,114,22,12,60,,24,-2,-8.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 6 Day 1 B,142,32,12,60,,24,8,33.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 7 Day 1 B,173,26,12,60,,24,2,8.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 8 Day 1 B,199,29,12,60,,24,5,20.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 9 Day 1 B,226,25,12,60,,24,1,4.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,248,29,12,60,,24,5,20.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 B,325,28,12,60,,24,4,16.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,-13,3.3,3.5,4.8,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Baseline,1,3.2,3.5,4.8,Y,3.2,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,3.3,3.5,4.8,,3.2,0.09999999999999964,3.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,15,3.3,3.5,4.8,,3.2,0.09999999999999964,3.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,30,3,3.5,4.8,,3.2,-0.20000000000000018,-6.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,58,3.3,3.5,4.8,,3.2,0.09999999999999964,3.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 4 Day 1 B,86,3.2,3.5,4.8,,3.2,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 5 Day 1 B,114,3.2,3.5,4.8,,3.2,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 6 Day 1 B,142,3.3,3.5,4.8,,3.2,0.09999999999999964,3.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 7 Day 1 B,173,3,3.5,4.8,,3.2,-0.20000000000000018,-6.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 8 Day 1 B,199,3.3,3.5,4.8,,3.2,0.09999999999999964,3.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 9 Day 1 B,226,3.1,3.5,4.8,,3.2,-0.10000000000000009,-3.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),End of Treatment B,248,3.3,3.5,4.8,,3.2,0.09999999999999964,3.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Follow-up 110 B,325,3,3.5,4.8,,3.2,-0.20000000000000018,-6.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,-13,58,31,95,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,50,31,95,Y,50,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,52,31,95,,50,2,4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,15,52,31,95,,50,2,4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,30,57,31,95,,50,7,14
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,58,51,31,95,,50,1,2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 B,86,47,31,95,,50,-3,-6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 B,114,52,31,95,,50,2,4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 6 Day 1 B,142,48,31,95,,50,-2,-4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 7 Day 1 B,173,45,31,95,,50,-5,-10
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 8 Day 1 B,199,45,31,95,,50,-5,-10
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 9 Day 1 B,226,45,31,95,,50,-5,-10
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,248,47,31,95,,50,-3,-6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 B,325,54,31,95,,50,4,8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-13,28,18,63,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,22,18,63,Y,22,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,26,18,63,,22,4,18.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,15,31,18,63,,22,9,40.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,30,22,18,63,,22,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,58,19,18,63,,22,-3,-13.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 B,86,24,18,63,,22,2,9.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 B,114,21,18,63,,22,-1,-4.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 6 Day 1 B,142,24,18,63,,22,2,9.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 7 Day 1 B,173,21,18,63,,22,-1,-4.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 8 Day 1 B,199,24,18,63,,22,2,9.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 9 Day 1 B,226,20,18,63,,22,-2,-9.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,248,25,18,63,,22,3,13.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 B,325,36,18,63,,22,14,63.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,,-13,18,6,22,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Baseline,1,15,6,22,Y,15,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 8 B,8,11,6,22,,15,-4,-26.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 15 B,15,19,6,22,,15,4,26.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 2 Day 1 B,30,20,6,22,,15,5,33.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 3 Day 1 B,58,17,6,22,,15,2,13.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 4 Day 1 B,86,14,6,22,,15,-1,-6.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 5 Day 1 B,114,18,6,22,,15,3,20
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 6 Day 1 B,142,19,6,22,,15,4,26.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 7 Day 1 B,173,16,6,22,,15,1,6.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 8 Day 1 B,199,12,6,22,,15,-3,-20
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 9 Day 1 B,226,16,6,22,,15,1,6.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,End of Treatment B,248,14,6,22,,15,-1,-6.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Follow-up 110 B,325,19,6,22,,15,4,26.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,,-13,25,22,27,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Baseline,1,25,22,27,Y,25,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,28,22,27,,25,3,12
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 15 B,15,26,22,27,,25,1,4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 2 Day 1 B,30,24,22,27,,25,-1,-4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 3 Day 1 B,58,27,22,27,,25,2,8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 4 Day 1 B,86,25,22,27,,25,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 5 Day 1 B,114,23,22,27,,25,-2,-8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 6 Day 1 B,142,29,22,27,,25,4,16
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 7 Day 1 B,173,28,22,27,,25,3,12
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 8 Day 1 B,199,26,22,27,,25,1,4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 9 Day 1 B,226,27,22,27,,25,2,8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,End of Treatment B,248,27,22,27,,25,2,8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Follow-up 110 B,325,26,22,27,,25,1,4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,-13,9.2,8.8,10.3,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Baseline,1,9.1,8.8,10.3,Y,9.1,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,9.7,8.8,10.3,,9.1,0.5999999999999996,6.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,15,9.9,8.8,10.3,,9.1,0.8000000000000007,8.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,30,9.6,8.8,10.3,,9.1,0.5,5.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,58,9.5,8.8,10.3,,9.1,0.40000000000000036,4.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 B,86,8.9,8.8,10.3,,9.1,-0.1999999999999993,-2.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 B,114,9,8.8,10.3,,9.1,-0.09999999999999964,-1.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 6 Day 1 B,142,9.8,8.8,10.3,,9.1,0.7000000000000011,7.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 7 Day 1 B,173,9.4,8.8,10.3,,9.1,0.3000000000000007,3.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 8 Day 1 B,199,9.5,8.8,10.3,,9.1,0.40000000000000036,4.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 9 Day 1 B,226,9.2,8.8,10.3,,9.1,0.09999999999999964,1.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),End of Treatment B,248,9,8.8,10.3,,9.1,-0.09999999999999964,-1.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Follow-up 110 B,325,9,8.8,10.3,,9.1,-0.09999999999999964,-1.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,-13,106,97,108,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Baseline,1,105,97,108,Y,105,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,106,97,108,,105,1,1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,15,104,97,108,,105,-1,-1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,30,104,97,108,,105,-1,-1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,58,103,97,108,,105,-2,-1.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 B,86,104,97,108,,105,-1,-1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 B,114,103,97,108,,105,-2,-1.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 6 Day 1 B,142,103,97,108,,105,-2,-1.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 7 Day 1 B,173,103,97,108,,105,-2,-1.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 8 Day 1 B,199,102,97,108,,105,-3,-2.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 9 Day 1 B,226,103,97,108,,105,-2,-1.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),End of Treatment B,248,103,97,108,,105,-2,-1.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Follow-up 110 B,325,103,97,108,,105,-2,-1.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,-13,0.76,0.61,1.24,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Baseline,1,0.81,0.61,1.24,Y,0.81,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,0.87,0.61,1.24,,0.81,0.05999999999999994,7.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,15,0.78,0.61,1.24,,0.81,-0.030000000000000027,-3.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,30,0.73,0.61,1.24,,0.81,-0.08000000000000007,-9.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,58,0.82,0.61,1.24,,0.81,0.009999999999999898,1.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 B,86,0.85,0.61,1.24,,0.81,0.039999999999999925,4.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 B,114,0.83,0.61,1.24,,0.81,0.019999999999999907,2.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 6 Day 1 B,142,0.81,0.61,1.24,,0.81,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 7 Day 1 B,173,0.81,0.61,1.24,,0.81,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 8 Day 1 B,199,0.96,0.61,1.24,,0.81,0.1499999999999999,18.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 9 Day 1 B,226,0.76,0.61,1.24,,0.81,-0.050000000000000044,-6.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),End of Treatment B,248,0.75,0.61,1.24,,0.81,-0.06000000000000005,-7.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Follow-up 110 B,325,0.78,0.61,1.24,,0.81,-0.030000000000000027,-3.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,,-13,132,70,199,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Baseline,1,201,70,199,Y,201,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 8 B,8,110,70,199,,201,-91,-45.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 15 B,15,128,70,199,,201,-73,-36.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 2 Day 1 B,30,138,70,199,,201,-63,-31.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 3 Day 1 B,58,173,70,199,,201,-28,-13.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 4 Day 1 B,86,159,70,199,,201,-42,-20.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 5 Day 1 B,114,210,70,199,,201,9,4.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 6 Day 1 B,142,192,70,199,,201,-9,-4.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 7 Day 1 B,173,217,70,199,,201,16,8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 8 Day 1 B,199,154,70,199,,201,-47,-23.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 9 Day 1 B,226,181,70,199,,201,-20,-10
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,End of Treatment B,248,153,70,199,,201,-48,-23.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Follow-up 110 B,325,199,70,199,,201,-2,-1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-13,247,102,199,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,277,102,199,Y,277,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,318,102,199,,277,41,14.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,15,249,102,199,,277,-28,-10.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,30,231,102,199,,277,-46,-16.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,58,612,102,199,,277,335,120.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 B,86,197,102,199,,277,-80,-28.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 B,114,280,102,199,,277,3,1.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 6 Day 1 B,142,221,102,199,,277,-56,-20.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 7 Day 1 B,173,231,102,199,,277,-46,-16.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 8 Day 1 B,199,231,102,199,,277,-46,-16.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 9 Day 1 B,226,209,102,199,,277,-68,-24.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,248,272,102,199,,277,-5,-1.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 B,325,216,102,199,,277,-61,-22
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,-13,5.5,3.5,5.1,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Baseline,1,4.8,3.5,5.1,Y,4.8,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.6,3.5,5.1,,4.8,-0.20000000000000018,-4.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,15,4.7,3.5,5.1,,4.8,-0.09999999999999964,-2.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,30,5.1,3.5,5.1,,4.8,0.2999999999999998,6.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,58,4.7,3.5,5.1,,4.8,-0.09999999999999964,-2.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 B,86,4.5,3.5,5.1,,4.8,-0.2999999999999998,-6.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 B,114,5.1,3.5,5.1,,4.8,0.2999999999999998,6.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 6 Day 1 B,142,4.8,3.5,5.1,,4.8,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 7 Day 1 B,173,4.1,3.5,5.1,,4.8,-0.7000000000000002,-14.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 8 Day 1 B,199,4.7,3.5,5.1,,4.8,-0.09999999999999964,-2.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 9 Day 1 B,226,4.5,3.5,5.1,,4.8,-0.2999999999999998,-6.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),End of Treatment B,248,4.4,3.5,5.1,,4.8,-0.39999999999999947,-8.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Follow-up 110 B,325,4.8,3.5,5.1,,4.8,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,,-13,139,135,145,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Baseline,1,138,135,145,Y,138,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 8 B,8,142,135,145,,138,4,2.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 15 B,15,141,135,145,,138,3,2.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 2 Day 1 B,30,138,135,145,,138,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 3 Day 1 B,58,138,135,145,,138,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 4 Day 1 B,86,138,135,145,,138,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 5 Day 1 B,114,134,135,145,,138,-4,-2.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 6 Day 1 B,142,137,135,145,,138,-1,-0.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 7 Day 1 B,173,138,135,145,,138,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 8 Day 1 B,199,136,135,145,,138,-2,-1.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 9 Day 1 B,226,138,135,145,,138,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,End of Treatment B,248,138,135,145,,138,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Follow-up 110 B,325,138,135,145,,138,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,-13,0.5,0.2,1.3,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Baseline,1,0.5,0.2,1.3,Y,0.5,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.6,0.2,1.3,,0.5,0.09999999999999998,20
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,15,0.5,0.2,1.3,,0.5,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,30,0.4,0.2,1.3,,0.5,-0.09999999999999998,-20
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,58,0.5,0.2,1.3,,0.5,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 4 Day 1 B,86,0.5,0.2,1.3,,0.5,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 5 Day 1 B,114,0.4,0.2,1.3,,0.5,-0.09999999999999998,-20
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 6 Day 1 B,142,0.5,0.2,1.3,,0.5,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 7 Day 1 B,173,0.6,0.2,1.3,,0.5,0.09999999999999998,20
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 8 Day 1 B,199,0.6,0.2,1.3,,0.5,0.09999999999999998,20
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 9 Day 1 B,226,0.8,0.2,1.3,,0.5,0.30000000000000004,60
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,End of Treatment B,248,0.6,0.2,1.3,,0.5,0.09999999999999998,20
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Follow-up 110 B,325,0.6,0.2,1.3,,0.5,0.09999999999999998,20
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,,-13,7.2,6,8.4,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Baseline,1,6.7,6,8.4,Y,6.7,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 8 B,8,7.2,6,8.4,,6.7,0.5,7.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 15 B,15,7.4,6,8.4,,6.7,0.7000000000000002,10.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 2 Day 1 B,30,7.2,6,8.4,,6.7,0.5,7.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 3 Day 1 B,58,7,6,8.4,,6.7,0.2999999999999998,4.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 4 Day 1 B,86,6.7,6,8.4,,6.7,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 5 Day 1 B,114,6.9,6,8.4,,6.7,0.20000000000000018,3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 6 Day 1 B,142,6.9,6,8.4,,6.7,0.20000000000000018,3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 7 Day 1 B,173,6.4,6,8.4,,6.7,-0.2999999999999998,-4.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 8 Day 1 B,199,7.1,6,8.4,,6.7,0.39999999999999947,6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 9 Day 1 B,226,6.5,6,8.4,,6.7,-0.20000000000000018,-3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,End of Treatment B,248,7.1,6,8.4,,6.7,0.39999999999999947,6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Follow-up 110 B,325,6.5,6,8.4,,6.7,-0.20000000000000018,-3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-13,28,22.6,34.5,Y,28,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 6 Day 1 B,142,26.7,22.6,34.5,,28,-1.3000000000000007,-4.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-13,1.1,0.9,1.3,Y,1.1,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 6 Day 1 B,142,1.1,0.9,1.3,,1.1,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Baseline,-13,13.6,NA,NA,Y,13.6,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 6 Day 1 B,142,14.1,NA,NA,,13.6,0.5,3.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,,-13,0.02,0,0.1,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Baseline,1,0.02,0,0.1,Y,0.02,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 8 B,8,0.01,0,0.1,,0.02,-0.01,-50
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 15 B,15,0.02,0,0.1,,0.02,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 2 Day 1 B,30,0.03,0,0.1,,0.02,0.009999999999999998,50
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 3 Day 1 B,58,0.03,0,0.1,,0.02,0.009999999999999998,50
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 4 Day 1 B,86,0.01,0,0.1,,0.02,-0.01,-50
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 5 Day 1 B,114,0.02,0,0.1,,0.02,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 6 Day 1 B,142,0.03,0,0.1,,0.02,0.009999999999999998,50
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 7 Day 1 B,173,0.02,0,0.1,,0.02,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 8 Day 1 B,199,0.03,0,0.1,,0.02,0.009999999999999998,50
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 9 Day 1 B,226,0.02,0,0.1,,0.02,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,End of Treatment B,248,0.04,0,0.1,,0.02,0.02,100
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Follow-up 110 B,325,0.02,0,0.1,,0.02,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,,-13,0.05,0,0.4,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Baseline,1,0.11,0,0.4,Y,0.11,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.09,0,0.4,,0.11,-0.020000000000000004,-18.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 15 B,15,0.06,0,0.4,,0.11,-0.05,-45.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 2 Day 1 B,30,0.08,0,0.4,,0.11,-0.03,-27.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 3 Day 1 B,58,0.05,0,0.4,,0.11,-0.06,-54.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 4 Day 1 B,86,0.11,0,0.4,,0.11,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 5 Day 1 B,114,0.07,0,0.4,,0.11,-0.039999999999999994,-36.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 6 Day 1 B,142,0.12,0,0.4,,0.11,0.009999999999999995,9.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 7 Day 1 B,173,0.12,0,0.4,,0.11,0.009999999999999995,9.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 8 Day 1 B,199,0.1,0,0.4,,0.11,-0.009999999999999995,-9.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 9 Day 1 B,226,0.11,0,0.4,,0.11,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,End of Treatment B,248,0.09,0,0.4,,0.11,-0.020000000000000004,-18.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Follow-up 110 B,325,0.03,0,0.4,,0.11,-0.08,-72.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),,-13,3.36,4.4,5.9,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Baseline,1,3.4,4.4,5.9,Y,3.4,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,3.42,4.4,5.9,,3.4,0.020000000000000018,0.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,15,3.57,4.4,5.9,,3.4,0.16999999999999993,5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,30,3.39,4.4,5.9,,3.4,-0.009999999999999787,-0.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,58,3.5,4.4,5.9,,3.4,0.10000000000000009,2.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 B,86,3.53,4.4,5.9,,3.4,0.1299999999999999,3.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 B,114,3.56,4.4,5.9,,3.4,0.16000000000000014,4.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 6 Day 1 B,142,3.74,4.4,5.9,,3.4,0.3400000000000003,10
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 7 Day 1 B,173,3.44,4.4,5.9,,3.4,0.040000000000000036,1.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 8 Day 1 B,199,3.39,4.4,5.9,,3.4,-0.009999999999999787,-0.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 9 Day 1 B,226,3.26,4.4,5.9,,3.4,-0.14000000000000012,-4.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),End of Treatment B,248,3.59,4.4,5.9,,3.4,0.18999999999999995,5.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,325,3.08,4.4,5.9,,3.4,-0.31999999999999984,-9.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),,-13,37.1,41,53,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Baseline,1,37.6,41,53,Y,37.6,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,37.3,41,53,,37.6,-0.30000000000000426,-0.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,15,38.6,41,53,,37.6,1,2.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,30,36.7,41,53,,37.6,-0.8999999999999986,-2.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,58,37.8,41,53,,37.6,0.19999999999999574,0.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 B,86,38,41,53,,37.6,0.3999999999999986,1.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 B,114,39,41,53,,37.6,1.3999999999999986,3.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 6 Day 1 B,142,39.7,41,53,,37.6,2.1000000000000014,5.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 7 Day 1 B,173,36.7,41,53,,37.6,-0.8999999999999986,-2.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 8 Day 1 B,199,36.9,41,53,,37.6,-0.7000000000000028,-1.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 9 Day 1 B,226,36,41,53,,37.6,-1.6000000000000014,-4.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),End of Treatment B,248,39.3,41,53,,37.6,1.6999999999999957,4.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Follow-up 110 B,325,33.5,41,53,,37.6,-4.100000000000001,-10.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),,-13,12.1,13.6,17.5,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Baseline,1,12,13.6,17.5,Y,12,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,12.1,13.6,17.5,,12,0.09999999999999964,0.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,15,12.4,13.6,17.5,,12,0.40000000000000036,3.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,30,11.8,13.6,17.5,,12,-0.1999999999999993,-1.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,58,12,13.6,17.5,,12,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 B,86,12.4,13.6,17.5,,12,0.40000000000000036,3.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 B,114,12.3,13.6,17.5,,12,0.3000000000000007,2.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 6 Day 1 B,142,12.7,13.6,17.5,,12,0.6999999999999993,5.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 7 Day 1 B,173,11.7,13.6,17.5,,12,-0.3000000000000007,-2.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 8 Day 1 B,199,12.1,13.6,17.5,,12,0.09999999999999964,0.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 9 Day 1 B,226,11.3,13.6,17.5,,12,-0.6999999999999993,-5.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),End of Treatment B,248,12.5,13.6,17.5,,12,0.5,4.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Follow-up 110 B,325,10.8,13.6,17.5,,12,-1.1999999999999993,-10
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,,-13,0.71,1,3.4,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Baseline,1,0.88,1,3.4,Y,0.88,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,0.64,1,3.4,,0.88,-0.24,-27.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 15 B,15,0.75,1,3.4,,0.88,-0.13,-14.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 2 Day 1 B,30,0.58,1,3.4,,0.88,-0.30000000000000004,-34.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 3 Day 1 B,58,0.43,1,3.4,,0.88,-0.45,-51.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 4 Day 1 B,86,0.68,1,3.4,,0.88,-0.19999999999999996,-22.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 5 Day 1 B,114,0.46,1,3.4,,0.88,-0.42,-47.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 6 Day 1 B,142,0.63,1,3.4,,0.88,-0.25,-28.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 7 Day 1 B,173,0.8,1,3.4,,0.88,-0.07999999999999996,-9.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 8 Day 1 B,199,0.71,1,3.4,,0.88,-0.17000000000000004,-19.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 9 Day 1 B,226,0.66,1,3.4,,0.88,-0.21999999999999997,-25
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,End of Treatment B,248,0.61,1,3.4,,0.88,-0.27,-30.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Follow-up 110 B,325,0.44,1,3.4,,0.88,-0.44,-50
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,,-13,0.39,0.2,0.8,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Baseline,1,0.42,0.2,0.8,Y,0.42,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 8 B,8,1.11,0.2,0.8,,0.42,0.6900000000000002,164.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 15 B,15,1.84,0.2,0.8,,0.42,1.4200000000000002,338.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 2 Day 1 B,30,0.69,0.2,0.8,,0.42,0.26999999999999996,64.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 3 Day 1 B,58,0.45,0.2,0.8,,0.42,0.030000000000000027,7.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 4 Day 1 B,86,0.5,0.2,0.8,,0.42,0.08000000000000002,19
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 5 Day 1 B,114,0.46,0.2,0.8,,0.42,0.040000000000000036,9.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 6 Day 1 B,142,0.48,0.2,0.8,,0.42,0.06,14.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 7 Day 1 B,173,0.6,0.2,0.8,,0.42,0.18,42.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 8 Day 1 B,199,0.57,0.2,0.8,,0.42,0.14999999999999997,35.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 9 Day 1 B,226,0.46,0.2,0.8,,0.42,0.040000000000000036,9.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,End of Treatment B,248,0.58,0.2,0.8,,0.42,0.15999999999999998,38.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Follow-up 110 B,325,0.36,0.2,0.8,,0.42,-0.06,-14.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,,-13,3.22,1.8,6.8,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Baseline,1,2.33,1.8,6.8,Y,2.33,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 8 B,8,2.75,1.8,6.8,,2.33,0.41999999999999993,18
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 15 B,15,3.78,1.8,6.8,,2.33,1.4499999999999997,62.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 2 Day 1 B,30,3.59,1.8,6.8,,2.33,1.2599999999999998,54.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 3 Day 1 B,58,5.59,1.8,6.8,,2.33,3.26,139.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 4 Day 1 B,86,2.89,1.8,6.8,,2.33,0.56,24
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 5 Day 1 B,114,5.19,1.8,6.8,,2.33,2.8600000000000003,122.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 6 Day 1 B,142,3.23,1.8,6.8,,2.33,0.8999999999999999,38.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 7 Day 1 B,173,3.57,1.8,6.8,,2.33,1.2399999999999998,53.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 8 Day 1 B,199,2.62,1.8,6.8,,2.33,0.29000000000000004,12.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 9 Day 1 B,226,3.37,1.8,6.8,,2.33,1.04,44.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,End of Treatment B,248,6.42,1.8,6.8,,2.33,4.09,175.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Follow-up 110 B,325,4.72,1.8,6.8,,2.33,2.3899999999999997,102.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),,-13,191,140,450,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Baseline,1,232,140,450,Y,232,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,212,140,450,,232,-20,-8.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,15,232,140,450,,232,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,30,275,140,450,,232,43,18.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,58,261,140,450,,232,29,12.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 1 B,86,198,140,450,,232,-34,-14.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 5 Day 1 B,114,213,140,450,,232,-19,-8.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 6 Day 1 B,142,210,140,450,,232,-22,-9.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 7 Day 1 B,173,240,140,450,,232,8,3.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 8 Day 1 B,199,253,140,450,,232,21,9.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 9 Day 1 B,226,217,140,450,,232,-15,-6.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),End of Treatment B,248,230,140,450,,232,-2,-0.9
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Follow-up 110 B,325,200,140,450,,232,-32,-13.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,,-13,4.4,3.4,10,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Baseline,1,3.8,3.4,10,Y,3.8,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,4.6,3.4,10,,3.8,0.7999999999999998,21.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 15 B,15,6.5,3.4,10,,3.8,2.7,71.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 2 Day 1 B,30,5,3.4,10,,3.8,1.2000000000000002,31.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 3 Day 1 B,58,6.6,3.4,10,,3.8,2.8,73.7
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 4 Day 1 B,86,4.2,3.4,10,,3.8,0.40000000000000036,10.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 5 Day 1 B,114,6.2,3.4,10,,3.8,2.4000000000000004,63.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 6 Day 1 B,142,4.5,3.4,10,,3.8,0.7000000000000002,18.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 7 Day 1 B,173,5.1,3.4,10,,3.8,1.2999999999999998,34.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 8 Day 1 B,199,4,3.4,10,,3.8,0.20000000000000018,5.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 9 Day 1 B,226,4.6,3.4,10,,3.8,0.7999999999999998,21.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,End of Treatment B,248,7.8,3.4,10,,3.8,4,105.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Follow-up 110 B,325,5.6,3.4,10,,3.8,1.7999999999999998,47.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,,-13,1.12,NA,NA,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Baseline,1,1.25,NA,NA,Y,1.25,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,30,0.47,NA,NA,,1.25,-0.78,-62.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 3 Day 1 B,58,0.28,NA,NA,,1.25,-0.97,-77.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 4 Day 1 B,86,0.36,NA,NA,,1.25,-0.89,-71.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 5 Day 1 B,114,0.52,NA,NA,,1.25,-0.73,-58.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 6 Day 1 B,142,0.78,NA,NA,,1.25,-0.47,-37.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 7 Day 1 B,173,0.94,NA,NA,,1.25,-0.31000000000000005,-24.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 8 Day 1 B,199,0.97,NA,NA,,1.25,-0.28,-22.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 9 Day 1 B,226,1.08,NA,NA,,1.25,-0.16999999999999993,-13.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,End of Treatment B,248,1.32,NA,NA,,1.25,0.07000000000000006,5.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Follow-up 110 B,325,0.56,NA,NA,,1.25,-0.69,-55.2
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 7 Day 1 B,173,14,NA,NA,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-13,5.76,0.45,4.12,,NA,NA,NA
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,4.12,0.45,4.12,Y,4.12,0,0
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,1.47,0.45,4.12,,4.12,-2.6500000000000004,-64.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,15,2.19,0.45,4.12,,4.12,-1.9300000000000002,-46.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,30,2.29,0.45,4.12,,4.12,-1.83,-44.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,58,2,0.45,4.12,,4.12,-2.12,-51.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 B,86,2.95,0.45,4.12,,4.12,-1.17,-28.4
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 B,114,2.94,0.45,4.12,,4.12,-1.1800000000000002,-28.6
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 6 Day 1 B,142,2.74,0.45,4.12,,4.12,-1.38,-33.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 7 Day 1 B,173,5.7,0.45,4.12,,4.12,1.58,38.3
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 8 Day 1 B,199,1.67,0.45,4.12,,4.12,-2.45,-59.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 9 Day 1 B,226,2.07,0.45,4.12,,4.12,-2.0500000000000003,-49.8
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,248,1.34,0.45,4.12,,4.12,-2.7800000000000002,-67.5
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 B,325,0.78,0.45,4.12,,4.12,-3.34,-81.1
6B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Triiodothyronine (T3),Cycle 7 Day 1 B,173,0.9,NA,NA,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,0,NA,NA,Y,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,30,0,NA,NA,,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,End of Treatment C,86,1,NA,NA,,0,1,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-20,21,0,55,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,34,0,55,Y,34,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,28,0,55,,34,-6,-17.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,16,72,0,55,,34,38,111.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,33,0,55,,34,-1,-2.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,30,44,0,55,,34,10,29.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,37,72,0,55,,34,38,111.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 C,58,46,0,55,,34,12,35.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,86,29,0,55,,34,-5,-14.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 C,142,44,0,55,,34,10,29.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-20,4.6,3.8,5,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4.4,3.8,5,Y,4.4,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,4.5,3.8,5,,4.4,0.09999999999999964,2.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,16,4.3,3.8,5,,4.4,-0.10000000000000053,-2.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,4.4,3.8,5,,4.4,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,30,4.4,3.8,5,,4.4,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,37,4.2,3.8,5,,4.4,-0.20000000000000018,-4.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,58,4.2,3.8,5,,4.4,-0.20000000000000018,-4.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,86,4.4,3.8,5,,4.4,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 C,142,4.3,3.8,5,,4.4,-0.10000000000000053,-2.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-20,92,0,130,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,94,0,130,Y,94,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,86,0,130,,94,-8,-8.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,16,110,0,130,,94,16,17
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,94,0,130,,94,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,30,95,0,130,,94,1,1.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,37,146,0,130,,94,52,55.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,58,138,0,130,,94,44,46.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,86,124,0,130,,94,30,31.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 C,142,103,0,130,,94,9,9.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-20,17,0,37,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,26,0,37,Y,26,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,22,0,37,,26,-4,-15.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,16,31,0,37,,26,5,19.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,20,0,37,,26,-6,-23.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,30,30,0,37,,26,4,15.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,37,32,0,37,,26,6,23.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,58,22,0,37,,26,-4,-15.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,86,29,0,37,,26,3,11.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 C,142,42,0,37,,26,16,61.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-20,16,6,20,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,18,6,20,Y,18,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,17,6,20,,18,-1,-5.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,16,20,6,20,,18,2,11.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,17,6,20,,18,-1,-5.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,30,18,6,20,,18,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,37,17,6,20,,18,-1,-5.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 C,58,16,6,20,,18,-2,-11.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,86,14,6,20,,18,-4,-22.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 C,142,14,6,20,,18,-4,-22.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-20,28,18,29,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,27,18,29,Y,27,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,29,18,29,,27,2,7.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,16,28,18,29,,27,1,3.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,27,18,29,,27,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,30,27,18,29,,27,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,37,26,18,29,,27,-1,-3.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 C,58,28,18,29,,27,1,3.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment C,86,28,18,29,,27,1,3.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 C,142,22,18,29,,27,-5,-18.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-20,9.4,8.5,10.5,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.2,8.5,10.5,Y,9.2,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,9.4,8.5,10.5,,9.2,0.20000000000000107,2.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,16,9.1,8.5,10.5,,9.2,-0.09999999999999964,-1.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,9.3,8.5,10.5,,9.2,0.10000000000000142,1.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,30,9,8.5,10.5,,9.2,-0.1999999999999993,-2.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,37,9.1,8.5,10.5,,9.2,-0.09999999999999964,-1.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,58,9.2,8.5,10.5,,9.2,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,86,9.3,8.5,10.5,,9.2,0.10000000000000142,1.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 C,142,9.3,8.5,10.5,,9.2,0.10000000000000142,1.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-20,100,98,109,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,100,98,109,Y,100,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,103,98,109,,100,3,3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,16,99,98,109,,100,-1,-1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,101,98,109,,100,1,1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,30,101,98,109,,100,1,1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,37,103,98,109,,100,3,3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,58,102,98,109,,100,2,2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,86,99,98,109,,100,-1,-1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 C,142,102,98,109,,100,2,2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-20,1,0.6,1.3,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.9,0.6,1.3,Y,0.9,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,0.9,0.6,1.3,,0.9,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,16,0.9,0.6,1.3,,0.9,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,0.9,0.6,1.3,,0.9,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,30,0.9,0.6,1.3,,0.9,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,37,1.1,0.6,1.3,,0.9,0.20000000000000007,22.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,58,0.9,0.6,1.3,,0.9,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,86,0.9,0.6,1.3,,0.9,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 C,142,0.8,0.6,1.3,,0.9,-0.09999999999999998,-11.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-20,239,70,140,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,212,70,140,Y,212,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,155,70,140,,212,-57,-26.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,16,192,70,140,,212,-20,-9.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,185,70,140,,212,-27,-12.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,30,191,70,140,,212,-21,-9.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,37,200,70,140,,212,-12,-5.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 C,58,200,70,140,,212,-12,-5.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,86,180,70,140,,212,-32,-15.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 C,142,170,70,140,,212,-42,-19.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-20,165,130,250,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,165,130,250,Y,165,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,195,130,250,,165,30,18.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,16,229,130,250,,165,64,38.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,180,130,250,,165,15,9.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,30,227,130,250,,165,62,37.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,37,241,130,250,,165,76,46.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 C,58,169,130,250,,165,4,2.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,86,215,130,250,,165,50,30.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 C,142,234,130,250,,165,69,41.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-20,4.6,3.5,5.1,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.6,3.5,5.1,Y,4.6,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,4.9,3.5,5.1,,4.6,0.3000000000000007,6.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,16,4.4,3.5,5.1,,4.6,-0.1999999999999993,-4.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.4,3.5,5.1,,4.6,-0.1999999999999993,-4.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,30,4.5,3.5,5.1,,4.6,-0.09999999999999964,-2.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,37,4.1,3.5,5.1,,4.6,-0.5,-10.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,58,4.2,3.5,5.1,,4.6,-0.39999999999999947,-8.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,86,4.5,3.5,5.1,,4.6,-0.09999999999999964,-2.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 C,142,4.3,3.5,5.1,,4.6,-0.2999999999999998,-6.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-20,137,133,143,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,137,133,143,Y,137,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,139,133,143,,137,2,1.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,16,134,133,143,,137,-3,-2.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,137,133,143,,137,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,30,137,133,143,,137,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,37,138,133,143,,137,1,0.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 C,58,140,133,143,,137,3,2.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,86,137,133,143,,137,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 C,142,135,133,143,,137,-2,-1.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-20,0.5,0,1.2,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.5,0,1.2,Y,0.5,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.3,0,1.2,,0.5,-0.2,-40
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,16,0.3,0,1.2,,0.5,-0.2,-40
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.6,0,1.2,,0.5,0.09999999999999998,20
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,30,0.3,0,1.2,,0.5,-0.2,-40
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,37,0.4,0,1.2,,0.5,-0.09999999999999998,-20
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,58,0.4,0,1.2,,0.5,-0.09999999999999998,-20
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,86,0.8,0,1.2,,0.5,0.30000000000000004,60
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 C,142,0.4,0,1.2,,0.5,-0.09999999999999998,-20
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-20,7.4,6.3,8.1,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.1,6.3,8.1,Y,7.1,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,7.2,6.3,8.1,,7.1,0.10000000000000053,1.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,16,7.1,6.3,8.1,,7.1,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,7.1,6.3,8.1,,7.1,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,30,7.2,6.3,8.1,,7.1,0.10000000000000053,1.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,37,7.1,6.3,8.1,,7.1,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 C,58,7.3,6.3,8.1,,7.1,0.20000000000000018,2.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,86,7.8,6.3,8.1,,7.1,0.7000000000000002,9.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 C,142,7.6,6.3,8.1,,7.1,0.5,7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-20,28.9,22.5,36.5,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,29.7,22.5,36.5,Y,29.7,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,8,26.8,22.5,36.5,,29.7,-2.8999999999999986,-9.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,16,26.4,22.5,36.5,,29.7,-3.3000000000000007,-11.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,22,28,22.5,36.5,,29.7,-1.6999999999999993,-5.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 1 C,30,27,22.5,36.5,,29.7,-2.6999999999999993,-9.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 C,37,29.1,22.5,36.5,,29.7,-0.5999999999999979,-2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 C,58,29.1,22.5,36.5,,29.7,-0.5999999999999979,-2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment C,86,27.7,22.5,36.5,,29.7,-2,-6.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-20,0.99,0.8,1.2,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,0.97,0.8,1.2,Y,0.97,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,8,0.94,0.8,1.2,,0.97,-0.030000000000000027,-3.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,16,1.02,0.8,1.2,,0.97,0.050000000000000044,5.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,22,1.01,0.8,1.2,,0.97,0.040000000000000036,4.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 1 C,30,1,0.8,1.2,,0.97,0.030000000000000027,3.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 C,37,1.05,0.8,1.2,,0.97,0.08000000000000007,8.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 C,58,1,0.8,1.2,,0.97,0.030000000000000027,3.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment C,86,1.08,0.8,1.2,,0.97,0.1100000000000001,11.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-20,12.9,11.1,15.2,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.7,11.1,15.2,Y,12.7,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,8,12.3,11.1,15.2,,12.7,-0.3999999999999986,-3.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,16,13.2,11.1,15.2,,12.7,0.5,3.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,22,13.1,11.1,15.2,,12.7,0.40000000000000036,3.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 1 C,30,13,11.1,15.2,,12.7,0.3000000000000007,2.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 C,37,13.5,11.1,15.2,,12.7,0.8000000000000007,6.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 C,58,13,11.1,15.2,,12.7,0.3000000000000007,2.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment C,86,13.8,11.1,15.2,,12.7,1.1000000000000014,8.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-20,0,0,0.2,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0.1,0,0.2,,0,0.1,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,16,0,0,0.2,,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.2,,0,0.1,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,30,0.1,0,0.2,,0,0.1,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 C,37,0.1,0,0.2,,0,0.1,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 C,58,0,0,0.2,,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,86,0,0,0.2,,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 C,142,0.1,0,0.2,,0,0.1,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-20,0,0,0.7,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0,0,0.7,Y,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0.1,0,0.7,,0,0.1,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,16,0,0,0.7,,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0.1,0,0.7,,0,0.1,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,30,0.2,0,0.7,,0,0.2,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 C,37,0.2,0,0.7,,0,0.2,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 C,58,0.2,0,0.7,,0,0.2,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,86,0,0,0.7,,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 C,142,0,0,0.7,,0,0,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-20,4.27,3.95,5.54,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.11,3.95,5.54,Y,4.11,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,4.04,3.95,5.54,,4.11,-0.07000000000000028,-1.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,16,4.09,3.95,5.54,,4.11,-0.020000000000000462,-0.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.99,3.95,5.54,,4.11,-0.1200000000000001,-2.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,30,4.13,3.95,5.54,,4.11,0.019999999999999574,0.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,37,3.71,3.95,5.54,,4.11,-0.40000000000000036,-9.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,58,3.67,3.95,5.54,,4.11,-0.4400000000000004,-10.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,86,3.99,3.95,5.54,,4.11,-0.1200000000000001,-2.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 C,142,4.17,3.95,5.54,,4.11,0.05999999999999961,1.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-20,38.6,37.5,49.3,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,36,37.5,49.3,Y,36,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,36.2,37.5,49.3,,36,0.20000000000000284,0.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,16,36.1,37.5,49.3,,36,0.10000000000000142,0.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,34.8,37.5,49.3,,36,-1.2000000000000028,-3.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,30,37.1,37.5,49.3,,36,1.1000000000000014,3.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,37,33.2,37.5,49.3,,36,-2.799999999999997,-7.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,58,32.7,37.5,49.3,,36,-3.299999999999997,-9.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,86,34.8,37.5,49.3,,36,-1.2000000000000028,-3.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 C,142,35.1,37.5,49.3,,36,-0.8999999999999986,-2.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-20,12.5,12.5,16.2,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.8,12.5,16.2,Y,11.8,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,11.6,12.5,16.2,,11.8,-0.20000000000000107,-1.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,16,11.3,12.5,16.2,,11.8,-0.5,-4.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,11.4,12.5,16.2,,11.8,-0.40000000000000036,-3.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,30,11.9,12.5,16.2,,11.8,0.09999999999999964,0.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,37,10.6,12.5,16.2,,11.8,-1.200000000000001,-10.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,58,10.5,12.5,16.2,,11.8,-1.3000000000000007,-11
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,86,11,12.5,16.2,,11.8,-0.8000000000000007,-6.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 C,142,10.9,12.5,16.2,,11.8,-0.9000000000000004,-7.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-20,1.1,0.9,3.2,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.7,0.9,3.2,Y,1.7,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,2.3,0.9,3.2,,1.7,0.5999999999999999,35.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,16,1.9,0.9,3.2,,1.7,0.19999999999999996,11.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,1.7,0.9,3.2,,1.7,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,30,2,0.9,3.2,,1.7,0.30000000000000004,17.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 C,37,1.6,0.9,3.2,,1.7,-0.09999999999999987,-5.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 C,58,1.3,0.9,3.2,,1.7,-0.3999999999999999,-23.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,86,1.1,0.9,3.2,,1.7,-0.5999999999999999,-35.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 C,142,1.3,0.9,3.2,,1.7,-0.3999999999999999,-23.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-20,0.3,0,1.3,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.4,0,1.3,Y,0.4,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,2.1,0,1.3,,0.4,1.7000000000000002,425
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,16,2.9,0,1.3,,0.4,2.5,625
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,1,0,1.3,,0.4,0.6,150
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,30,3.2,0,1.3,,0.4,2.8000000000000003,700
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 C,37,2.2,0,1.3,,0.4,1.8000000000000003,450
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 C,58,0.4,0,1.3,,0.4,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,86,0.5,0,1.3,,0.4,0.09999999999999998,25
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 C,142,0.6,0,1.3,,0.4,0.19999999999999996,50
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-20,4.4,1.5,7.5,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3,1.5,7.5,Y,3,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,5.1,1.5,7.5,,3,2.0999999999999996,70
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,16,3.8,1.5,7.5,,3,0.7999999999999998,26.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,3.2,1.5,7.5,,3,0.20000000000000018,6.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,30,6.7,1.5,7.5,,3,3.7,123.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 C,37,5.3,1.5,7.5,,3,2.3,76.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 C,58,4.3,1.5,7.5,,3,1.2999999999999998,43.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,86,4.4,1.5,7.5,,3,1.4000000000000004,46.7
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 C,142,7.6,1.5,7.5,,3,4.6,153.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-20,313,160,400,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,323,160,400,Y,323,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,326,160,400,,323,3,0.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,16,259,160,400,,323,-64,-19.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,395,160,400,,323,72,22.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,30,413,160,400,,323,90,27.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,37,268,160,400,,323,-55,-17
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,58,345,160,400,,323,22,6.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,86,320,160,400,,323,-3,-0.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 C,142,402,160,400,,323,79,24.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-20,5.9,4,11,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.2,4,11,Y,5.2,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,9.7,4,11,,5.2,4.499999999999999,86.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,16,8.6,4,11,,5.2,3.3999999999999995,65.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,6.1,4,11,,5.2,0.8999999999999995,17.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,30,12.3,4,11,,5.2,7.1000000000000005,136.5
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,37,9.3,4,11,,5.2,4.1000000000000005,78.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 C,58,6.3,4,11,,5.2,1.0999999999999996,21.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,86,6,4,11,,5.2,0.7999999999999998,15.4
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 C,142,9.6,4,11,,5.2,4.3999999999999995,84.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-20,72.43,NA,NA,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,151.33,NA,NA,Y,151.33,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,277.91,NA,NA,,151.33,126.58000000000001,83.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,30,359.6,NA,NA,,151.33,208.27,137.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,58,856.3,NA,NA,,151.33,704.9699999999999,465.8
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,86,1313.59,NA,NA,,151.33,1162.26,768
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 C,142,1277.04,NA,NA,,151.33,1125.71,743.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-20,1.18,0.6,4.8,,NA,NA,NA
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.66,0.6,4.8,Y,2.66,0,0
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,2.13,0.6,4.8,,2.66,-0.5300000000000002,-19.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,16,1.64,0.6,4.8,,2.66,-1.0200000000000002,-38.3
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,1.54,0.6,4.8,,2.66,-1.12,-42.1
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,30,1.43,0.6,4.8,,2.66,-1.2300000000000002,-46.2
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,37,1.28,0.6,4.8,,2.66,-1.3800000000000001,-51.9
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,58,2.06,0.6,4.8,,2.66,-0.6000000000000001,-22.6
6C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,86,1.45,0.6,4.8,,2.66,-1.2100000000000002,-45.5
7A,A,NKTR-214 + Nivolumab,N,N,,CTC,Baseline,1,5,NA,NA,Y,5,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 A,23,5,NA,NA,,5,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-2,7,1,45,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,8,1,45,Y,8,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,9,15,1,45,,8,7,87.5
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,23,9,1,45,,8,1,12.5
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,30,9,1,45,,8,1,12.5
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 A,140,6,1,45,,8,-2,-25
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-2,3.9,3.5,4.9,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.8,3.5,4.9,Y,3.8,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,9,3.5,3.5,4.9,,3.8,-0.2999999999999998,-7.9
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,23,4,3.5,4.9,,3.8,0.20000000000000018,5.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,30,3.4,3.5,4.9,,3.8,-0.3999999999999999,-10.5
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment A,72,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 A,140,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-2,109,38,126,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,109,38,126,Y,109,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,9,101,38,126,,109,-8,-7.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,23,113,38,126,,109,4,3.7
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,30,133,38,126,,109,24,22
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,72,128,38,126,,109,19,17.4
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 A,140,240,38,126,,109,131,120.2
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-2,11,1,35,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,12,1,35,Y,12,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,9,16,1,35,,12,4,33.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,23,13,1,35,,12,1,8.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,30,10,1,35,,12,-2,-16.7
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,72,9,1,35,,12,-3,-25
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 A,140,12,1,35,,12,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-2,18,6,23,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,106,6,23,Y,106,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,9,9,6,23,,106,-97,-91.5
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,23,16,6,23,,106,-90,-84.9
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 8 A,30,77,6,23,,106,-29,-27.4
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,End of Treatment A,72,17,6,23,,106,-89,-84
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 A,140,23,6,23,,106,-83,-78.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-2,29,22,30,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,27,22,30,Y,27,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,9,27,22,30,,27,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,23,27,22,30,,27,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,30,25,22,30,,27,-2,-7.4
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment A,72,28,22,30,,27,1,3.7
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 A,140,25,22,30,,27,-2,-7.4
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-2,9.4,8.5,10.5,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.2,8.5,10.5,Y,9.2,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,9,8.7,8.5,10.5,,9.2,-0.5,-5.4
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,23,9.6,8.5,10.5,,9.2,0.40000000000000036,4.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,30,9.2,8.5,10.5,,9.2,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment A,72,9,8.5,10.5,,9.2,-0.1999999999999993,-2.2
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 A,140,9.3,8.5,10.5,,9.2,0.10000000000000142,1.1
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-2,104,96,108,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,105,96,108,Y,105,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,9,106,96,108,,105,1,1
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,23,102,96,108,,105,-3,-2.9
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,30,105,96,108,,105,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment A,72,103,96,108,,105,-2,-1.9
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 A,140,102,96,108,,105,-3,-2.9
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-2,1.29,0.7,1.3,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1.26,0.7,1.3,Y,1.26,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,9,1.25,0.7,1.3,,1.26,-0.010000000000000009,-0.8
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,23,1.24,0.7,1.3,,1.26,-0.020000000000000018,-1.6
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,30,1.36,0.7,1.3,,1.26,0.10000000000000009,7.9
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment A,72,1.58,0.7,1.3,,1.26,0.32000000000000006,25.4
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 A,140,1.85,0.7,1.3,,1.26,0.5900000000000001,46.8
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-2,105,60,100,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,81,60,100,Y,81,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 A,9,95,60,100,,81,14,17.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,23,89,60,100,,81,8,9.9
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,30,81,60,100,,81,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment A,72,93,60,100,,81,12,14.8
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 A,140,99,60,100,,81,18,22.2
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-2,149,100,220,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,131,100,220,Y,131,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,9,184,100,220,,131,53,40.5
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,23,152,100,220,,131,21,16
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,30,228,100,220,,131,97,74
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment A,72,161,100,220,,131,30,22.9
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 A,140,170,100,220,,131,39,29.8
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-2,4.4,3.5,5.2,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.2,3.5,5.2,Y,4.2,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,9,4.3,3.5,5.2,,4.2,0.09999999999999964,2.4
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,23,5,3.5,5.2,,4.2,0.7999999999999998,19
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,30,4.6,3.5,5.2,,4.2,0.39999999999999947,9.5
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment A,72,4.5,3.5,5.2,,4.2,0.2999999999999998,7.1
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 A,140,4.9,3.5,5.2,,4.2,0.7000000000000002,16.7
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-2,141,135,145,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,140,135,145,Y,140,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,9,139,135,145,,140,-1,-0.7
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,23,137,135,145,,140,-3,-2.1
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,30,140,135,145,,140,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment A,72,137,135,145,,140,-3,-2.1
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 A,140,137,135,145,,140,-3,-2.1
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-2,0.3,0.1,1.2,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.3,0.1,1.2,Y,0.3,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,9,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,23,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,30,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment A,72,0.4,0.1,1.2,,0.3,0.10000000000000003,33.3
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 A,140,0.3,0.1,1.2,,0.3,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-2,6.1,6,8.3,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,5.9,6,8.3,Y,5.9,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,9,5.9,6,8.3,,5.9,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,23,7,6,8.3,,5.9,1.0999999999999996,18.6
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,30,6.2,6,8.3,,5.9,0.2999999999999998,5.1
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment A,72,6.4,6,8.3,,5.9,0.5,8.5
7A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 A,140,7.1,6,8.3,,5.9,1.1999999999999993,20.3
7A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-27,27.9,25.4,34.9,Y,27.9,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment A,72,31.8,25.4,34.9,,27.9,3.900000000000002,14
7A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-27,0.9,2,3,Y,0.9,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment A,72,1,2,3,,0.9,0.09999999999999998,11.1
7A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,-27,12.1,12.3,14.9,Y,12.1,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment A,72,13.1,12.3,14.9,,12.1,1,8.3
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-2,0,0,0.2,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0,0,0.2,,0,0,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0,0,0.2,,0,0,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,9,0,0,0.2,,0,0,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,23,0.1,0,0.2,,0,0.1,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,30,0,0,0.2,,0,0,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,End of Treatment A,72,0,0,0.2,,0,0,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 A,140,0,0,0.2,,0,0,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-2,0.2,0,0.6,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.2,0,0.6,Y,0.2,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.2,0,0.6,,0.2,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.3,0,0.6,,0.2,0.09999999999999998,50
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,9,0.8,0,0.6,,0.2,0.6000000000000001,300
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,23,0.7,0,0.6,,0.2,0.49999999999999994,250
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 8 A,30,7.2,0,0.6,,0.2,7,3500
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment A,72,0.4,0,0.6,,0.2,0.2,100
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 A,140,0.4,0,0.6,,0.2,0.2,100
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-2,4.08,4.5,6,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.9,4.5,6,Y,3.9,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,4.02,4.5,6,,3.9,0.11999999999999966,3.1
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,4.12,4.5,6,,3.9,0.2200000000000002,5.6
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,9,4.07,4.5,6,,3.9,0.17000000000000037,4.4
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,23,4.04,4.5,6,,3.9,0.14000000000000012,3.6
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,30,3.99,4.5,6,,3.9,0.0900000000000003,2.3
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment A,72,3.84,4.5,6,,3.9,-0.06000000000000005,-1.5
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 A,140,3.34,4.5,6,,3.9,-0.56,-14.4
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-2,35.8,42,52,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,34.5,42,52,Y,34.5,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,35.3,42,52,,34.5,0.7999999999999972,2.3
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,35.8,42,52,,34.5,1.2999999999999972,3.8
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,9,35.6,42,52,,34.5,1.1000000000000014,3.2
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,23,35.2,42,52,,34.5,0.7000000000000028,2
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,30,34.5,42,52,,34.5,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment A,72,33.5,42,52,,34.5,-1,-2.9
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 A,140,27.9,42,52,,34.5,-6.600000000000001,-19.1
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-2,12.1,13.9,16.3,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.6,13.9,16.3,Y,11.6,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,11.7,13.9,16.3,,11.6,0.09999999999999964,0.9
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,12.1,13.9,16.3,,11.6,0.5,4.3
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,9,11.5,13.9,16.3,,11.6,-0.09999999999999964,-0.9
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,23,11.6,13.9,16.3,,11.6,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,30,11.4,13.9,16.3,,11.6,-0.1999999999999993,-1.7
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment A,72,11.1,13.9,16.3,,11.6,-0.5,-4.3
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 A,140,9.4,13.9,16.3,,11.6,-2.1999999999999993,-19
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-2,1.1,1,4.5,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1,1,4.5,Y,1,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.3,1,4.5,,1,-0.7,-70
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.2,1,4.5,,1,-0.8,-80
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,9,2.7,1,4.5,,1,1.7000000000000002,170
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,23,1.9,1,4.5,,1,0.8999999999999999,90
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,30,4,1,4.5,,1,3,300
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment A,72,0.7,1,4.5,,1,-0.30000000000000004,-30
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 A,140,1.1,1,4.5,,1,0.10000000000000009,10
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-2,0.3,0.2,1,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.3,0.2,1,Y,0.3,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.4,0.2,1,,0.3,0.10000000000000003,33.3
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.4,0.2,1,,0.3,0.10000000000000003,33.3
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,9,0.4,0.2,1,,0.3,0.10000000000000003,33.3
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,23,0.3,0.2,1,,0.3,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,30,0.5,0.2,1,,0.3,0.2,66.7
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment A,72,0.2,0.2,1,,0.3,-0.09999999999999998,-33.3
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 A,140,0.3,0.2,1,,0.3,0,0
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-2,3.7,1.9,8,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,2.8,1.9,8,Y,2.8,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,4.5,1.9,8,,2.8,1.7000000000000002,60.7
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,5.5,1.9,8,,2.8,2.7,96.4
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,9,3,1.9,8,,2.8,0.20000000000000018,7.1
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,23,3.5,1.9,8,,2.8,0.7000000000000002,25
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,30,1.69,1.9,8,,2.8,-1.1099999999999999,-39.6
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment A,72,4.7,1.9,8,,2.8,1.9000000000000004,67.9
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 A,140,4.2,1.9,8,,2.8,1.4000000000000004,50
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-2,208,150,450,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,211,150,450,Y,211,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,205,150,450,,211,-6,-2.8
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,178,150,450,,211,-33,-15.6
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,9,229,150,450,,211,18,8.5
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,23,326,150,450,,211,115,54.5
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,30,245,150,450,,211,34,16.1
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment A,72,228,150,450,,211,17,8.1
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 A,140,299,150,450,,211,88,41.7
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-2,5.3,4.5,11,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,4.3,4.5,11,Y,4.3,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,5.4,4.5,11,,4.3,1.1000000000000005,25.6
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,6.5,4.5,11,,4.3,2.2,51.2
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,9,6.9,4.5,11,,4.3,2.6000000000000005,60.5
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,23,6.5,4.5,11,,4.3,2.2,51.2
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,30,14.1,4.5,11,,4.3,9.8,227.9
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment A,72,6,4.5,11,,4.3,1.7000000000000002,39.5
7A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 A,140,6.1,4.5,11,,4.3,1.7999999999999998,41.9
7A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-27,60.3,NA,NA,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,62.67,NA,NA,Y,62.67,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,23,53.14,NA,NA,,62.67,-9.530000000000001,-15.2
7A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment A,72,87.94,NA,NA,,62.67,25.269999999999996,40.3
7A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 A,140,221.12,NA,NA,,62.67,158.45,252.8
7A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),Baseline,1,0.55,0.8,1.5,Y,0.55,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-2,32.6,0.4,4.2,,NA,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,42.4,0.4,4.2,Y,42.4,NA,NA
7A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,23,49,0.4,4.2,,42.4,6.600000000000001,15.6
7A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Triiodothyronine (T3),Baseline,1,57,2.5,3.9,Y,57,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Baseline,1,62,NA,NA,Y,62,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,End of Treatment B,31,110,NA,NA,,62,48,77.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-219,14,1,45,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-3,19,1,45,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,18,1,45,Y,18,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,19,1,45,,18,1,5.6
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,15,20,1,45,,18,2,11.1
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,31,21,1,45,,18,3,16.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,31,21,1,45,,18,3,16.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-219,3.7,3.5,4.9,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-3,3.9,3.5,4.9,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4,3.5,4.9,Y,4,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,4,3.5,4.9,,4,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,15,3.7,3.5,4.9,,4,-0.2999999999999998,-7.5
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,31,4,3.5,4.9,,4,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment B,31,4,3.5,4.9,,4,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-219,149,38,126,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-3,84,38,126,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,90,38,126,Y,90,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,94,38,126,,90,4,4.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,15,83,38,126,,90,-7,-7.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,31,99,38,126,,90,9,10
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,31,99,38,126,,90,9,10
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-219,41,1,35,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-3,27,1,35,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,28,1,35,Y,28,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,28,1,35,,28,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,15,31,1,35,,28,3,10.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,31,41,1,35,,28,13,46.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,31,41,1,35,,28,13,46.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-219,13,6,23,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-3,12,6,23,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Baseline,1,11,6,23,Y,11,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 B,8,11,6,23,,11,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 15 B,15,15,6,23,,11,4,36.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 B,31,13,6,23,,11,2,18.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,End of Treatment B,31,13,6,23,,11,2,18.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-219,18.7,22,30,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-3,22.9,22,30,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,20.4,22,30,Y,20.4,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,27.2,22,30,,20.4,6.800000000000001,33.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 15 B,15,23.7,22,30,,20.4,3.3000000000000007,16.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 B,31,23.2,22,30,,20.4,2.8000000000000007,13.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment B,31,23.2,22,30,,20.4,2.8000000000000007,13.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-219,8.8,8.5,10.5,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-3,9.3,8.5,10.5,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.4,8.5,10.5,Y,9.4,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,9.6,8.5,10.5,,9.4,0.1999999999999993,2.1
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,15,9,8.5,10.5,,9.4,-0.40000000000000036,-4.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,31,9.3,8.5,10.5,,9.4,-0.09999999999999964,-1.1
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment B,31,9.3,8.5,10.5,,9.4,-0.09999999999999964,-1.1
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-219,107,96,108,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-3,109,96,108,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,108,96,108,Y,108,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,105,96,108,,108,-3,-2.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,15,106,96,108,,108,-2,-1.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,31,109,96,108,,108,1,0.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment B,31,109,96,108,,108,1,0.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-219,0.63,0.7,1.3,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-3,1.07,0.7,1.3,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.85,0.7,1.3,Y,0.85,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,0.9,0.7,1.3,,0.85,0.050000000000000044,5.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,15,1.03,0.7,1.3,,0.85,0.18000000000000005,21.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,31,0.89,0.7,1.3,,0.85,0.040000000000000036,4.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment B,31,0.89,0.7,1.3,,0.85,0.040000000000000036,4.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-219,135,60,100,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-3,81,60,100,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,101,60,100,Y,101,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 B,8,102,60,100,,101,1,1
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 15 B,15,133,60,100,,101,32,31.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 B,31,110,60,100,,101,9,8.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,End of Treatment B,31,110,60,100,,101,9,8.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-3,378,100,220,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,398,100,220,Y,398,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,455,100,220,,398,57,14.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,15,520,100,220,,398,122,30.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,31,650,100,220,,398,252,63.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,31,650,100,220,,398,252,63.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-219,3.5,3.5,5.2,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-3,3.8,3.5,5.2,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,3.7,3.5,5.2,Y,3.7,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.1,3.5,5.2,,3.7,0.39999999999999947,10.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,15,3.3,3.5,5.2,,3.7,-0.40000000000000036,-10.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,31,3.7,3.5,5.2,,3.7,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment B,31,3.7,3.5,5.2,,3.7,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-219,139,135,145,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-3,142,135,145,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,142,135,145,Y,142,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 B,8,141,135,145,,142,-1,-0.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 15 B,15,140,135,145,,142,-2,-1.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 B,31,140,135,145,,142,-2,-1.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,End of Treatment B,31,140,135,145,,142,-2,-1.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-219,0.4,0.1,1.2,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-3,0.3,0.1,1.2,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.2,0.1,1.2,Y,0.2,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.2,0.1,1.2,,0.2,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,15,0.2,0.1,1.2,,0.2,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,31,0.2,0.1,1.2,,0.2,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment B,31,0.2,0.1,1.2,,0.2,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-219,7,6,8.3,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-3,6.8,6,8.3,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.1,6,8.3,Y,7.1,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 B,8,7.4,6,8.3,,7.1,0.3000000000000007,4.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 15 B,15,6.6,6,8.3,,7.1,-0.5,-7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 B,31,7.4,6,8.3,,7.1,0.3000000000000007,4.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment B,31,7.4,6,8.3,,7.1,0.3000000000000007,4.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-3,28.6,25.4,34.9,Y,28.6,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 1 B,2,28.7,25.4,34.9,,28.6,0.09999999999999787,0.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,30.1,25.4,34.9,,28.6,1.5,5.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 15 B,15,30.6,25.4,34.9,,28.6,2,7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,31,30.7,25.4,34.9,,28.6,2.099999999999998,7.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,31,30.7,25.4,34.9,,28.6,2.099999999999998,7.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-3,1,2,3,Y,1,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 1 B,2,1,2,3,,1,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,1,2,3,,1,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 15 B,15,1.1,2,3,,1,0.10000000000000009,10
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,31,1,2,3,,1,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,31,1,2,3,,1,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,-3,12.7,12.3,14.9,Y,12.7,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 1 B,2,13,12.3,14.9,,12.7,0.3000000000000007,2.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,13.2,12.3,14.9,,12.7,0.5,3.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 15 B,15,13.9,12.3,14.9,,12.7,1.200000000000001,9.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,31,12.7,12.3,14.9,,12.7,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment B,31,12.7,12.3,14.9,,12.7,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,,-3,0.1,0,0.2,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 B,8,0,0,0.2,,0,0,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 15 B,15,0.1,0,0.2,,0,0.1,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 B,31,0.1,0,0.2,,0,0.1,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,End of Treatment B,31,0.1,0,0.2,,0,0.1,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 B,148,0,0,0.2,,0,0,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,,-3,0.2,0,0.6,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.2,0,0.6,Y,0.2,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.3,0,0.6,,0.2,0.09999999999999998,50
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 15 B,15,0.4,0,0.6,,0.2,0.2,100
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 B,31,0.3,0,0.6,,0.2,0.09999999999999998,50
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment B,31,0.3,0,0.6,,0.2,0.09999999999999998,50
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 B,148,0,0,0.6,,0.2,-0.2,-100
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-3,3.92,4.5,6,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.99,4.5,6,Y,3.99,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,4.02,4.5,6,,3.99,0.02999999999999936,0.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,15,3.6,4.5,6,,3.99,-0.3900000000000001,-9.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,31,3.54,4.5,6,,3.99,-0.4500000000000002,-11.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,31,3.54,4.5,6,,3.99,-0.4500000000000002,-11.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,148,2.88,4.5,6,,3.99,-1.1100000000000003,-27.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-3,34.1,42,52,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,34,42,52,Y,34,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,34.5,42,52,,34,0.5,1.5
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,15,30.6,42,52,,34,-3.3999999999999986,-10
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,31,29.8,42,52,,34,-4.199999999999999,-12.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment B,31,29.8,42,52,,34,-4.199999999999999,-12.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 B,148,24.9,42,52,,34,-9.100000000000001,-26.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-3,11.5,13.9,16.3,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.7,13.9,16.3,Y,11.7,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,11.6,13.9,16.3,,11.7,-0.09999999999999964,-0.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,15,10.4,13.9,16.3,,11.7,-1.299999999999999,-11.1
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,31,10.2,13.9,16.3,,11.7,-1.5,-12.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment B,31,10.2,13.9,16.3,,11.7,-1.5,-12.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 B,148,8.4,13.9,16.3,,11.7,-3.299999999999999,-28.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,,-3,1.8,1,4.5,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.7,1,4.5,Y,1.7,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,1.9,1,4.5,,1.7,0.19999999999999996,11.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 15 B,15,2.1,1,4.5,,1.7,0.40000000000000013,23.5
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 B,31,1.9,1,4.5,,1.7,0.19999999999999996,11.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment B,31,1.9,1,4.5,,1.7,0.19999999999999996,11.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 B,148,0.6,1,4.5,,1.7,-1.1,-64.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,,-3,0.6,0.2,1,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.6,0.2,1,Y,0.6,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 B,8,2.6,0.2,1,,0.6,2,333.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 15 B,15,4.5,0.2,1,,0.6,3.9,650
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 B,31,0.8,0.2,1,,0.6,0.20000000000000007,33.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,End of Treatment B,31,0.8,0.2,1,,0.6,0.20000000000000007,33.3
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 B,148,0.6,0.2,1,,0.6,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,,-3,3.5,1.9,8,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,5,1.9,8,Y,5,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 B,8,4,1.9,8,,5,-1,-20
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 15 B,15,7.42,1.9,8,,5,2.42,48.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 B,31,4.8,1.9,8,,5,-0.20000000000000018,-4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment B,31,4.8,1.9,8,,5,-0.20000000000000018,-4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 B,148,5,1.9,8,,5,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-3,250,150,450,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,271,150,450,Y,271,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,253,150,450,,271,-18,-6.6
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,15,292,150,450,,271,21,7.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,31,330,150,450,,271,59,21.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment B,31,330,150,450,,271,59,21.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 B,148,136,150,450,,271,-135,-49.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,TESTR,Baseline,-3,6.46,300,1080,Y,6.46,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,,-3,6.2,4.5,11,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,14.5,4.5,11,Y,14.5,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,8.9,4.5,11,,14.5,-5.6,-38.6
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 15 B,15,14,4.5,11,,14.5,-0.5,-3.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 B,31,8,4.5,11,,14.5,-6.5,-44.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment B,31,8,4.5,11,,14.5,-6.5,-44.8
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 B,148,6.2,4.5,11,,14.5,-8.3,-57.2
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,,-3,54.35,NA,NA,,NA,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,61.85,NA,NA,Y,61.85,0,0
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,31,87.75,NA,NA,,61.85,25.9,41.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment B,31,87.75,NA,NA,,61.85,25.9,41.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 B,148,261.36,NA,NA,,61.85,199.51000000000002,322.6
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,-3,0.85,0.4,4.2,Y,0.85,NA,NA
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 B,2,0.87,0.4,4.2,,0.85,0.020000000000000018,2.4
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,1.06,0.4,4.2,,0.85,0.21000000000000008,24.7
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,15,0.97,0.4,4.2,,0.85,0.12,14.1
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,31,0.9,0.4,4.2,,0.85,0.050000000000000044,5.9
7B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,31,0.93,0.4,4.2,,0.85,0.08000000000000007,9.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,3,NA,NA,Y,3,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,30,3,NA,NA,,3,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 C,58,11,NA,NA,,3,8,266.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 3 Day 1 C,86,22,NA,NA,,3,19,633.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,10,0,55,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,15,10,0,55,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,30,11,0,55,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-17,3.8,3.8,5,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.9,3.8,5,Y,3.9,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,3.7,3.8,5,,3.9,-0.19999999999999973,-5.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,15,3.7,3.8,5,,3.9,-0.19999999999999973,-5.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,3.6,3.8,5,,3.9,-0.2999999999999998,-7.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,30,3.7,3.8,5,,3.9,-0.19999999999999973,-5.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,37,3.6,3.8,5,,3.9,-0.2999999999999998,-7.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,58,3.7,3.8,5,,3.9,-0.19999999999999973,-5.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,86,3.7,3.8,5,,3.9,-0.19999999999999973,-5.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 C,177,3.6,3.8,5,,3.9,-0.2999999999999998,-7.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-17,198,0,130,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,263,0,130,Y,263,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,295,0,130,,263,32,12.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,15,345,0,130,,263,82,31.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,297,0,130,,263,34,12.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,30,329,0,130,,263,66,25.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,37,323,0,130,,263,60,22.8
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,58,378,0,130,,263,115,43.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,86,469,0,130,,263,206,78.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 C,177,209,0,130,,263,-54,-20.5
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-17,14,0,37,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,12,0,37,Y,12,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,14,0,37,,12,2,16.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,15,23,0,37,,12,11,91.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,14,0,37,,12,2,16.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,30,14,0,37,,12,2,16.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,37,17,0,37,,12,5,41.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,58,18,0,37,,12,6,50
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,86,17,0,37,,12,5,41.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 C,177,22,0,37,,12,10,83.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-17,19,6,20,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,22,6,20,Y,22,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,24,6,20,,22,2,9.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,15,27,6,20,,22,5,22.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,25,6,20,,22,3,13.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,30,17,6,20,,22,-5,-22.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,37,16,6,20,,22,-6,-27.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 C,58,19,6,20,,22,-3,-13.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,86,20,6,20,,22,-2,-9.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 C,177,23,6,20,,22,1,4.5
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-17,24,18,29,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,26,18,29,Y,26,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,24,18,29,,26,-2,-7.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,15,28,18,29,,26,2,7.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,26,18,29,,26,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,30,25,18,29,,26,-1,-3.8
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,37,25,18,29,,26,-1,-3.8
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 C,58,23,18,29,,26,-3,-11.5
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment C,86,25,18,29,,26,-1,-3.8
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 C,177,20,18,29,,26,-6,-23.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-17,9.3,8.5,10.5,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.4,8.5,10.5,Y,9.4,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,9.4,8.5,10.5,,9.4,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,15,8.9,8.5,10.5,,9.4,-0.5,-5.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,8.9,8.5,10.5,,9.4,-0.5,-5.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,30,9.1,8.5,10.5,,9.4,-0.3000000000000007,-3.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,37,8.9,8.5,10.5,,9.4,-0.5,-5.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,58,9,8.5,10.5,,9.4,-0.40000000000000036,-4.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,86,8.9,8.5,10.5,,9.4,-0.5,-5.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 C,177,9.5,8.5,10.5,,9.4,0.09999999999999964,1.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-17,108,98,109,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,108,98,109,Y,108,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,108,98,109,,108,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,15,110,98,109,,108,2,1.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,108,98,109,,108,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,30,109,98,109,,108,1,0.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,37,110,98,109,,108,2,1.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,58,107,98,109,,108,-1,-0.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,86,107,98,109,,108,-1,-0.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 C,177,108,98,109,,108,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-17,0.9,0.6,1.3,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.9,0.6,1.3,Y,0.9,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,0.9,0.6,1.3,,0.9,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,15,1,0.6,1.3,,0.9,0.09999999999999998,11.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,1,0.6,1.3,,0.9,0.09999999999999998,11.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,30,0.9,0.6,1.3,,0.9,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,37,1,0.6,1.3,,0.9,0.09999999999999998,11.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,58,0.9,0.6,1.3,,0.9,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,86,0.9,0.6,1.3,,0.9,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 C,177,0.9,0.6,1.3,,0.9,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-17,100,70,140,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,98,70,140,Y,98,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,95,70,140,,98,-3,-3.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,15,66,70,140,,98,-32,-32.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,107,70,140,,98,9,9.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,30,96,70,140,,98,-2,-2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,37,86,70,140,,98,-12,-12.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 C,58,96,70,140,,98,-2,-2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,86,71,70,140,,98,-27,-27.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 C,177,117,70,140,,98,19,19.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-17,239,130,250,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,182,130,250,Y,182,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,193,130,250,,182,11,6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,15,297,130,250,,182,115,63.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,217,130,250,,182,35,19.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,30,219,130,250,,182,37,20.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,37,233,130,250,,182,51,28
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 C,58,222,130,250,,182,40,22
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,86,216,130,250,,182,34,18.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 C,177,334,130,250,,182,152,83.5
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-17,4.6,3.5,5.1,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.6,3.5,5.1,Y,4.6,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,4.6,3.5,5.1,,4.6,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,15,3.9,3.5,5.1,,4.6,-0.6999999999999997,-15.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4,3.5,5.1,,4.6,-0.5999999999999996,-13
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,30,3.7,3.5,5.1,,4.6,-0.8999999999999995,-19.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,37,4.4,3.5,5.1,,4.6,-0.1999999999999993,-4.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,58,4.2,3.5,5.1,,4.6,-0.39999999999999947,-8.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,86,4.1,3.5,5.1,,4.6,-0.5,-10.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 C,177,4.2,3.5,5.1,,4.6,-0.39999999999999947,-8.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-17,141,133,143,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,142,133,143,Y,142,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,140,133,143,,142,-2,-1.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,15,143,133,143,,142,1,0.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,142,133,143,,142,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,30,142,133,143,,142,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,37,142,133,143,,142,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 C,58,140,133,143,,142,-2,-1.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,86,141,133,143,,142,-1,-0.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 C,177,139,133,143,,142,-3,-2.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-17,0.4,0,1.2,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.2,0,1.2,Y,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.3,0,1.2,,0.2,0.09999999999999998,50
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,15,0.2,0,1.2,,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.2,0,1.2,,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,30,0.2,0,1.2,,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,37,0.2,0,1.2,,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,58,0.3,0,1.2,,0.2,0.09999999999999998,50
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,86,0.2,0,1.2,,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 C,177,0.3,0,1.2,,0.2,0.09999999999999998,50
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-17,6.9,6.3,8.1,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.8,6.3,8.1,Y,6.8,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,6.5,6.3,8.1,,6.8,-0.2999999999999998,-4.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,15,6.4,6.3,8.1,,6.8,-0.39999999999999947,-5.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,6.5,6.3,8.1,,6.8,-0.2999999999999998,-4.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,30,6.6,6.3,8.1,,6.8,-0.20000000000000018,-2.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,37,6.5,6.3,8.1,,6.8,-0.2999999999999998,-4.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 C,58,6.6,6.3,8.1,,6.8,-0.20000000000000018,-2.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,86,6.6,6.3,8.1,,6.8,-0.20000000000000018,-2.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 C,177,6.9,6.3,8.1,,6.8,0.10000000000000053,1.5
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-17,30.9,22.5,36.5,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,28,22.5,36.5,Y,28,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,8,25.7,22.5,36.5,,28,-2.3000000000000007,-8.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,15,26.4,22.5,36.5,,28,-1.6000000000000014,-5.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,22,26.5,22.5,36.5,,28,-1.5,-5.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 1 C,30,28.5,22.5,36.5,,28,0.5,1.8
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 C,37,26.4,22.5,36.5,,28,-1.6000000000000014,-5.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 C,58,25.5,22.5,36.5,,28,-2.5,-8.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment C,86,26.1,22.5,36.5,,28,-1.8999999999999986,-6.8
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Follow-up 110 C,177,34.4,22.5,36.5,,28,6.399999999999999,22.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-17,1.06,0.8,1.2,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,0.97,0.8,1.2,Y,0.97,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,8,0.97,0.8,1.2,,0.97,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,15,1.03,0.8,1.2,,0.97,0.06000000000000005,6.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,22,1.03,0.8,1.2,,0.97,0.06000000000000005,6.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 1 C,30,1,0.8,1.2,,0.97,0.030000000000000027,3.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 C,37,0.97,0.8,1.2,,0.97,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 C,58,0.96,0.8,1.2,,0.97,-0.010000000000000009,-1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment C,86,0.97,0.8,1.2,,0.97,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Follow-up 110 C,177,1.05,0.8,1.2,,0.97,0.08000000000000007,8.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-17,13.7,11.1,15.2,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.7,11.1,15.2,Y,12.7,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,8,12.7,11.1,15.2,,12.7,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,15,13.3,11.1,15.2,,12.7,0.6000000000000014,4.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,22,13.3,11.1,15.2,,12.7,0.6000000000000014,4.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 1 C,30,13,11.1,15.2,,12.7,0.3000000000000007,2.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 C,37,12.7,11.1,15.2,,12.7,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 C,58,12.6,11.1,15.2,,12.7,-0.09999999999999964,-0.8
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment C,86,12.7,11.1,15.2,,12.7,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Follow-up 110 C,177,13.6,11.1,15.2,,12.7,0.9000000000000004,7.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-17,0,0,0.2,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0.1,0,0.2,,0,0.1,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,15,0.2,0,0.2,,0,0.2,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.2,,0,0.1,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,30,0.1,0,0.2,,0,0.1,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 C,37,0.3,0,0.2,,0,0.3,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 C,58,0,0,0.2,,0,0,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,86,0,0,0.2,,0,0,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 C,177,0,0,0.2,,0,0,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-17,0.2,0,0.7,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.2,0,0.7,Y,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0.2,0,0.7,,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,15,0.1,0,0.7,,0.2,-0.1,-50
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0.2,0,0.7,,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,30,0.3,0,0.7,,0.2,0.09999999999999998,50
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 C,37,0.8,0,0.7,,0.2,0.6000000000000001,300
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 C,58,0.5,0,0.7,,0.2,0.3,150
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,86,0.2,0,0.7,,0.2,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 C,177,0,0,0.7,,0.2,-0.2,-100
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-17,3.3,3.95,5.54,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.62,3.95,5.54,Y,3.62,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,3.63,3.95,5.54,,3.62,0.009999999999999787,0.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,15,3.7,3.95,5.54,,3.62,0.08000000000000007,2.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.7,3.95,5.54,,3.62,0.08000000000000007,2.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,30,3.85,3.95,5.54,,3.62,0.22999999999999998,6.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,37,3.75,3.95,5.54,,3.62,0.1299999999999999,3.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,58,3.6,3.95,5.54,,3.62,-0.020000000000000018,-0.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,86,3.68,3.95,5.54,,3.62,0.06000000000000005,1.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 C,177,3.71,3.95,5.54,,3.62,0.08999999999999986,2.5
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-17,33.1,37.5,49.3,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,36.6,37.5,49.3,Y,36.6,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,34.9,37.5,49.3,,36.6,-1.7000000000000028,-4.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,15,36.2,37.5,49.3,,36.6,-0.3999999999999986,-1.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,35.9,37.5,49.3,,36.6,-0.7000000000000028,-1.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,30,37.9,37.5,49.3,,36.6,1.2999999999999972,3.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,37,35.5,37.5,49.3,,36.6,-1.1000000000000014,-3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,58,34.1,37.5,49.3,,36.6,-2.5,-6.8
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,86,34.8,37.5,49.3,,36.6,-1.8000000000000043,-4.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 C,177,33.3,37.5,49.3,,36.6,-3.3000000000000043,-9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-17,10.5,12.5,16.2,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,11.5,12.5,16.2,Y,11.5,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,11.2,12.5,16.2,,11.5,-0.3000000000000007,-2.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,15,11.5,12.5,16.2,,11.5,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,11.5,12.5,16.2,,11.5,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,30,11.8,12.5,16.2,,11.5,0.3000000000000007,2.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,37,11.2,12.5,16.2,,11.5,-0.3000000000000007,-2.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,58,10.8,12.5,16.2,,11.5,-0.6999999999999993,-6.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,86,10.9,12.5,16.2,,11.5,-0.5999999999999996,-5.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 C,177,10.5,12.5,16.2,,11.5,-1,-8.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-17,0.8,0.9,3.2,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1,0.9,3.2,Y,1,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,1.3,0.9,3.2,,1,0.30000000000000004,30
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,15,1.5,0.9,3.2,,1,0.5,50
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,1.3,0.9,3.2,,1,0.30000000000000004,30
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,30,1.7,0.9,3.2,,1,0.7,70
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 C,37,2.4,0.9,3.2,,1,1.4,140
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 C,58,1,0.9,3.2,,1,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,86,1,0.9,3.2,,1,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 C,177,0.7,0.9,3.2,,1,-0.30000000000000004,-30
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-17,0.4,0,1.3,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.3,0,1.3,Y,0.3,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,1.4,0,1.3,,0.3,1.0999999999999999,366.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,15,1.7,0,1.3,,0.3,1.4,466.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,1.7,0,1.3,,0.3,1.4,466.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,30,3.2,0,1.3,,0.3,2.9000000000000004,966.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 C,37,3.2,0,1.3,,0.3,2.9000000000000004,966.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 C,58,0.4,0,1.3,,0.3,0.10000000000000003,33.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,86,0.3,0,1.3,,0.3,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 C,177,0.7,0,1.3,,0.3,0.39999999999999997,133.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-17,4.1,1.5,7.5,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,4.3,1.5,7.5,Y,4.3,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,4.2,1.5,7.5,,4.3,-0.09999999999999964,-2.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,15,5.5,1.5,7.5,,4.3,1.2000000000000002,27.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,5.6,1.5,7.5,,4.3,1.2999999999999998,30.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,30,7.5,1.5,7.5,,4.3,3.2,74.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 C,37,6.6,1.5,7.5,,4.3,2.3,53.5
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 C,58,5.4,1.5,7.5,,4.3,1.1000000000000005,25.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,86,3.6,1.5,7.5,,4.3,-0.6999999999999997,-16.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 C,177,8.1,1.5,7.5,,4.3,3.8,88.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-17,376,160,400,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,255,160,400,Y,255,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,235,160,400,,255,-20,-7.8
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,15,158,160,400,,255,-97,-38
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,321,160,400,,255,66,25.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,30,330,160,400,,255,75,29.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,37,212,160,400,,255,-43,-16.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,58,229,160,400,,255,-26,-10.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,86,160,160,400,,255,-95,-37.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 C,177,237,160,400,,255,-18,-7.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-17,5.5,4,11,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.9,4,11,Y,5.9,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,7.2,4,11,,5.9,1.2999999999999998,22
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,15,9,4,11,,5.9,3.0999999999999996,52.5
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,8.8,4,11,,5.9,2.9000000000000004,49.2
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,30,12.9,4,11,,5.9,7,118.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,37,13.1,4,11,,5.9,7.199999999999999,122
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 C,58,7.4,4,11,,5.9,1.5,25.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,86,5.1,4,11,,5.9,-0.8000000000000007,-13.6
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 C,177,9.6,4,11,,5.9,3.6999999999999993,62.7
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-17,41.73,NA,NA,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,46.76,NA,NA,Y,46.76,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,55.21,NA,NA,,46.76,8.450000000000003,18.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,30,69.83,NA,NA,,46.76,23.07,49.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,58,123.02,NA,NA,,46.76,76.25999999999999,163.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,86,177.65,NA,NA,,46.76,130.89000000000001,279.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 C,177,350.47,NA,NA,,46.76,303.71000000000004,649.5
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-17,1.9,0.6,4.8,,NA,NA,NA
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.94,0.6,4.8,Y,2.94,0,0
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,3.47,0.6,4.8,,2.94,0.5300000000000002,18
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,15,2.35,0.6,4.8,,2.94,-0.5899999999999999,-20.1
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,1.68,0.6,4.8,,2.94,-1.26,-42.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,30,1.91,0.6,4.8,,2.94,-1.03,-35
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,37,2.18,0.6,4.8,,2.94,-0.7599999999999998,-25.9
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,58,1.99,0.6,4.8,,2.94,-0.95,-32.3
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,86,2.37,0.6,4.8,,2.94,-0.5699999999999998,-19.4
7C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 C,177,2.04,0.6,4.8,,2.94,-0.8999999999999999,-30.6
8A,A,NKTR-214 + Nivolumab,N,N,,CTC,Baseline,1,4,NA,NA,Y,4,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 A,22,6,NA,NA,,4,2,50
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-19,26,1,45,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,23,1,45,Y,23,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,8,51,1,45,,23,28,121.7
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,22,43,1,45,,23,20,87
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 8 A,31,162,1,45,,23,139,604.3
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment A,50,37,1,45,,23,14,60.9
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 A,136,15,1,45,,23,-8,-34.8
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-19,4.3,3.5,4.9,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4,3.5,4.9,Y,4,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,8,3.8,3.5,4.9,,4,-0.20000000000000018,-5
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,22,4,3.5,4.9,,4,0,0
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 8 A,31,3.7,3.5,4.9,,4,-0.2999999999999998,-7.5
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment A,50,3.9,3.5,4.9,,4,-0.10000000000000009,-2.5
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 A,136,3.9,3.5,4.9,,4,-0.10000000000000009,-2.5
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-19,45,38,126,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,52,38,126,Y,52,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,8,75,38,126,,52,23,44.2
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,22,51,38,126,,52,-1,-1.9
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 8 A,31,99,38,126,,52,47,90.4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment A,50,60,38,126,,52,8,15.4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 A,136,52,38,126,,52,0,0
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-19,21,1,35,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,18,1,35,Y,18,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,8,40,1,35,,18,22,122.2
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,22,29,1,35,,18,11,61.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 8 A,31,82,1,35,,18,64,355.6
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment A,50,25,1,35,,18,7,38.9
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 A,136,19,1,35,,18,1,5.6
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,,-19,18,6,23,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,16,6,23,Y,16,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 A,8,9,6,23,,16,-7,-43.8
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 A,22,17,6,23,,16,1,6.3
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 8 A,31,13,6,23,,16,-3,-18.8
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,End of Treatment A,50,12,6,23,,16,-4,-25
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 A,136,18,6,23,,16,2,12.5
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,,-19,26,22,30,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,25,22,30,Y,25,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,8,23,22,30,,25,-2,-8
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,22,26,22,30,,25,1,4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 8 A,31,32,22,30,,25,7,28
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment A,50,27.3,22,30,,25,2.3000000000000007,9.2
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 A,136,25,22,30,,25,0,0
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-19,9.7,8.5,10.5,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.9,8.5,10.5,Y,9.9,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,8,8.9,8.5,10.5,,9.9,-1,-10.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,22,10,8.5,10.5,,9.9,0.09999999999999964,1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 8 A,31,9.4,8.5,10.5,,9.9,-0.5,-5.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment A,50,9.5,8.5,10.5,,9.9,-0.40000000000000036,-4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 A,136,8.9,8.5,10.5,,9.9,-1,-10.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-19,105,96,108,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,106,96,108,Y,106,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,8,102,96,108,,106,-4,-3.8
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,22,106,96,108,,106,0,0
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 8 A,31,104,96,108,,106,-2,-1.9
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment A,50,106,96,108,,106,0,0
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 A,136,107,96,108,,106,1,0.9
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-19,0.76,0.7,1.3,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.66,0.7,1.3,Y,0.66,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,8,0.79,0.7,1.3,,0.66,0.13,19.7
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,22,0.7,0.7,1.3,,0.66,0.039999999999999925,6.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 8 A,31,0.7,0.7,1.3,,0.66,0.039999999999999925,6.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment A,50,0.62,0.7,1.3,,0.66,-0.040000000000000036,-6.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 A,136,0.7,0.7,1.3,,0.66,0.039999999999999925,6.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,,-19,97,60,100,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,127,60,100,Y,127,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 A,8,135,60,100,,127,8,6.3
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 A,22,110,60,100,,127,-17,-13.4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 8 A,31,105,60,100,,127,-22,-17.3
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment A,50,115,60,100,,127,-12,-9.4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 A,136,123,60,100,,127,-4,-3.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-19,182,100,220,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,169,100,220,Y,169,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,22,217,100,220,,169,48,28.4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 8 A,31,404,100,220,,169,235,139.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment A,50,218,100,220,,169,49,29
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Follow-up 110 A,136,212,100,220,,169,43,25.4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-19,4.3,3.5,5.2,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.1,3.5,5.2,Y,4.1,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,8,3.7,3.5,5.2,,4.1,-0.39999999999999947,-9.8
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,22,4.8,3.5,5.2,,4.1,0.7000000000000002,17.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 8 A,31,4,3.5,5.2,,4.1,-0.09999999999999964,-2.4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment A,50,4.5,3.5,5.2,,4.1,0.40000000000000036,9.8
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 A,136,4.3,3.5,5.2,,4.1,0.20000000000000018,4.9
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,,-19,140,135,145,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,142,135,145,Y,142,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 A,8,138,135,145,,142,-4,-2.8
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 A,22,142,135,145,,142,0,0
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 8 A,31,141,135,145,,142,-1,-0.7
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment A,50,139,135,145,,142,-3,-2.1
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 A,136,141,135,145,,142,-1,-0.7
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-19,0.5,0.1,1.2,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.3,0.1,1.2,Y,0.3,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,8,0.6,0.1,1.2,,0.3,0.3,100
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,22,0.7,0.1,1.2,,0.3,0.39999999999999997,133.3
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 8 A,31,0.6,0.1,1.2,,0.3,0.3,100
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment A,50,0.4,0.1,1.2,,0.3,0.10000000000000003,33.3
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 A,136,0.5,0.1,1.2,,0.3,0.2,66.7
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,,-19,7.1,6,8.3,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.8,6,8.3,Y,6.8,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 A,8,7.1,6,8.3,,6.8,0.2999999999999998,4.4
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 A,22,6.9,6,8.3,,6.8,0.10000000000000053,1.5
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 8 A,31,6.7,6,8.3,,6.8,-0.09999999999999964,-1.5
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment A,50,6.8,6,8.3,,6.8,0,0
8A,A,NKTR-214 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 A,136,6.6,6,8.3,,6.8,-0.20000000000000018,-2.9
8A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-19,25.6,25.4,34.9,Y,25.6,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 8 A,31,25.7,25.4,34.9,,25.6,0.09999999999999787,0.4
8A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-19,0.9,2,3,Y,0.9,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 8 A,31,1,2,3,,0.9,0.09999999999999998,11.1
8A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,-19,11.9,12.3,14.9,Y,11.9,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 8 A,31,13,12.3,14.9,,11.9,1.0999999999999996,9.2
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,,-19,0,0,0.2,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0,0,0.2,,0,0,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0,0,0.2,,0,0,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 A,8,0,0,0.2,,0,0,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 A,22,0.1,0,0.2,,0,0.1,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 8 A,31,0,0,0.2,,0,0,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,End of Treatment A,50,0,0,0.2,,0,0,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 A,136,0.1,0,0.2,,0,0.1,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,,-19,0.1,0,0.6,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.1,0,0.6,Y,0.1,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.2,0,0.6,,0.1,0.1,100
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.2,0,0.6,,0.1,0.1,100
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 A,8,0.7,0,0.6,,0.1,0.6,600
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 A,22,0.8,0,0.6,,0.1,0.7000000000000001,700
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment A,50,1.4,0,0.6,,0.1,1.2999999999999998,1300
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 A,136,0.3,0,0.6,,0.1,0.19999999999999998,200
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-19,3.78,4.5,6,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.73,4.5,6,Y,3.73,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,3.76,4.5,6,,3.73,0.029999999999999805,0.8
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,3.75,4.5,6,,3.73,0.020000000000000018,0.5
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,8,3.64,4.5,6,,3.73,-0.08999999999999986,-2.4
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,22,3.58,4.5,6,,3.73,-0.1499999999999999,-4
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 8 A,31,3.6,4.5,6,,3.73,-0.1299999999999999,-3.5
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment A,50,3.73,4.5,6,,3.73,0,0
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 A,136,3.96,4.5,6,,3.73,0.22999999999999998,6.2
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-19,36.5,42,52,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,35.5,42,52,Y,35.5,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,36.1,42,52,,35.5,0.6000000000000014,1.7
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,35.9,42,52,,35.5,0.3999999999999986,1.1
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,8,34.2,42,52,,35.5,-1.2999999999999972,-3.7
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,22,34.8,42,52,,35.5,-0.7000000000000028,-2
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 8 A,31,34.6,42,52,,35.5,-0.8999999999999986,-2.5
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment A,50,35.3,42,52,,35.5,-0.20000000000000284,-0.6
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 A,136,36.4,42,52,,35.5,0.8999999999999986,2.5
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-19,12.5,13.9,16.3,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,12.4,13.9,16.3,Y,12.4,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,12.5,13.9,16.3,,12.4,0.09999999999999964,0.8
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,12.5,13.9,16.3,,12.4,0.09999999999999964,0.8
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,8,11.8,13.9,16.3,,12.4,-0.5999999999999996,-4.8
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,22,11.7,13.9,16.3,,12.4,-0.7000000000000011,-5.6
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 8 A,31,11.7,13.9,16.3,,12.4,-0.7000000000000011,-5.6
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment A,50,11.9,13.9,16.3,,12.4,-0.5,-4
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 A,136,12.1,13.9,16.3,,12.4,-0.3000000000000007,-2.4
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,,-19,0.7,1,4.5,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.6,1,4.5,Y,0.6,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.2,1,4.5,,0.6,-0.39999999999999997,-66.7
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.1,1,4.5,,0.6,-0.5,-83.3
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,8,1.6,1,4.5,,0.6,1,166.7
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,22,0.9,1,4.5,,0.6,0.30000000000000004,50
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 8 A,31,1.6,1,4.5,,0.6,1,166.7
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment A,50,0.9,1,4.5,,0.6,0.30000000000000004,50
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 A,136,0.8,1,4.5,,0.6,0.20000000000000007,33.3
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,,-19,0.5,0.2,1,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.3,0.2,1,Y,0.3,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.5,0.2,1,,0.3,0.2,66.7
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.7,0.2,1,,0.3,0.39999999999999997,133.3
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 A,8,0.7,0.2,1,,0.3,0.39999999999999997,133.3
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 A,22,0.3,0.2,1,,0.3,0,0
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 8 A,31,0.6,0.2,1,,0.3,0.3,100
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment A,50,0.5,0.2,1,,0.3,0.2,66.7
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 A,136,0.6,0.2,1,,0.3,0.3,100
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,,-19,3.7,1.9,8,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.8,1.9,8,Y,3.8,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,5.1,1.9,8,,3.8,1.2999999999999998,34.2
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,6.5,1.9,8,,3.8,2.7,71.1
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 A,8,4.8,1.9,8,,3.8,1,26.3
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 A,22,2.6,1.9,8,,3.8,-1.1999999999999997,-31.6
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 8 A,31,3.82,1.9,8,,3.8,0.020000000000000018,0.5
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment A,50,2.5,1.9,8,,3.8,-1.2999999999999998,-34.2
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 A,136,5.9,1.9,8,,3.8,2.1000000000000005,55.3
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-19,172,150,450,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,193,150,450,Y,193,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,189,150,450,,193,-4,-2.1
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,167,150,450,,193,-26,-13.5
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,8,155,150,450,,193,-38,-19.7
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,22,212,150,450,,193,19,9.8
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 8 A,31,176,150,450,,193,-17,-8.8
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment A,50,182,150,450,,193,-11,-5.7
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 A,136,197,150,450,,193,4,2.1
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,TESTR,Baseline,-19,20.99,300,1080,Y,20.99,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,,-19,5.1,4.5,11,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,4.8,4.5,11,Y,4.8,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,6,4.5,11,,4.8,1.2000000000000002,25
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,7.5,4.5,11,,4.8,2.7,56.3
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,8,7.8,4.5,11,,4.8,3,62.5
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,22,4.6,4.5,11,,4.8,-0.20000000000000018,-4.2
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 8 A,31,10.9,4.5,11,,4.8,6.1000000000000005,127.1
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment A,50,5.4,4.5,11,,4.8,0.6000000000000005,12.5
8A,A,NKTR-214 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 A,136,7.7,4.5,11,,4.8,2.9000000000000004,60.4
8A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-19,12.6,NA,NA,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,18.42,NA,NA,Y,18.42,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,22,16.01,NA,NA,,18.42,-2.41,-13.1
8A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment A,50,16.5,NA,NA,,18.42,-1.9200000000000017,-10.4
8A,A,NKTR-214 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 A,136,11.15,NA,NA,,18.42,-7.270000000000001,-39.5
8A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-19,1.8,0.4,4.2,,NA,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.9,0.4,4.2,Y,1.9,NA,NA
8A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,22,1.4,0.4,4.2,,1.9,-0.5,-26.3
8A,A,NKTR-214 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment A,50,0.03,0.4,4.2,,1.9,-1.8699999999999999,-98.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Baseline,1,0,NA,NA,Y,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 2 Day 1 B,29,0,NA,NA,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 3 Day 1 B,57,0,NA,NA,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 4 Day 1 B,85,0,NA,NA,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 5 Day 1 B,113,0,NA,NA,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 6 Day 1 B,142,1,NA,NA,,0,1,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 7 Day 1 B,171,0,NA,NA,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 8 Day 1 B,199,0,NA,NA,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 9 Day 1 B,227,0,NA,NA,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 10 Day 1 B,255,1,NA,NA,,0,1,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,Cycle 11 Day 1 B,283,1,NA,NA,,0,1,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,,CTC,End of Treatment B,311,4,NA,NA,,0,4,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),,-11,15,1,45,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,16,1,45,Y,16,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,14,1,45,,16,-2,-12.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,16,15,1,45,,16,-1,-6.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,29,12,1,45,,16,-4,-25
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,57,13,1,45,,16,-3,-18.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 B,85,13,1,45,,16,-3,-18.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 B,113,13,1,45,,16,-3,-18.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 6 Day 1 B,142,13,1,45,,16,-3,-18.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 7 Day 1 B,171,16,1,45,,16,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 8 Day 1 B,199,10,1,45,,16,-6,-37.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 9 Day 1 B,227,10,1,45,,16,-6,-37.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 10 Day 1 B,255,10,1,45,,16,-6,-37.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Cycle 11 Day 1 B,283,11,1,45,,16,-5,-31.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,311,9,1,45,,16,-7,-43.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 B,416,9,1,45,,16,-7,-43.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),,-11,3.8,3.5,4.9,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Baseline,1,4.1,3.5,4.9,Y,4.1,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,3.8,3.5,4.9,,4.1,-0.2999999999999998,-7.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,16,4,3.5,4.9,,4.1,-0.09999999999999964,-2.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,29,3.9,3.5,4.9,,4.1,-0.19999999999999973,-4.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,57,3.8,3.5,4.9,,4.1,-0.2999999999999998,-7.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 4 Day 1 B,85,4.1,3.5,4.9,,4.1,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 5 Day 1 B,113,4.3,3.5,4.9,,4.1,0.20000000000000018,4.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 6 Day 1 B,142,4.2,3.5,4.9,,4.1,0.10000000000000053,2.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 7 Day 1 B,171,4.2,3.5,4.9,,4.1,0.10000000000000053,2.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 8 Day 1 B,199,3.9,3.5,4.9,,4.1,-0.19999999999999973,-4.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 9 Day 1 B,227,3.8,3.5,4.9,,4.1,-0.2999999999999998,-7.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 10 Day 1 B,255,3.7,3.5,4.9,,4.1,-0.39999999999999947,-9.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Cycle 11 Day 1 B,283,3.5,3.5,4.9,,4.1,-0.5999999999999996,-14.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),End of Treatment B,311,3.5,3.5,4.9,,4.1,-0.5999999999999996,-14.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Albumin (g/dL),Follow-up 110 B,416,3.8,3.5,4.9,,4.1,-0.2999999999999998,-7.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),,-11,93,38,126,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,114,38,126,Y,114,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,101,38,126,,114,-13,-11.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,16,105,38,126,,114,-9,-7.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,29,104,38,126,,114,-10,-8.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,57,100,38,126,,114,-14,-12.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 B,85,85,38,126,,114,-29,-25.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 B,113,83,38,126,,114,-31,-27.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 6 Day 1 B,142,76,38,126,,114,-38,-33.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 7 Day 1 B,171,76,38,126,,114,-38,-33.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 8 Day 1 B,199,67,38,126,,114,-47,-41.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 9 Day 1 B,227,75,38,126,,114,-39,-34.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 10 Day 1 B,255,90,38,126,,114,-24,-21.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Cycle 11 Day 1 B,283,97,38,126,,114,-17,-14.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,311,85,38,126,,114,-29,-25.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 B,416,74,38,126,,114,-40,-35.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),,-11,15,1,35,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,18,1,35,Y,18,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,15,1,35,,18,-3,-16.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,16,17,1,35,,18,-1,-5.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,29,16,1,35,,18,-2,-11.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,57,17,1,35,,18,-1,-5.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 B,85,20,1,35,,18,2,11.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 B,113,20,1,35,,18,2,11.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 6 Day 1 B,142,19,1,35,,18,1,5.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 7 Day 1 B,171,18,1,35,,18,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 8 Day 1 B,199,16,1,35,,18,-2,-11.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 9 Day 1 B,227,14,1,35,,18,-4,-22.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 10 Day 1 B,255,16,1,35,,18,-2,-11.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 11 Day 1 B,283,16,1,35,,18,-2,-11.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,311,16,1,35,,18,-2,-11.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 B,416,13,1,35,,18,-5,-27.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,,-11,13,6,23,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Baseline,1,15,6,23,Y,15,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 8 B,8,13,6,23,,15,-2,-13.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 1 Day 15 B,16,17,6,23,,15,2,13.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 2 Day 1 B,29,19,6,23,,15,4,26.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 3 Day 1 B,57,14,6,23,,15,-1,-6.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 4 Day 1 B,85,12,6,23,,15,-3,-20
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 5 Day 1 B,113,17,6,23,,15,2,13.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 6 Day 1 B,142,16,6,23,,15,1,6.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 7 Day 1 B,171,18,6,23,,15,3,20
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 8 Day 1 B,199,13,6,23,,15,-2,-13.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 9 Day 1 B,227,12,6,23,,15,-3,-20
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 10 Day 1 B,255,16,6,23,,15,1,6.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Cycle 11 Day 1 B,283,9,6,23,,15,-6,-40
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,End of Treatment B,311,13,6,23,,15,-2,-13.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,BUN,Follow-up 110 B,416,21,6,23,,15,6,40
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,,-11,29,22,30,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Baseline,1,29,22,30,Y,29,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,23.6,22,30,,29,-5.399999999999999,-18.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 1 Day 15 B,16,25,22,30,,29,-4,-13.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 2 Day 1 B,29,26,22,30,,29,-3,-10.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 3 Day 1 B,57,26.9,22,30,,29,-2.1000000000000014,-7.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 4 Day 1 B,85,22.8,22,30,,29,-6.199999999999999,-21.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 5 Day 1 B,113,24.2,22,30,,29,-4.800000000000001,-16.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 6 Day 1 B,142,25.3,22,30,,29,-3.6999999999999993,-12.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 7 Day 1 B,171,22.3,22,30,,29,-6.699999999999999,-23.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 8 Day 1 B,199,22.2,22,30,,29,-6.800000000000001,-23.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 9 Day 1 B,227,24,22,30,,29,-5,-17.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 10 Day 1 B,255,23.2,22,30,,29,-5.800000000000001,-20
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Cycle 11 Day 1 B,283,22.4,22,30,,29,-6.600000000000001,-22.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,End of Treatment B,311,23.8,22,30,,29,-5.199999999999999,-17.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Bicarbonate,Follow-up 110 B,416,27.9,22,30,,29,-1.1000000000000014,-3.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),,-11,8.8,8.5,10.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Baseline,1,9.6,8.5,10.5,Y,9.6,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,9.5,8.5,10.5,,9.6,-0.09999999999999964,-1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,16,9.5,8.5,10.5,,9.6,-0.09999999999999964,-1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,29,9.4,8.5,10.5,,9.6,-0.1999999999999993,-2.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,57,9.5,8.5,10.5,,9.6,-0.09999999999999964,-1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 B,85,9.2,8.5,10.5,,9.6,-0.40000000000000036,-4.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 B,113,9.3,8.5,10.5,,9.6,-0.29999999999999893,-3.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 6 Day 1 B,142,9.5,8.5,10.5,,9.6,-0.09999999999999964,-1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 7 Day 1 B,171,9,8.5,10.5,,9.6,-0.5999999999999996,-6.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 8 Day 1 B,199,9.1,8.5,10.5,,9.6,-0.5,-5.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 9 Day 1 B,227,8.9,8.5,10.5,,9.6,-0.6999999999999993,-7.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 10 Day 1 B,255,9,8.5,10.5,,9.6,-0.5999999999999996,-6.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Cycle 11 Day 1 B,283,8.4,8.5,10.5,,9.6,-1.1999999999999993,-12.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),End of Treatment B,311,8.8,8.5,10.5,,9.6,-0.7999999999999989,-8.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Calcium (mmol/L),Follow-up 110 B,416,9.2,8.5,10.5,,9.6,-0.40000000000000036,-4.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),,-11,103,96,108,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Baseline,1,103,96,108,Y,103,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,101,96,108,,103,-2,-1.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,16,103,96,108,,103,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,29,106,96,108,,103,3,2.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,57,103,96,108,,103,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 B,85,103,96,108,,103,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 B,113,103,96,108,,103,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 6 Day 1 B,142,104,96,108,,103,1,1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 7 Day 1 B,171,105,96,108,,103,2,1.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 8 Day 1 B,199,109,96,108,,103,6,5.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 9 Day 1 B,227,104,96,108,,103,1,1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 10 Day 1 B,255,104,96,108,,103,1,1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Cycle 11 Day 1 B,283,107,96,108,,103,4,3.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),End of Treatment B,311,105,96,108,,103,2,1.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Chloride (mmol/L),Follow-up 110 B,416,97,96,108,,103,-6,-5.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),,-11,0.58,0.7,1.3,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Baseline,1,0.56,0.7,1.3,Y,0.56,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,0.5,0.7,1.3,,0.56,-0.06000000000000005,-10.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,16,0.55,0.7,1.3,,0.56,-0.010000000000000009,-1.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,29,0.63,0.7,1.3,,0.56,0.06999999999999995,12.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,57,0.7,0.7,1.3,,0.56,0.1399999999999999,25
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 B,85,0.64,0.7,1.3,,0.56,0.07999999999999996,14.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 B,113,0.7,0.7,1.3,,0.56,0.1399999999999999,25
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 6 Day 1 B,142,0.72,0.7,1.3,,0.56,0.15999999999999992,28.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 7 Day 1 B,171,0.68,0.7,1.3,,0.56,0.12,21.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 8 Day 1 B,199,0.68,0.7,1.3,,0.56,0.12,21.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 9 Day 1 B,227,0.62,0.7,1.3,,0.56,0.05999999999999994,10.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 10 Day 1 B,255,0.68,0.7,1.3,,0.56,0.12,21.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Cycle 11 Day 1 B,283,0.55,0.7,1.3,,0.56,-0.010000000000000009,-1.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),End of Treatment B,311,0.61,0.7,1.3,,0.56,0.04999999999999993,8.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Creatinine (umol/L),Follow-up 110 B,416,1.03,0.7,1.3,,0.56,0.47,83.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,,-11,239,60,100,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Baseline,1,279,60,100,Y,279,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 8 B,8,307,60,100,,279,28,10
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 1 Day 15 B,16,296,60,100,,279,17,6.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 2 Day 1 B,29,339,60,100,,279,60,21.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 3 Day 1 B,57,223,60,100,,279,-56,-20.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 4 Day 1 B,85,185,60,100,,279,-94,-33.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 5 Day 1 B,113,179,60,100,,279,-100,-35.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 6 Day 1 B,142,198,60,100,,279,-81,-29
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 7 Day 1 B,171,223,60,100,,279,-56,-20.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 8 Day 1 B,199,224,60,100,,279,-55,-19.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 9 Day 1 B,227,185,60,100,,279,-94,-33.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 10 Day 1 B,255,227,60,100,,279,-52,-18.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Cycle 11 Day 1 B,283,217,60,100,,279,-62,-22.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,End of Treatment B,311,162,60,100,,279,-117,-41.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Glucose,Follow-up 110 B,416,293,60,100,,279,14,5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),,-11,147,100,220,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,164,100,220,Y,164,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,181,100,220,,164,17,10.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 15 B,16,190,100,220,,164,26,15.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,29,168,100,220,,164,4,2.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,57,173,100,220,,164,9,5.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 4 Day 1 B,85,150,100,220,,164,-14,-8.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 B,113,179,100,220,,164,15,9.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 6 Day 1 B,142,175,100,220,,164,11,6.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 7 Day 1 B,171,159,100,220,,164,-5,-3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 8 Day 1 B,199,169,100,220,,164,5,3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 9 Day 1 B,227,155,100,220,,164,-9,-5.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 10 Day 1 B,255,160,100,220,,164,-4,-2.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 11 Day 1 B,283,169,100,220,,164,5,3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment B,311,183,100,220,,164,19,11.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),,-11,4.2,3.5,5.2,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Baseline,1,4.5,3.5,5.2,Y,4.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,5.4,3.5,5.2,,4.5,0.9000000000000004,20
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,16,4.8,3.5,5.2,,4.5,0.2999999999999998,6.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,29,4.9,3.5,5.2,,4.5,0.40000000000000036,8.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,57,4.8,3.5,5.2,,4.5,0.2999999999999998,6.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 B,85,4,3.5,5.2,,4.5,-0.5,-11.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 B,113,4.4,3.5,5.2,,4.5,-0.09999999999999964,-2.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 6 Day 1 B,142,4.5,3.5,5.2,,4.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 7 Day 1 B,171,4.3,3.5,5.2,,4.5,-0.20000000000000018,-4.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 8 Day 1 B,199,4.1,3.5,5.2,,4.5,-0.40000000000000036,-8.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 9 Day 1 B,227,4.3,3.5,5.2,,4.5,-0.20000000000000018,-4.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 10 Day 1 B,255,4.5,3.5,5.2,,4.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Cycle 11 Day 1 B,283,4.6,3.5,5.2,,4.5,0.09999999999999964,2.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),End of Treatment B,311,4.6,3.5,5.2,,4.5,0.09999999999999964,2.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Potassium (mmol/L),Follow-up 110 B,416,4.5,3.5,5.2,,4.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,,-11,141,135,145,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Baseline,1,141,135,145,Y,141,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 8 B,8,138,135,145,,141,-3,-2.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 1 Day 15 B,16,140,135,145,,141,-1,-0.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 2 Day 1 B,29,143,135,145,,141,2,1.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 3 Day 1 B,57,140,135,145,,141,-1,-0.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 4 Day 1 B,85,140,135,145,,141,-1,-0.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 5 Day 1 B,113,137,135,145,,141,-4,-2.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 6 Day 1 B,142,139,135,145,,141,-2,-1.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 7 Day 1 B,171,139,135,145,,141,-2,-1.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 8 Day 1 B,199,142,135,145,,141,1,0.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 9 Day 1 B,227,140,135,145,,141,-1,-0.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 10 Day 1 B,255,139,135,145,,141,-2,-1.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Cycle 11 Day 1 B,283,139,135,145,,141,-2,-1.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,End of Treatment B,311,138,135,145,,141,-3,-2.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Sodium,Follow-up 110 B,416,135,135,145,,141,-6,-4.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,,-11,0.4,0.1,1.2,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Baseline,1,0.3,0.1,1.2,Y,0.3,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,16,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,29,0.3,0.1,1.2,,0.3,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,57,0.3,0.1,1.2,,0.3,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 4 Day 1 B,85,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 5 Day 1 B,113,0.3,0.1,1.2,,0.3,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 6 Day 1 B,142,0.3,0.1,1.2,,0.3,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 7 Day 1 B,171,0.3,0.1,1.2,,0.3,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 8 Day 1 B,199,0.3,0.1,1.2,,0.3,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 9 Day 1 B,227,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 10 Day 1 B,255,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Cycle 11 Day 1 B,283,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,End of Treatment B,311,0.1,0.1,1.2,,0.3,-0.19999999999999998,-66.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Bilirubin,Follow-up 110 B,416,0.2,0.1,1.2,,0.3,-0.09999999999999998,-33.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,,-11,6.5,6,8.3,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Baseline,1,6.9,6,8.3,Y,6.9,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 8 B,8,6.8,6,8.3,,6.9,-0.10000000000000053,-1.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 1 Day 15 B,16,6.9,6,8.3,,6.9,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 2 Day 1 B,29,6.9,6,8.3,,6.9,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 3 Day 1 B,57,6.9,6,8.3,,6.9,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 4 Day 1 B,85,6.8,6,8.3,,6.9,-0.10000000000000053,-1.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 5 Day 1 B,113,7.2,6,8.3,,6.9,0.2999999999999998,4.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 6 Day 1 B,142,7.2,6,8.3,,6.9,0.2999999999999998,4.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 7 Day 1 B,171,7,6,8.3,,6.9,0.09999999999999964,1.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 8 Day 1 B,199,6.7,6,8.3,,6.9,-0.20000000000000018,-2.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 9 Day 1 B,227,6.6,6,8.3,,6.9,-0.3000000000000007,-4.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 10 Day 1 B,255,6.7,6,8.3,,6.9,-0.20000000000000018,-2.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Cycle 11 Day 1 B,283,6.5,6,8.3,,6.9,-0.40000000000000036,-5.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,End of Treatment B,311,6.6,6,8.3,,6.9,-0.3000000000000007,-4.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Chemistry,Total Protein,Follow-up 110 B,416,7.4,6,8.3,,6.9,0.5,7.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),,-11,35.5,25.4,34.9,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,33.5,25.4,34.9,Y,33.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,36.7,25.4,34.9,,33.5,3.200000000000003,9.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 15 B,16,37.1,25.4,34.9,,33.5,3.6000000000000014,10.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,29,35.2,25.4,34.9,,33.5,1.7000000000000028,5.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 B,57,39.9,25.4,34.9,,33.5,6.399999999999999,19.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 7 Day 1 B,171,34.8,25.4,34.9,,33.5,1.2999999999999972,3.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 8 Day 1 B,199,35.9,25.4,34.9,,33.5,2.3999999999999986,7.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 9 Day 1 B,227,37.2,25.4,34.9,,33.5,3.700000000000003,11
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 10 Day 1 B,255,38.2,25.4,34.9,,33.5,4.700000000000003,14
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),Cycle 11 Day 1 B,283,40.2,25.4,34.9,,33.5,6.700000000000003,20
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment B,311,37.9,25.4,34.9,,33.5,4.399999999999999,13.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-11,1,2,3,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1,2,3,Y,1,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,1.1,2,3,,1,0.10000000000000009,10
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 15 B,16,1,2,3,,1,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,29,1.1,2,3,,1,0.10000000000000009,10
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 B,57,1.1,2,3,,1,0.10000000000000009,10
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 7 Day 1 B,171,1,2,3,,1,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 8 Day 1 B,199,1,2,3,,1,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 9 Day 1 B,227,1,2,3,,1,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 10 Day 1 B,255,1.1,2,3,,1,0.10000000000000009,10
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 11 Day 1 B,283,1.1,2,3,,1,0.10000000000000009,10
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment B,311,1.1,2,3,,1,0.10000000000000009,10
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),,-11,12.9,12.3,14.9,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Baseline,1,12.9,12.3,14.9,Y,12.9,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,13.4,12.3,14.9,,12.9,0.5,3.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 1 Day 15 B,16,13,12.3,14.9,,12.9,0.09999999999999964,0.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,29,13.7,12.3,14.9,,12.9,0.7999999999999989,6.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 B,57,13.4,12.3,14.9,,12.9,0.5,3.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 7 Day 1 B,171,13.2,12.3,14.9,,12.9,0.29999999999999893,2.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 8 Day 1 B,199,13.1,12.3,14.9,,12.9,0.1999999999999993,1.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 9 Day 1 B,227,12.8,12.3,14.9,,12.9,-0.09999999999999964,-0.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 10 Day 1 B,255,13.4,12.3,14.9,,12.9,0.5,3.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),Cycle 11 Day 1 B,283,13.2,12.3,14.9,,12.9,0.29999999999999893,2.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Coagulation,Prothrombin Time (PT),End of Treatment B,311,13.9,12.3,14.9,,12.9,1,7.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,,-11,0,0,0.2,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 8 B,8,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 1 Day 15 B,16,0.1,0,0.2,,0,0.1,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 2 Day 1 B,29,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 3 Day 1 B,57,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 4 Day 1 B,85,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 5 Day 1 B,113,0.8,0,0.2,,0,0.8,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 6 Day 1 B,142,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 7 Day 1 B,171,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 8 Day 1 B,199,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 9 Day 1 B,227,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 10 Day 1 B,255,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Cycle 11 Day 1 B,283,0,0,0.2,,0,0,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,End of Treatment B,311,0.1,0,0.2,,0,0.1,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Basophils,Follow-up 110 B,416,0.1,0,0.2,,0,0.1,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,,-11,0.2,0,0.6,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Baseline,1,0.2,0,0.6,Y,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 1 Day 15 B,16,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 2 Day 1 B,29,0.3,0,0.6,,0.2,0.09999999999999998,50
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 3 Day 1 B,57,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 4 Day 1 B,85,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 5 Day 1 B,113,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 6 Day 1 B,142,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 7 Day 1 B,171,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 8 Day 1 B,199,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 9 Day 1 B,227,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 10 Day 1 B,255,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Cycle 11 Day 1 B,283,0.2,0,0.6,,0.2,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,End of Treatment B,311,0.4,0,0.6,,0.2,0.2,100
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Eosinophils,Follow-up 110 B,416,0.1,0,0.6,,0.2,-0.1,-50
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),,-11,3.82,4.5,6,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Baseline,1,3.73,4.5,6,Y,3.73,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,3.7,4.5,6,,3.73,-0.029999999999999805,-0.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,16,3.76,4.5,6,,3.73,0.029999999999999805,0.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,29,3.61,4.5,6,,3.73,-0.1200000000000001,-3.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,57,3.66,4.5,6,,3.73,-0.06999999999999984,-1.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 B,85,3.45,4.5,6,,3.73,-0.2799999999999998,-7.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 B,113,3.38,4.5,6,,3.73,-0.3500000000000001,-9.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 6 Day 1 B,142,3.53,4.5,6,,3.73,-0.20000000000000018,-5.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 7 Day 1 B,171,3.4,4.5,6,,3.73,-0.33000000000000007,-8.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 8 Day 1 B,199,3.35,4.5,6,,3.73,-0.3799999999999999,-10.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 9 Day 1 B,227,3.33,4.5,6,,3.73,-0.3999999999999999,-10.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 10 Day 1 B,255,3.37,4.5,6,,3.73,-0.3599999999999999,-9.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Cycle 11 Day 1 B,283,3.31,4.5,6,,3.73,-0.41999999999999993,-11.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),End of Treatment B,311,3.56,4.5,6,,3.73,-0.16999999999999993,-4.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,416,3.33,4.5,6,,3.73,-0.3999999999999999,-10.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),,-11,34.6,42,52,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Baseline,1,33.8,42,52,Y,33.8,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,33.4,42,52,,33.8,-0.3999999999999986,-1.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,16,33.7,42,52,,33.8,-0.09999999999999432,-0.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,29,32.2,42,52,,33.8,-1.5999999999999943,-4.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,57,31.6,42,52,,33.8,-2.1999999999999957,-6.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 B,85,30,42,52,,33.8,-3.799999999999997,-11.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 B,113,29.5,42,52,,33.8,-4.299999999999997,-12.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 6 Day 1 B,142,30.4,42,52,,33.8,-3.3999999999999986,-10.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 7 Day 1 B,171,29.3,42,52,,33.8,-4.4999999999999964,-13.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 8 Day 1 B,199,29,42,52,,33.8,-4.799999999999997,-14.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 9 Day 1 B,227,28.7,42,52,,33.8,-5.099999999999998,-15.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 10 Day 1 B,255,28.7,42,52,,33.8,-5.099999999999998,-15.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Cycle 11 Day 1 B,283,27.9,42,52,,33.8,-5.899999999999999,-17.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),End of Treatment B,311,28.9,42,52,,33.8,-4.899999999999999,-14.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hematocrit (RATIO),Follow-up 110 B,416,25.8,42,52,,33.8,-7.9999999999999964,-23.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),,-11,11.2,13.9,16.3,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Baseline,1,11.6,13.9,16.3,Y,11.6,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,11.3,13.9,16.3,,11.6,-0.29999999999999893,-2.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,16,11.2,13.9,16.3,,11.6,-0.40000000000000036,-3.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,29,10.6,13.9,16.3,,11.6,-1,-8.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,57,10.5,13.9,16.3,,11.6,-1.0999999999999996,-9.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 B,85,10,13.9,16.3,,11.6,-1.5999999999999996,-13.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 B,113,9.9,13.9,16.3,,11.6,-1.6999999999999993,-14.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 6 Day 1 B,142,10.3,13.9,16.3,,11.6,-1.299999999999999,-11.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 7 Day 1 B,171,9.8,13.9,16.3,,11.6,-1.799999999999999,-15.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 8 Day 1 B,199,9.7,13.9,16.3,,11.6,-1.9000000000000004,-16.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 9 Day 1 B,227,9.5,13.9,16.3,,11.6,-2.0999999999999996,-18.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 10 Day 1 B,255,9.5,13.9,16.3,,11.6,-2.0999999999999996,-18.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Cycle 11 Day 1 B,283,9.3,13.9,16.3,,11.6,-2.299999999999999,-19.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),End of Treatment B,311,9.3,13.9,16.3,,11.6,-2.299999999999999,-19.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Hemoglobin (g/dL),Follow-up 110 B,416,8.4,13.9,16.3,,11.6,-3.1999999999999993,-27.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,,-11,1.7,1,4.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Baseline,1,1.7,1,4.5,Y,1.7,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,0.8,1,4.5,,1.7,-0.8999999999999999,-52.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 1 Day 15 B,16,1.3,1,4.5,,1.7,-0.3999999999999999,-23.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 2 Day 1 B,29,1,1,4.5,,1.7,-0.7,-41.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 3 Day 1 B,57,1,1,4.5,,1.7,-0.7,-41.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 4 Day 1 B,85,1.4,1,4.5,,1.7,-0.30000000000000004,-17.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 5 Day 1 B,113,1.1,1,4.5,,1.7,-0.5999999999999999,-35.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 6 Day 1 B,142,1.2,1,4.5,,1.7,-0.5,-29.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 7 Day 1 B,171,0.8,1,4.5,,1.7,-0.8999999999999999,-52.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 8 Day 1 B,199,1.3,1,4.5,,1.7,-0.3999999999999999,-23.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 9 Day 1 B,227,0.9,1,4.5,,1.7,-0.7999999999999999,-47.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 10 Day 1 B,255,1.1,1,4.5,,1.7,-0.5999999999999999,-35.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Cycle 11 Day 1 B,283,0.7,1,4.5,,1.7,-1,-58.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,End of Treatment B,311,0.7,1,4.5,,1.7,-1,-58.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Lymphocytes,Follow-up 110 B,416,1.1,1,4.5,,1.7,-0.5999999999999999,-35.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,,-11,0.6,0.2,1,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Baseline,1,0.5,0.2,1,Y,0.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 8 B,8,1.3,0.2,1,,0.5,0.8,160
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 1 Day 15 B,16,2.7,0.2,1,,0.5,2.2,440
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 2 Day 1 B,29,0.9,0.2,1,,0.5,0.4,80
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 3 Day 1 B,57,0.6,0.2,1,,0.5,0.09999999999999998,20
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 4 Day 1 B,85,0.5,0.2,1,,0.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 5 Day 1 B,113,0.5,0.2,1,,0.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 6 Day 1 B,142,0.5,0.2,1,,0.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 7 Day 1 B,171,0.8,0.2,1,,0.5,0.30000000000000004,60
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 8 Day 1 B,199,0.5,0.2,1,,0.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 9 Day 1 B,227,0.6,0.2,1,,0.5,0.09999999999999998,20
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 10 Day 1 B,255,0.7,0.2,1,,0.5,0.19999999999999996,40
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Cycle 11 Day 1 B,283,0.7,0.2,1,,0.5,0.19999999999999996,40
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,End of Treatment B,311,0.7,0.2,1,,0.5,0.19999999999999996,40
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Monocytes,Follow-up 110 B,416,0.6,0.2,1,,0.5,0.09999999999999998,20
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,,-11,2.9,1.9,8,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Baseline,1,2.1,1.9,8,Y,2.1,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 8 B,8,2.6,1.9,8,,2.1,0.5,23.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 1 Day 15 B,16,3.1,1.9,8,,2.1,1,47.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 2 Day 1 B,29,4.6,1.9,8,,2.1,2.4999999999999996,119
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 3 Day 1 B,57,4.5,1.9,8,,2.1,2.4,114.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 4 Day 1 B,85,1.9,1.9,8,,2.1,-0.20000000000000018,-9.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 5 Day 1 B,113,2.6,1.9,8,,2.1,0.5,23.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 6 Day 1 B,142,2.3,1.9,8,,2.1,0.19999999999999973,9.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 7 Day 1 B,171,2.9,1.9,8,,2.1,0.7999999999999998,38.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 8 Day 1 B,199,2.6,1.9,8,,2.1,0.5,23.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 9 Day 1 B,227,2.7,1.9,8,,2.1,0.6000000000000001,28.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 10 Day 1 B,255,3.6,1.9,8,,2.1,1.5,71.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Cycle 11 Day 1 B,283,3.9,1.9,8,,2.1,1.7999999999999998,85.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,End of Treatment B,311,3.7,1.9,8,,2.1,1.6,76.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Neutrophils,Follow-up 110 B,416,3.4,1.9,8,,2.1,1.2999999999999998,61.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),,-11,227,150,450,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Baseline,1,212,150,450,Y,212,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,235,150,450,,212,23,10.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,16,224,150,450,,212,12,5.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,29,289,150,450,,212,77,36.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,57,329,150,450,,212,117,55.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 4 Day 1 B,85,202,150,450,,212,-10,-4.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 5 Day 1 B,113,235,150,450,,212,23,10.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 6 Day 1 B,142,235,150,450,,212,23,10.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 7 Day 1 B,171,253,150,450,,212,41,19.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 8 Day 1 B,199,230,150,450,,212,18,8.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 9 Day 1 B,227,231,150,450,,212,19,9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 10 Day 1 B,255,265,150,450,,212,53,25
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Cycle 11 Day 1 B,283,294,150,450,,212,82,38.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),End of Treatment B,311,305,150,450,,212,93,43.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,Platelets (10^9/L),Follow-up 110 B,416,430,150,450,,212,218,102.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,TESTR,Baseline,-11,22.07,300,1080,Y,22.07,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,,-11,5.4,4.5,11,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Baseline,1,4.5,4.5,11,Y,4.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,4.9,4.5,11,,4.5,0.40000000000000036,8.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 1 Day 15 B,16,7.4,4.5,11,,4.5,2.9000000000000004,64.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 2 Day 1 B,29,6.8,4.5,11,,4.5,2.3,51.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 3 Day 1 B,57,6.3,4.5,11,,4.5,1.7999999999999998,40
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 4 Day 1 B,85,4.1,4.5,11,,4.5,-0.40000000000000036,-8.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 5 Day 1 B,113,4.4,4.5,11,,4.5,-0.09999999999999964,-2.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 6 Day 1 B,142,4.2,4.5,11,,4.5,-0.2999999999999998,-6.7
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 7 Day 1 B,171,4.7,4.5,11,,4.5,0.20000000000000018,4.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 8 Day 1 B,199,4.6,4.5,11,,4.5,0.09999999999999964,2.2
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 9 Day 1 B,227,4.5,4.5,11,,4.5,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 10 Day 1 B,255,5.6,4.5,11,,4.5,1.0999999999999996,24.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Cycle 11 Day 1 B,283,5.6,4.5,11,,4.5,1.0999999999999996,24.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,End of Treatment B,311,5.6,4.5,11,,4.5,1.0999999999999996,24.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Hematology,White Blood Cells,Follow-up 110 B,416,5.2,4.5,11,,4.5,0.7000000000000002,15.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,,-11,27.13,NA,NA,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Baseline,1,28.49,NA,NA,Y,28.49,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,29,20.63,NA,NA,,28.49,-7.859999999999999,-27.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 3 Day 1 B,57,5.72,NA,NA,,28.49,-22.77,-79.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 4 Day 1 B,85,3.98,NA,NA,,28.49,-24.509999999999998,-86
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 5 Day 1 B,113,3.72,NA,NA,,28.49,-24.77,-86.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 6 Day 1 B,142,3.55,NA,NA,,28.49,-24.939999999999998,-87.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 7 Day 1 B,171,3.96,NA,NA,,28.49,-24.529999999999998,-86.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 8 Day 1 B,199,4.16,NA,NA,,28.49,-24.33,-85.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 9 Day 1 B,227,5.11,NA,NA,,28.49,-23.38,-82.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 10 Day 1 B,255,7,NA,NA,,28.49,-21.49,-75.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Cycle 11 Day 1 B,283,21.84,NA,NA,,28.49,-6.649999999999999,-23.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,End of Treatment B,311,50.88,NA,NA,,28.49,22.390000000000004,78.6
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Prostate-specific antigen,PSA,Follow-up 110 B,416,108.79,NA,NA,,28.49,80.30000000000001,281.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 3 Day 1 B,57,0.49,0.8,1.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 4 Day 1 B,85,0.61,0.8,1.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 5 Day 1 B,113,0.57,0.8,1.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 6 Day 1 B,142,0.77,0.8,1.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 10 Day 1 B,255,0.99,0.8,1.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Cycle 11 Day 1 B,283,1.01,0.8,1.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),End of Treatment B,311,0.79,0.8,1.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Free thyroxine (FT4),Follow-up 110 B,416,1.11,0.8,1.5,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-11,2.33,0.4,4.2,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.93,0.4,4.2,Y,2.93,0,0
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,1.47,0.4,4.2,,2.93,-1.4600000000000002,-49.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 15 B,16,4.19,0.4,4.2,,2.93,1.2600000000000002,43
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,29,0.19,0.4,4.2,,2.93,-2.74,-93.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,57,25.47,0.4,4.2,,2.93,22.54,769.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 B,85,49.35,0.4,4.2,,2.93,46.42,1584.3
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 B,113,49.09,0.4,4.2,,2.93,46.160000000000004,1575.4
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 6 Day 1 B,142,42.86,0.4,4.2,,2.93,39.93,1362.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 7 Day 1 B,171,31.32,0.4,4.2,,2.93,28.39,968.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 8 Day 1 B,199,35.57,0.4,4.2,,2.93,32.64,1114
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 9 Day 1 B,227,20.45,0.4,4.2,,2.93,17.52,598
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 10 Day 1 B,255,11.86,0.4,4.2,,2.93,8.93,304.8
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 11 Day 1 B,283,11.09,0.4,4.2,,2.93,8.16,278.5
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,311,17.73,0.4,4.2,,2.93,14.8,505.1
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 B,416,15.32,0.4,4.2,,2.93,12.39,422.9
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Triiodothyronine (T3),Cycle 3 Day 1 B,57,1.95,2.5,3.9,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Triiodothyronine (T3),Cycle 4 Day 1 B,85,2.26,2.5,3.9,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Triiodothyronine (T3),Cycle 5 Day 1 B,113,1.6,2.5,3.9,,NA,NA,NA
8B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,Y,Y,Thyroid Function Testing,Triiodothyronine (T3),Cycle 6 Day 1 B,142,2.19,2.5,3.9,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,14,NA,NA,Y,14,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,30,16,NA,NA,,14,2,14.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 C,58,11,NA,NA,,14,-3,-21.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 3 Day 1 C,86,30,NA,NA,,14,16,114.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 4 Day 1 C,114,55,NA,NA,,14,41,292.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 5 Day 1 C,142,87,NA,NA,,14,73,521.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,End of Treatment C,170,210,NA,NA,,14,196,1400
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-6,23,0,45,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,20,11,66,Y,20,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,27,11,66,,20,7,35
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,16,47,11,66,,20,27,135
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,51,11,66,,20,31,155
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,30,35,11,66,,20,15,75
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,37,63,0,45,,20,43,215
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 C,58,126,11,66,,20,106,530
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 C,86,54,11,66,,20,34,170
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 4 Day 1 C,114,57,11,66,,20,37,185
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 5 Day 1 C,142,28,0,45,,20,8,40
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,170,20,0,45,,20,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-6,3.9,3.5,5.5,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4,3.4,5,Y,4,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,4.1,3.4,5,,4,0.09999999999999964,2.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,16,4.3,3.4,5,,4,0.2999999999999998,7.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,4,3.4,5,,4,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,30,4.1,3.4,5,,4,0.09999999999999964,2.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,37,4.1,3.5,5.5,,4,0.09999999999999964,2.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,58,3.9,3.4,5,,4,-0.10000000000000009,-2.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 C,86,4,3.4,5,,4,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 4 Day 1 C,114,4.1,3.4,5,,4,0.09999999999999964,2.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 5 Day 1 C,142,4.1,3.5,5.5,,4,0.09999999999999964,2.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,170,4.2,3.5,5.5,,4,0.20000000000000018,5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-6,76,0,124,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,68,38,126,Y,68,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,78,38,126,,68,10,14.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,16,76,38,126,,68,8,11.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,92,38,126,,68,24,35.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,30,91,38,126,,68,23,33.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,37,132,0,124,,68,64,94.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,58,65,38,126,,68,-3,-4.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 C,86,76,38,126,,68,8,11.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 4 Day 1 C,114,100,38,126,,68,32,47.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 5 Day 1 C,142,91,0,124,,68,23,33.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,170,89,0,124,,68,21,30.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-6,24,0,35,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,29,15,46,Y,29,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,34,15,46,,29,5,17.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,16,56,15,46,,29,27,93.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,54,15,46,,29,25,86.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,30,40,15,46,,29,11,37.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,37,57,0,35,,29,28,96.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,58,73,15,46,,29,44,151.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 C,86,50,15,46,,29,21,72.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 4 Day 1 C,114,49,15,46,,29,20,69
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 5 Day 1 C,142,33,0,35,,29,4,13.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,170,31,0,35,,29,2,6.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-6,17.1,5,25,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,23,7,20,Y,23,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,21,7,20,,23,-2,-8.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,16,24,7,20,,23,1,4.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,21,7,20,,23,-2,-8.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,30,18,7,20,,23,-5,-21.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,37,18,5,25,,23,-5,-21.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 C,58,19,7,20,,23,-4,-17.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 C,86,20,7,20,,23,-3,-13
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 4 Day 1 C,114,20,7,20,,23,-3,-13
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 5 Day 1 C,142,23.4,5,25,,23,0.3999999999999986,1.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,170,21.5,5,25,,23,-1.5,-6.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-6,30,23,31,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,30,22,30,Y,30,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,28,22,30,,30,-2,-6.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,16,27,22,30,,30,-3,-10
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,29,22,30,,30,-1,-3.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,30,26,22,30,,30,-4,-13.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,37,26,23,31,,30,-4,-13.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 C,58,27,22,30,,30,-3,-10
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 C,86,25,22,30,,30,-5,-16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 4 Day 1 C,114,27,22,30,,30,-3,-10
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 5 Day 1 C,142,25,23,31,,30,-5,-16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment C,170,24,23,31,,30,-6,-20
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-6,8.8,8.9,10.1,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.2,8.4,10.5,Y,9.2,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,8.7,8.4,10.5,,9.2,-0.5,-5.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,16,9.1,8.4,10.5,,9.2,-0.09999999999999964,-1.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,9.2,8.4,10.5,,9.2,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,30,8.7,8.4,10.5,,9.2,-0.5,-5.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,37,8.7,8.9,10.1,,9.2,-0.5,-5.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,58,8.8,8.4,10.5,,9.2,-0.3999999999999986,-4.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 C,86,9.1,8.4,10.5,,9.2,-0.09999999999999964,-1.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 4 Day 1 C,114,8.8,8.4,10.5,,9.2,-0.3999999999999986,-4.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 5 Day 1 C,142,9.3,8.9,10.1,,9.2,0.10000000000000142,1.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,170,9.1,8.9,10.1,,9.2,-0.09999999999999964,-1.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-6,102,96,108,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,105,98,107,Y,105,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,103,98,107,,105,-2,-1.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,16,104,98,107,,105,-1,-1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,107,98,107,,105,2,1.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,30,106,98,107,,105,1,1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,37,104,96,108,,105,-1,-1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,58,105,98,107,,105,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 C,86,107,98,107,,105,2,1.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 4 Day 1 C,114,104,98,107,,105,-1,-1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 5 Day 1 C,142,105,96,108,,105,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,170,103,96,108,,105,-2,-1.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-6,0.75,0.4,1.2,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.6,0.7,1.5,Y,0.6,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,0.7,0.7,1.5,,0.6,0.09999999999999998,16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,16,0.7,0.7,1.5,,0.6,0.09999999999999998,16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,0.7,0.7,1.5,,0.6,0.09999999999999998,16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,30,0.7,0.7,1.5,,0.6,0.09999999999999998,16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,37,0.83,0.4,1.2,,0.6,0.22999999999999998,38.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,58,0.8,0.7,1.5,,0.6,0.20000000000000007,33.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 C,86,0.7,0.7,1.5,,0.6,0.09999999999999998,16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 4 Day 1 C,114,0.7,0.7,1.5,,0.6,0.09999999999999998,16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 5 Day 1 C,142,0.84,0.4,1.2,,0.6,0.24,40
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,170,0.98,0.4,1.2,,0.6,0.38,63.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-6,88,NA,NA,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,105,65,110,Y,105,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,96,65,110,,105,-9,-8.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,16,96,65,110,,105,-9,-8.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,117,65,110,,105,12,11.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,30,137,65,110,,105,32,30.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,37,87,NA,NA,,105,-18,-17.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 C,58,105,65,110,,105,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 C,86,144,65,110,,105,39,37.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 4 Day 1 C,114,102,65,110,,105,-3,-2.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 5 Day 1 C,142,121,NA,NA,,105,16,15.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,170,88,NA,NA,,105,-17,-16.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-6,192,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,204,0,259,Y,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,8,211,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,16,297,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,22,242,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,30,248,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,37,326,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,58,211,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,86,184,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,114,191,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 5 Day 1 C,142,240,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,170,412,0,259,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-6,4.4,3.5,5,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.5,3.6,5,Y,4.5,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,4,3.6,5,,4.5,-0.5,-11.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,16,4.6,3.6,5,,4.5,0.09999999999999964,2.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.7,3.6,5,,4.5,0.20000000000000018,4.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,30,3.9,3.6,5,,4.5,-0.6000000000000001,-13.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,37,4.7,3.5,5,,4.5,0.20000000000000018,4.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,58,4.4,3.6,5,,4.5,-0.09999999999999964,-2.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 C,86,4.1,3.6,5,,4.5,-0.40000000000000036,-8.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 4 Day 1 C,114,4.2,3.6,5,,4.5,-0.2999999999999998,-6.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 5 Day 1 C,142,4.5,3.5,5,,4.5,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,170,4.5,3.5,5,,4.5,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-6,140,135,145,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,140,137,145,Y,140,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,139,137,145,,140,-1,-0.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,16,140,137,145,,140,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,145,137,145,,140,5,3.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,30,139,137,145,,140,-1,-0.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,37,140,135,145,,140,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 C,58,140,137,145,,140,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 C,86,140,137,145,,140,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 4 Day 1 C,114,139,137,145,,140,-1,-0.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 5 Day 1 C,142,140,135,145,,140,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,170,139,135,145,,140,-1,-0.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-6,0.4,0.1,1.2,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.4,0.2,1.3,Y,0.4,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.4,0.2,1.3,,0.4,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,16,0.3,0.2,1.3,,0.4,-0.10000000000000003,-25
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.4,0.2,1.3,,0.4,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,30,0.4,0.2,1.3,,0.4,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,37,0.5,0.1,1.2,,0.4,0.09999999999999998,25
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,58,0.6,0.2,1.3,,0.4,0.19999999999999996,50
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 C,86,0.5,0.2,1.3,,0.4,0.09999999999999998,25
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 4 Day 1 C,114,0.6,0.2,1.3,,0.4,0.19999999999999996,50
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 5 Day 1 C,142,0.6,0.1,1.2,,0.4,0.19999999999999996,50
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,170,0.6,0.1,1.2,,0.4,0.19999999999999996,50
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-6,6.1,6,8.5,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,6.6,6.4,8.2,Y,6.6,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,7.1,6.4,8.2,,6.6,0.5,7.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,16,7.1,6.4,8.2,,6.6,0.5,7.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,6.8,6.4,8.2,,6.6,0.20000000000000018,3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,30,6.9,6.4,8.2,,6.6,0.3000000000000007,4.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,37,6.5,6,8.5,,6.6,-0.09999999999999964,-1.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 C,58,6.9,6.4,8.2,,6.6,0.3000000000000007,4.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 C,86,6.9,6.4,8.2,,6.6,0.3000000000000007,4.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 4 Day 1 C,114,7,6.4,8.2,,6.6,0.40000000000000036,6.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 5 Day 1 C,142,6.8,6,8.5,,6.6,0.20000000000000018,3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,170,7.2,6,8.5,,6.6,0.6000000000000005,9.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,-6,25,NA,NA,Y,25,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment C,170,26,NA,NA,,25,1,4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,-6,1,NA,NA,Y,1,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment C,170,1,NA,NA,,1,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,-6,12.3,NA,NA,Y,12.3,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment C,170,9.8,NA,NA,,12.3,-2.5,-20.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-6,0.09,NA,NA,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0.06,0,0.2,Y,0.06,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0.07,0,0.2,,0.06,0.010000000000000009,16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,16,0.08,0,0.2,,0.06,0.020000000000000004,33.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0.1,0,0.2,,0.06,0.04000000000000001,66.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,30,0.09,0,0.2,,0.06,0.03,50
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 C,58,0.08,0,0.2,,0.06,0.020000000000000004,33.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 C,86,0.04,0,0.2,,0.06,-0.019999999999999997,-33.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 4 Day 1 C,114,0.06,0,0.2,,0.06,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 5 Day 1 C,142,0.05,NA,NA,,0.06,-0.009999999999999995,-16.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,170,0.09,NA,NA,,0.06,0.03,50
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-6,1.25,0.03,0.44,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,1.19,0,0.7,Y,1.19,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0.65,0,0.7,,1.19,-0.5399999999999999,-45.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,16,0.73,0,0.7,,1.19,-0.45999999999999996,-38.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,0.33,0,0.7,,1.19,-0.8599999999999999,-72.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,30,0.42,0,0.7,,1.19,-0.77,-64.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 C,58,0.61,0,0.7,,1.19,-0.58,-48.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 C,86,0.49,0,0.7,,1.19,-0.7,-58.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 4 Day 1 C,114,0.44,0,0.7,,1.19,-0.75,-63
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 5 Day 1 C,142,0.42,0.03,0.44,,1.19,-0.77,-64.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,170,0.48,0.03,0.44,,1.19,-0.71,-59.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-6,4.23,3.97,5.65,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.33,4.7,6.1,Y,4.33,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,4.13,4.7,6.1,,4.33,-0.20000000000000018,-4.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,16,4.48,4.7,6.1,,4.33,0.15000000000000036,3.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,4.13,4.7,6.1,,4.33,-0.20000000000000018,-4.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,30,4.25,4.7,6.1,,4.33,-0.08000000000000007,-1.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,37,4.2,3.97,5.65,,4.33,-0.1299999999999999,-3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,58,4.1,4.7,6.1,,4.33,-0.23000000000000043,-5.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 C,86,4.52,4.7,6.1,,4.33,0.1899999999999995,4.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 4 Day 1 C,114,4.52,4.7,6.1,,4.33,0.1899999999999995,4.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 5 Day 1 C,142,4.78,3.97,5.65,,4.33,0.4500000000000002,10.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,170,4.79,3.97,5.65,,4.33,0.45999999999999996,10.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-6,40.1,37.5,49.9,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,40,42,52,Y,40,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,37.7,42,52,,40,-2.299999999999997,-5.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,16,41,42,52,,40,1,2.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,38.4,42,52,,40,-1.6000000000000014,-4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,30,39,42,52,,40,-1,-2.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,37,40.3,37.5,49.9,,40,0.29999999999999716,0.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,58,37.5,42,52,,40,-2.5,-6.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 C,86,41.2,42,52,,40,1.2000000000000028,3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 4 Day 1 C,114,40.9,42,52,,40,0.8999999999999986,2.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 5 Day 1 C,142,42.4,37.5,49.9,,40,2.3999999999999986,6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,170,44.2,37.5,49.9,,40,4.200000000000003,10.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-6,13.1,13,17,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,13,14,18,Y,13,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,12.5,14,18,,13,-0.5,-3.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,16,13.2,14,18,,13,0.1999999999999993,1.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,12.3,14,18,,13,-0.6999999999999993,-5.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,30,12.6,14,18,,13,-0.40000000000000036,-3.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,37,12.4,13,17,,13,-0.5999999999999996,-4.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,58,12,14,18,,13,-1,-7.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 C,86,13.1,14,18,,13,0.09999999999999964,0.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 4 Day 1 C,114,12.8,14,18,,13,-0.1999999999999993,-1.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 5 Day 1 C,142,13.8,13,17,,13,0.8000000000000007,6.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,170,14,13,17,,13,1,7.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-6,0.7,0.85,3,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,0.77,0.6,3.4,Y,0.77,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,0.8,0.6,3.4,,0.77,0.030000000000000027,3.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,16,0.79,0.6,3.4,,0.77,0.020000000000000018,2.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,0.83,0.6,3.4,,0.77,0.05999999999999994,7.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,30,0.86,0.6,3.4,,0.77,0.08999999999999997,11.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 C,58,0.68,0.6,3.4,,0.77,-0.08999999999999997,-11.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 C,86,0.7,0.6,3.4,,0.77,-0.07000000000000006,-9.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 4 Day 1 C,114,0.7,0.6,3.4,,0.77,-0.07000000000000006,-9.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 5 Day 1 C,142,0.83,0.85,3,,0.77,0.05999999999999994,7.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,170,1.01,0.85,3,,0.77,0.24,31.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-6,0.37,0.19,0.77,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.46,0,0.9,Y,0.46,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,1.13,0,0.9,,0.46,0.6699999999999999,145.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,16,2.9,0,0.9,,0.46,2.44,530.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,1.75,0,0.9,,0.46,1.29,280.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,30,1.74,0,0.9,,0.46,1.28,278.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 C,58,0.29,0,0.9,,0.46,-0.17000000000000004,-37
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 C,86,0.31,0,0.9,,0.46,-0.15000000000000002,-32.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 4 Day 1 C,114,0.49,0,0.9,,0.46,0.02999999999999997,6.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 5 Day 1 C,142,0.38,0.19,0.77,,0.46,-0.08000000000000002,-17.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,170,0.37,0.19,0.77,,0.46,-0.09000000000000002,-19.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-6,2.34,1.82,7.42,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.82,2,6.9,Y,3.82,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,3,2,6.9,,3.82,-0.8199999999999998,-21.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,16,3.48,2,6.9,,3.82,-0.33999999999999986,-8.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,2.27,2,6.9,,3.82,-1.5499999999999998,-40.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,30,4.72,2,6.9,,3.82,0.8999999999999999,23.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 C,58,2.77,2,6.9,,3.82,-1.0499999999999998,-27.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 C,86,2.39,2,6.9,,3.82,-1.4299999999999997,-37.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 4 Day 1 C,114,2.61,2,6.9,,3.82,-1.21,-31.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 5 Day 1 C,142,2.79,1.82,7.42,,3.82,-1.0299999999999998,-27
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,170,3.84,1.82,7.42,,3.82,0.020000000000000018,0.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-6,171,150,450,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,195,130,400,Y,195,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,191,130,400,,195,-4,-2.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,16,151,130,400,,195,-44,-22.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,225,130,400,,195,30,15.4
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,30,261,130,400,,195,66,33.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,37,147,150,450,,195,-48,-24.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,58,203,130,400,,195,8,4.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 C,86,173,130,400,,195,-22,-11.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 4 Day 1 C,114,183,130,400,,195,-12,-6.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 5 Day 1 C,142,169,150,450,,195,-26,-13.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,170,179,150,450,,195,-16,-8.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-6,4.76,4,11,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,6.3,4.8,10.8,Y,6.3,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,5.65,4.8,10.8,,6.3,-0.6499999999999995,-10.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,16,7.98,4.8,10.8,,6.3,1.6800000000000006,26.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,5.28,4.8,10.8,,6.3,-1.0199999999999996,-16.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,30,7.83,4.8,10.8,,6.3,1.5300000000000002,24.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,37,7.78,4,11,,6.3,1.4800000000000004,23.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 C,58,4.43,4.8,10.8,,6.3,-1.87,-29.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 C,86,3.9,4.8,10.8,,6.3,-2.4,-38.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 4 Day 1 C,114,4.3,4.8,10.8,,6.3,-2,-31.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 5 Day 1 C,142,4.49,4,11,,6.3,-1.8099999999999996,-28.7
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,170,5.82,4,11,,6.3,-0.47999999999999954,-7.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-6,8.84,NA,NA,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,11.16,NA,NA,Y,11.16,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,14.1,NA,NA,,11.16,2.9399999999999995,26.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,30,15.47,NA,NA,,11.16,4.3100000000000005,38.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,58,20.32,NA,NA,,11.16,9.16,82.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 C,86,30.3,NA,NA,,11.16,19.14,171.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 4 Day 1 C,114,52.47,NA,NA,,11.16,41.31,370.2
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 5 Day 1 C,142,73.8,NA,NA,,11.16,62.64,561.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,170,103.19,NA,NA,,11.16,92.03,824.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-6,3.08,0.39,4.6,,NA,NA,NA
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.76,0.39,4.6,Y,1.76,0,0
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,1.52,0.39,4.6,,1.76,-0.24,-13.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,16,1.99,0.39,4.6,,1.76,0.22999999999999998,13.1
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,1.03,0.39,4.6,,1.76,-0.73,-41.5
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,30,1.52,0.39,4.6,,1.76,-0.24,-13.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,37,1.72,0.39,4.6,,1.76,-0.040000000000000036,-2.3
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,58,1.77,0.39,4.6,,1.76,0.010000000000000009,0.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 C,86,1.08,0.39,4.6,,1.76,-0.6799999999999999,-38.6
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 4 Day 1 C,114,1.55,0.39,4.6,,1.76,-0.20999999999999996,-11.9
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 5 Day 1 C,142,2.69,0.39,4.6,,1.76,0.9299999999999999,52.8
8C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,170,8.83,0.39,4.6,,1.76,7.07,401.7
9A,A,NKTR-214 + Nivolumab,Y,N,,CTC,Baseline,1,15,NA,NA,Y,15,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,,CTC,Cycle 2 Day 1 A,20,0,NA,NA,,15,-15,-100
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),,-26,18,0,59,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,19,0,59,Y,19,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 A,9,31,0,59,,19,12,63.2
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 A,20,62,0,59,,19,43,226.3
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Albumin (g/dL),,-26,3.5,3.5,4.7,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Baseline,1,3.6,3.5,4.7,Y,3.6,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 A,9,3.5,3.5,4.7,,3.6,-0.10000000000000009,-2.8
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 A,20,3.1,3.5,4.7,,3.6,-0.5,-13.9
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),,-26,176,56,119,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,186,56,119,Y,186,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 A,9,147,56,119,,186,-39,-21
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 A,20,160,56,119,,186,-26,-14
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),,-26,19,0,41,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,19,0,41,Y,19,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 A,9,21,0,41,,19,2,10.5
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 A,20,80,0,41,,19,61,321.1
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,BUN,,-26,18,6,20,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,BUN,Baseline,1,21,6,20,Y,21,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,BUN,Cycle 1 Day 8 A,9,17,6,20,,21,-4,-19
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,BUN,Cycle 2 Day 1 A,20,22,6,20,,21,1,4.8
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Bicarbonate,,-26,26,21,32,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Bicarbonate,Baseline,1,26,21,32,Y,26,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Bicarbonate,Cycle 1 Day 8 A,9,28,21,32,,26,2,7.7
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Bicarbonate,Cycle 2 Day 1 A,20,26,21,32,,26,0,0
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),,-26,9.6,8.6,10.2,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Baseline,1,9.6,8.6,10.2,Y,9.6,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 A,9,8.9,8.6,10.2,,9.6,-0.6999999999999993,-7.3
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 A,20,8.7,8.6,10.2,,9.6,-0.9000000000000004,-9.4
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),,-26,105,97,108,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Baseline,1,105,97,108,Y,105,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 A,9,103,97,108,,105,-2,-1.9
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 A,20,104,97,108,,105,-1,-1
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),,-26,0.95,0.7,1.3,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Baseline,1,0.96,0.7,1.3,Y,0.96,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 A,9,0.98,0.7,1.3,,0.96,0.020000000000000018,2.1
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 A,20,0.85,0.7,1.3,,0.96,-0.10999999999999999,-11.5
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Glucose,,-26,101,70,99,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Glucose,Baseline,1,92,70,99,Y,92,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Glucose,Cycle 1 Day 8 A,9,81,70,99,,92,-11,-12
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Glucose,Cycle 2 Day 1 A,20,133,70,99,,92,41,44.6
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),,-26,158,0,250,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,157,0,250,Y,157,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 A,9,198,0,250,,157,41,26.1
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 A,20,336,0,250,,157,179,114
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),,-26,3.8,3.4,5,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Baseline,1,4.3,3.4,5,Y,4.3,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 A,9,3.5,3.4,5,,4.3,-0.7999999999999998,-18.6
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 A,20,4,3.4,5,,4.3,-0.2999999999999998,-7
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Sodium,,-26,140,136,145,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Sodium,Baseline,1,141,136,145,Y,141,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Sodium,Cycle 1 Day 8 A,9,140,136,145,,141,-1,-0.7
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Sodium,Cycle 2 Day 1 A,20,140,136,145,,141,-1,-0.7
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Total Bilirubin,,-26,0.2,0.3,1.2,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Total Bilirubin,Baseline,1,0.2,0.3,1.2,Y,0.2,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 A,9,0.3,0.3,1.2,,0.2,0.09999999999999998,50
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 A,20,0.3,0.3,1.2,,0.2,0.09999999999999998,50
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Total Protein,,-26,7.5,6.4,8.2,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Total Protein,Baseline,1,7.3,6.4,8.2,Y,7.3,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Total Protein,Cycle 1 Day 8 A,9,7.4,6.4,8.2,,7.3,0.10000000000000053,1.4
9A,A,NKTR-214 + Nivolumab,Y,N,Chemistry,Total Protein,Cycle 2 Day 1 A,20,6.7,6.4,8.2,,7.3,-0.5999999999999996,-8.2
9A,A,NKTR-214 + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),,-26,37.9,22.5,34.5,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,32.9,22.5,34.5,Y,32.9,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 A,9,30.3,22.5,34.5,,32.9,-2.599999999999998,-7.9
9A,A,NKTR-214 + Nivolumab,Y,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 A,20,30.5,22.5,34.5,,32.9,-2.3999999999999986,-7.3
9A,A,NKTR-214 + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-26,0.97,0.8,1.2,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.02,0.8,1.2,Y,1.02,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 A,9,1.05,0.8,1.2,,1.02,0.030000000000000027,2.9
9A,A,NKTR-214 + Nivolumab,Y,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 A,20,1.03,0.8,1.2,,1.02,0.010000000000000009,1
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Basophils,,-26,0.03,0,0.1,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Basophils,Baseline,1,0.03,0,0.1,Y,0.03,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Basophils,Cycle 1 Day 2 A,2,0.04,0,0.1,,0.03,0.010000000000000002,33.3
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Basophils,Cycle 1 Day 3 A,3,0.01,0,0.1,,0.03,-0.019999999999999997,-66.7
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Basophils,Cycle 1 Day 8 A,9,0.04,0,0.1,,0.03,0.010000000000000002,33.3
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Basophils,Cycle 2 Day 1 A,20,0.04,0,0.1,,0.03,0.010000000000000002,33.3
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Eosinophils,,-26,0.06,0,0.5,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Eosinophils,Baseline,1,0.09,0,0.5,Y,0.09,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Eosinophils,Cycle 1 Day 2 A,2,0.18,0,0.5,,0.09,0.09,100
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Eosinophils,Cycle 1 Day 3 A,3,0.21,0,0.5,,0.09,0.12,133.3
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Eosinophils,Cycle 1 Day 8 A,9,0.67,0,0.5,,0.09,0.5800000000000001,644.4
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Eosinophils,Cycle 2 Day 1 A,20,0.16,0,0.5,,0.09,0.07,77.8
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),,-26,4.02,4.5,6,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.11,4.5,6,Y,4.11,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 2 A,2,4.25,4.5,6,,4.11,0.13999999999999968,3.4
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 3 A,3,4.04,4.5,6,,4.11,-0.07000000000000028,-1.7
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 A,9,4.27,4.5,6,,4.11,0.15999999999999925,3.9
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 A,20,3.87,4.5,6,,4.11,-0.2400000000000002,-5.8
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),,-26,37.8,41,53,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Baseline,1,39.1,41,53,Y,39.1,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 2 A,2,40.2,41,53,,39.1,1.1000000000000014,2.8
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 3 A,3,37.9,41,53,,39.1,-1.2000000000000028,-3.1
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 A,9,40.8,41,53,,39.1,1.6999999999999957,4.3
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 A,20,36,41,53,,39.1,-3.1000000000000014,-7.9
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),,-26,12.2,13.5,17.5,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Baseline,1,12.5,13.5,17.5,Y,12.5,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 2 A,2,13.1,13.5,17.5,,12.5,0.5999999999999996,4.8
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 3 A,3,12.6,13.5,17.5,,12.5,0.09999999999999964,0.8
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 A,9,13,13.5,17.5,,12.5,0.5,4
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 A,20,11.9,13.5,17.5,,12.5,-0.5999999999999996,-4.8
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Lymphocytes,,-26,1.27,1,4.8,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Lymphocytes,Baseline,1,1.63,1,4.8,Y,1.63,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Lymphocytes,Cycle 1 Day 2 A,2,0.87,1,4.8,,1.63,-0.7599999999999999,-46.6
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Lymphocytes,Cycle 1 Day 3 A,3,0.3,1,4.8,,1.63,-1.3299999999999998,-81.6
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Lymphocytes,Cycle 1 Day 8 A,9,3.47,1,4.8,,1.63,1.8400000000000003,112.9
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Lymphocytes,Cycle 2 Day 1 A,20,1.46,1,4.8,,1.63,-0.16999999999999993,-10.4
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Monocytes,,-26,0.48,0.1,0.9,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Monocytes,Baseline,1,0.5,0.1,0.9,Y,0.5,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Monocytes,Cycle 1 Day 2 A,2,0.47,0.1,0.9,,0.5,-0.030000000000000027,-6
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Monocytes,Cycle 1 Day 3 A,3,0.45,0.1,0.9,,0.5,-0.04999999999999999,-10
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Monocytes,Cycle 1 Day 8 A,9,0.67,0.1,0.9,,0.5,0.17000000000000004,34
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Monocytes,Cycle 2 Day 1 A,20,0.58,0.1,0.9,,0.5,0.07999999999999996,16
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Neutrophils,,-26,3.25,1.8,7.7,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Neutrophils,Baseline,1,3.89,1.8,7.7,Y,3.89,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Neutrophils,Cycle 1 Day 2 A,2,3.72,1.8,7.7,,3.89,-0.16999999999999993,-4.4
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Neutrophils,Cycle 1 Day 3 A,3,3.87,1.8,7.7,,3.89,-0.020000000000000018,-0.5
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Neutrophils,Cycle 1 Day 8 A,9,5.17,1.8,7.7,,3.89,1.2799999999999998,32.9
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Neutrophils,Cycle 2 Day 1 A,20,3.94,1.8,7.7,,3.89,0.04999999999999982,1.3
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Platelets (10^9/L),,-26,246,150,400,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Baseline,1,263,150,400,Y,263,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Cycle 1 Day 2 A,2,254,150,400,,263,-9,-3.4
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Cycle 1 Day 3 A,3,210,150,400,,263,-53,-20.2
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 A,9,195,150,400,,263,-68,-25.9
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 A,20,223,150,400,,263,-40,-15.2
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,White Blood Cells,,-26,5.1,3.5,10.8,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,White Blood Cells,Baseline,1,6.15,3.5,10.8,Y,6.15,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,White Blood Cells,Cycle 1 Day 2 A,2,5.29,3.5,10.8,,6.15,-0.8600000000000003,-14
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,White Blood Cells,Cycle 1 Day 3 A,3,4.85,3.5,10.8,,6.15,-1.3000000000000007,-21.1
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,White Blood Cells,Cycle 1 Day 8 A,9,10.05,3.5,10.8,,6.15,3.9000000000000004,63.4
9A,A,NKTR-214 + Nivolumab,Y,N,Hematology,White Blood Cells,Cycle 2 Day 1 A,20,6.19,3.5,10.8,,6.15,0.040000000000000036,0.7
9A,A,NKTR-214 + Nivolumab,Y,N,Prostate-specific antigen,PSA,,-26,2.32,NA,NA,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Prostate-specific antigen,PSA,Baseline,1,2.17,NA,NA,Y,2.17,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 A,20,0.5,NA,NA,,2.17,-1.67,-77
9A,A,NKTR-214 + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-26,3.42,0.44,7.11,,NA,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.71,0.44,7.11,Y,2.71,NA,NA
9A,A,NKTR-214 + Nivolumab,Y,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 A,20,0.01,0.44,7.11,,2.71,-2.7,-99.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Baseline,1,150,NA,NA,Y,150,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 2 Day 1 B,31,65,NA,NA,,150,-85,-56.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,Cycle 3 Day 1 B,59,136,NA,NA,,150,-14,-9.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,,CTC,End of Treatment B,66,284,NA,NA,,150,134,89.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-11,16,1,45,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,13,1,45,Y,13,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 B,8,13,1,45,,13,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 15 B,15,16,1,45,,13,3,23.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 B,31,19,1,45,,13,6,46.2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 B,59,46,1,45,,13,33,253.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment B,85,14,1,45,,13,1,7.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 B,171,10,1,45,,13,-3,-23.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-11,3.9,3.5,4.9,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,4,3.5,4.9,Y,4,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 B,8,3.7,3.5,4.9,,4,-0.2999999999999998,-7.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 15 B,15,3.8,3.5,4.9,,4,-0.20000000000000018,-5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 B,31,3.5,3.5,4.9,,4,-0.5,-12.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 B,59,3.9,3.5,4.9,,4,-0.10000000000000009,-2.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment B,85,4,3.5,4.9,,4,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 B,171,3.8,3.5,4.9,,4,-0.20000000000000018,-5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-11,65,38,126,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,83,38,126,Y,83,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 B,8,76,38,126,,83,-7,-8.4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 15 B,15,77,38,126,,83,-6,-7.2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 B,31,69,38,126,,83,-14,-16.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 B,59,58,38,126,,83,-25,-30.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment B,85,69,38,126,,83,-14,-16.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 B,171,138,38,126,,83,55,66.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-11,20,1,35,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,14,1,35,Y,14,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 B,8,17,1,35,,14,3,21.4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 15 B,15,19,1,35,,14,5,35.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 B,31,15,1,35,,14,1,7.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 B,59,47,1,35,,14,33,235.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment B,85,24,1,35,,14,10,71.4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 B,171,14,1,35,,14,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,,-11,15,6,23,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Baseline,1,19,6,23,Y,19,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 B,8,18,6,23,,19,-1,-5.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 15 B,15,24,6,23,,19,5,26.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 B,31,19,6,23,,19,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 B,59,19,6,23,,19,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,End of Treatment B,85,21,6,23,,19,2,10.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 B,171,14,6,23,,19,-5,-26.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,,-11,16,22,30,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,24.2,22,30,Y,24.2,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 B,8,23.6,22,30,,24.2,-0.5999999999999979,-2.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 15 B,15,21.8,22,30,,24.2,-2.3999999999999986,-9.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 B,31,22.7,22,30,,24.2,-1.5,-6.2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 B,59,19,22,30,,24.2,-5.199999999999999,-21.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment B,85,25,22,30,,24.2,0.8000000000000007,3.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 B,171,26.6,22,30,,24.2,2.400000000000002,9.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-11,9.1,8.5,10.5,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9.6,8.5,10.5,Y,9.6,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 B,8,8.1,8.5,10.5,,9.6,-1.5,-15.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 15 B,15,9.3,8.5,10.5,,9.6,-0.29999999999999893,-3.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 B,31,9.5,8.5,10.5,,9.6,-0.09999999999999964,-1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 B,59,9.6,8.5,10.5,,9.6,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment B,85,9.9,8.5,10.5,,9.6,0.3000000000000007,3.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 B,171,9.4,8.5,10.5,,9.6,-0.1999999999999993,-2.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-11,106,96,108,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,106,96,108,Y,106,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 B,8,109,96,108,,106,3,2.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 15 B,15,106,96,108,,106,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 B,31,107,96,108,,106,1,0.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 B,59,106,96,108,,106,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment B,85,100,96,108,,106,-6,-5.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 B,171,105,96,108,,106,-1,-0.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-11,0.63,0.7,1.3,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,0.74,0.7,1.3,Y,0.74,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 B,8,0.74,0.7,1.3,,0.74,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 15 B,15,0.8,0.7,1.3,,0.74,0.06000000000000005,8.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 B,31,0.72,0.7,1.3,,0.74,-0.020000000000000018,-2.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 B,59,0.9,0.7,1.3,,0.74,0.16000000000000003,21.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment B,85,1.59,0.7,1.3,,0.74,0.8500000000000001,114.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 B,171,1,0.7,1.3,,0.74,0.26,35.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,,-11,92,60,100,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,104,60,100,Y,104,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 B,8,117,60,100,,104,13,12.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 15 B,15,97,60,100,,104,-7,-6.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 B,31,105,60,100,,104,1,1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 B,59,95,60,100,,104,-9,-8.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,End of Treatment B,85,104,60,100,,104,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 B,171,96,60,100,,104,-8,-7.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-11,307,100,220,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,267,100,220,Y,267,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 B,8,284,100,220,,267,17,6.4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 B,31,285,100,220,,267,18,6.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 B,59,329,100,220,,267,62,23.2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-11,4.3,3.5,5.2,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,5,3.5,5.2,Y,5,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 B,8,4.4,3.5,5.2,,5,-0.5999999999999996,-12
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 15 B,15,4.9,3.5,5.2,,5,-0.09999999999999964,-2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 B,31,4.4,3.5,5.2,,5,-0.5999999999999996,-12
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 B,59,4.6,3.5,5.2,,5,-0.40000000000000036,-8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment B,85,4.8,3.5,5.2,,5,-0.20000000000000018,-4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 B,171,4.8,3.5,5.2,,5,-0.20000000000000018,-4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,,-11,137,135,145,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,139,135,145,Y,139,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 B,8,138,135,145,,139,-1,-0.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 15 B,15,140,135,145,,139,1,0.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 B,31,140,135,145,,139,1,0.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 B,59,138,135,145,,139,-1,-0.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,End of Treatment B,85,137,135,145,,139,-2,-1.4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 B,171,140,135,145,,139,1,0.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,,-11,0.6,0.1,1.2,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,0.6,0.1,1.2,Y,0.6,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 B,8,0.3,0.1,1.2,,0.6,-0.3,-50
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 15 B,15,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 B,31,0.5,0.1,1.2,,0.6,-0.09999999999999998,-16.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 B,59,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment B,85,0.4,0.1,1.2,,0.6,-0.19999999999999996,-33.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 B,171,0.6,0.1,1.2,,0.6,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,,-11,6.8,6,8.3,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.1,6,8.3,Y,7.1,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 B,8,6.5,6,8.3,,7.1,-0.5999999999999996,-8.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 15 B,15,6,6,8.3,,7.1,-1.0999999999999996,-15.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 B,31,6.9,6,8.3,,7.1,-0.1999999999999993,-2.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 B,59,7.4,6,8.3,,7.1,0.3000000000000007,4.2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment B,85,7.8,6,8.3,,7.1,0.7000000000000002,9.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 B,171,6.7,6,8.3,,7.1,-0.39999999999999947,-5.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-11,27.9,25.4,34.9,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,29.3,25.4,34.9,Y,29.3,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 B,8,30,25.4,34.9,,29.3,0.6999999999999993,2.4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 B,31,30.5,25.4,34.9,,29.3,1.1999999999999993,4.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 B,59,30.4,25.4,34.9,,29.3,1.0999999999999979,3.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-11,1.1,2,3,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1.1,2,3,Y,1.1,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 B,8,1.1,2,3,,1.1,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 B,31,1.1,2,3,,1.1,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 B,59,1.1,2,3,,1.1,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-11,13.6,12.3,14.9,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,14,12.3,14.9,Y,14,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 B,8,14.2,12.3,14.9,,14,0.1999999999999993,1.4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 B,31,14.3,12.3,14.9,,14,0.3000000000000007,2.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 B,59,13.3,12.3,14.9,,14,-0.6999999999999993,-5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,,-11,0,0,0.2,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 B,8,0,0,0.2,,0,0,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 15 B,15,0,0,0.2,,0,0,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 B,31,0,0,0.2,,0,0,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 B,62,0,0,0.2,,0,0,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,End of Treatment B,85,0.1,0,0.2,,0,0.1,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 B,171,0,0,0.2,,0,0,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,,-11,0.1,0,0.6,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.2,0,0.6,Y,0.2,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 B,8,0.3,0,0.6,,0.2,0.09999999999999998,50
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 15 B,15,0.3,0,0.6,,0.2,0.09999999999999998,50
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 B,31,0.1,0,0.6,,0.2,-0.1,-50
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 B,62,0.3,0,0.6,,0.2,0.09999999999999998,50
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment B,85,0.4,0,0.6,,0.2,0.2,100
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 B,171,0,0,0.6,,0.2,-0.2,-100
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-11,4.22,4.5,6,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,4.5,4.5,6,Y,4.5,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 B,8,4.07,4.5,6,,4.5,-0.4299999999999997,-9.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 15 B,15,4.2,4.5,6,,4.5,-0.2999999999999998,-6.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 B,31,4.42,4.5,6,,4.5,-0.08000000000000007,-1.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 B,62,4.29,4.5,6,,4.5,-0.20999999999999996,-4.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment B,85,3.8,4.5,6,,4.5,-0.7000000000000002,-15.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 B,171,3.17,4.5,6,,4.5,-1.33,-29.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-11,31.1,42,52,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,33.2,42,52,Y,33.2,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 B,8,30.4,42,52,,33.2,-2.8000000000000043,-8.4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 15 B,15,30.6,42,52,,33.2,-2.6000000000000014,-7.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 B,31,32,42,52,,33.2,-1.2000000000000028,-3.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 B,62,30.3,42,52,,33.2,-2.900000000000002,-8.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment B,85,26.4,42,52,,33.2,-6.800000000000004,-20.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 B,171,25.8,42,52,,33.2,-7.400000000000002,-22.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-11,9.9,13.9,16.3,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,10.3,13.9,16.3,Y,10.3,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 B,8,9.5,13.9,16.3,,10.3,-0.8000000000000007,-7.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 15 B,15,9.7,13.9,16.3,,10.3,-0.6000000000000014,-5.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 B,31,10.1,13.9,16.3,,10.3,-0.20000000000000107,-1.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 B,62,9.6,13.9,16.3,,10.3,-0.7000000000000011,-6.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment B,85,9.6,13.9,16.3,,10.3,-0.7000000000000011,-6.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 B,171,8.3,13.9,16.3,,10.3,-2,-19.4
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,,-11,1.7,1,4.5,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.8,1,4.5,Y,1.8,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 B,8,1.9,1,4.5,,1.8,0.09999999999999987,5.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 15 B,15,2,1,4.5,,1.8,0.19999999999999996,11.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 B,31,1.4,1,4.5,,1.8,-0.40000000000000013,-22.2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 B,62,1.5,1,4.5,,1.8,-0.30000000000000004,-16.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment B,85,1.8,1,4.5,,1.8,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 B,171,0.9,1,4.5,,1.8,-0.9,-50
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,,-11,0.5,0.2,1,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.6,0.2,1,Y,0.6,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 B,8,2.1,0.2,1,,0.6,1.5,250
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 15 B,15,4.5,0.2,1,,0.6,3.9,650
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 B,31,0.6,0.2,1,,0.6,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 B,62,0.4,0.2,1,,0.6,-0.19999999999999996,-33.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,End of Treatment B,85,0.4,0.2,1,,0.6,-0.19999999999999996,-33.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 B,171,0.8,0.2,1,,0.6,0.20000000000000007,33.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,,-11,2.8,1.9,8,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,2.9,1.9,8,Y,2.9,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 B,8,5.77,1.9,8,,2.9,2.8699999999999997,99
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 15 B,15,8.06,1.9,8,,2.9,5.16,177.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 B,31,3.5,1.9,8,,2.9,0.6000000000000001,20.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 B,62,3.8,1.9,8,,2.9,0.8999999999999999,31
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment B,85,4,1.9,8,,2.9,1.1,37.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 B,171,2.46,1.9,8,,2.9,-0.43999999999999995,-15.2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-11,288,150,450,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,290,150,450,Y,290,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 B,8,264,150,450,,290,-26,-9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 15 B,15,235,150,450,,290,-55,-19
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 B,31,313,150,450,,290,23,7.9
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 B,62,363,150,450,,290,73,25.2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment B,85,376,150,450,,290,86,29.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 B,171,188,150,450,,290,-102,-35.2
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,TESTR,Baseline,-11,14.46,300,1080,Y,14.46,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,,-11,5.1,4.5,11,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.5,4.5,11,Y,5.5,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 B,8,9.3,4.5,11,,5.5,3.8000000000000007,69.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 15 B,15,12.6,4.5,11,,5.5,7.1,129.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 B,31,5.7,4.5,11,,5.5,0.20000000000000018,3.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 B,62,6,4.5,11,,5.5,0.5,9.1
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment B,85,6.7,4.5,11,,5.5,1.2000000000000002,21.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 B,171,4.4,4.5,11,,5.5,-1.0999999999999996,-20
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,,-11,8.62,NA,NA,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,9.16,NA,NA,Y,9.16,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 B,31,29.54,NA,NA,,9.16,20.38,222.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 B,59,15.62,NA,NA,,9.16,6.459999999999999,70.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment B,85,15.28,NA,NA,,9.16,6.119999999999999,66.8
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 B,171,41.46,NA,NA,,9.16,32.3,352.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),Cycle 3 Day 1 B,59,0.42,0.8,1.5,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),End of Treatment B,85,0.42,0.8,1.5,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Free thyroxine (FT4),Follow-up 110 B,171,0.93,0.8,1.5,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-11,2.5,0.4,4.2,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,2.96,0.4,4.2,Y,2.96,0,0
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 B,8,1.65,0.4,4.2,,2.96,-1.31,-44.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 B,31,0.01,0.4,4.2,,2.96,-2.95,-99.7
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 B,59,43.67,0.4,4.2,,2.96,40.71,1375.3
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment B,85,138.1,0.4,4.2,,2.96,135.14,4565.5
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 B,171,19.08,0.4,4.2,,2.96,16.119999999999997,544.6
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Triiodothyronine (T3),End of Treatment B,85,1,2.5,3.9,,NA,NA,NA
9B,B,SBRT + CDX-301 + poly-ICLC + Nivolumab,N,N,Thyroid Function Testing,Triiodothyronine (T3),Follow-up 110 B,171,2.04,2.5,3.9,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Baseline,1,0,NA,NA,Y,0,0,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 1 Day 1 C,44,0,NA,NA,,0,0,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 2 Day 1 C,72,2,NA,NA,,0,2,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,,CTC,Cycle 3 Day 1 C,102,12,NA,NA,,0,12,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),,-14,11,1,45,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Baseline,1,13,1,45,Y,13,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,8,10,1,45,,13,-3,-23.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),I-P Lead In C,22,14,1,45,,13,1,7.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 1 C,44,11,1,45,,13,-2,-15.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 1 Day 8 C,51,11,1,45,,13,-2,-15.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 2 Day 1 C,72,11,1,45,,13,-2,-15.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Cycle 3 Day 1 C,102,16,1,45,,13,3,23.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),End of Treatment C,123,11,1,45,,13,-2,-15.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alanine Aminotransferase (IU/L),Follow-up 110 C,226,7,1,45,,13,-6,-46.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),,-14,3.8,3.5,4.9,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Baseline,1,3.8,3.5,4.9,Y,3.8,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,8,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),I-P Lead In C,22,3.6,3.5,4.9,,3.8,-0.19999999999999973,-5.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 1 C,44,3.5,3.5,4.9,,3.8,-0.2999999999999998,-7.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 1 Day 8 C,51,3.6,3.5,4.9,,3.8,-0.19999999999999973,-5.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 2 Day 1 C,72,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Cycle 3 Day 1 C,102,3.8,3.5,4.9,,3.8,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),End of Treatment C,123,3.7,3.5,4.9,,3.8,-0.09999999999999964,-2.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Albumin (g/dL),Follow-up 110 C,226,3,3.5,4.9,,3.8,-0.7999999999999998,-21.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),,-14,139,38,126,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Baseline,1,147,38,126,Y,147,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,8,149,38,126,,147,2,1.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),I-P Lead In C,22,140,38,126,,147,-7,-4.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 1 C,44,125,38,126,,147,-22,-15
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 1 Day 8 C,51,142,38,126,,147,-5,-3.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 2 Day 1 C,72,126,38,126,,147,-21,-14.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Cycle 3 Day 1 C,102,158,38,126,,147,11,7.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),End of Treatment C,123,223,38,126,,147,76,51.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Alkaline Phosphatase (IU/L),Follow-up 110 C,226,126,38,126,,147,-21,-14.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),,-14,20,1,35,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Baseline,1,18,1,35,Y,18,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,8,22,1,35,,18,4,22.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),I-P Lead In C,22,19,1,35,,18,1,5.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 1 C,44,17,1,35,,18,-1,-5.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 1 Day 8 C,51,19,1,35,,18,1,5.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 2 Day 1 C,72,16,1,35,,18,-2,-11.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Cycle 3 Day 1 C,102,23,1,35,,18,5,27.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),End of Treatment C,123,27,1,35,,18,9,50
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Aspartate Aminotransferase (IU/L),Follow-up 110 C,226,19,1,35,,18,1,5.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,,-14,13,6,23,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Baseline,1,16,6,23,Y,16,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,8,12,6,23,,16,-4,-25
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,I-P Lead In C,22,9,6,23,,16,-7,-43.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 1 C,44,14,6,23,,16,-2,-12.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 1 Day 8 C,51,11,6,23,,16,-5,-31.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 2 Day 1 C,72,12,6,23,,16,-4,-25
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Cycle 3 Day 1 C,102,10,6,23,,16,-6,-37.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,End of Treatment C,123,24,6,23,,16,8,50
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,BUN,Follow-up 110 C,226,20,6,23,,16,4,25
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,,-14,20.8,22,30,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Baseline,1,24,22,30,Y,24,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,8,23.9,22,30,,24,-0.10000000000000142,-0.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,I-P Lead In C,22,22,22,30,,24,-2,-8.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 1 C,44,23.2,22,30,,24,-0.8000000000000007,-3.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 1 Day 8 C,51,22.4,22,30,,24,-1.6000000000000014,-6.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 2 Day 1 C,72,22.1,22,30,,24,-1.8999999999999986,-7.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Cycle 3 Day 1 C,102,22.8,22,30,,24,-1.1999999999999993,-5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,End of Treatment C,123,20.2,22,30,,24,-3.8000000000000007,-15.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Bicarbonate,Follow-up 110 C,226,29.2,22,30,,24,5.199999999999999,21.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),,-14,8.7,8.5,10.5,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Baseline,1,9,8.5,10.5,Y,9,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,8,8.5,8.5,10.5,,9,-0.5,-5.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),I-P Lead In C,22,8.8,8.5,10.5,,9,-0.1999999999999993,-2.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 1 C,44,8.9,8.5,10.5,,9,-0.09999999999999964,-1.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 1 Day 8 C,51,9,8.5,10.5,,9,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 2 Day 1 C,72,8.7,8.5,10.5,,9,-0.3000000000000007,-3.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Cycle 3 Day 1 C,102,9.1,8.5,10.5,,9,0.09999999999999964,1.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),End of Treatment C,123,9.5,8.5,10.5,,9,0.5,5.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Calcium (mmol/L),Follow-up 110 C,226,9.6,8.5,10.5,,9,0.5999999999999996,6.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),,-14,104,96,108,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Baseline,1,102,96,108,Y,102,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,8,99,96,108,,102,-3,-2.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),I-P Lead In C,22,102,96,108,,102,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 1 C,44,103,96,108,,102,1,1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 1 Day 8 C,51,102,96,108,,102,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 2 Day 1 C,72,104,96,108,,102,2,2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Cycle 3 Day 1 C,102,98,96,108,,102,-4,-3.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),End of Treatment C,123,97,96,108,,102,-5,-4.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Chloride (mmol/L),Follow-up 110 C,226,98,96,108,,102,-4,-3.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),,-14,0.98,0.7,1.3,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Baseline,1,1.1,0.7,1.3,Y,1.1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,8,1.02,0.7,1.3,,1.1,-0.08000000000000007,-7.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),I-P Lead In C,22,0.97,0.7,1.3,,1.1,-0.13000000000000012,-11.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 1 C,44,0.96,0.7,1.3,,1.1,-0.14000000000000012,-12.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 1 Day 8 C,51,0.94,0.7,1.3,,1.1,-0.16000000000000014,-14.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 2 Day 1 C,72,1,0.7,1.3,,1.1,-0.10000000000000009,-9.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Cycle 3 Day 1 C,102,1,0.7,1.3,,1.1,-0.10000000000000009,-9.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),End of Treatment C,123,0.98,0.7,1.3,,1.1,-0.1200000000000001,-10.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Creatinine (umol/L),Follow-up 110 C,226,0.78,0.7,1.3,,1.1,-0.32000000000000006,-29.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,,-14,93,60,100,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Baseline,1,86,60,100,Y,86,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,8,104,60,100,,86,18,20.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,I-P Lead In C,22,89,60,100,,86,3,3.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 1 C,44,103,60,100,,86,17,19.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 1 Day 8 C,51,108,60,100,,86,22,25.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 2 Day 1 C,72,107,60,100,,86,21,24.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Cycle 3 Day 1 C,102,110,60,100,,86,24,27.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,End of Treatment C,123,105,60,100,,86,19,22.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Glucose,Follow-up 110 C,226,114,60,100,,86,28,32.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),,-14,195,100,220,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Baseline,1,173,100,220,Y,173,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,8,186,100,220,,173,13,7.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),I-P Lead In C,22,225,100,220,,173,52,30.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 1 C,44,190,100,220,,173,17,9.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 1 Day 8 C,51,179,100,220,,173,6,3.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 2 Day 1 C,72,180,100,220,,173,7,4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),Cycle 3 Day 1 C,102,301,100,220,,173,128,74
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Lactate Dehydrogenase (IU/L),End of Treatment C,123,979,100,220,,173,806,465.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),,-14,4.3,3.5,5.2,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Baseline,1,4.2,3.5,5.2,Y,4.2,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,8,4.6,3.5,5.2,,4.2,0.39999999999999947,9.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),I-P Lead In C,22,4.1,3.5,5.2,,4.2,-0.10000000000000053,-2.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 1 C,44,4.1,3.5,5.2,,4.2,-0.10000000000000053,-2.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 1 Day 8 C,51,4.4,3.5,5.2,,4.2,0.20000000000000018,4.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 2 Day 1 C,72,4.1,3.5,5.2,,4.2,-0.10000000000000053,-2.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Cycle 3 Day 1 C,102,3.7,3.5,5.2,,4.2,-0.5,-11.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),End of Treatment C,123,4,3.5,5.2,,4.2,-0.20000000000000018,-4.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Potassium (mmol/L),Follow-up 110 C,226,4.1,3.5,5.2,,4.2,-0.10000000000000053,-2.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,,-14,137,135,145,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Baseline,1,136,135,145,Y,136,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,8,132,135,145,,136,-4,-2.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,I-P Lead In C,22,135,135,145,,136,-1,-0.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 1 C,44,136,135,145,,136,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 1 Day 8 C,51,134,135,145,,136,-2,-1.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 2 Day 1 C,72,135,135,145,,136,-1,-0.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Cycle 3 Day 1 C,102,134,135,145,,136,-2,-1.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,End of Treatment C,123,131,135,145,,136,-5,-3.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Sodium,Follow-up 110 C,226,136,135,145,,136,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,,-14,0.9,0.1,1.2,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Baseline,1,1.3,0.1,1.2,Y,1.3,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,8,0.7,0.1,1.2,,1.3,-0.6000000000000001,-46.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,I-P Lead In C,22,0.9,0.1,1.2,,1.3,-0.4,-30.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 1 C,44,0.6,0.1,1.2,,1.3,-0.7000000000000001,-53.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 1 Day 8 C,51,1,0.1,1.2,,1.3,-0.30000000000000004,-23.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 2 Day 1 C,72,1,0.1,1.2,,1.3,-0.30000000000000004,-23.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Cycle 3 Day 1 C,102,1,0.1,1.2,,1.3,-0.30000000000000004,-23.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,End of Treatment C,123,1.2,0.1,1.2,,1.3,-0.10000000000000009,-7.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Bilirubin,Follow-up 110 C,226,0.9,0.1,1.2,,1.3,-0.4,-30.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,,-14,7,6,8.3,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Baseline,1,7.2,6,8.3,Y,7.2,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,8,6.8,6,8.3,,7.2,-0.40000000000000036,-5.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,I-P Lead In C,22,7,6,8.3,,7.2,-0.20000000000000018,-2.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 1 C,44,7,6,8.3,,7.2,-0.20000000000000018,-2.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 1 Day 8 C,51,7.1,6,8.3,,7.2,-0.10000000000000053,-1.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 2 Day 1 C,72,6.9,6,8.3,,7.2,-0.2999999999999998,-4.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Cycle 3 Day 1 C,102,7,6,8.3,,7.2,-0.20000000000000018,-2.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,End of Treatment C,123,7.7,6,8.3,,7.2,0.5,6.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Chemistry,Total Protein,Follow-up 110 C,226,6.1,6,8.3,,7.2,-1.1000000000000005,-15.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),,-14,38,25.4,34.9,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Baseline,1,38.4,25.4,34.9,Y,38.4,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,8,42.1,25.4,34.9,,38.4,3.700000000000003,9.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),I-P Lead In C,22,37.5,25.4,34.9,,38.4,-0.8999999999999986,-2.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 1 C,44,41.2,25.4,34.9,,38.4,2.8000000000000043,7.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 1 Day 8 C,51,40.9,25.4,34.9,,38.4,2.5,6.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 2 Day 1 C,72,47.5,25.4,34.9,,38.4,9.100000000000001,23.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Cycle 3 Day 1 C,102,42,25.4,34.9,,38.4,3.6000000000000014,9.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),End of Treatment C,123,37.8,25.4,34.9,,38.4,-0.6000000000000014,-1.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Partial Thromboplastin Time (PTT),Follow-up 110 C,198,27,25.4,34.9,,38.4,-11.399999999999999,-29.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),,-14,1,2,3,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Baseline,1,1,2,3,Y,1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,8,1,2,3,,1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),I-P Lead In C,22,1,2,3,,1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 1 C,44,1,2,3,,1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 1 Day 8 C,51,1,2,3,,1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 2 Day 1 C,72,1,2,3,,1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Cycle 3 Day 1 C,102,1,2,3,,1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),End of Treatment C,123,1.1,2,3,,1,0.10000000000000009,10
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Intl. Normalized Ratio (RATIO),Follow-up 110 C,198,1.1,2,3,,1,0.10000000000000009,10
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),,-14,13,12.3,14.9,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Baseline,1,12.8,12.3,14.9,Y,12.8,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,8,13,12.3,14.9,,12.8,0.1999999999999993,1.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),I-P Lead In C,22,13.1,12.3,14.9,,12.8,0.29999999999999893,2.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 1 C,44,12.8,12.3,14.9,,12.8,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 1 Day 8 C,51,12.6,12.3,14.9,,12.8,-0.20000000000000107,-1.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 2 Day 1 C,72,12.5,12.3,14.9,,12.8,-0.3000000000000007,-2.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Cycle 3 Day 1 C,102,13.3,12.3,14.9,,12.8,0.5,3.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),End of Treatment C,123,13.4,12.3,14.9,,12.8,0.5999999999999996,4.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Coagulation,Prothrombin Time (PT),Follow-up 110 C,198,13.2,12.3,14.9,,12.8,0.3999999999999986,3.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,,-14,0.1,0,0.2,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Baseline,1,0,0,0.2,Y,0,0,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,8,0,0,0.2,,0,0,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,I-P Lead In C,22,0.6,0,0.2,,0,0.6,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 1 C,44,2,0,0.2,,0,2,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 1 Day 8 C,51,0.1,0,0.2,,0,0.1,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 2 Day 1 C,72,0.1,0,0.2,,0,0.1,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Cycle 3 Day 1 C,102,0,0,0.2,,0,0,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,End of Treatment C,123,0,0,0.2,,0,0,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Basophils,Follow-up 110 C,226,0,0,0.2,,0,0,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,,-14,0.3,0,0.6,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Baseline,1,0.3,0,0.6,Y,0.3,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,8,0.1,0,0.6,,0.3,-0.19999999999999998,-66.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,I-P Lead In C,22,1.8,0,0.6,,0.3,1.5,500
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 1 C,44,3,0,0.6,,0.3,2.7,900
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 1 Day 8 C,51,0.2,0,0.6,,0.3,-0.09999999999999998,-33.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 2 Day 1 C,72,0.5,0,0.6,,0.3,0.2,66.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Cycle 3 Day 1 C,102,0.7,0,0.6,,0.3,0.39999999999999997,133.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,End of Treatment C,123,0.4,0,0.6,,0.3,0.10000000000000003,33.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Eosinophils,Follow-up 110 C,226,0,0,0.6,,0.3,-0.3,-100
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),,-14,3.67,4.5,6,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Baseline,1,3.75,4.5,6,Y,3.75,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,8,3.58,4.5,6,,3.75,-0.16999999999999993,-4.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),I-P Lead In C,22,3.66,4.5,6,,3.75,-0.08999999999999986,-2.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 1 C,44,3.59,4.5,6,,3.75,-0.16000000000000014,-4.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 1 Day 8 C,51,3.59,4.5,6,,3.75,-0.16000000000000014,-4.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 2 Day 1 C,72,3.63,4.5,6,,3.75,-0.1200000000000001,-3.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Cycle 3 Day 1 C,102,3.69,4.5,6,,3.75,-0.06000000000000005,-1.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),End of Treatment C,123,3.82,4.5,6,,3.75,0.06999999999999984,1.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Erythrocytes (10^12/L),Follow-up 110 C,226,3,4.5,6,,3.75,-0.75,-20
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),,-14,36.7,42,52,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Baseline,1,37.6,42,52,Y,37.6,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,8,36,42,52,,37.6,-1.6000000000000014,-4.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),I-P Lead In C,22,36.3,42,52,,37.6,-1.3000000000000043,-3.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 1 C,44,35.8,42,52,,37.6,-1.8000000000000043,-4.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 1 Day 8 C,51,35.8,42,52,,37.6,-1.8000000000000043,-4.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 2 Day 1 C,72,36,42,52,,37.6,-1.6000000000000014,-4.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Cycle 3 Day 1 C,102,36.3,42,52,,37.6,-1.3000000000000043,-3.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),End of Treatment C,123,37.1,42,52,,37.6,-0.5,-1.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hematocrit (RATIO),Follow-up 110 C,226,30.3,42,52,,37.6,-7.300000000000001,-19.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),,-14,12.7,13.9,16.3,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Baseline,1,13.1,13.9,16.3,Y,13.1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,8,12.4,13.9,16.3,,13.1,-0.6999999999999993,-5.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),I-P Lead In C,22,12.6,13.9,16.3,,13.1,-0.5,-3.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 1 C,44,12.4,13.9,16.3,,13.1,-0.6999999999999993,-5.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 1 Day 8 C,51,12.4,13.9,16.3,,13.1,-0.6999999999999993,-5.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 2 Day 1 C,72,12.4,13.9,16.3,,13.1,-0.6999999999999993,-5.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Cycle 3 Day 1 C,102,12.5,13.9,16.3,,13.1,-0.5999999999999996,-4.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),End of Treatment C,123,12.6,13.9,16.3,,13.1,-0.5,-3.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Hemoglobin (g/dL),Follow-up 110 C,226,10.4,13.9,16.3,,13.1,-2.6999999999999993,-20.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,,-14,1.2,1,4.5,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Baseline,1,1.5,1,4.5,Y,1.5,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,8,1,1,4.5,,1.5,-0.5,-33.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,I-P Lead In C,22,1.8,1,4.5,,1.5,0.30000000000000004,20
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 1 C,44,1.1,1,4.5,,1.5,-0.3999999999999999,-26.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 1 Day 8 C,51,1.3,1,4.5,,1.5,-0.19999999999999996,-13.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 2 Day 1 C,72,20.9,1,4.5,,1.5,19.4,1293.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Cycle 3 Day 1 C,102,1,1,4.5,,1.5,-0.5,-33.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,End of Treatment C,123,0.9,1,4.5,,1.5,-0.6,-40
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Lymphocytes,Follow-up 110 C,226,0.2,1,4.5,,1.5,-1.3,-86.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,,-14,0.8,0.2,1,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Baseline,1,0.6,0.2,1,Y,0.6,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,8,1.9,0.2,1,,0.6,1.2999999999999998,216.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,I-P Lead In C,22,2.7,0.2,1,,0.6,2.1,350
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 1 C,44,1.4,0.2,1,,0.6,0.7999999999999999,133.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 1 Day 8 C,51,0.8,0.2,1,,0.6,0.20000000000000007,33.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 2 Day 1 C,72,0.6,0.2,1,,0.6,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Cycle 3 Day 1 C,102,0.6,0.2,1,,0.6,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,End of Treatment C,123,0.8,0.2,1,,0.6,0.20000000000000007,33.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Monocytes,Follow-up 110 C,226,0.4,0.2,1,,0.6,-0.19999999999999996,-33.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,,-14,4.4,1.9,8,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Baseline,1,3.1,1.9,8,Y,3.1,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,8,3.23,1.9,8,,3.1,0.1299999999999999,4.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,I-P Lead In C,22,4.6,1.9,8,,3.1,1.4999999999999996,48.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 1 C,44,2.45,1.9,8,,3.1,-0.6499999999999999,-21
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 1 Day 8 C,51,3.4,1.9,8,,3.1,0.2999999999999998,9.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 2 Day 1 C,72,3.3,1.9,8,,3.1,0.19999999999999973,6.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Cycle 3 Day 1 C,102,4.6,1.9,8,,3.1,1.4999999999999996,48.4
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,End of Treatment C,123,8,1.9,8,,3.1,4.9,158.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Neutrophils,Follow-up 110 C,226,4.2,1.9,8,,3.1,1.1,35.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),,-14,120,150,450,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Baseline,1,132,150,450,Y,132,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,8,111,150,450,,132,-21,-15.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),I-P Lead In C,22,220,150,450,,132,88,66.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 1 C,44,185,150,450,,132,53,40.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 1 Day 8 C,51,133,150,450,,132,1,0.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 2 Day 1 C,72,102,150,450,,132,-30,-22.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Cycle 3 Day 1 C,102,121,150,450,,132,-11,-8.3
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),End of Treatment C,123,145,150,450,,132,13,9.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,Platelets (10^9/L),Follow-up 110 C,226,87,150,450,,132,-45,-34.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,,-14,6.8,4.5,11,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Baseline,1,5.7,4.5,11,Y,5.7,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,8,6.1,4.5,11,,5.7,0.39999999999999947,7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,I-P Lead In C,22,9.4,4.5,11,,5.7,3.7,64.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 1 C,44,5.1,4.5,11,,5.7,-0.6000000000000005,-10.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 1 Day 8 C,51,5.8,4.5,11,,5.7,0.09999999999999964,1.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 2 Day 1 C,72,5.6,4.5,11,,5.7,-0.10000000000000053,-1.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Cycle 3 Day 1 C,102,6.9,4.5,11,,5.7,1.2000000000000002,21.1
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,End of Treatment C,123,10.1,4.5,11,,5.7,4.3999999999999995,77.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Hematology,White Blood Cells,Follow-up 110 C,226,4.8,4.5,11,,5.7,-0.9000000000000004,-15.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,,-14,41.36,NA,NA,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Baseline,1,55.86,NA,NA,Y,55.86,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,I-P Lead In C,22,125.58,NA,NA,,55.86,69.72,124.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 1 Day 1 C,44,197.67,NA,NA,,55.86,141.81,253.9
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 2 Day 1 C,72,398.18,NA,NA,,55.86,342.32,612.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Cycle 3 Day 1 C,102,804.09,NA,NA,,55.86,748.23,1339.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,End of Treatment C,123,1886.66,NA,NA,,55.86,1830.8000000000002,3277.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Prostate-specific antigen,PSA,Follow-up 110 C,226,7052.76,NA,NA,,55.86,6996.9000000000005,12525.8
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),,-14,1.39,0.4,4.2,,NA,NA,NA
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Baseline,1,1.73,0.4,4.2,Y,1.73,0,0
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,8,0.68,0.4,4.2,,1.73,-1.0499999999999998,-60.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),I-P Lead In C,22,1.28,0.4,4.2,,1.73,-0.44999999999999996,-26
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 1 C,44,1.25,0.4,4.2,,1.73,-0.48,-27.7
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 1 Day 8 C,51,1.45,0.4,4.2,,1.73,-0.28,-16.2
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 2 Day 1 C,72,1.15,0.4,4.2,,1.73,-0.5800000000000001,-33.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Cycle 3 Day 1 C,102,1.81,0.4,4.2,,1.73,0.08000000000000007,4.6
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),End of Treatment C,123,0.7,0.4,4.2,,1.73,-1.03,-59.5
9C,C,CDX-301 + INO-5151 + Nivolumab,N,N,Thyroid Function Testing,Thyroid stimulating hormone (TSH),Follow-up 110 C,226,0.46,0.4,4.2,,1.73,-1.27,-73.4
